

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO	
RAD: 14-43406- -3	FECHA: 2015-07-17 18:00:37
DEP: 2020 DIRECCION DE NUEVAS CREACIONES	EVE: 378 FASE NACIONAL INCLUIDO CAPITULO I
TRA: 11 PCT-PATENTE DE INVENCION CAPITULOS I Y II	FOLIOS: 8
ACT: 519 TRASLADOINFORME	

DIRECCIÓN DE NUEVAS CREACIONES

2020
Bogotá, D.C.,

Abogado(a)/Señor(a)
CARLOS R. OLARTE GARCIA

Asunto: Radicación: 14-43406- -3
Trámite: 11
Evento: 378
Actuación: 519
Oficio: 8395
Folios: 8

Patente de Invención	X			Patente de Modelo de Utilidad	
Vía Nacional					
Vía PCT (Fase Nacional)	X	Capítulo I	X	Capítulo II	
No. Solicitud Internacional	PCT/IB2012/054501				
Fecha de Presentación Internacional	31/08/2012				

Como resultado del examen de fondo realizado, con fundamento en el Artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se comunica:

1. Documentos estudiados

Descripción:	Radicado N° 14-043406-00000-0000	28/Febrero/2014
Reivindicaciones:	Radicado N° 14-043406-00000-0000	28/Febrero/2014
	Radicado N° 14-043406-00002-0000	24/Septiembre/2014
Prioridad:	US 61/530,049	01/Septiembre/2011
	US 61/680,119	06/Agosto/2012

2. Análisis de la Prioridad

Se acepta la reivindicación de prioridad porque ésta solicitud fue presentada dentro del plazo establecido (Art. 9 D 486) y su contenido técnico corresponde con el de la prioridad reivindicada.

3. Objeto de la invención


De acuerdo con lo establecido en el numeral 1.2.2.2 del capítulo primero del Título 10 de la Circular Única para efectos del examen de patentabilidad, se tendrá en cuenta la tasa pagada por la solicitante al momento de comenzar el examen para las

reivindicaciones adicionales; esto es que cuando la solicitud contenga más de diez (10) reivindicaciones y no se haya pagado la tasa complementaria, sólo se estudiarán las cubiertas por la tasa pagada. En el presente caso se estudiarán las reivindicaciones 1 a 18 del capítulo reivindicatorio (Radicado N°. 14-043406-00002-0000).


Título de la solicitud: “DERIVADOS DE HETEROCICLOS BICÍCLICOS PARA EL TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL PULMONAR”

El problema planteado en esta solicitud consiste en la necesidad de proporcionar compuestos inhibidores para PDGFR que puedan ser útiles en el tratamiento de varios trastornos cardiovasculares, pulmonares, de remodelación de tejidos, e hipertróficos, muchos cánceres y otras indicaciones en las que las respuestas funcionales promovidas por PDGF contribuyen a la patología, incluyendo la hipertensión arterial pulmonar.

Para resolver este problema técnico la solicitud en estudio proporciona derivados de heterociclos bicíclicos de la fórmula I útiles en la inhibición de la actividad biológica mediada por el receptor PDGF.



(I) En donde A es:



El objeto de la presente solicitud se relaciona con la Clasificación Internacional de Patentes (CIP): C07D 471/04, A61K 31/4162, A61K 31/4188, A61P 9/12.

4. De la solicitud de patente

Titulo

El título de la solicitud hace referencia a materia no patentable, como lo son los métodos de tratamiento. Se sugiere a la solicitante modificarlo para incluir las características estructurales o funcionales de los compuestos reclamados, haciéndolo más concreto.



Reivindicaciones (Art 30 D 486, Art 22 PCT)

La reivindicación 1 no es clara porque la expresión “*opcionalmente sustituido*” no limita el alcance de la reivindicación. Se sugiere incluir las características opcionales o preferentes en una reivindicación dependiente

La reivindicación 17 no es clara ya que al tratarse de una composición farmacéutica sus características técnicas esenciales son sus ingredientes que deben estar adecuadamente caracterizados, así como las cantidades o proporciones en las que estos se encuentran, por lo se sugiere definir los componentes por medio de su nombre IUPAC, Denominación común internacional o estructura, y no de acuerdo a su función o actividad dadas por términos como “*vehículos farmacéuticamente aceptables*”, y las proporciones por medio de rangos concretos evitando expresiones ambiguas como “*cantidad terapéuticamente efectiva*”.

La reivindicación 18 no es clara por que no establece las características técnicas esenciales de la composición que se reclama, puesto que únicamente se establece que comprende “*un segundo agente activo*”. Sin embargo no es claro a que corresponde dicho componente.

La reivindicación 1 no es concisa porque las definiciones de los sustituyentes R^{1a} , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 son muy generales puesto que corresponden a grupos funcionales, y dan lugar a una gran cantidad de compuestos posibles, que no están debidamente soportados por la descripción. Se sugiere restringir la solicitud a una razonable generalización del tipo de compuestos que ha sido sintetizado ó probado, es decir, que se encuentran debidamente sustentados.

Sustituciones	Soporte de los ejemplos presentados
R^1	-F, -CH ₃ , -Br,
R^{1a}	-H, -F,
R^2	
R^3	H, 
R^5	-H,
R^6	

La reivindicación 1 no está sustentada en la descripción porque los compuestos en los que R^5 es diferente de hidrógeno no se encuentran ejemplificados, por lo tanto, se considera que este sustituyentes es esencial para los compuestos reclamados, por lo que se sugiere a la solicitante que lo defina de esta forma.

La reivindicación 13 no está soportada en la descripción, puesto que no muestra un desarrollo de composiciones farmacéuticas que cumplan las características esenciales descritas en dicha reivindicación.

La reivindicación 18 no está soportada en la descripción, puesto que no muestra un desarrollo de composiciones farmacéuticas que comprendan un segundo agente activo, es decir que correspondan a las características esenciales descritas en dicha reivindicación.

Descripción (Art 28 D 486)

La descripción no soporta adecuadamente el alcance dado por el capítulo reivindicatorio, dado que los ejemplos de compuestos mostrados resultan ser insuficientes para dar soporte a la totalidad de los compuestos al alcance de la reivindicación 1. La descripción no proporciona ejemplos de compuestos en los que R^5 es diferente a hidrógeno, por lo tanto no existe evidencia de que compartan la actividad farmacológica de aquellos que han sido ensayados.


La descripción no presenta una divulgación suficiente para dar sustento al capítulo reivindicatorio, ya que no existen ejemplos de composiciones farmacéuticas que comprenden los compuestos reclamados.

5. Determinación del Estado de la Técnica


El estado de la técnica se determinó con base en la fecha de presentación de la solicitud de prioridad: 01 de septiembre de 2011 y se encontraron los siguientes documentos que anticipan el objeto de esta solicitud:

Ítem	Documento	Título	Fecha de Publicación
D1	WO2008144253	Protein kinase inhibitors and methods for using thereof	27/Noviembre/2008
D2	US 20100093718	Compounds	15/Abril/2010

El documento D1¹ divulga compuestos y composiciones farmacéuticas de los mismos, útiles como inhibidores de proteínas quinasas. Los compuestos divulgados en este documento corresponden a la formula (I). (Párr. [0004]- [0006]).



El documento D2² divulga derivados bicíclicos heterocíclicos de formula (I) y composiciones que los comprenden. Los compuestos divulgados en este documento presentan actividad como inhibidores de proteínas quinasas entre las que se encuentra PDGFR (Resumen).










6. Examen de Patentabilidad (Art 14 D486)

Nivel inventivo (Art 18 D486)

La reivindicación 1 consiste en: “Un compuesto representado por la fórmula (I) o una sal farmacéuticamente aceptable del mismo, en donde, (...)” (Radicado N°. 14-043406-00002-00000).

Comparación de las características técnicas esenciales, con las del estado de la técnica:

1http://worldwide.espacenet.com/publicationDetails/originalDocument?CC=WO&NR=2008144253A1&KC=A1&FT=D&ND=&date=20081127&DB=&&locale=en_EP
2http://worldwide.espacenet.com/publicationDetails/originalDocument?CC=US&NR=2010093718A1&KC=A1&FT=D&ND=&date=20100415&DB=&&locale=en_EP

Características esenciales	D1	D2
Un compuesto de fórmula I  (I) O una sal farmacéuticamente aceptable del mismo, en donde: X es -N- o -CH- R⁴ es H A es:  O	Un compuesto de fórmula (I):  (I) O una sal farmacéuticamente aceptable del mismo, en donde L¹ y L² son independientemente NRCO o CONR (Reivindicación 1)	Un compuesto de formula (I)  Dónde X₁, X₂, X₃ y X₄ se seleccionan de N o C, siempre que al menos uno de X₁-X₃ es N. (Pág. 152, Reivindicaciones)
R¹ es alquiloC₁-C₄; alcoxiloC₁-C₄ opcionalmente sustituido por uno o más átomos de halógeno; CN: o halógeno	R² es halo, o un grupo alquiloC₁-C₆ opcionalmente halogenado	No se menciona
R^{1a} es H; halógeno; alquiloC₁-C₄ o haloalquiloC₁-C₄		
R² es H; alquiloC₁-C₈; haloalquiloC₁-C₈; alquiniloC₂-C₈; cicloalquiloC₃-C₁₀; -(alquiloC₁-C₄) - cicloalquiloC₃-C₈; alcoxiloC₁-C₈; -(alquiloC₀-C₄)-NR⁹R¹¹; -(alquiloC₀-C₄)-CO₂R¹⁵; -(alquiloC₀-C₄)-C(O)NR⁹R¹¹; -(alquiloC₀-C₄)-arilo C₆-C₁₄; -(alquiloC₀-C₄)-heterociclo de 3 a 14 miembros	R⁴ es H, halo, NR⁶R⁷, NR⁵(CR²)_pNR⁶R⁷, NR⁵CONR⁶R⁷ o NRCO₂R⁶	R² y R⁶ independientemente representan halógeno, H, alquiloC₁-C₆, alcoxiloC₁-C₆, -alqueniloC₂-C₆, alquiniloC₂-C₆, -CN, cicloalquiloC₃-C₈, cicloalquenilo C₃-C₈, -NHSO₂R^w; -CH=N-OR^w.
R³ es H; alquiloC₁-C₈; haloalquiloC₁-C₈; alquiniloC₂-C₈; cicloalquiloC₃-C₁₀; -(alquiloC₁-C₄) - cicloalquiloC₃-C₈; alcoxiloC₁-C₈; OH; CN; halógeno; -(alquiloC₀-C₄)-NR⁹R¹¹; -(alquiloC₀-C₄)-CO₂R¹⁵; -(alquiloC₀-C₄)-C(O)NR⁹R¹¹; -(alquiloC₀-C₄)-arilo C₆-C₁₄; -(alquiloC₀-C₄)-heterociclo de 3 a 14 miembros		
R⁵ es H, alquiloC₁-C₄ o haloalquiloC₁-C₄	Y-(R³)_n Donde Y es un arilo o heteroarilo de 5 a 7 miembros que contiene N, O o S. R³ es halo, alquilo C1-6 opcionalmente halogenado, (CR₂)_qR⁸ o O(CR₂)_qR⁹	No se menciona
R⁶ se selecciona de alquiloC₁-C₈, haloalquiloC₁-C₈;-(alquiloC₀-C₄) - cicloalquiloC₃-C₈; alcoxiloC₁-C₈; -NR¹⁹R²¹; -(alquiloC₀-C₄)-arilo C₆-C₁₄; y -(alquiloC₀-C₄)-heterociclo de 3 a 14 miembros		
Comparación de ejemplos específicos		
 (Pág. 78, Ej. 1.5)	 (Pág. 59, compuesto 69)	 (Pág. 65, Ej. 9)

El documento D1 se considera el estado de la técnica cercano a la solicitud definida en la reivindicación 1 porque divulga compuestos de formula (I) y composiciones

farmacéuticas que los comprenden (Párr. [0004]- [0006]) útiles como inhibidores de kinasas, entre las que se encuentra PDGFR (Párr. [0016]), el documento también menciona la inclusión de un segundo agente terapéutico en las composiciones útiles para el tratamiento de una condición o enfermedad mediada por quinasas.

La diferencia entre la solicitud, definida en la reivindicación 1 y los compuestos divulgados en D1 consiste en la estructura del anillo bicíclico, puesto que en la solicitud este corresponde a imidazol[1,2-a]piridina o pirazo[1,5-a]piridina, mientras que en el documento D1 no se mencionan estos anillos.

No se evidencia un efecto técnico asociado al cambio de estructura del anillo bicíclico de los compuestos reclamados, puesto que los valores de IC₅₀ contra PDGFR encontrado para los compuestos de la solicitud se encuentran en rangos entre 0.002-0.182µM (Págs. 59-60), mientras que por su parte los compuestos descritos en el documento D1 presentan valores en un rango de 1nM a 10 µM (Pág. 71, Párr. [0155]).

Por lo tanto, el problema técnico objetivo que pretende resolver esta invención se puede considerar como la necesidad de proporcionar compuestos alternativos a los divulgados en D1 que posean actividad inhibidora sobre PDGFR.

Sin embargo, inhibidores de quinasas tales como PDGFR que comprenden anillos bicíclicos de imidazol[1,2-a]piridina o pirazo[1,5-a]piridina, se encuentra divulgada en el documento D2, que se refiere a compuestos bicíclicos y composiciones que los comprenden, que actúan como inhibidores de quinasas entre las que se menciona PDGFR (Resumen). El documento menciona anillos como pirazo[1,5-a]piridina (Pág. 4, Párr. [0131]) y imidazol[1,2-a]piridina (Pág. 17, Párr. [0317]).

En consecuencia, la persona del oficio normalmente versada en la materia, incluiría anillos bicíclicos tales como imidazol[1,2-a]piridina o pirazo[1,5-a]piridina de acuerdo a lo divulgado en D2 en compuestos inhibidores de PDGFR tales como los mostrados en el documento D1, para llegar así al objeto de la reivindicación 1 de la solicitud. Por lo cual la materia reclamada se considera obvia.

Puesto que las reivindicaciones 2-18 no mencionan características inventivas adicionales tampoco se pueden considerar inventivas.

Conclusión:

Las reivindicaciones 1-18 cumplen el requisito de novedad (Art. 16), pero no cumplen con el requisito de nivel inventivo (Art. 18).

7. Conclusión

Los requisitos de Patentabilidad de la presente solicitud están afectados así:

Ítem	Documento	Reivindicaciones afectadas	Requisito que afecta
D1	WO2008144253	1-18	Nivel inventivo
D2	US 20100093718	1-18	Nivel Inventivo

En cumplimiento del artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se le indica que debe dar respuesta dentro del término de sesenta (60) días contados a partir del día siguiente de la fecha de notificación de la presente comunicación. En caso de no dar respuesta al presente requerimiento, o si a pesar de la respuesta subsistieran los impedimentos para la concesión, se denegará la patente.

Se invita al solicitante se sirva indicar, si así lo considera, su renuncia al término faltante de sesenta (60) días para dar respuesta a este requerimiento y presentarla por escrito.

Finalmente, se le recuerda al solicitante que si como respuesta a este requerimiento llegara a modificar el capítulo reivindicatorio y éste contenga más de diez (10) reivindicaciones, no pagará la tasa de modificación voluntaria pero sí la correspondiente al pago por reivindicación adicional.

Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal e), del capítulo quinto del título primero de la Circular Única No. 10 de 2001.



JOSÉ LUIS SALAZAR LÓPEZ
Director de Nuevas Creaciones (c)

El anterior requerimiento fue notificado por fijación en lista, de fecha 2015-07-21

Elaboró: Ruth Andrea Rodriguez
Revisó: Jeny Paola Villate Becerra

INFORME DE BÚSQUEDA DE PATENTES PARA EL RADICADO 14-043406-00002-0000						
CRITERIOS PARA LA BÚSQUEDA						
Palabras clave utilizadas		PDGFR inhibitors				
CLASIFICACIONES INTERNACIONALES UTILIZADAS PARA LA BÚSQUEDA		C07D 471/04				
BASES DE DATOS CONSULTADAS.						
Google patents		Espacenet		Patbase		
INFORMES DE EXÁMENES REALIZADOS EN OTRAS OFICINAS						
Oficina	Fecha del examen o de reporte de búsqueda de documentos	Anterioridades encontradas para el examen o reportados en el examen de búsqueda(relacionarlos todos)	Reiv. afectadas	RELEVANCIA (requisito que afecta)	FUERON TENIDOS EN CUENTA PARA EL EXAMEN EN LA OFICINA COLOMBIANA	
					SI	NO
EUROPEA	18/03/14	WO2008144253	1-18	NI	X	
		WO2007022380				X
		WO2006108640				X
		WO2011090738				X
USPTO	07/19/2013	CAS STN Abstract, 2008, RN 1007820-93-0				X
		CAS STN Abstract, 2008, RN 1007820-93-0				X
DOCUMENTOS ADICIONALES ENCONTRADOS POR EL EXAMINADOR DE ACUERDO A LOS CRITERIOS DE BÚSQUEDA.						
US 20100093718						
WO0114375						
WO0216359						
BÚSQUEDA DE SECUENCIAS						
Número de depósito / patente y N° de secuencia % de identidad						
SEQ ID NO (de la solicitud)	NCBI	The Lens	EMBL-EBI	DDJB	Genome Quest	
N/A						

Ruth Rodriguez

Search history

- Search 1: PN=(WO2013032693) (Results 1)
- Search 2: [SP]: brief description of the figures [0098] fig. 1 shows the comparison of the growth rate of burkholderia a396 to burkholderia multivorans atcc 17616.[0099] fig. 2 show general scheme used to obtain fractions and compounds from an mbi-206 culture.[0101] fig. 4 shows insecticidal (sucking) activities of tested compounds against milkwe compounds against lygus hesperus. (Results 11)
- Search 3: [SP]: technical field [0001] provided herein is a species of burkholderia sp with no known pathogenicity to vertebrates, such as mammals, fish and birds but pesticidal act formulations and compositions comprising said species. also provided are natural products, formulations and compositions derived from a culture of said species and met products. background [0002] natural products are substances produced by microbes, plants, and other organisms. microbial natural products offer an abundant source of purposes. one such compound is fr901228 isolated from chromobacterium and has been found to be useful as an antibacterial agent and antitumor agent (see, for exam microbes have also been successfully found to have uses for weed and pest control in agricultural applications (see, for example, nakajima et al. 1991 duke et al., 2000 I also successfully developed into agricultural insecticides (see, for example, salama et al. 1981 thompson et al., 2000 krieg et al. 1983). sometimes, such natural product 4,808,207). acaricides [0004] acaricides are compounds that kill mites (miticides) and ticks (ixodocides). this class of pesticides is large and includes antibiotics, carbamat besides chemical pesticides, diatomaceous earth and fatty acids can be used to control mites. they typically work through disruption of the cuticle, which dries out the mite great variety of known acaricide compounds, mites remain a serious problem in agriculture because of the damage they cause to the crops. they can produce several gen products used. hence, new pesticide products with new target sites and novel modes of action are critically needed. algicides [0005] algae come in many forms. these incl sheets and macroalgae that look like plants (2) algae that live inside the outer integument ("skin") or calcium shell of some corals, anemones, and other sessile inverteb aquarium panels which also are not algae, but diatom or radiolarian colonies (microscopic, one-celled, animals with hard shells) with algae incorporated in their matrix.[00 time can be considerable, which is highly undesirable. as a result, algae can cause clogging of filters in water filtration devices, undesirable smells and appearance in poo to being present in water, algae may also be present in industrial materials which are exposed to the weather and light, such as coatings containing organic film formers c algae control can be divided into four categories: biological, mechanical, physical and chemical controls. a few pertinent facts hold for all methods of algae control. for ex are the most widely used scavengers, and generally the best choice. some parts of the country seem to favor the use of sea urchins, dwarf angels. the former die too easi invertebrates. other methods include functional protein skimmers, with or without ozone and ultraviolet sterilizers. these physical filters remove and destroy algae on expo they treat the symptoms only without dealing with the cause(s) of the algae problem. the factors can contribute to water system being out of balance. copper, usually in t parasite preventative. this metal is useful in treatment and quarantine tanks, dips and fish-only arrangements but it is persistent and toxic to all life, especially non-fish. more than 40 species that inhabit diverse ecological niches (compant et al., 2008). the bacterial species in the genus burkholderia are ubiquitous organisms in soil and rt have been known as plant pathogens, b. cepacia being the first one discovered and identified as the pathogen causing disease in onions (burkholder, 1950). several bur cabballero-mellado et al., 2004, chen et al., 2007). some burkholderia species have also been found to be opportunistic human pathogens (see, for example, cheng and to have potential as biocontrol products (see for example, burkhead et al., 1994 knudsen et al., 1987 jansiewicz et al., 1988 gouge et al., us patent application no. 2003 al., wo2001055398 zhang et al., u.s. pat. no. 7,141,407). some species of in this genus have been effective in bioremediation to decontaminate polluted soil or groundw secrete a variety of extracellular enzymes with proteolytic, lipolytic and hemolytic activities, as well as toxins, antibiotics, and siderophores (see, for example, ludovic et al burkholderia a396 and compounds derived from said species with no known pathogenicity to vertebrates with activity against plants, insects, fungi and nematodes. oxazol algae, sponges, and microorganisms. a large number of natural products contain one or more of the five-membered oxazole, thiazole and indole nucleus/moieties. these for example, bleomycin a (tomohisa et al.), a widely prescribed anticancer drug, effects the oxidative degradation of dna and uses a bithiazole moiety to bind its target d peptide antibiotic, interdicts bacterial cell wall new biosynthesis by complexation with c55-bactoprenolpyrophosphate. thiagazole (kunze et al., 1993) contains a tandem a other oxazole/thiazole-containing natural products such as thiostrepton (anderson et al., 1970) and ge2270a (selva et al., 1997) inhibit translation steps in bacterial prot microorganisms. one-third of these compounds are peptides with masses beyond 500 da where the indole is tryptophan derived. the structural variety of the remaining tw antimicrobial, antiviral, cytotoxic, insecticidal, antithrombotic, or enzyme inhibitory activity. brief summary [0011] provided herein is an isolated strain of a non-burkholderi following characteristics: (a) has a 16rrna gene sequence comprising a forward sequences having at least 99.5 percent identity to the sequences set forth in seq id no:8, 1 (b) has pesticidal, in particular, herbicidal, algicidal, acaricidal, insecticidal, fungicidal and nematocidal activity(c) produces at least one of the compounds selected from the about 525-555 as determined by liquid chromatography/mass spectroscopy (lc/ms) (b) 1h nmr values of 6.22, 5.81, 5.69, 5.66, 5.65, 4.64, 4.31, 3.93, 3.22, 3.21, 3.15, 172.93, 169.57, 169.23, 167.59, 130.74, 130.12, 129.93, 128.32, 73.49, 62.95, 59.42, 57.73, 38.39, 38.00, 35.49, 30.90, 30.36, 29.26, 18.59, 18.38, 18.09, 17.93, 12. on a reversed phase c-18 hplc column using a water:acetonitrile (ch3cn) gradient(ii) a compound having an oxazolyl-indole structure comprising at least one indole moiety ester group at least 17 carbons and at least 3 oxygen and 2 nitrogens(iii) a compound having an oxazolyl-benzyl structure comprising at least one benzyl moiety, at least 15 carbons and at least 2 oxygen and 2 nitrogens(iv) a compound having at least one ester, at least one amide, at least three methylene groups, at least one tetrahydro three hydroxyl groups, at least twenty five carbons and at least eight oxygen and one nitrogen and(d) is non-pathogenic (non-infectious) to vertebrate animals, such as imipenem, and a combination of sulphemethoxazole and trimethoprim and(f) contains the fatty acids 16:0, cyclo 17:0, 16:0 3-oh, 14:0, cyclo 19:0 78c, 18:0.[0022] in a (nrri accession no. b-50319).[0023] in a particular embodiment, the first substance is a supernatant. in yet even a more particular embodiment, the supernatant is a cell-comprising[0025] (a) a first substance selected from the group consisting of a pure culture, cell fraction or supernatant derived from the burkholderia strain set forth abov carrier, diluent, surfactant, adjuvant, or chemical or biological pesticide (e.g., algicide, acaricide, herbicide, fungicide, insecticide, nematocide and particularly, algicide or a or composition.[0027] in a particular embodiment, the composition or formulation may comprise:[0028] (a) a first substance selected from the group consisting of a pure thereof for use optionally as a pesticide[0029] (b) fatty acids 16:0, cyclo 17:0, 16:0 3-oh, 14:0, cyclo 19:0 78c, 18:0, c1-c7 paraben, c2-c17 alcohol and detergent and[00 insecticide, algicide, acaricide (e.g., miticide), herbicide, nematocide).[0031] in a particular embodiment, the c1-c7 aliphatic paraben is present in the amount of about 0. detergent is present in the amount of about 0.001-10 percent.[0032] also provided are the pesticidal substances derived from the formulation set forth above, combinati for producing these pesticidal substances. in a particular embodiment, these pesticidal substances comprise at least one of the following characteristics:[0033] (a) has pe [0034] (b) has a molecular weight of about 210-240 and more particularly, 222 as determined by liquid chromatography/mass spectroscopy (lc/ms)[0035] (e) has 1h nmr delta 166.84, 162.12, 131.34 (2c), 121.04, 114.83 (2c), 64.32, 31.25, 28.43, 25.45, 22.18. 12.93[0037] (e) has an high pressure liquid chromatography (hplc) retention 17.45 min on a reversed phase c-18 hplc (phenomenex, luna 5 micro c18(2) 100 a, 100x4.60 mm) column using a water:acetonitrile (ch3cn) with a gradient solvent syst aqueous ch3cn, 27-30 min 90 percent aqueous ch3cn) at 0.5 ml/min flow rate and uv detection of 210 nm[0038] (f) the 13c nmr spectrum exhibited 13 discrete carbon si quaternary carbons[0039] (g) has a molecular formula of c13h18o3 which was determined by interpretation of the esims and nmr data analysis[0040] (h) has uv absorpti are compounds having the structure shown below:[ftimg=60402135][0042] wherein[0043] x, is independently -o, -nr, or -s, wherein r is h or c1-c10 alkyl r1, r2, r3, r4, r5, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alk oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl.[0044] in particular, the substance may have the structure[ftimg=60402136][0045] wherein[0046] x, is independen alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heteroc hydroxy, halogen, amino, amido, carboxyl, -c(o)h, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl.[0047] in a more particular embodiment, the compound is the compound is hexyl parben with the following structure:[ftimg=60402138][0049] in a more particular embodiment, the compound is octyl parben with the following stru above may obtained by[0051] (a) providing the formulation set forth above[0052] (b) incubating or storing the formulation provided for a sufficient time (e.g., between a c) to produce the pesticidal substance(s) and[0053] (c) isolating the pesticidal substance.[0054] in a related aspect, disclosed is a method for modulating proliferation an and particularly, algae, arachnid (e.g., mites, ticks) comprising applying to a location where modulation of proliferation and/or growth of a pest is desired an amount of:[0 pure cell culture, cell fraction, supernatant derived from the burkholderia strain set forth above or extract thereof and (b) optionally another substance, wherein said subst substances derived from said formulation set forth above, effective to modulate proliferation and/or growth of a pest at said location.[0057] disclosed herein are isolated organisms capable of producing these compounds that can be used to control various pests, particularly plant phytopathogenic pests, examples of which include but are n herbicides, acaricides or algicides.[0058] in particular, the isolated pesticidal compounds may include but are not limited to:[0059] (a) a compound having the following pr spectroscopy (lc/ms) (ii) 41 nmr values of 6.22, 5.81, 5.69, 5.66, 5.65, 4.64, 4.31, 3.93, 3.22, 3.21, 3.15, 3.10, 2.69, 2.62, 2.26, 2.23. 1.74, 1.15, 1.12, 1.05, 1.02 (iii) 73.49, 62.95, 59.42, 57.73, 38.39, 38.00, 35.49, 30.90, 30.36, 29.26, 18.59, 18.38, 18.09, 17.93, 12.51 and (iv) an high pressure liquid chromatography (hplc) retentio (ch3cn) gradient[0060] (b) a compound having an oxazolyl-indole structure comprising at least one indole moiety, at least one oxazole moiety, at least one substituted a nitrogens[0061] (c) a compound having an oxazolyl-benzyl structure comprising at least one benzyl moiety, at least one oxazole moiety, at least one substituted alkyl gr [0062] (d) a compound having at least one ester, at least one amide, at least three methylene groups, at least one tetrahydropyranose moiety and at least three olefinic carbons and at least eight oxygen and one nitrogen and[0063] (e) a compound having at least one ester, at least one amide, an epoxide methylene group, at least one least three hydroxyl groups, at least 25 carbons, at least 8 oxygens and at least 1 nitrogen.[0064] in a particular embodiment, the isolated compounds may include but a one indole moiety, at least one oxazole moiety, at least one substituted alkyl group, at least one carboxylic ester group, at least 17 carbons, at least 3 oxygens and at le 435 (ii) 1h nmr delta values at 8.44, 8.74, 8.19, 7.47, 7.31, 3.98, 2.82, 2.33, 1.08 (iii) 13c nmr values of delta 163.7, 161.2, 154.8, 136.1, 129.4, 125.4, 123.5, 123.3, 1 chromatography (hplc) retention time of about 10-20 minutes on a reversed phase c-18 hplc column using a water:acetonitrile (ch3cn) with a gradient solvent system and compound having an oxazolyl-benzyl structure comprising at least one benzyl moiety, at least one oxazole moiety, at least one substituted alkyl group and at least one the following characteristics: (i) a molecular weight of about 240-290 as determined by liquid chromatography/mass spectroscopy (lc/ms) (ii) 1h nmr delta values at about 132.6, 129.5, 129.5, 127.3, 121.8, 115.2, 115.2, 41.2, 35.3, 26.7, 21.5, 21.5 (iv) a high pressure liquid chromatography (hplc) retention time of about 6-15 minutes, on absorption bands at about 230, 285, 323 nm[0067] (c) a non-epoxide compound comprising at least one ester, at least one amide, at least three methylene groups, at l groups, at least three hydroxyl groups, at least twenty five carbons, at least eight oxygens and one nitrogen and at least one of the following characteristics: (i) a molecu 1h nmr values of delta 6.40, 6.39, 6.00, 5.97, 5.67, 5.54, 4.33, 3.77, 3.73, 3.70, 3.59, 3.47, 3.41, 2.44, 2.35, 2.26, 1.97, 1.81, 1.76, 1.42, 1.37, 1.16, 1.12, 1.04 (iii) 1 82.20, 78.22, 76.69, 71.23, 70.79, 70.48, 69.84, 60.98, 48.84, 36.89, 33.09, 30.63, 28.55, 25.88, 20.37, 18.11, 14.90, 12.81, 9.41 (iv) a high pressure liquid chromatog water:acetonitrile (ch3cn) with a gradient solvent system and uv detection of 210 nm (v) a molecular formula of c28h45no10 which was determined by interpretation of the compound comprising (i) at least one ester, at least one amide, an epoxide methylene group, at least one tetrahydropyranose moiety and at least three olefinic double b oxygens and at least 1 nitrogen, (ii) 13c nmr values of delta174.03, 166.12, 143.63, 137.50, 134.39, 128.70, 126.68, 124.41, 98.09, 80.75, 76.84, 75.23, 69.87, 69.08, (iii) a molecular formula of c28h43no9 and at least one of: (a) 17h nm 6 values at about 6.41, 6.40, 6.01, 5.97, 5.67, 5.55, 4.33, 3.77, 3.75, 3.72, 3.64, 3.59, 3.54, 3.5 chromatography (hplc) retention time of about 6-15 minutes, on a reversed phase c-18 hplc column using a water:acetonitrile (ch3cn) gradient (c) uv absorption band bet embodiment, provided are compounds including but not limited to:[0070] (a) a compound having the structure ##str001##[ftimg=60402140] or a pesticidally acceptable 1 or 2 x is o, nh or nr r1, r2 and r3 are the same or different and independently an amino acid side-chain moiety or an amino acid side-chain derivative and r is a lower ch [ftimg=60402141] wherein x, y and z are each independently -o, -nr1, or -s, wherein r1 is -h or c1-c10 alkyl r1, r2 and m are each independently-h, alkyl, substituted alk substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen "m" may be located anywhere on the oxazole ring[0072] (c) a compound having the structure ##str002a##.[ftimg=60402142] wherein r1 is -h or c1-c10 alkyl r2 is an alk y are each independently -oh, -nr1, or -s, wherein r1 is -h or c1-c10 alkyl r1, r2 and m, a substituent on the oxazole ring, are each independently -h, alkyl, substituted al substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen [0074] (e) a compound having the structure ##str003a##[ftimg=60402144] wherein r1 is -h or c1-c10 alkyl[0075] (f) a compound having the structure ##str004a##[ftim

r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, and r13 are each independently h, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -c(o)h, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfonyl, wherein r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, and r13 are each independently h, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -c(o)h, acyl, oxyacyl, carbamate, [ftimg=60402147] wherein r1, r2, r3, r4, r5, r6, r7, r8, r11, are each independently h, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -c(o)h, acyl, oxyacyl, carbamate, [ftimg=60402148] wherein x and y are each independently -oh, -nr1, or -s, wherein r1, r2 are each independently -h, alkyl (e.g., c1-c10 alkyl), substituted alkyl, alkenyl, heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, a compound having the structure ##str006a## [ftimg=60402149] wherein x, y and z are each independently -o-, -nr, or -s, wherein r is h or c1-c10 alkyl r1, r2, r3, r4, r5, r6, alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy (o)h, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfonyl. [0080] in a most particular embodiment, the compounds may include but are not limited to [0081] (i) the fr901228 [ftimg=60402150] [ftimg=60402151] [ftimg=60402152] [ftimg=60402153] [0086] (xi) fr901465 [0087] (xii) f8h17, an active compound from fraction f8, which has positive esi mode and further confirmed by the negative esims with base peak at 1079.92. this compound showed uv absorption at 234 nm. [0088] in a related aspect, di nematode, insect, fungus) comprising applying to a location where modulation of proliferation and/or growth of a pest (e.g., algae, arachnid, nematode, insect, fungus) is substance, wherein said substance is an algicide or (ii) the composition or combination set forth above in an amount effective to modulate proliferation and/or growth of p proliferation and/or growth of algae and/or modulation of infestation of an arachnid and/or modulation of emergence and/or growth of said weed is desired an amount of [0092] (a) the form combination set forth above [0094] (c) templamide a [0095] (d) templamide b [0096] (e) fr901465 [0097] (f) fr901228 effective to modulate said proliferation and/or growth dicotyledonous weeds at said location. the nematode and/or insect infestation is modulated with templamide a, templamide b, fr901465 and/or fr901228. in a more part sp. and/or free living nematodes and/or parasitic nematodes (e.g., m. incognita) are modulated. brief description of the figures [0098] fig. 1 shows the comparison of the general scheme used to obtain fractions from formulated mbi-206. [0100] fig. 3 shows the general scheme used to obtain fractions and compounds from an mbi-206 cult (oncopeltus fasciatus). [0102] fig. 5 shows insecticidal (feeding) activities of pure compounds against lygus hesperus. detailed description of embodiments [0103] while th forms, exemplary embodiments will herein be described in detail. it should be understood, however, that there is no intent to limit the invention to the particular forms dis falling within the spirit and scope of the invention as defined by the appended [0104] where a range of values is provided, it is understood that each intervening value, to upper and lower limit of that range and any other stated or intervening value in that stated range, is included therein. smaller ranges are also included. the upper and low in the stated range. [0105] unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary sk equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. [0106] it "the" include plural references unless the context clearly dictates otherwise. [0107] as defined herein, "derived from" means directly isolated or obtained from a particular obtained from a particular source. [0108] as defined herein, an "isolated compound" is essentially free of other compounds or substances, e.g., at least about 20 percent preferably about 80 percent pure, most preferably about 90 percent pure, and even most preferably about 95 percent pure, as determined by analytical methods, includin term "alkyl" refers to a monovalent straight or branched chain hydrocarbon group having from one to about 12 carbon atoms, including methyl, ethyl, n-propyl, isopropyl, to alkyl groups further bearing one or more substituents selected from hydroxy, alkoxy, mercapto, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, cyano, nitro, amino, amido, -c(o)h, acyl, oxyacyl, carboxyl, sulfonyl, sulfonamide, sulfonyl, and the like. [0111] as used herein, "alkenyl" refers to straight or branched cha about 2 up to 12 carbon atoms, and "substituted alkenyl" refers to alkenyl groups further bearing one or more substituents as set forth above. [0112] as used herein, "al triple bond, and having in the range of about 2 up to 12 carbon atoms, and "substituted alkynyl" refers to alkynyl groups further bearing one or more substituents as set 14 carbon atoms and "substituted aryl" refers to aryl groups further bearing one or more substituents as set forth above. [0114] as used herein, "heteroaryl" refers to aro structure, and having in the range of 3 up to 14 carbon atoms and "substituted heteroaryl" refers to heteroaryl groups further bearing one or more substituents as set forth above, and "substituted alkoxy" refers to alkoxy groups further bearing one or more substituents as set forth above. [0116] as used herein, "thioalkyl" refers to the moie further bearing one or more substituents as set forth above. [0117] as used herein, "cycloalkyl" refers to ring-containing alkyl groups containing in the range of about 3 u more substituents as set forth above. [0118] as used herein, "heterocyclic", refers to cyclic (i.e., ring-containing) groups containing one or more heteroatoms (e.g., n, o, s "substituted heterocyclic" refers to heterocyclic groups further bearing one or more substituent's as set forth above. [0119] as used herein "algae" refers to any of various the giant leap. the term may further refer to photosynthetic protists responsible for much of the photosynthesis on earth. as a group, the algae are polyphyletic. according chloraraachniophytes, cryptomonads, euglenids, glaucophytes, haptophytes, red algae such as rhodophyta, stramenopiles, and viridiplantae. the term refers to the gree cyanobacteria in the prokaryotes. the term also refers to green algae, blue algae, and red algae. [0120] as used herein "algicide" refers to one or more agents, compoun "algicidal" as used herein means the killing of algae. [0122] as used herein "algaistatic" as used herein means inhibiting the growth of algae, which can be reversible under burkholderia cepacia complex, non-burkholderia plantarii, non-burkholderia gladioli, burkholderia sp and non-pathogenic to vertebrates, such as birds, mammals and fish. lorch et al., 1995. the burkholderia strain may be isolated from many different types of soil or growth medium. the sample is then plated on potato dextrose agar (pda). pink and pinkish-brown in color and mucoid or slimy over time. [0124] colonies are isolated from the potato dextrose agar plates and screened for those that have biologi invention set forth in the examples below. in particular, the burkholderia strain has a 16s rna gene comprising a forward sequence that is at least about 99.5 percent, mo set forth in seq id no: 8, 11 and 12 and a forward sequence that is at least about 99.5 percent, more preferably about 99.9 percent and most preferably about 100 perce analysis. furthermore, as set forth below, this burkholderia strain may, as set forth below, have pesticidal activity, particularly, virucidal, herbicidal, germicidal, fungicidal, n insecticidal, fungicidal and nematocidal activity. it is not pathogenic to vertebrate animals, such as mammals, birds, and fish. [0125] additionally, the burkholderia strain pr strain is susceptible to kanamycin, chloramphenicol, ciprofloxacin, piperacillin, imipenem, and a combination of sulphamethoxazole and trimethoprim and contains the fat obtained by culturing a microorganism having the identifying characteristics of burkholderia a396 (nrl accession no. b-50319) on potato dextrose agar (pda) or in a ferme and undefined nitrogen sources such as peptone, tryptone, soytone, and n2 amine. algalicidal and acaricidal compounds the algalicidal and acaricidal compounds disclosed h a396 (b) is, in particular, toxic to most common agricultural insect pests (c) has a molecular weight of about 525-555 and more particularly, 540 as determined by liquid c 4.64, 4.31, 3.93, 3.22, 3.21, 3.15, 3.10, 2.69, 2.62, 2.26, 2.23, 1.74, 1.15, 1.12, 1.05, 1.02 (d) has 13c nmr values of 172.99, 172.93, 169.57, 169.23, 167.59, 169.23, 130.74, 18.59, 18.38, 18.09, 17.93, 12.51 (e) has an high pressure liquid chromatography (hplc) retention time of about 10-15 minutes, more specifically about 12 minutes and c18 (2) 100 a, 100x4.60 mm) column using a water:acetonitrile (ch3cn) with a gradient solvent system (0-20 min 90-0 percent aqueous ch3cn, 20-24 min 100 percent ch flow rate and uv detection of 210 nm (f) has a molecular formula, c24h36n4o6s2, which is determined by interpretation of 1h, 13c nmr and lc/ms data (g) a 13c nmr spect carbons and (g) 1h nmr spectrum displaying characteristics of a typical desipsidepeptide, illustrating three-amino protons [4.63, 4.31, 3.93], and one ester carbinol proton [5. or a pesticidally acceptable salt or stereoisomers thereof, wherein m is 1, 2, 3 or 4 n is 0, 1, 2, or 3 p and q are independently 1 or 2 x is o, nh or nr r1, r2 and r3 are the derivative and r is a lower chain alkyl, aryl or arylalkyl moiety. [0128] in an even more particular embodiment, the compound has the structure of fr901228: [ftimg=604021 x, y and z are each independently -o-, -nr1, or -s, wherein r1 is -h or c1-c10 alkyl r1, r2 and m are each independently -h, alkyl, substituted alkyl, alkenyl, substituted alken heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carbox particular embodiment, family ##str002## compounds may be the compounds set forth in (vi)-(xix). [ftimg=60402157] [ftimg=60402158] [ftimg=60402159] [0131] these synthesis. natural sources of family ##str002## compounds include, but are not limited to, microorganisms, alga, and sponges. in a more particular embodiment, microor alternatively, family ##str002## compounds may be derived from species such as streptovorticillum waksmanii (compound vi) (umehara, et al., 1984), streptomyces p02 (koyama y., et al., 1981), streptomyces sp (compounds xi, xii) (watabe et al., 1988), pseudomonas syringae (compounds xiii, xiv) (pettit et al., 2002). family ##str002## (n'diaye, et al., 1996), red alga martensia fragilis (compound xvi) (takahashi s. et al., 1998), diazonia chinensis (compounds xvii and xviii) (lindquist n. et al., 1991), rho ##str003## : [ftimg=60402160] wherein: x and y are each independently -oh, -nr1, or -s, wherein r1 is -h or c1-c10 alkyl r1, r2 and m, a substituent on the oxazole ring, alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalk carbamate, sulfonyl, sulfonamide, or sulfonyl. [0133] further provided is ##str005## : [ftimg=60402161] wherein x and y are each independently -oh, -nr1, or -s, wherein r1 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy (o)h, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfonyl. [0134] in a particular embodiment, family ##str005## compounds such as compounds from xx-xxiii set [ftimg=60402162] [0135] natural sources of family ##str005## compounds include, but are not limited to plants, corals, microorganisms, and sponges. the microorganism streptomyces albus (compound xxi) (werner et al., 1980). family str004 compounds may also be derived from algae including but not limited to haraldiphyllo sp (comp one embodiment, the compound may be derived from or is obtainable from a microorganism, and in particular from burkholderia species and characterized as having a st least one tetrahydropyranose moiety and at least three olefinic double bonds, at least six methyl groups, at least three hydroxyl groups, at least twenty five carbons and following characteristics: [0137] (a) pesticidal properties and in particular, nematocidal, fungicidal, insecticidal, acaricidal, algalicidal and herbicidal properties [0138] (b) a mol chromatography/mass spectroscopy (lc/ms) [0139] (c) 1h nmr values of delta 6.40, 6.39, 6.00, 5.97, 5.67, 5.54, 4.33, 3.77, 3.73, 3.70, 3.59, 3.47, 3.41, 2.44, 2.35, 2.2 145.06, 138.76, 135.71, 129.99, 126.20, 123.35, 99.75, 82.20, 78.22, 76.69, 71.23, 70.79, 70.48, 69.84, 60.98, 48.84, 36.89, 33.09, 30.63, 28.55, 25.88, 20.37, 18.11 about 7-12 minutes, more specifically about 10 minutes and even more specifically about 10.98 min on a reversed phase c-18 hplc (phenomenex, luna 5 micro c18(2) 10 min 90-0 percent aqueous ch3cn, 20-24 min 100 percent ch3cn, 24-27 min 0-90 percent aqueous ch3cn, 27-30 min 90 percent aqueous ch3cn) at 0.5 ml/min flow rate an which may be attributed to six methyls, four methylene carbons, and thirteen methines including five sp2, four quaternary carbons [0143] (g) a molecular formula of c28h absorption bands between about 210-450 nm and most particularly at about 234 nm. [0145] also provided are compounds having the structure ##str004a## : [ftimg=6040 r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, and r13 are each independently h, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -c(o)h, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, ##str004b## : [ftimg=60402164] wherein r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, and r13 are as previously defined for ##str004a## . [0147] in a more particular emb embodiment, provided is a compound having formula ##str004c## : [ftimg=60402166] wherein r1, r2, r3, r4, r5, r6, r7, r8, and r11 are as previously defined for ##str004 burkholderia species and characterized as having a structure comprising at least one ester, at least one amide, an epoxide methylene group, at least one tetrahydropyra hydroxyl groups, at least 25 carbons and at least 8 oxygen and at least 1 nitrogen, and pesticide activity. the compound further comprises at least one of the following characteris acaricidal, algalicidal and herbicidal properties [0150] (b) a molecular weight of about 520-560 and particularly 537 as determined by liquid chromatography/mass spectrosc. 3.75, 3.72, 3.64, 3.59, 3.54, 3.52, 2.44, 2.34, 2.25, 1.96, 1.81, 1.76, 1.42, 1.38, 1.17, 1.12, 1.04 [0152] (d) 13c nmr values of delta 174.03, 166.12, 143.63, 137.50, 13 41.07, 35.45, 31.67, 29.19, 27.12, 24.55, 19.20, 18.95, 13.48, 11.39, 8.04 [0153] (e) high pressure liquid chromatography (hplc) retention time of about 6-15 minutes, (ch3cn) gradient, particularly, an high pressure liquid chromatography (hplc) retention time of about 8-15 minutes, more specifically about 11 minutes and even more spe 100x4.60 mm) column using a water:acetonitrile (ch3cn) with a gradient solvent system (0-20 min 90-0 percent aqueous ch3cn, 20-24 min 100 percent ch3cn, 24-27 min detection of 210 nm [0154] (f) a molecular formula of c28h43no9 which was determined by interpretation of the esims and nmr data analysis [0155] (g) uv absorption ban the compound has the structure ##str006a## : [ftimg=60402167] wherein x, y and z are each independently -o-, -nr, or -s, wherein r is h or c1-c10 alkyl r1, r2, r3, r4, r5, r alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy (o)h, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfonyl. [0157] in a particular embodiment, the compound has the structure: [ftimg=60402168] in another embod r4, r5, r6, r7, r8, and r11 are as previously defined for ##str006a## . [0158] in a more particular embodiment, the compound is templamide b with the following structure: from burkholderia species and characterized as having a structure comprising at least one ester, at least one amide, an epoxide methylene group, at least one tetrahydro three hydroxyl groups, at least 25 carbons and at least 8 oxygen and at least 1 nitrogen. the compound further comprises at least one of the following characteristics: [01 algalicidal and herbicidal properties [0161] (b) a molecular weight of about 510-550 and particularly about 523 as determined by liquid chromatography/mass spectroscopy (3.75, 3.72, 3.65, 3.59, 3.55, 3.50, 2.44, 2.26, 2.04, 1.96, 1.81, 1.75, 1.37, 1.17, 1.04 [0163] (d) 13c nmr values of delta 172.22, 167.55, 144.98, 138.94, 135.84, 130.1 30.63, 25.99, 21.20, 20.38, 18.14, 14.93, 12.84 [0164] (e) an high pressure liquid chromatography (hplc) retention time of about 6-15 minutes, more specifically about 8 particularly, an high pressure liquid chromatography (hplc) retention time of about 8-15 minutes, more specifically about 10 minutes and even more specifically about 10. column using a water:acetonitrile (ch3cn) with a gradient solvent system (0-20 min 90-0 percent aqueous ch3cn, 20-24 min 100 percent ch3cn, 24-27 min 0-90 percent aq 210 nm [0165] (f) a molecular formula of c27h41no9 which was determined by interpretation of the esims and nmr data analysis [0166] (g) uv absorption bands at about compound is a known compound fr901465 which was isolated earlier from culture broth of a bacterium of pseudomonas sp. no. 2663 (nakajima et al. 1996) and had bee another particular embodiment, family ##str006a## compounds may be the compounds set forth in xxiv to xxxix. these are from either natural materials or compounds o ##str006a## compounds include, but are not limited to, microorganisms, alga, and sponges. in a more particular embodiment, microorganisms which include the family # (compounds xxiv-xxvi) (nakajima et al., 1996), the synthetic analogues of the fr901464 (xxvii-xxxix) which have been synthesized and patented as anticancer compoun pesticidal compounds produced by the formulation set forth above which comprises at least one of the following characteristics: [0170] (a) has pesticidal properties and in weight of about 210-240 and more particularly, 222 as determined by liquid chromatography/mass spectroscopy (lc/ms) [0172] (e) has 1h nmr values of delta 7.90, 6.85, (2c), 121.04, 114.83 (2c), 64.32, 31.25, 28.43, 25.45, 22.18. 12.93 [0174] (e) has an high pressure liquid chromatography (hplc) retention time of about 15-20 minutes, phase c-18 hplc (phenomenex, luna 5 c18(2) 100 a, 100x4.60 mm) column using a water:acetonitrile (ch3cn) with a gradient solvent system (0-20 min 90-0 percent aq percent aqueous ch3cn) at 0.5 ml/min flow rate and uv detection of 210 nm [0175] (f) the 13c nmr spectrum exhibited 13 discrete carbon signals which were attributed to molecular formula of c13h18o3 which was determined by interpretation of the esims and nmr data analysis [0177] (h) has uv absorption bands between about 210-450 n shown below [ftimg=60402172] [0179] wherein x, is independently -o-, -nr, or -s, wherein r is h or c1-c10 alkyl r1, r2, r3, r4, r5, and r6 are each independently h, alkyl, sub

heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydro sulfuryl.[0180] in a more particular embodiment, the compound is butyl parben with the following structure:[ftimg=60402173][0181] in a more particular embodiment, the particular embodiment, the compound is octyl parben with the following structure:[ftimg=60402175][0183] in yet another embodiment, the compound is 7h18, which has supernatant and compounds produced by the burkholderia strain disclosed herein, all of which are alternatively referred to as "active ingredient(s)", may be formulated into supernatant.[0185] the active ingredient(s) set forth above can be formulated in any manner. non-limiting formulation examples include but are not limited to emulsifiable concentrate solutions (ulv), soluble powders (sp), microencapsulation, water dispersed granules, flowables (fl), microemulsions (me), nano-emulsions (ne), dusts, emulsions within a range of 0.01 percent to 99.99 percent.[0186] a solid composition can be prepared by suspending a solid carrier in a solution of pesticidal compounds and drying evaporation at 65 degrees centigrade or lower. alternatively, a solid composition may be derived via spray-drying or freeze-drying.[0187] when referring to solid compositions, powders, particulates, pellets, tablets, agglomerates, granules, floating solids and other known solid formulations are included. the artisan of ordinary skill will be known to those of ordinary skill in the art.[0188] the composition may comprise gel-encapsulated compounds derived from the burkholderia strain set forth above. such gel or lignin) with a solution of algicidal compounds and inducing gel formation of the agent.[0189] the composition may additionally comprise a surfactant to be used for the stabilization of active ingredients, and improvement of fluidity or rust inhibition. in a particular embodiment, the surfactant is a non-phytotoxic non-ionic surfactant which is polyoxyethylene (20) monolaurate. the concentration of surfactants may range between 0.1-35 percent of the total formulation, preferred range is 5-25 percent. the choice of dispersing and emulsifying agents, and the amount employed is determined by the nature of the composition and the ability of the agent to facilitate the dispersion of the agent in the form of dusts, granules, water dispersible powders, aqueous dispersions, or emulsions and dispersions in organic liquids, the carrier or diluent agent in dispersing agent, humidifying agent, or emulsifying agent, or any suitable combination of these. generally, when liquids and wettable powders are prepared, a conditioner sufficient to render a given composition containing the active material, the microorganism, dispersible in water or oil.[0191] since these compositions can be applied as an example, water, organic solvents, decane, dodecane, oils, vegetable oil, mineral oil, alcohol, glycol, polyethylene glycol, agents that result in a differential distribution of ordinary skill can be used.[0192] the present compositions can also include other substances which are not detrimental to the active ingredient(s) such as adjuvants, surf combination as needed.[0193] it will be understood by the artisan of ordinary skill that various additives or agents that predispose pests susceptible to the active ingredient enhances the pesticidal action of the active ingredient" is meant any compound, solvent, reagent, substance, or agent that increases the effect of the active ingredient to in the absence of said additive. in some embodiments, these additives will increase the susceptibility of a particular pest to the active ingredient. additional additives include agents can include salts, such as nacl and cacl2.[0194] the composition may further comprise another microorganism and/or pesticide (e.g. nematocide, fungicide, insecticide derived from bacillus sp., pseudomonas sp., brevibacillus sp., lecanicillium sp., non-ampelomyces sp., pseudozyma sp., streptomyces sp, burkholderia sp, trichoderma sp herbicidal, arachid, algicidal, nematocidal and/or insecticidal activity (e.g., paraffinic oil, tea tree oil, lemongrass oil, clove oil, cinnamon oil, citrus oil, rosemary oil).[0195] is not limited to avermectin, bacillus thuringiensis, neem oil and azadirachtin, spinosads, chromobacterium subsp. eucalyptus extract, entomopathogenic bacterium or but not limited to organochlorine compounds, organophosphorus compounds, carbamates, pyrethroids, and neonicotinoids.[0196] the composition may further comprise fenamiphos, aldicarb, oxamyl, carbofuran, natural product neamticide, avermectin, the fungi paecilomyces lilacinus and muscodor spp., the bacteria bacillus firmus and other biofungicide such as extract of r. sachalinensis (regalia) or a fungicide. such fungicides include, but are not limited to, a single site anti-fungal agent which may include butyrimidine, triazole), morpholine, hydroxypyrimidine, anilinothiazolidine, phosphorothiolate, quinone outside inhibitor, quinoline, dicarboximide, carbosulfonamide, phenylamide, polyamine, calamine, phthalimide, benzenoid (xylylaniline). in yet a further embodiment, the antifungal agent is a demethylation inhibitor selected from the group consisting of myclobutanil, penconazole, propiconazole, triadimefon, bromuconazole, cyproconazole, diniconazole, fenbuconazole, tebuconazole, tetraconazole, propiconazole, selected from the group consisting of a nitrile (e.g., chloronitrile or fludioxonil), quinoxaline, sulphamide, phosphonate, phosphite, dithiocarbamate, chloralkylthios, phenyl known in the art. specifically, these compositions may be applied to plants or plant parts. plants are to be understood as meaning in the present context all plants and plants occurring crop plants). crop plants can be plants which can be obtained by conventional plant breeding and optimization methods or by biotechnological and genetic engineering the plant cultivars protectable or not protectable by plant breeders' rights. plant parts are to be understood as meaning all parts and organs of plants above and below the needles, stalks, stems, flowers, fruit bodies, fruits, seeds, roots, tubers and rhizomes. the plant parts also include harvested material, and vegetative and generative parts of the plants and plant parts with the compositions set forth above may be carried out directly or by allowing the compositions to act on their surroundings, habitat or storage. in the case that the composition is applied to a seed, the composition may be applied to the seed as one or more coats prior to planting the seed using one or herbicidal compositions. the composition may further comprise one or more herbicides. these may include, but are not limited to, a bioherbicide and/or a chemical herbicide lemongrass oil, citrus oil, orange peel oil, tentoxin, cornexistin, aal-toxin, manuka oil, leptospermon, thaxtomin, sarmentine, momilactone b, sorgoleone, ascalatolxin and salts thereof, dicamba and salts thereof, topramezone, tembotrione, s-metolachlor, atrazine, mesotrione, primisulfuron-methyl, 2,4-dichlorophenoxyacetic acid, nicosulfuron, oxyfluorfen, rimsulfuron, mecoprop, and quinclorac, thiobencarb, clomazone, cyhalofop, propanil, bensulfuron-methyl, penoxsulam, triclopyr, imazethapyr, haloacifluorfen, glyphosate, glufosinate and orthosulfamuron.[0202] herbicidal compositions may be applied in liquid or solid form as pre-emergence or post-emergence form (diameter) but the granules can be either smaller or larger depending on the required ground coverage. granules may comprise porous or non-porous particles.[0204] attapulgite clays and similar swelling clays, thickeners such as xanthan gums, gum arabic and other polysaccharide thickeners as well as dispersion stabilizers such as non-embodiment, the composition may comprise in addition to the active ingredient another microorganism and/or algicide and/or acaricide. the microorganism may include but [0206] the compositions may also as set forth above, be algicidal compositions which can further comprise other algicides such as copper sulphate, diquat or thaxtomin a. acaricides such as antibiotics, carbamates, formamidate acaricides, pyrethroids, mite growth regulators, organophosphate acaricides and diatomaceous earth. uses [0208] may be used as pesticides, particularly as insecticides, nematocides, fungicides, algicides, acaricides and herbicides.[0209] specifically, nematodes that may be controlled knot, ring, sting, lance, cyst, and lesion nematodes, including but not limited to free living nematodes, meloidogyne, heterodera and globodera spp particularly meloidogyne (potato cyst nematode) heterodera glycines (soybean cyst nematode) heterodera schachtii (beet cyst nematode) oligonychus pratensis (banks grass mite) eriophyes cyn cyst nematode).[0210] phytopathogenic insects controlled by the method of the present invention include, but are not limited to, insects from the order[0211] (a) lepidoptera spp., antarsia gemmatilis, archips spp., argyrotaenia spp., autographa spp., busseola fusca, cadra cautella, carposina nipponensis, chilo spp., choristoneura sp crocidolomia binotalis, cryptophlebia leucotreta, cydia spp., diatraea spp., diparopsis castanea, earias spp., ephesia spp., eucosma spp., eupocilia ambiguaella, euproctis cunea, keiferia lycopersicella, leucopetra scitella, lithocolletis spp., lobesia botrana, lymantria spp., lyonetia spp., malacosoma spp., mamestra brassicae, manduca sexta pectinophora gossypiella, phthorimaea operculella, pieris rapae, pieris spp., plutella xylostella, prays spp., scirpophaga spp., sesamia spp., sparganothis spp., spodoptera [0212] (b) coleoptera, for example, agrotis spp., anthrenus spp., atomaria linearis, chaetocnema tibialis, cosmopolites spp., curculio spp., dermestes spp., diabrotica spp., erycaepilius spp., otiorhynchus spp., phlyctinus spp., popillia spp., psylliodes spp., rhizopertha spp., scarabeidae, sitophilus spp., sitotroga spp., tenebrio spp., trib spp., leucophaea maderae, locusta spp., periplaneta spp. and schistocerca spp. (d) isoptera, for example, reticulitermes spp. (e) psocoptera, for example, liposcelis spp. and phylloxera spp. (g) mallophaga, for example, damalinae spp. and trichodectes spp. (h) thysanoptera, for example, frankliniella spp., hirsutiopoda spp., tetranychus distantiella theobroma, dydercus spp., euschistus spp., eurygaster spp., leptocoris spp., nezara spp., piesma spp., rhodnius spp., sahlbergella singularis, scotinophara s floccosus, aleyrodes brassicae, aonidiella spp., aphididae, aphid spp., aspidiotus spp., bemisia tabaci, ceroplaster spp., chrysomphalus conidum, chrysomphalus dictyosporiophalax spp., lecanium corni, lepidosaphes spp., macrosiphus spp., myzus spp., neotetratix spp., nilaparvata spp., paratioria spp., pemphigus spp., planococcus spp., rhopalosiphum spp., saissetia spp., scaphoideus spp., schizaphis spp., sitobion spp., thripsurodes vaporariorum, trioxa erythraea and unaspis citri (k) hymenoptera, for example hoplocampa spp., lasius spp., monomorium pharaonis, neodiprion spp., solenopsis spp. and vespa spp. (1) diptera, for example, aedes spp., antherigona soccata, bibio dacus spp., drosophila melanogaster, fannia spp., gastrophilus spp., glossina spp., hypoderma spp., hyppobosca spp., liriomyza spp., lucilia spp., melanagromyza spp., rhagoletis pomonella, sciara spp., stomoxys spp., tabanus spp., tannia spp. and tipula spp. (m) siphonaptera, for example, ceratophyllus spp. and xenopsylla cheopis a to the invention may further be used for controlling crucifer flea beetles (phyllotreta spp.), root maggots (delia spp.), cabbage seedpod weevil (ceutorhynchus spp.) and a maize. in a particular embodiment, the insect may be a member of the spodoptera, more particularly, spodoptera exigua, myzus persicae, plutella xylostella or euschistus pre-emergent or post-emergent formulation of monocotyledonous. including sedges and grasses, or dicotyledonous weeds. in a particular embodiment, the weeds may be in helianthus sp. (e.g. h. annuus), ludwigia sp. (e.g. l. hexapetala), ambrosia sp. (e.g. a. artemesifolia), amaranthus sp. (e.g., a. retroflexus, a. palmeri), convolvulus sp. (officinalis), centaurea sp. (e.g. c. stoltitalis), conyza sp. (e.g. c. bonariensis), cirsium sp. (e.g. c. arvense), lepidium spp., galium sp., solanum sp. (e.g. s. nigrum), malva hydrilla sp., azolla sp., digitaria sp. (e.g. d. sanguinalis), setaria sp. (e.g. s. lutescens), cynodon dactylon, bromus sp. (e.g., b. teclorum), poa sp. (e.g. p. annua), p. prate (e.g. f. arundinaceae), echinocloa sp. (e.g., e. crus-galli, e. phyllopopon).[0214] the burkholderia strain, compounds and compositions set forth above may also be used as colletotrichum sp., verticillium sp., microphomina sp., phytophthora sp., mucor sp., podosphaera sp., rhizoctonia sp., peronospora sp., geotrichum sp., phoma, and penicillium compositions can be used to control, reduce and/or eliminate the growth and proliferation of marine and non-marine micro and macro algae including but not limited to u subcapitata, rhizoclonium sp., cladophora sp., anabaena sp., nostoc sp., hydrodictyon sp., chara sp., microcystis and didymo sp., chlamydomonas sp., scenedesmus sp., rhodmenia sp., callithamnion sp., undaria sp., through algae and algaecidal activity.[0216] the active ingredient(s) and compositions set forth above may be applied lake, stream, river, aquarium, water treatment facility, power plant or a solid surface, such as plastic, concrete, wood, fiberglass, pipes made of iron and polyvinyl chloride, (s) and compositions set forth above may be applied to locations containing arachnids, such as mites, including but not limited to, panonychus sp. such as panonychus citi kanzawi (kanzawa spider mite), tetranychus urticae (2 spotted spider mite), tetranychus pacificus (pacific spider mite), tetranychus turkestanii (strawberry mite) and tetranychus brown mite), oligonychus perseae (perseae mite), oligonychus pratensis (banks grass mite) and oligonychus coffeae, aculus sp. such as aculus cornatus (peach silver mite) such as eotetranychus wilametti, eotetranychus yuensis (yuma spider mite) and eotetranychus sexmaculatus (6-spotted mite), bryobia rubriculcus (brown mite), epitrimer polyphagotarsonemus latus (broad mite), eriophyes sheldoni (citrus bud mite), brevipalpus lewisii (citrus flat mite), phyllocoptura oleivora (citrus rust mite), petrobria latea diptacus gigantorhynchus (bigheaded plum mite) and penthalea major (winter grass mite), avocado red mite, flat mite, black and red mango spider mite, papaya leaf ed mite, wilamette spider mitepink citrus rust mite.[0218] such locations may include but are not limited to crops that are infested with such mites or other arachnids (e.g., a non-limiting examples. examples [0220] the compositions and methods set forth above will be further illustrated in the following, non-limiting examples. the examples are materials, conditions, weight ratios, process parameters and the like recited herein. 1. example 1 isolation and identification of the microbe [0221] 1.1 isolation of the microbe sample collected under an evergreen tree at the rinnoji temple, nikko, japan. the isolation is done using potato dextrose agar (pda) using a procedure described in detail is plated in a solid agar medium such as potato dextrose agar (pda). the plates are grown at 25 degrees centigrade for five days, after which individual microbial colonies opaque cream-colored colonies that change to pink and pinkish-brown in color and mucoid or slimy over time.[0223] 1.2. identification of the microorganism[0224] the microorganism rna region. the following protocol is used: burkholderia sp. a396 is cultured on potato-dextrose agar plates. growth from a 24 hour-old plate is scraped with a sterile loop dna extraction kit. dna extract is checked for quality/quantity by running 5 micro l on a 1 percent agarose gel. pcr reactions are set up as follows: 2 micro l dna extract, 5 1.25 micro l reverse primer (907r (seq id no:2)) and 0.25 micro l taq enzyme. the reaction volume is made up to 50 micro l using sterile nuclease-free water. the pcr reaction cycles of 94 degrees centigrade /30 sec, 57 degrees centigrade /20 sec, 72 degrees centigrade /30 sec, and a final extension step at 72 degrees centigrade for 10 minutes volume on a 1 percent agarose gel and comparing the product band to a mass ladder.[0226] excess primers, dntps and enzyme are removed from the pcr product with ethanol (as above), 530f (seq id no:3)), 1114f (seq id no:4)) and 1525r (seq id no:5)), 1100r (seq id no:6)), 519r (seq id no:7)).[0227] the 16s rna gene sequence of strain a396 proteobacteria using blast. strain a395 a396 is closely related to members of the burkholderia cepacia complex, with 99 percent or higher similarity to several isolates of excluding the b. cepacia complex, showed 98 percent similarity to b. plantarii, b. gladioli and burkholderia sp. isolates.[0228] a distance tree of results using the neighbor cepacia complex isolates. burkholderia plantarii and burkholderia glumae grouped in a separate branch of the tree.[0229] the isolated burkholderia strain was found to be (seq id no:8) reverse sequence, 1453 bp, using primers 1525r, 1100r, 519r (seq id no:9) reverse sequence 824 by using primer 907r (seq id no: 10) forward sequence 1 no:12) reverse sequence 1223 by using 1525r primer (seq no:13) reverse sequence 1216 by using 1100r primer (seq id no:14) reverse sequence 1194 by using 519r primer cepacia complex[0231] 1.3.1 molecular biology work using specific pcr primers[0232] in order to confirm the identification of burkholderia a396 as burkholderia multivorans known member of the burkholderia cepacia complex. efforts are focused on pcr of recA genes, as described by mahenthiralingam et al., 2000. the following primers are used match and (b) bcrbm1 and bcrbm2 set forth mahenthiralingam et al, 2000 to confirm b. multivorans match. a product-yielding pcr reaction for the first primer set would confirm the second primer set would confirm that the microbe is indeed b. multivorans. [0233] no pcr product is obtained for either pair of primers. the performance of the pcr reaction pseudomonas fluorescens (negative control). strong bands are observed both for b. multivorans using both sets of primers. no bands are observed for pseudomonas fluorescens complex, and not burkholderia multivorans. this is also demonstrated in a comparative culture experiment in which both a396 and a type culture of b. multivorans are grown measurements at 600 nm. under the set conditions, species a396 grew much faster than the b. multivorans type strain (fig. 1).[0234] 1.3.2 dna-dna hybridization[0235] experiment with burkholderia multivorans (the closest 16srna sequence match) is conducted. biomass for both a396 and b. multivorans is produced in isp2 broth, grown harvested by centrifugation. the broth is decanted and the cell pellet is resuspended in a 1:1 solution of water: isopropanol. dna-dna hybridization experiments are performed isolated using a french pressure cell (thermo spectronic) and is purified by chromatography on hydroxyapatite as described by cashion et al., 1977. dna-dna hybridization by huss et al., 1983 using a model Cary 100 bio uv/vis-spectrophotometer equipped with a peltier thermostatted 6x6 multicell changer and a temperature controller with in and burkholderia multivorans of 37.4 percent. the results indicate that burkholderia sp strain a396 does not belong to the species burkholderia multivorans when the recombination species by the ad hoc committee (wayne et al., 1987) are considered.[0237] 1.4. biochemical profile using biolog gn2 plates[0238] for the carbon source utilization profile produce an adequate culture for biolog experiments as recommended by the manufacturer (biolog, hayward, calif.).[0239] the biochemical profile of the microorganism is incubation using the microlog 4-automated microstation system. identification of the unknown bacteria is attempted by comparing its carbon utilization pattern with the microlog closest matches all had less than 35 percent similarity with a396: pseudomonas spinosa (burkholderia), burkholderia cepacia, and burkholderia pseudomallei. the results a396 substrate results substrate results cetyl-dextrin-l-arabinose-dextrin-d-arabitol-glycogen-d-cellobiose-tween 40+erythritol-tween 80+d-fructose-n-acetyl-d-galactoseamine-l-glucose+esteracetic acid-m-inositol-cis-aconitic acid-d-lactose-citric acid-lactulose-formic acid+maltose-d-galactonic acid lactone-d-mannitol-d-galacturonic acid-d-mannos

psicose-a-hydroxybutyric acid-d-*raffinose*- beta -hydroxybutyric acid+*l*-*ramanose*-gamma-hydroxybutyric acid-d-sorbitol-p-hydroxyphenylacetic acid-sucrose-itaconic acid-methyl-*esther*,*l*-lactic acid-uridine-malonic acid-thymidine-propionic acid+phenethyl-amine-quinic acid-putrescine-d-saccharic acid-2-aminoethanol-sebacic acid-2,3-buta glucose-1-*-phosphate*glucuronamide-d-glucose-6-phosphate-*l*-alaninamide+gamma-amino butyric acid+d-alanine-urocanic acid-*l*-alanine-*l*-alanyl-glycine-*l*-phen glycy-*l*-aspartic acid-*l*-serine-glycyl-*l*-glutamic acid-*l*-threonine-*l*-histidine-*d*,*l*-carnitine-hydroxy-*l*-proline+*l*-ornithine-*l*-leucine-[0241] 1.5. fatty acid composition[0242] afte fatty acid methyl esters are prepared, separated and identified using the sherlock microbial identification system (midi) as described (see vandamme et al., 1992). the pr 17:0 (7.1 percent), 16:0 3-oh (4.4 percent), 14:0 (3.6 percent), 19:0 78c (2.6 percent) cyclo, 18:0 (1.0 percent). summed feature 8 (comprising 18:1 77c) and summed f the total peak area, respectively. summed feature 2 comprising 12:0 alde, 16:1 iso i, and 14:0 3-oh) corresponded to 5.8 percent of the total peak area while summed f detected in a396 in minor quantities included: 13:1 at 12-13 (0.2 percent), 14:1 75c (0.2 percent), 15:0 3-oh (0.13 percent), 17:1 77c (0.14 percent), 17:0 (0.15 percent 18:1 2-oh (0.4 percent).[0243] a comparison of the fatty acid composition of a396 with those of known microbial strains in the midi database suggested that the fatty acid resistance to antibiotics[0245] antibiotic susceptibility of burkholderia a396 is tested using antibiotic disks on muller-hinton medium as described in pml microbiological's t presented in table 2 below.table 2susceptibility of mbi-206 to various antibiotics. +++ verysusceptible, ++ susceptible, - resistantconcentration (micro g)susceptibletracy oxytetracycline30-chloramphenicol30++ciprofloxacin5++gentamicin10-piperacilin100+++cefuroxime30-imipenem10+++sulphamethoxazole-23.75/25++trimethoprim[024 different from pathogenic b. cepacia complex strains. burkholderia a396 is susceptible to kanamycin, chloramphenicol, ciprofloxacin, piperacillin, imipenem, and a combin susceptibility of 2,621 different strains in b. cepacia complex isolated from cystic fibrosis patients, and found that only 7 percent and 5 percent of all strains were suscepti resistant to chloramphenicol (15 percent susceptible), and 95 percent to be resistant (5 percent susceptible) to the combination of sulphamethoxazole and trimethoprim. resistance among 366 b. cepacia isolates and reported that most of them are resistant to ciprofloxacin, cefuroxime, imipenem, chloramphenicol, tetracycline, and sulpha product [0247] the following procedure is used for the purification of compounds extracted from a formulated product of mbi-206 containing a whole cell broth of a culture (a396) in hy soy growth medium and formulated using methyl 0.1 percent and propyl paraben, 0.1 percent hexanol 0.67 percent and glycosperse 0-20, 0.67 percent is ex derived actinomycete of the genus streptomyces strain cnq-085." j. nat. prod. 69:1756-1759. 2006) by shaking the cell suspension with resin at 225 rpm for two hours at washed with di water to remove salts. the resin, cell mass, and cheesecloth are then soaked for 2 h in acetone after which the acetone is filtered and dried under vacuum fractionated by using reversed-phase c18 vacuum liquid chromatography (h2o/ch3oh gradient 80:20 to 0:100 percent) to give 10 fractions (see fig. 1 for schematic). these are screened for biological activity using a whole plant herbicidal assay. the active fractions, fractions 3, 4, 5 and 6 and indicated as mbi-206-fp-3, mbi-206-fp-4, mbi-206 separation (spectra system p4000 (thermo scientific) to give pure compounds, which are then screened in above-mentioned bioassays to locate/identify the active compo a thermo high performance liquid chromatography (hplc) instrument equipped with finnigan surveyor pda plus detector, autosampler plus, ms pump and a 4.6 mmx100 acetonitrile (solvent b). the mobile phase begins at 10 percent solvent b and is linearly increased to 100 percent solvent b over 20 min and then kept for 4 min, and final injection volume is 10 micro l and the samples are kept at room temperature in an auto sampler.[0251] to discover the identity of the compound, additional spectroscopic time of 17.45 minutes is not found in any of the starting materials, which indicates that the compound is a product of a chemical reaction between natural products in the specifically, this fraction was analyzed using esi-lcms on a thermo finnigan lcq decx xp plus electrospray (esi) instrument using both positive and negative ionization mod electron corp., san jose, calif.). mass spectroscopy analysis is performed under the following conditions: the flow rate of the nitrogen gas was fixed at 30 and 15 arb for th spray voltage set at 5000 v and a capillary voltage at 35.0 v. the capillary temperature was set at 400 degrees centigrade the data was analyzed on xcalibur software. the (rt=14.74 min) and 222 (rt=17.43 min)[0252] 2.2 bioassay[0253] healthy radish plants with two to three true leaves were selected for testing. the radish plants are 13 da area and plant height. the pots are labeled with treatment number and repetition number. three repetitions per treatment are tested.[0254] ten fractions of mbi-206 from the formulated product and broth are also tested. an untreated control (treated with deionized water) and a positive control (roundup super concentrate at a rate of 2.5 flu in table 3:table 3test descriptiontreatmentssample iddescription1mbi-206-fp-f14 percent ethanol/water (0.2 percent glycosperse)2mbi-206-fp-f24 percent ethanol/water (0. fp-f44 percent ethanol/water (0.2 percent glycosperse)5mbi-206-fp-f54 percent ethanol/water (0.2 percent glycosperse)6mbi-206-fp-f64 percent ethanol/water (0.2 percen percent ethanol/water (0.2 percent glycosperse)9mbi-206-fp-f94 percent ethanol/water (0.2 percent glycosperse)10mbi-206-fp-f104 percent ethanol/water (0.2 percent gly percent ethanol/water (0.2 percent glycosperse)13utcutc (di water)14positive controlpos. control (roundup @ 2.5 fl oz/gal(ai: glyphosate @ 50.2 percent)))[0256] all produ a 2-ounce spray bottle. separate spray nozzles were used for each treatment. the plant foliage is sprayed evenly and with a moderate volume (i.e. neither a light misting simultaneously over the three repetitions of each treatment so that each plant is treated with approximately 0.67 milliliters of treatment solution.[0257] the plants are all name and treatment date and placed on the laboratory greenhouse shelves. the laboratory greenhouse maintains a temperature of 70-80 degrees fahrenheit and a relati holding trays with an appropriate amount of water so that plant foliage remained dry.[0258] results are taken at 3, 8, and 14 days after treatment. symptoms included fol efficacy. ratings are determined by observing the following factors relative to the plants of the untreated control: overall plant health, average plant height, and foliage he warped/twisted/curled leaves, side branching (due to damaged apical meristem), plant dieback, or death.table 4rating scale0 0 percent control symptoms0.5 75 percent c symptoms4 75 percent control symptoms5100 percent control symptoms[0259] the mean of three readings is shown in fig. 2. in a whole plant herbicide test, fractions 4 a formulation[0261] this fraction was further purified using a hplc c-18 column (phenomenex, luna 10u c18(2) 100 a, 250x30), water:acetonitrile gradient solvent system (0 percent aqueous ch3cn, 50-60 min 50-70 percent aqueous ch3cn, 60-80 min 70-0 percent aqueous ch3cn, 80-85 min 0-20 percent aqueous ch3cn) at 8 ml/min flow rate and hexyl paraben, retention time 74.59 min (mbi206-fp-f5h40) respectively.[0262] 2.3.1 nmr spectroscopy analysis of compounds[0263] nmr spectra were measured on tetramethylsilane (tms, 0.00 ppm).[0264] 2.3.1.1 structure elucidation of hexyl paraben (mbi206-fp-f5h40)[0265] the active compound was isolated as a colorless solid, the molecular weight of 222. the compound exhibited 1h nmr delta signals at 7.90, 6.85, 4.28, 1.76, 1.46, 1.38, 1.37, 0.94 and has 13c nmr values of 166.84, 162.12, 1 of c13h18o3 (5 degrees of unsaturation), was assigned by combination of nmr and esi mass spectrometry data. the 1h nmr spectrum exhibited signals for an a2b2-type spectrum revealed the presence of -ch2-ch2-ch2-ch2-ch2-ch3 group, at delta 4.28, 2h, t, j=7.3 hz 1.76, 2h, m 1.46, 2h, m 1.38, 2h, m 1.37, 2h, m, and 0.94, 3h, t, j=7.3 established as hexyl paraben, which was confirmed by detail analysis of the cosy, hmqc and hmbc experiments. a literature search revealed that this compound has been f5h32)[0267] this compound was obtained as a colorless solid with uv max at 248 nm. the lcms analysis in the negative mode showed molecular ion at m/z 193 correspo paraben with mw 222, this compound was found to be the analogue of hexyl paraben. the only difference between them was only in the side chain. thus, the structure of this compound is also known as a synthetic compound.[0268] 2.3.2 herbicidal activity[0269] the pure compounds (butyl paraben [mbi206-fp-f5h32] and hexyl paraben [untreated control (treated with deionized water), the formulation blank (at 3 percent v/v and 10 percent v/v), and a positive control (roundup super concentrate at a rate o as shown in table 5:table 5treatment regimentest descriptiontreat-vol (ml)mentsample iddescriptionof sample1utcutc (di water)22butyl paraben4 percent ethanol/water2(f5h40)(0.2 percent glycosperse)4blankformulation2blank @ 3 percent v/v5blankformulation2blank @ 10 percent v/v6positive controlpositive control2(roundup @ 2.5 fl oz/ results/day-1 reading/day-7 readingrepli-controlreplicatecontrolcatesstdstreatment123avgdev123avgdev1 0 0 00.00000.0022552518.311.5 251037.524.2 13.8 3757 00.0087.587.57583.3 7.2 based on the data presented in the table above, hexyl paraben was found to be the most potent herbicidal compound. [0271] 2.3.3 insecticid (mbi206-fp-f5h40) were tested in a laboratory assay using a 96-well diet overlay assay with 1st instar beet armyworm (spodoptera exigua) larvae using microtiter plates w test sample (containing 40 ug of sample) is pipetted on the top of the diet (one sample in each well), and the sample is let dry under flowing air until the surface is dry. e negative and positive controls, respectively. one first instar larvae of the test insect (beet armyworm-spodoptera exigua) was placed in each well, and the plate was covers for 6 days with daily mortality evaluations. based on the results presented in table 7, hexyl paraben and butyl paraben resulted in 71 percent and 9 percent mortality, res (mbi206-fp-f5h40) against 1st instarbeet army worm (spodoptera exigua).sample informationday 3day 4butyl paraben mbi206-fp-f5h32) @ 40 micro g/well8.938.9286he dipel25.0025 8 percent dipel0.002516 percent dipel0.00032 percent dipel0.00064 percent dipel25.0010040 percent etoh14.2914.286dipel33.33100h200.000[0273] 2.3.4 (mbi206-fp-f5h40):[0274] the pure sample of butyl paraben and hexyl paraben was used in an in vitro 96-well plastic cell-culture plate bioassays. 15-20 nematodes in a 5 period at 25 degrees centigrade once the incubation period was completed, results were recorded based on a visual grading of immobility of the juvenile nematodes (j2's) shown in table 8, which shows the results of two different 96-well plate extract bioassays of compounds. three controls are included in each trial 1 positive (1 percent avid trail (t2) was carried out using m. hapla nematodes, the samples were dissolved in 100 percent dmso. the hexyl paraben (mbi206-fp-f5h40) showed the excellent control percent immobility.table 8effect of hexyl paraben and butyl paraben on m. incognita andm. hapla. percent immobility percent immobilitymean percent sample informatio f5h4087.510093.75(hexyl paraben)avid (1 percent)757575dmso6.2503.12water000[0275] 2.3.5 study of formation of parabens during formulation of the product[0276] i formulation was taken into consideration. the different carbon chain alcohols were used in the formulation and the formation of the new parabens were monitored using lc and cetyl alcohol and all other ingredients were kept same. the formulation products were extracted over the period of 2 days and 3 weeks. the crude extract obtained fro except for cetyl alcohol. the yield of the parabens was found to be the highest for butyl paraben, followed by hexyl paraben and then octyl paraben for the one day old for parabenhexyl parabenoctyl paraben. thus, the rate of formation of these parabens such as butyl paraben, hexyl paraben and octyl paraben was found to depend on the c formulation (butanol (c4)hexanol (c6)octanol (c8) etc). the formation of cetyl paraben was not detected till 3 weeks. the yields of these parabens were found to increase o cell broth (wcb) in the formation of the new paraben analogues. in 4 different expt. with were carried out with following changes in the formulation-1 expt-1: propyl parab +wcb+other ingredientsexpt-3: no parabens (both)+wcb+other ingredients.expt-4: methyl paraben+propyl paraben+other ingredients+no wcb. the above formulations wer formation of the hexyl paraben was observed only in the first two experiments. thus, these experiments suggested that wcb plays a very important role in the formation i following procedure is used for the purification of templazole a and b extracted from cell culture of burkholderia sp (see fig. 3):[0284] the culture broth derived from the 1 resin (asolkar et al., 2006) by shaking the cell suspension with resin at 225 rpm for two hours at room temperature. the resin and cell mass are collected by filtration thro cheesecloth are then soaked for 2 h in acetone after which the acetone is filtered and dried under vacuum using rotary evaporator to give the crude extract. the crude extr gradient 90:10 to 0:100 percent) to give 11 fractions. these fractions are then concentrated to dryness using rotary evaporator and the resulting dry residues are screened subjected to reversed phase hplc (spectra system p4000 (thermo scientific) to give pure compounds, which are then screened in above mentioned bioassays to locate/ide such as lc/ms and nmr is recorded.[0286] the active fraction 5 is purified further by using hplc c-18 column (phenomenex, luna 10u c18(2) 100 a, 250x30), water:acetonitrile aqueous ch3cn, 25-50 min 65-50 percent aqueous ch3cn, 50-60 min 50-70 percent ch3cn, 60-80 min 70-0 percent aqueous ch3cn, 80-85 min 0-20 percent aqueous ch3c min. the other active fraction 7 is also purified using hplc c-18 column (phenomenex, luna 10u c18(2) 100 a, 250x30), water:acetonitrile gradient solvent system (0-10 ml aqueous ch3cn, 50-60 min 40 percent ch3cn, 60-80 min 40-0 percent aqueous ch3cn, 80-85 min 0-20 percent aqueous ch3cn) at 8 ml/min flow rate and uv detection of 2 compounds is performed on a thermo finnigan lcq decx xp plus electrospray (esi) instrument using both positive and negative ionization modes in a full scan mode (m/z thermo high performance liquid chromatography (hplc) instrument equipped with finnigan surveyor pda plus detector, autosampler plus, ms pump and a 4.6 mmx100 m acetonitrile (solvent b). the mobile phase begins at 10 percent solvent b and is linearly increased to 100 percent solvent b over 20 min and then kept for 4 min, and final injection volume was 10 micro l and the samples are kept at room temperature in an auto sampler. the compounds are analyzed by lc-ms utilizing the lc and reversed ph the following conditions: the flow rate of the nitrogen gas was fixed at 30 and 15 arb for the sheath and aux/sweep gas flow rate, respectively. electrospray ionization was temperature was set at 400 degrees centigrade the data was analyzed on xcalibur software. the active compound templazole a has a molecular mass of 298 and showed a molecular mass of 258 and exhibited m/z ion at 257.74 in negative ionization mode.[0288] 1h, 13c and 2d nmr spectra were measured on a bruker 500 mhz delta 600 (tms, 0.00 ppm).[0289] for structure elucidation of templazole a, the purified compound with a molecular weight 298 is further analyzed using a 500 mhz nmr instrument, nmr values of delta 163.7, 161.2, 154.8, 136.1, 129.4, 125.4, 123.5, 123.3, 121.8, 121.5, 111.8, 104.7, 52.2, 37.3, 28.1, 22.7, 22.7. templazole a has uv absorption ba formula, c17h18n2o3, was determined by interpretation of 1h, 13c nmr and hresi ms data m/z 299.1396 (m+h)+ (calcd for c17h19n2o3, 299.1397), which entails a high c signals for all 17 carbons, including two methyls, a methoxy, a methylene carbon, an aliphatic methine, an ester carbonyl, and eleven aromatic carbons. the presence of 3 hmbc also indicated the presence of a carboxylic acid methyl ester group and a -ch2-ch-(ch3)2 side chain. from the detailed analysis of 1h-1h cosy, 13c, and hmbc data it that the iso-butyl side chain was attached at c-2 position, a carboxylic acid methyl ester at c-4 position and the indole unit at c-5 position to give templazole a.[0290] the using a 500 mhz nmr instrument, and has 1h nmr delta values at 7.08, 7.06, 6.75, 3.75, 2.56, 2.15, 0.93, 0.93 and 13c nmr values of delta 158.2, 156.3, 155.5, 132.6, assigned as c15h18n2o2, which is determined by interpretation of 1h, 13c nmr and mass data. the 13c nmr spectrum revealed signals for all 15 carbons, including two me carbons. the general nature of the structure was deduced from 1h and 13c nmr spectra that showed a para-substituted aromatic ring [delta 7.08 (2h, d, j=8.8 hz), 6.75 (2 structure together with the 1h-1h cosy and hsqc spectra, displayed characteristic signals for an isobutyl moiety [delta 0.93 (6h, d, j=6.9 hz), 2.15 (1h, sept., j=6.9 hz), 2.5 carbon group (delta 158.9) were also found in the 1h and 13c nmr spectra. on inspection of the hmbc spectrum, the h-1' signal in the isobutyl moiety correlated with the o 156.3 and c-17, 41.2). the methylene signal at delta 3.75 correlated with c-5, c-4 as well as the c-2? of the para-substituted aromatic moiety. all these observed correlatio the skeleton of the structure as shown. in addition, the carboxamide group is assigned at the para position of the benzyl moiety based on the hmbc correlation from the designated as templazole b. 4. example 4 isolation of fr901228 [0291] the whole cell broth from the fermentation of burkholderia sp. in an undefined growth medium is at 225 rpm for two hours at room temperature. the resin and cell mass are collected by filtration through cheesecloth and washed with di water to remove salts. the resin, and dried under vacuum using rotary evaporator to give the crude extract. the crude extract is then fractionated by using reversed-phase c18 vacuum liquid chromatograp concentrated to dryness using rotary evaporator and the resulting dry residues are screened for biological activity using both insect bioassay as well as herbicidal bioassay. thermo scientific) to give pure compounds, which are then screened in herbicidal, insecticidal and nematocidal bioassays described below to locate/identify the active comp nmr is recorded.[0292] mass spectroscopy analysis of active peaks is performed on a thermo finnigan lcq decx xp plus electrospray (esi) instrument using both positive a spectrometer (thermo electron corp., san jose, calif.). thermo high performance liquid chromatography (hplc) instrument equipped with finnigan surveyor pda plus detect the solvent system consists of water (solvent a) and acetonitrile (solvent b). the mobile phase begins at 10 percent solvent b and is linearly increased to 100 percent solv and kept for 3 min. the flow rate is 0.5 ml/min. the injection volume is 10 micro l and the samples are kept at room temperature in an auto sampler. the compounds are of the present compounds is performed under the following conditions: the flow rate of the nitrogen gas is fixed at 30 and 15 arb for the sheath and aux/sweep gas flow r capillary voltage at 35.0 v. the capillary temperature is set at 400 degrees centigrade the data is analyzed on xcalibur software. based on the lc-ms analysis, the active in [0293] for structure elucidation, the purified insecticidal compound from fraction 6 with molecular weight 540 is further analyzed using a 500 mhz nmr instrument, and has

Page 5 of 133

material has been deposited under the terms of the budapest treaty with the agricultural research culture collection (nrri), 1815 n. university street, peoria, ill. 61604 usa, b-50319sep. 15, 2009[0319] the strain has been deposited under conditions that assure that access to the culture will be available during the pendency of this patent ap under 37 c.f.r. 1.14 and 35 u.s.c. 122. the deposit represents a substantially pure culture of the deposited strain. the deposit is available as required by foreign patent la should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by government the details thereof are not to be construed as limiting, as it is obvious that one can use various equivalents, changes and modifications and still be within the scope of the is incorporated herein by reference in its entirety. literature cited anderson, et al. "the structure of thiostrepton," nature 225: 233-235. 1970.andra, "endotoxin-like proper stimulation and biophysical characterization." biol. chem. 387: 301-310. 2006.arena, et al. "the mechanism of action of avermectins in caenorhabditis elegans-correlation activity." j. parasitol. 81: 286-294. 1995.asolkar, et al., "weakly cytotoxic polyketides from a marine-derived actinomycete of the genus streptomyces strain cnq-085." j. n pseudomonas cepacia b37w in culture and in colonized wounds of potatoes." appl. environ. microbiol. 60: 2031-2039. 1994.burkholder, w. h "sour skin, a bacterial rot of sp. nov., an n2-fixing rhizospheric and endophytic species." int. j. syst. evol. microbiol. 54: 1165-1172. 2004.cashion et al. "rapid method for base ratio determination of al., "burkholderia nodosa sp. nov., isolated from root nodules of the woody brazilian legumes mimosa bimucronata and mimosa scabrella" int. j. syst. evol. microbiol. 57: management." clin. microbiol. 18: 383-416. 2005.coenye, t. and p. vandamme, p. "diversity and significance of burkholderia species occupying diverse ecological niches." in the natural environment." fems microbiol. rev. 32: 607-626. 2008.de ley et al. "the quantitative measurement of dna hybridization from renaturation rates." eur. j. bioc future trends." weed res 40: 99-111. 2000.gerwick et al., u.s. pat. no. 7,393,812.gottlieb et al., u.s. pat. no. 4,808,207.gouge et al., us patent application pub. no. 2003/ oxazole moiety and its putative biogenetic precursors, from a senegalese delleseeracean sea weed." hely. chim acta 77: 1999-2006. 1994.guella et al., "isolation, syntheses tetrahedron. 62: 1165-1170. 2006.henderson, p. j. and lardy h. a. "bongkreic acid. an inhibitor of the adenine nucleotide translocase of mitochondria." j. biol. chem. 245 tryptophan." agri. biol. chem. 42: 147-151. 1978.hu, f.-p. and young, j. m. "biocidal activity in plant pathogenic acidovorax, burkholderia, herbaspirillum, ralstonia, and x spectrophotometric determination of dna hybridization from renaturation rates." system. appl. microbiol. 4: 184-192. 1983.jansiewicz, w. j. and roltman j. "biological conti 1697-1700. 1988.jeddoloh et al., wo2001/055398.jansen et al., "thiangazole: a novel inhibitor of hiv-1 from polyangium spec." liebigs ann. chem. 4: 357-3359. 1992.jeon inducing bacterial wilt in many field crops." plant disease 87: 890-895. 2003.knudsen, g. r. and spurrr, j. "field persistence and efficacy of five bacterial preparations for co three kinds of beta-tubulins from rice." dna research 2: 21-26. 1995.koide et al. us patent application pub. no. 2008/0096879.koyama et al., "isolation, characterization, olivoreticuli." agri. biol. chem. 45: 1285-1287. 1981.krieg et al. "bacillus thuringiensis var. tenebrionis: ein neuer, gegenuber larven von coleopteren wirksamer pathotyp." polyangium sp (myxobacteria production, antimicrobial activity and mechanism of action." j. antibiot., 46: 1752-1755. 1993.leahy et al. "comparison of factors influencing 833. 1996.lessie et al. "genomic complexity and plasticity of burkholderia cepacia." fems microbiol. lett. 144: 117-128. 1996.lindquist, n. et al. "isolation and structure de diazonia chinensis." j. am. chem. soc. 113: 2303-2304. 1991.lorch, h et al. "basic methods for counting microorganisms in soil and water. in methods in applied soil microb 161. 1995.ludovic et al. "burkholderia diveristy and versatility: an inventory of the extracellular products." j. microbiol. biotechnol. 17: 1407-1429. 2007.lydon, j. and duke singh., ed. new york, usa, marcel decker. pp. 445-464. 1999.mahenthiralingam et al. "dna-based diagnostic approaches for identification of burkholderia cepacia complex cepacia genomovars i and iii." j. clin. microbiol. 38: 3165-3173. 2000.ming, l.-j. and epperson. "metal binding and structure-activity relationship of the metalloantibiotic p pharm. bull. 26: 1487-1490. 2003.nagamatsu, t. "syntheses, transformation, and biological activities of 7-azapteridine antibiotics: toxoflavin, fervenulin, reumycin, and t extracellular alkaloid produced by streptomyces cdrl-312: fermentation, isolation and pharmacological activity." j. biotech. 88: 1-10. 2001.nakajima et al., "antitumor sub properties and biological activities." j. antibiot. 49: 1196-1203. 1996.nakajima et al. u.s. pat. no. 5,545,542.nakajima et al., "hydantocidin: a new compound with herbicid marine alkaloids of an unidentified red seaweed of the family delleseeraceae from the coasts of senegal." tet lett. 35: 4827-4830. 1994.n'diaye, i. et al., "almazole d, a senegal." tet lett. 37: 3049-3050. 1996.nierman et al., "structural flexibility in the burkholderia mallei genome." proc. natl. acad. sci. usa 101: 14246-14251.2004.okaza aminocyclopropane-1-carboxylate deaminase." microbes environ. 19: 99-111. 2004.parke, j. l. and d. gurian-sherman, d. 2001. "diversity of the burkholderia cepacia co phytopathology 39: 225-258. 2001.parke, et al. u.s. pat. no. 6,077,505.pettit, g. et al. "isolation of labradorinis 1 and 2 from pseudomonas syringae." j. nat. prod. 65: 1 (pseudomonas) cepacia isolates from patients with cystic fibrosis in the united kingdom and the republic of ireland." j. med. microbiol. 44: 203-210. 1996.ramette et al., environ. microbiol. 71: 1193-1201. 2005.resi et al., "burkholderia tropica sp. nov., a novel nitrogen-fixing, plant-associated bacterium." int. j. syst. evol. microbiol. 54: 21 thuringiensis against some cotton pests." z. angew. entomol. 91: 388-398. 1981.selva et al., "targeted screening for elongation factor tu binding antibiotics." j. antibiot. 5 alga, inhibits lipid peroxidation." chem. pharm. bull. 46: 1527-1529. 1998.thompson et al. "spinosad-a case study: an example from a natural products discovery progra revised structures of bleomycin and phleomycin." j. antibiot. 31: 801-804. 1978.tran van et al., "repeated beneficial effects of rice inoculation with a strain of burkholderia plant and soil 218: 273-284. 2000.tsuruo et al., "rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincr 7,396,665.umehara, k. et al. "studies of new antiplatelet agents ws-30581 a and b." j. antibiot. 37: 1153-1160. 1984.vandamme et al. polyphasic taxonomic study of the an aerotolerant bacterium isolated from veterinary specimens." int. j. syst. bacteriol. 42: 344-356. 1992.vanderwall et al., "a model of the structure of hoo-c4 bleomycin b cleavage, chem. biol. 4: 373-387. 1997.vermis k., et al. "evaluation of species-specific reca-based pcr tests for genomovar level identification within the burkholderia cep 4-chloro-5-(3' indolyl)oxazole, produced by streptomyces." meiji seika kenkyu nenpo 27: 55-62. 1988.wayne et al., "report of the ad hoc committee on reconciliation of a "uptake of indolmycin in gram-positive bacteria." antimicrob agents chemotherapy 18: 858-862. 1980.wilson et al. "toxicity of rhizonin a, isolated from rhizopus microspor bonitierungsschema zur feldausswertung von wurzelgallenbefall. pflanzenschutznachrichten." bayer 24, 1: 144-147. 1971. zhang et al., u.s. pat. no. 7,141,407.zhou et al., patients with cystic fibrosis." antimicrobial agents and chemotherapy 51: 1085-1088. 2007. (Results 99)

Search 4: fn=(50961099 or 57466012 or 58695160 or 34356244 or 2153304 or 28628927 or 29966567 or 41744035 or 49470779 or 30353515) (Results 10)

Search 5: TAC=(Burkholderia and pesticidal) and CPC=(C12P17/187 OR C12P17/188) (Results 2)

Search 6: TAC=(Burkholderia) and CPC=(C12P17/187 OR C12P17/188) (Results 4)

Search 7: TAC=(Burkholderia) and CPC=(C12P17/187 AND C12P17/188) (Results 1)

Search 8: TAC=(Burkholderia and pesticidal) (Results 16)

Search 9: PN=(Wo2013030802) (Results 1)

Search 10: [SP]: 1. a method for treating a disease or disorder mediated by the pdgfr receptor, wherein the method comprises administering to a subject in need thereof a compound [ftimg=64854455] r1 is c1-c4 alkyl c1-c4 alkoxy optionally substituted by one or more halogen atoms cn or halogen r1a is h, halogen, c1-c4 alkyl or c1-c4 haloalkyl x is n haloalkyl c2-c8 alkynyl substituted by one or more halogen, oh, -nr9r11 or c1-c4 alkoxy c3-c10 cycloalkyl -c1-c4 alkyl-c3-c8 cycloalkyl c1-c8 alkoxy optionally substituted -(c0-c4 alkyl)-c(o)nr9r11 -(c0-c4 alkyl)-c6-c14 aryl or -(c0-c4 alkyl)-3 to 14 membered heterocyclyl wherein the cycloalkyl, -(c0-c4 alkyl)-c6-c14 aryl and -(c0-c4 alkyl)-3 to c1-c8 alkyl optionally substituted by one or more oh, -nr9r11 or c1-c4 alkoxy c1-c8 haloalkyl c2-c8 alkynyl substituted by one or more halogen, oh, -nr9r11, or c1-c4 alkoxy more halogen, -nr9r11 or oh oh cn halogen -(c0-c4 alkyl)-nr9r11 -(c0-c4 alkyl)-co2r15 -(c0-c4 alkyl)-c(o)nr9r11 -(c0-c4 alkyl)-c6-c14 aryl or -(c0-c4 alkyl)-3 to 14 member heterocyclyl are each optionally substituted by one or more za substituents each za is independently oh -(c0-c4 alkyl)-c6 aryl c1-c4 alkyl optionally substituted by more oh, -co2r19a -nr19ar21a or c1-c4 alkoxy -nr18ac(o)r21a -(c(o)nr19ar21a -nr18ac(o)nr19ar21a -nr19ar21a -(c0-c4 alkyl)-c(o)or18a -(c0-c4 alkyl)-c(o)r19a oxo cn no2 the -(c0-c4 alkyl)-c6 aryl, o-c6 aryl, -(c0-c4 alkyl)-4 to 6 membered heterocyclyl and -(o-4 to 6 membered heterocyclyl) are each optionally substituted by oh, halogen, c1-h, c1-c4 alkyl or c1-c4 haloalkyl r6 is selected from c1-c8 alkyl optionally substituted by one or more c1-c4 alkoxy or -nr19r21 c1-c8 haloalkyl -(c0-c4alkyl)-c3-c8cycloalkyl c14aryl and -(c0-c4 alkyl)-3 to 14 membered heterocyclyl wherein the -(c0-c4alkyl)-c3-c8cycloalkyl, -(c0-c4 alkyl)-c6-c14aryl and -(c0-c4 alkyl)-3 to 14 heterocyclyl are eac alkyl)-c6 aryl o-c6 aryl c1-c6 alkyl optionally substituted by one or more c1-c6 alkoxy, cn or -nr19r21 c1-c6 haloalkyl c1-c6 alkoxy optionally substituted by one or more -n membered heterocyclyl and wherein the aryl and heterocyclyl are each optionally substituted by one or more halogen, c1-c6 alkyl, c1-c6 haloalkyl and c1-c6 alkoxy option alkyl optionally substituted by one or more c1-c4 alkoxy or oh c1-c6 haloalkyl -(c0-c1alkyl)-c3-c6 cycloalkyl (c0-c4 alkyl)-c6-c14aryl optionally substituted by one or more heterocyclyl optionally substituted by one or more groups selected from halogen, oxo, c1-c6 alkyl and c(o)c1-c6 alkyl or r9 and r11 together with the nitrogen atom to whic further heteroatoms selected from n, o and s, the heterocyclyl being optionally substituted by one or more substituents selected from oh halogen phenyl, 5- to 10-memb or c1-c4 alkoxy and c(o)oc1-c6alkyl wherein the phenyl and heterocyclyl substituent groups are themselves optionally substituted by c1-c6 alkyl, c1-c6 haloalkyl or c1-c6 al cycloalkyl -(c0-c4 alkyl)-c6-c10aryl and -(c0-c4 alkyl)-3 to 14 membered heterocyclyl group wherein the c3-c10 cycloalkyl, -(c1-c4alkyl)-c3-c8 cycloalkyl, -(c0-c4 alkyl)-c6-c one or more z substituents r18a is independently h or c1-c6 alkyl c1-r19a and r21a are each independently h c1-c6 alkyl optionally substituted by one or more c1-c4 alkoxy, substituted by one or more groups selected from c1-c6 alkyl, c1-c6 alkoxy and halogen or -(c0-c4 alkyl)-3- to 14-membered heterocyclyl optionally substituted by one or with the nitrogen atom to which they attached form a 5- to 10-membered heterocyclyl, which heterocyclyl includes 0 to 3 further heteroatoms selected from n, o and s, the phenyl 5- to 10-membered heterocyclyl c1-c6 alkyl c1-c6 haloalkyl c1-c6 alkoxy optionally substituted by one or more oh or c1-c4 alkoxy and c(o)oc1-c6alkyl wherein the c6 haloalkyl or c1-c6 alkoxy r18 is independently h or c1-c6 alkyl r19 and r21 are each independently c1-c6 alkyl optionally substituted by one or more c1-c4 alkoxy c1-c6 more groups selected from c1-c6 alkyl, c1-c6 alkoxy and halogen or -(c0-c4 alkyl)-3- to 14-membered heterocyclyl, optionally substituted by one or more groups selected which they attached form a 5- to 10-membered heterocyclyl, which heterocyclyl includes 0 to 3 further heteroatoms selected from n, o and s, the heterocyclyl being option heterocyclyl c1-c6 alkyl c1-c6 haloalkyl c1-c6 alkoxy optionally substituted by one or more c1-c4 alkoxy and c(o)oc1-c6alkyl wherein the phenyl and heterocyclyl substituen haloalkyl and c1-c6 alkoxy and r22 and r23 are each independently h or c1-c6 alkyl wherein the disease or condition is a metabolic disease, a fibrotic disease, cardiac hyp an autoimmune disease. 2. the method of claim 1, wherein the disease or condition is asthma, allergic rhinitis, irritable bowel syndrome (ibs), inflammatory bowel diseas scleroderma, urticaria, dermatoses, atopic dermatitis, type i diabetes or type ii diabetes. 3. the method of claim 2, wherein the disease or condition is pulmonary artery by one or more c1-c4 alkoxy phenyl c1-c4 haloalkyl tetrahydrofuran pyrrolidine, -ch2-pyrrolidine or -ch2-piperidine wherein phenyl, tetrahydrofuran, pyrrolidine, -ch2-pyrrol is independently c1-c4 alkoxy, halogen, c1-c4 alkyl or c1-c4 haloalkyl. 5. the method of claim 1, wherein r2 is h c1-c8 alkyl optionally substituted by one or more oh, -nr9r or c1-c4 alkoxy c3-c10 cycloalkyl -(c1-c4 alkyl)-c3-c8 cycloalkyl c1-c8 alkoxy optionally substituted by one or more halogen, -nr9r11 or oh oh cn halogen -(c0-c4 alkyl)-nr9 14 membered heterocyclyl wherein the cycloalkyl, -(c0-c4 alkyl)-c6-c14 aryl and -(c0-c4 alkyl)-3 to 14 membered heterocyclyl are each optionally substituted by one or mo one or more c1-c4 alkoxy or oh c1-c6 haloalkyl -(c0-c4alkyl)-c3-c6cycloalkyl (c0-c4 alkyl)-c6-c14 aryl optionally substituted by one or more groups selected from c1-c6 alk by one or more groups selected from halogen, oxo, c1-c6 alkyl and c(o)c1-c6 alkyl za is independently oh -(c0-c4 alkyl)-c6 aryl o-c6 aryl c1-c4 alkyl optionally substituted more oh, -co2r19a, -nr19ar21a or c1-c4 alkoxy -nr18ac(o)r21a -(c(o)nr19ar21a -nr18ac(o)nr19ar21a -nr19ar21a -(c0-c4 alkyl)-c(o)or18a -(c0-c4 alkyl)-c(o)r19a oxo cn no2 optionally substituted by halogen, c1-c4 alkyl, c1-c4 haloalkyl or c1-c4 alkoxy optionally substituted by one or more halogens r18a is independently h or c1-c6 alkyl r19a or oh c1-c6 haloalkyl -(c0-c4alkyl)-c3-c0cycloalkyl -(c0-c4 alkyl)-c6-c14 optionally substituted by one or more groups selected from c1-c6 alkyl, c1-c6 alkoxy and halogen selected from halogen, oxo, c1-c6 alkyl and c(o)c1-c6 alkyl or r19a and r21a together with the nitrogen atom to which they attached form a 5- to 10-membered heterocycl being optionally substituted by one or more substituents selected from oh halogen phenyl 5- to 10-membered heterocyclyl c1-c6 alkyl c1-c6 haloalkyl c1-c6 alkoxy option heterocyclyl substituent groups are themselves optionally substituted by c1-c6 alkyl, c1-c6 haloalkyl or c1-c6 alkoxy. 6. the method of claim 1, wherein r2 is h c1-c4 alkyl substituted by one or more halogen, -nr9r11 or oh oh cn halogen -(c0-c4 alkyl)-nr9r11 -(c0-c4 alkyl)-c(o)nr9r11 phenyl or -(c0-c4 alkyl)-5 to 6 membered heterocyclyl wh one or more za substituents r3 is h r9 and r11 are each independently h c1-c6 alkyl optionally substituted by one or more c1-c4 alkoxy or oh c1-c6 haloalkyl -(c0-c4alkyl)- c6 alkyl, c1-c6 alkoxy and halogen or (c0-c4 alkyl)-5- to 6-membered heterocyclyl optionally substituted by one or more groups selected from halogen, oxo, c1-c6 alkyl a or -nr19ar21a c1-c4 haloalkyl c1-c4 alkoxy optionally substituted by one or more oh, c1-c4 alkoxy or -nr19ar21a -(c(o)nr19ar21a cn halogen or -(c0-c4 alkyl)-4 to 6 memb haloalkyl or c1-c4 alkoxy optionally substituted by one or more halogens r19a and r21a are each independently h c1-c4 alkyl optionally substituted by one or more c1-c4 substituted by one or more groups selected from c1-c6 alkyl, c1-c6 alkoxy and halogen or -(c0-c4 alkyl)-5- to 6-membered heterocyclyl optionally substituted by one or m wherein r1 is fluorine or methyl r1a is h r2 is h, f, br, [ftimg=64854456][ftimg=64854457] r3 is h r4 is h r5 is h and r6 is [ftimg=64854458]8. the method of claim 1, wher benzylycarbamoyl)phenyl)-7-(1-methyl-1h-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamide 7-(3-fluoro-4-(2-hydroxyethylcarbamoyl)phenyl)-n-(2-fluoro-5-(2-(4-methyl methyl)-5-(2-(4-methyl)piperazin-1-yl)benzylycarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide 7-(1-methyl-1h-pyrazol-5-yl)-n-(2-methyl-5-(2-(4-methyl)piperazin- methyl)piperazin-1-yl)benzylycarbamoyl)phenyl)-7-(pyridine-3-yl)imidazo[1,2-a]pyridine-3-carboxamide n-(2-fluoro-5-(2-(4-methyl)piperazin-1-yl)benzylycarbamoyl)phenyl)-difluorobenzylycarbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-5-yl) imidazo[1,2-a]pyridine-3-carboxamide n-(5-(benzylycarbamoyl)-2-fluorophenyl)-6-(1-methyl-1h-py yl) benzylycarbamoyl)phenyl)-7-(pyridine-3-yl)imidazo[1,2-a]pyridine-3-carboxamide n-(5-(3,4-difluorobenzylycarbamoyl)-2-fluorophenyl)-7-(6-(3-(dimethylamino) propox ethylcarbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamide 7-(4-(aminomethyl)phenyl)-n-(2-fluoro-5-(2-(4-methyl)piperazin-1-yl butoxyethylcarbamoyl)-2-fluorophenyl)-7-(1-(2-morpholinoethyl)-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide n-(5-(5,5-dimethyltetrahydrofuran-2-yl)methyl c carboxamide n-(2-fluoro-5-(2-(4-methyl)piperazin-1-yl)benzylycarbamoyl)phenyl)-7-(6-methoxy pyridine-3-yl)imidazo[1,2-a]pyridine-3-carboxamide n-(2-fluoro-5-(2-(4-m 3-carboxamide 1-(2-(4-fluoro-3-(7-(pyridine-3-yl)imidazo[1,2-a]pyridine-3-carboxamido)benzamido)ethyl)-2,6-cis-dimethylpiperidine n-(5-(2-tert-butoxyethylcarbamoyl)

carboxamide n-(2-methyl-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)-7-(pyridine-3-yl)imidazo[1,2-a]pyridine-3-carboxamide 1-methyl-4-(2-((6-methyl-5-(7-(piperazin-1-yl)-1-methyl-1h-pyrazol-4-yl)-imidazo[1,2-a]pyridine-3-carboxylic acid {5-(2-(2,6-cis-dimethylpiperidin-1-yl)ethylcarbamoyl)-2-fluoro-phenyl)-amide n-(imidazo[1,2-a]pyridine-3-carboxamide n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(6-(2-(pyrrolidin-1-yl)ethoxy) pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxa phenyl)pyrazolo[1,5-a]pyridine-3-carboxamide n-(2-bromo-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide n-(2-bromo-5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-hydroxy-3-methyl butyl)imidazo[1,2-a]pyridine-3-carboxamide n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-(2-(tetrahydro-2h-pyran-4-yl)ethylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide n-(5-(3,4-difluor [1,2-a]pyridine-3-carboxamide n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(1-(3-(dimethyl amino)propyl)-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxami 2h-pyran-4-ylamino)methyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (s)-n-(5-(((5,5-dimethyltetrahydrofuran-2-yl)methyl) carbamoyl)-2-fluorophenyl)-7-(5-(((2 dimethyltetrahydrofuran-2-yl)methyl) carbamoyl)-2-fluorophenyl)-7-(5-(((2-methoxyethyl) (methyl)amino)methyl)pyridin-3-yl) imidazo[1,2-a]pyridine-3-carboxamide (r)- carbamoyl)-2-fluorophenyl) imidazo[1,2-a]pyridine-3-carboxamide n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(6-(2-(pyrrolidin-1-yl)ethoxy) pyridin-3-yl)imida (pyrrolidin-1-yl) ethoxy)pyridin-3-yl) imidazo[1,2-a]pyridine-3-carboxamide n-(5-(((5,5-dimethyl tetrahydrofuran-2-yl)methyl)carbamoyl)-2-fluorophenyl)-7-(6-(1-methyl yl)-n-(2-methyl-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)pyrazolo[1,5-a]pyridine-3-carboxamide n-(2-bromo-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl) benzylcarbamoyl)phenyl)pyrazolo[1,5-a]pyridine-3-carboxamide n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-hydroxy-3-methyl butyl)imidazo[1,2-a]pyridine- yl)ethylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-(2-(tetrahydro-2h-pyran-4-yl)ethylcarb carbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide n-(5-(2-(2,2-dimethylpyrrolidin-1-yl)ethylcarbamoyl)-2-fluorophenyl)-7-(3 n-(5-(2-(2,2-dimethylpyrrolidin-1-yl)ethylcarbamoyl)-2-methylpyridin-3-yl)-6-(3-fluoro-4-(1-hydroxy-2-methylpropan-2-ylcarbamoyl)phenyl)pyrazolo[1,5-a]pyridine-3-carb propylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide n-(5-(2-(2,6-cis-dimethylpiperidin-1-yl)ethylcarbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-(1-hydroxy-2-methyl fluoroethylcarbamoyl)phenyl)-n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide n-(2-fluoro-5-(2-(4-methylpiperazi pyridine-3-carboxamide n-(5-(2-(2,2-dimethylpyrrolidin-1-yl)ethylcarbamoyl)-2-methylpyridin-3-yl)-6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carboxamide (s pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide n-(2-fluoro-5-(2-(3-propylpyrrolidin-1-yl)ethylcarbamoyl)phenyl)-7-(1-methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridin phenyl)-7-(1-methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide n-(5-(2-(3,5-dimethylpiperidin-1-yl)ethylcarbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazo ethyl)carbamoyl)phenyl)-7-(1-methyl-1h-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamide n-(5-(((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)- [1,2-a]pyridine-3-carboxamide n-(5-(((2-(3,3-dimethylmorpholino)ethyl)carbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-((1-hydroxy-2-methylpropan-2-yl)carbamoyl)phenyl)imi phenyl)-n-(2-fluoro-5-(2-(2-(methoxymethyl)pyrrolidin-1-yl)ethyl) carbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide n-(5-(3,4-difluorobenzyl)carbamoyl)-2-fluoro carboxamide n-(5-(((2-(2,2-dimethylpiperidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carboxamide n-(5-(2-(2 pyrazolo[1,5-a]pyridine-3-carboxamide n-(5-(((2-(2s,3r)-2,3-diethylazetidin-1-yl)ethyl) carbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3 (methyl)amino)methyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide n-(5-(3,4-difluorobenzyl)carbamoyl)-2-fluorophenyl)-7-(6-(methyl (phenethyl)amino)methyl)p fluorophenyl)-7-(5-(((methylamino) methyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide 7-(5-(cyclohexyl amino)methyl)pyridin-3-yl)-n-(5-(((3,4-difluorobenzyl) carb carbamoyl)-2-fluorophenyl)-7-(5-(2-(methoxyethyl) (methyl)amino)methyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide or a pharmaceutically acceptable salt there or 6-membered heterocyclyl, each optionally substituted by one, two or three za substituents. 11. the method of claim 10, wherein r6 is -(c0-c2 alkyl)-5 to 6 membered h wherein each z is independently c1-c4 alkoxy, halogen, c1-c4 alkyl or c1-c4 haloalkyl. 13. the method of claim 1, wherein the compound of formula (i) is n-(5-(2-(2,2-di pyridine-3-carboxamide or a pharmaceutically acceptable salt thereof. 14. the method of claim 1, wherein the compound of formula (i) is n-(5-(2-(2,6-cis-dimethylpiperidi carboxamide or a pharmaceutically acceptable salt thereof. 15. the method of claim 1, wherein the compound of formula (i) is n-(5-(2-(2,2-dimethylpyrrolidin-1-yl)ethylca carboxamide or a pharmaceutically acceptable salt thereof. 16. the method of claim 1, wherein the compound of formula (i) is 7-(1-methyl-1h-pyrazol-4-yl)-imidazo[1,2- phenyl)-amide or a pharmaceutically acceptable salt thereof. 17. the method of claim 1, wherein the compound of formula (i) is n-(5-(2-(2,2-dimethylpyrrolidin-1-yl)ethy carboxamide or a pharmaceutically acceptable salt thereof. 18. the method of claim 1, wherein the compound of formula (i) is n-(5-(2-(2,6-cis-dimethylpiperidin-1-yl)ethyl imidazo[1,2-a]pyridine-3-carboxamide or a pharmaceutically acceptable salt thereof. 19. a method of treating pulmonary arterial hypertension in a subject in need thereof selected from: n-(5-(2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide n-(5-(2-(2,6-cis a]pyridine-3-carboxamide n-(5-(2-(2,2-dimethylpyrrolidin-1-yl)ethylcarbamoyl)-2-methylpyridin-3-yl)-6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carboxamide piperidin-1-yl)-ethylcarbamoyl]-2-fluoro-phenyl)-amide n-(5-(2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-6-(1-methyl-1h-pyrazol-5-yl)pyrazolo fluorophenyl)-7-(3-fluoro-4-(1-hydroxy-2-methylpropan-2-ylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide or a pharmaceutically acceptable salt thereof. (Resu

Search 11: fn=(57313512 or 57313512 or 58695317 or 59548275 or 30782862 or 1986827 or 10970478 or 10328755 or 30466403 or 30620321 or 35914540 or 31808748 or 30828 or 11495207 or 29022323 or 20661120 or 20661120 or 29785959 or 48770757 or 30947220 or 30910989 or 15288445 or 30382213 or 15304284 or 32885684 or 23130 or 23469018 or 23483869 or 15998746 or 14267472 or 14267472 or 30009017 or 15998736 or 30009052 or 42247157 or 23204202 or 23204219 or 42245353 or 34241 or 30049602 or 30049602 or 26834514 or 30922924 or 26834293 or 23203770 or 23304271 or 26834895 or 42245670 or 29176579 or 29176862 or 29427701 or 29427 or 30182664 or 30221201 or 30159883 or 30260656 or 30260672 or 30260686 or 23921181 or 24121683 or 32428691 or 30352549 or 30352549 or 30352551 or 30352 or 24090496 or 30422897 or 30423667 or 30423686 or 30423690 or 30423691 or 30466403 or 30667206 or 26834675 or 26834675 or 30354406 or 27924440 or 26835 or 30828547 or 30828547 or 43941857 or 30963354 or 31413164 or 31346408 or 28838866 or 14860818 or 34288328 or 30434410 or 32886770 or 31958917 or 32021 or 32008271 or 34298802 or 34323338 or 32634716 or 39601869 or 41007371 or 44090639 or 33007272 or 41802181 or 41832440 or 42011672 or 42585254 or 42572 or 46397799 or 46423023 or 48345572 or 48789416 or 49339900 or 50118528 or 50480340 or 50739133 or 8331904 or 8393367 or 30174303 or 20249701 or 2023793

Search 12: [SP]: cross-reference to related applications [0001] this application is a divisional application of u.s. ser. no. 13/599,267, filed aug. 30, 2012, which claims the benefit of 2011 and u.s. provisional patent application no. 61/680,119, filed aug. 6, 2012, the disclosures of which are incorporated herein by reference in their entirety and for all p derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them. more particularly the present invention relates to their use i a large set of structurally related phosphoryl transferases having highly conserved structures and catalytic functions. protein kinases are enzymatic components of the sign hydroxy group of tyrosine, serine and/or threonine residues of proteins, and are therefore categorized into families by the substrates they phosphorylate: protein tyrosine the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes, wherein protein kinases are key overexpression or inappropriate expression of normal or mutant protein kinases plays a significant role in the development of many diseases and disorders including, cen diseases such as osteoporosis, metabolic disorders such as diabetes, blood vessel proliferative disorders such as angiogenesis, autoimmune diseases such as rheumatoi restenosis, schizophrenia, pain sensation, transplant rejection and infectious diseases such as viral, and fungal infections.[0005] the agents of the invention act as inhibit activated by binding of the growth factor pdgf to the extracellular portion of the receptor. upon activation pdgfr phosphorylates many substrate proteins and controls a wid multiple cell types including those of the mesenchymal lineage, fibroblasts, vascular smooth muscles cells and pericytes.[0006] pdgfr kinase inhibition is expected to be a hypertrophic disorders, many cancers and other indications in which pdgf driven functional responses contribute to pathology, including pah. pdgfr, pdgfr ligands and activa lesions in the pulmonary vasculature of pah patients and animal models of pah. furthermore, the tyrosine kinase inhibitor gleeev(c) has been shown to be efficacious in t of the invention may contribute to the efficacy of the agents in pah, asthma and other indications. for example, c-kit inhibition contributes to the depletion of mast cells a in a first aspect of the invention, embodiment 1, we provide a compound of formula (i)[f]tmg=64854333) or a pharmaceutically acceptable salt thereof, wherein, [0008] a atoms cn or halogen r1a is h, halogen, c1-c4 alkyl or c1-c4 haloalkyl x is n or ch [0009] r2 is h c1-c8 alkyl optionally substituted by one or more oh, -nr9r11 or c1-c4 alko c3-c10 cycloalkyl -(c1-c4 alkyl)-c3-c8 cycloalkyl c1-c8 alkoxy optionally substituted by one or more halogen, -nr9r11 or oh oh cn halogen -(c0-c4 alkyl)-nr9r11 -(c0-c4 alkyl heterocyclyl wherein the cycloalkyl, -(c0-c4 alkyl)-c6-c14 aryl and -(c0-c4 alkyl)-3 to 14 heterocyclyl are each optionally substituted by one or more za substituents r3 is h c c alkynyl substituted by one or more halogen, oh, -nr9r11, or c1-c4 alkoxy c3-c10 cycloalkyl -(c1-c4 alkyl)-c3-c8 cycloalkyl c1-c8 alkoxy optionally substituted by one or mor (o)n9r11 -(c0-c4 alkyl)-c6-c14 aryl or -(c0-c4 alkyl)-3 to 14 membered heterocyclyl wherein the cycloalkyl, -(c0-c4 alkyl)-c6-c14 aryl and -(c0-c4 alkyl)-3 to 14 heterocyclyl c4 alkyl)-c6 aryl -o-c6 aryl c1-c4 alkyl optionally substituted by one or more oh, cn or -nr19ar21a c1-c4 haloalkyl c1-c4 alkoxy optionally substituted by one or more oh, -c nr19ar21a -(c0-c4 alkyl)-c4)or18a -(c0-c4 alkyl)-c(o)r19a oxo cn no2 halogen or -(c0-c4 alkyl)-4 to 6 membered heterocyclyl wherein the aryl and heterocyclyl are each o by one or more halogens r4 is h, c1-c4 alkyl or c1-c4 haloalkyl r5 is h, c1-c4 alkyl or c1-c4 haloalkyl r6 is selected from c1-c8 alkyl optionally substituted by one or more c or more halogen atoms -nr19r21 -(c0-c4 alkyl)-c8-c14aryl -(c0-c4 alkyl)-3 to 14 membered heterocyclyl and -(c0-c4 alkyl)-co2r16 wherein the -(c0-c4alkyl)-c3-c8cycloalkyl one or more z substituents each z is independently selected from oh (c0-c4 alkyl)-c6 aryl o-c6 aryl c1-c6 alkyl optionally substituted by one or more oh, cn or -nr19r21 c1-alkoxy -nr18c(o)r19 -c(o)nr19r21 -nr18c(o)nr19r21 -nr19r21 (c0-c4 alkyl)-c(o)or19 (c0-c4 alkyl)-c(o)r19 oxo cn no2 halogen and (c0-c4 alkyl)-4 to 6 membered heterocyl c1-c6 alkyl, c1-c6 haloalkyl and c1-c6 alkoxy optionally substituted by one or more halogens r9 and r11 are each independently selected from h c1-c8 alkyl optionally sub alkyl)-c6-c14aryl optionally substituted by one or more groups selected from c1-c8 alkyl, c1-c8 alkoxy and halogen and (c0-c4 alkyl)-3- to 14-membered heterocyclyl opti alkyl or r9 and r11 together with the nitrogen atom to which they are attached form a 5- to 10-membered heterocyclyl, which heterocyclyl includes 0 to 3 further heterato substituents selected from oh halogen phenyl, 5- to 10-membered heterocyclyl c1-c6 alkyl c1-c6 haloalkyl c1-c6 alkoxy optionally substituted by one or more oh or c1-c4 optionally substituted by c1-c6 alkyl, c1-c6 haloalkyl or c1-c6 alkoxy r15 is selected from h c1-c8 alkyl c1-c8 haloalkyl c3-c10 cycloalkyl -(c1-c4alkyl)-c3-c8 cycloalkyl -(c0-c aryl and heterocyclyl groups are each optionally substituted by one or more z substituents r18a is independently h or c1-c6 alkyl r19a and r21a are each independently h c c3-c6cycloalkyl (c0-c4 alkyl)-c6-c14aryl optionally substituted by one or more groups selected from c1-c6 alkyl, c1-c6 alkoxy and halogen or (c0-c4 alkyl)-3- to 14-membe alkyl and c(o)c1-c6 alkyl or r19a and r21a together with the nitrogen atom to which they attached form a 5- to 10-membered heterocyclyl, which heterocyclyl includes 0 to or more substituents selected from oh halogen phenyl 5- to 10-membered heterocyclyl c1-c6 alkyl c1-c6 haloalkyl c1-c6 alkoxy optionally substituted by one or more oh o themselves optionally substituted by c1-c6 alkyl, c1-c6 haloalkyl or c1-c6 alkoxy r18 is independently h or c1-c6 alkyl r19 and r21 are each independently h c1-c6 alkyl opt (c0-c4 alkyl)-c6-c14aryl optionally substituted by one or more groups selected from c1-c6 alkyl, c1-c6 alkoxy and halogen or (c0-c4 alkyl)-3- to 14-membered heterocyclyl c6 alkyl or r19 and r21 together with the nitrogen atom to which they attached form a 5- to 10-membered heterocyclyl, which heterocyclyl includes 0 to 3 further heterato substituents selected from oh halogen phenyl 5- to 10-membered heterocyclyl c1-c6 alkyl c1-c6 haloalkyl c1-c6 alkoxy optionally substituted by one or more oh or c1-c4 a optionally substituted by a substituent selected from c1-c6 alkyl, c1-c6 haloalkyl and c1-c6 alkoxy. definitions [0010] for purposes of interpreting this specification, the foll the plural and vice versa.[0011] as used herein, the term "alkyl" refers to a fully saturated branched or unbranched hydrocarbon moiety having up to 20 carbon atoms. un carbon atoms, or 1 to 4 carbon atoms. representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, sec-butyl, iso-butyl, te dimethylpentyl, n-heptyl, or n-octyl.[0012] as used herein, the term "alkoxy" refers to alkyl-o-, wherein alkyl is defined herein above. representative examples of alkoxy pentyloxy, hexyloxy, cyclopropyloxy-, cyclohexyloxy- and the like. typically, alkoxy groups have about 1-6, more preferably about 1-4 carbons.[0013] as used herein, the groups as defined herein. the haloalkyl can be monohaloalkyl, dihaloalkyl or polyhaloalkyl including perhaloalkyl. a monohaloalkyl can have one iodo, bromo, chloro or fl halo atoms or a combination of different halo groups within the alkyl. typically the polyhaloalkyl contains up to 12, or 10, or 8, or 6, or 5, or 4, or 3, or 2 halo groups. non dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropr used herein, the term "cycloalkyl" refers to saturated or unsaturated monocyclic, bicyclic or tricyclic hydrocarbon groups of 3-10 carbon atoms. unless otherwise provided, c 3 and 8 ring carbon atoms. exemplary monocyclic hydrocarbon groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexyl or cyclo tetrahydronaphthyl, decahydronaphthyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, 6,6-dimethylbicyclo[3.1.1]heptyl, 2,6,6-trimethylbicyclo[3.1.1]hep branched saturated hydrocarbon group containing from 2 to 8 carbon atoms that contains at least one carbon to carbon triple bond. examples of such groups include ethyl having 6-14 carbon atoms in the ring portion. typically, aryl is monocyclic or bicyclic aryl having 6-14 carbon atoms and includes one aromatic ring fused to one non-roma tetrahydronaphthyl.[0017] as used herein, the term "aryloxy" refers to both an -o-aryl and an -o-heteroaryl group, wherein aryl and heteroaryl are defined herein.[0018] 10-membered heterocyclyl", "3- to 14-membered heterocyclyl", "4- to 14-membered heterocyclyl" and "5- to 14-membered heterocyclyl", refers, respectively, to 4- to 8-m 5- to 14-membered heterocyclic rings containing at least one ring heteroatom selected from the group consisting of nitrogen, oxygen and sulphur, which may be saturate ring groups and bridged groups. examples of such heterocyclyl include, but are not limited to, furan, pyrrole, pyrrolidine, pyrazole, imidazole, triazole, isotriazole, tetrazol pyridazine, pyrimidine, piperazine, pyrrolidine, pyrrolidinone, morpholine, triazine, oxazine, tetrahydrofuran, tetrahydrothiophene, tetrahydrothiopyran, tetrahydropryan, 1,4 dihydrobenzofuran or thiazole.[0019] "heteroaryl" is a subset of heterocyclyl, wherein "heteroaryl" are completely unsaturated (aromatic). examples of such groups are py bromo, and iodo.[0021] various embodiments of the invention are described herein. it will be recognized that features specified in each embodiment may be combined wi formula (i)[f]tmg=64854335) or a pharmaceutically acceptable salt thereof, wherein, [0023] a is [f]tmg=64854336) r1 is c1-c4 alkyl c1-c4 alkoxy optionally substituted by ch [0024] r2 is h c1-c8 alkyl optionally substituted by one or more oh, -nr9r11 or c1-c4 alkoxy c1-c8 haloalkyl c2-c58alkynyl substituted by one or more halogen, oh, -nr9r substituted by one or more halogen, -nr9r11 or oh oh cn halogen -(c0-c4 alkyl)-nr9r11 -(c0-c4 alkyl)-co2r15 -(c0-c4 alkyl)-c(o)nr9r11 -(c0-c4 alkyl)-c6-c14 aryl or -(c0-c4 alkyl)-3 to 14 heterocyclyl are each optionally substituted by one or more za substituents r3 is h c1-c8 alkyl optionally substituted by one or more oh, -nr9r11 or c1-c4 alk c3-c10 cycloalkyl -(c1-c4 alkyl)-c3-c8 cycloalkyl c1-c8 alkoxy optionally substituted by one or more halogen, -nr9r11 or oh oh cn halogen -(c0-c4 alkyl)-nr9r11 -(c0-c4 alkyl heterocyclyl wherein the cycloalkyl, -(c0-c4 alkyl)-c6-c14 aryl and -(c0-c4 alkyl)-3 to 14 heterocyclyl are each optionally substituted by one or more za substituents each za oh, cn or -nr19ar21a c4 haloalkyl c1-c4 alkoxy optionally substituted by one or more oh, -co2r19a, -nr19ar21a or c1-c4 alkoxy -nr18a(c)o)r21a -c(o)nr19ar21a -nr18a(c)o)nr alky)-4 to 6 membered heterocyclyl or -o-(4 to 6 membered heterocyclyl) wherein the (c0-c4 alkyl)-c6 aryl, o-c6 aryl, -(c0-c4 alkyl)-4 to 6 membered heterocyclyl and -o- haloalkyl or c1-c4 alkoxy optionally substituted by one or more halogens r4 is h [0025] r5 is h, c1-c4 alkyl or c1-c4 haloalkyl r6 is selected from c1-c8 alkyl optionally sub c8alkoxy optionally substituted by one or more halogen atoms -nr19r21 -(c0-c4 alkyl)-c6-c14aryl and -(c0-c4 alkyl)-3 to 14 membered heterocyclyl wherein the -(c0-c4alk

optionally substituted by one or more z substituents each z is independently selected from (c0-c4 alkyl)-c6 aryl o-c6 aryl c1-c6 alkyl optionally substituted by one or more nr19r21 or c1-c4 alkoxy -nr19r21 (c0-c4 alkyl)-c(o)r19 cn halogen and (c0-c4 alkyl)-4 to 6 membered heterocyclyl and wherein the aryl and heterocyclyl are each optionally substituted by one or more halogens r9 and r11 are each independently selected from h c1-c6 alkyl optionally substituted by one or more c1-c4 alkoxy or oh c1-c6 haloal groups selected from c1-c6 alkyl, c1-c6 alkoxy and halogen and (c0-c4 alkyl)-3- to 14-membered heterocyclyl optionally substituted by one or more groups selected from which they are attached form a 5- to 10-membered heterocyclyl, which heterocyclyl includes 0 to 3 further heteroatoms selected from n, o and s, the heterocyclyl being op membered heterocyclyl c1-c6 alkyl c1-c6 haloalkyl c1-c6 alkoxy optionally substituted by one or more oh or c1-c4 alkoxy and c(o)oc1-c6alkyl wherein the phenyl and heter c1-c6 alkoxy r15 is selected from h c1-c8 alkyl c1-c8 haloalkyl c3-c10 cycloalkyl (c1-c4alkyl)-c3-c8 cycloalkyl (c0-c4 alkyl)-c6-c14aryl and (c0-c4 alkyl)-3 to 14 membre c14aryl and (c0-c4 alkyl)-3 to 14 membered heterocyclyl groups are each optionally substituted by one or more z substituents r18a is independently h or c1-c6 alkyl r19a -nr22r23', or oh c1-c6 haloalkyl (c0-c4alkyl)-c3-c6cycloalkyl (c0-c4 alkyl)-c6-c14aryl optionally substituted by one or more groups selected from c1-c6 alkyl, c1-c6 alkoxy more groups selected from halogen, oxo, c1-c6 alkyl and c(o)c1-c6 alkyl or r19a and r21a together with the nitrogen atom to which they attached form a 5- to 10-member the heterocyclyl being optionally substituted by one or more substituents selected from oh halogen phenyl 5- to 10-membered heterocyclyl c1-c6 alkyl c1-c6 haloalkyl c1-c phenyl and heterocyclyl substituted groups are themselves optionally substituted by c1-c6 alkyl, c1-c6 haloalkyl or c1-c6 alkoxy r18 is independently h or c1-c6 alkyl r19 a haloalkyl (c0-c1alkyl)-c3-c6cycloalkyl (c0-c4 alkyl)-c6-c14aryl optionally substituted by one or more groups selected from c1-c6 alkyl, c1-c6 alkoxy and halogen or (c0-c from halogen, c1-c6 alkyl and (c0)c1-c6 alkyl or r19 and r21 together with the nitrogen atom to which they attached form a 5- to 10-membered heterocyclyl, which hetero substituted by one or more substituents selected from halogen phenyl 5- to 10-membered heterocyclyl c1-c6 alkyl c1-c6 haloalkyl c1-c6 alkoxy optionally substituted by o groups are themselves optionally substituted by a substituent selected from c1-c6 alkyl, c1-c6 haloalkyl and c1-c6 alkoxy and r22 and r23 are each independently h or c1- embodiment 2, wherein r1 is c1-c4 alkyl, c1-c4 alkoxy, cn or halogen. embodiment 4 [0027] a compound of formula (i), according to any preceding embodiment, wherein preceding embodiment, wherein r1 is methyl or halogen. embodiment 6 [0029] a compound of formula (i), according to any preceding embodiment, wherein r1 is methyl wherein r1a is h, methyl or f particularly r1a is h. embodiment 8 [0031] a compound of formula (i), according to any preceding embodiment, wherein x is n. embodiment embodiment 10 [0033] a compound of formula (i), according to any preceding embodiment, wherein r2 is h c1-c6 alkyl optionally substituted by one or more oh, -nr9r11 c1-c4 alkoxy c3-c6 cycloalkyl (c1-c4 alkyl)-c3-c6 cycloalkyl c1-c6 alkoxy optionally substituted by one or more halogen, -nr9r11 or oh oh cn halogen (c0-c4 alkyl)-nr9r11 membered heterocyclyl wherein the c3-c6cycloalkyl, (c0-c4 alkyl)-c6-c14aryl and (c0-c4 alkyl)-3 to 14 heterocyclyl are each optionally substituted by one or more za subs embodiment, wherein r2 is h c1-c4 alkyl optionally substituted by one or more oh, -nr9r11 or c1-c4 alkoxy c1-c4 haloalkyl c2-c6 alkynyl substituted by one or more haloge optionally substituted by one or more halogen, -nr9r11 or oh oh cn halogen (c0-c4 alkyl)-co2r15 (c0-c4 alkyl)-c(o)nr19r11 (c0-c4 alkyl)-c6-c14aryl c14aryl and (c0-c4 alkyl)-3 to 14 heterocyclyl are each optionally substituted by one or more za substituents. embodiment 12 [0035] a compound of formula (i), accordin oh or -nr9r11 c1-c4 haloalkyl c1-c4 alkoxy optionally substituted by one or more halogen, -nr9r11 or oh oh cn halogen (c0-c4 alkyl)-nr9r11 (c0-c4 alkyl)-c(o)nr9r11 phen heterocyclyl are each optionally substituted by one or more za substituents. embodiment 13 [0036] a compound of formula (i), according to any preceding embodiment, substituted by one or more -nr9r11 or oh f br (c1-c6 alkyl)-nr9r11 (c0-c4 alkyl)-nr9r11 phenyl or (c0-c4 alkyl)-5 to 6 membered heterocyclyl wherein the phenyl and (c0-c4 alkyl 14 [0037] a compound of formula (i), according to any preceding embodiment, wherein r2 is h c1-c4 alkyl optionally substituted by one or more oh or -nh2 c1-c4 alkoxy o membered heterocyclyl wherein the phenyl and (c0-c4 alkyl)-5 to 6 heterocyclyl are each optionally substituted by one or more za substituents. embodiment 15 [0038] a optionally substituted by one or more oh c1-c4 alkoxy optionally substituted by -nr9r11 f br (c0-c4 alkyl)-nr9r11 phenyl or (c0-c4 alkyl)-5 to 6 membered heterocyclyl wherein the more za substituents. embodiment 16 [0039] a compound of formula (i), according to any preceding embodiment, wherein r2 is phenyl or (c0-c4 alkyl)-5 to 6 membre [0040] a compound of formula (i), according to any preceding embodiment, wherein r2 is phenyl or 5- or 6-membered heterocyclyl, each optionally substituted by one, tw of embodiments 1 to 15, wherein r2 is h, f, br,[ftimg=64854337][ftimg=64854338] embodiment 19 [0042] a compound of formula (i), according to any preceding embod c1-c4 haloalkyl c2-c6 alkynyl substituted by one or more halogen, oh, -nr9r11 or c1-c4alkoxy c3-c6 cycloalkyl (c1-c4 alkyl)-c3-c8 cycloalkyl (c1-c4alkoxy optionally substit c02r15 (c0-c4 alkyl)-c(o)nr9r11 (c0-c4 alkyl)-c6aryl or (c0-c4 alkyl)-5 to 6 membered heterocyclyl wherein the c3-c6 cycloalkyl, (c0-c4 alkyl)-c6aryl and (c0-c4 alkyl)-5 [0043] a compound of formula (i), according to any preceding embodiment, wherein r3 is h c1-c4 alkyl optionally substituted by one or more oh or -nr9r11 c1-c4 haloalkyl halogen (c0-c4 alkyl)-c(o)nr19r21 phenyl or -5 to 6 membered heterocyclyl, wherein the c3-c6 cycloalkyl, phenyl and 5 to 6 heterocyclyl are each optionally substituted by preceding embodiment, wherein r3 is h c1-c4 alkyl c1-c4alkoxy oh cn halogen (c0-c4 alkyl)-nr9r11 phenyl or -5 to 6 membered heterocyclyl wherein the phenyl and 5 to 6 heteroc compound of formula (i), according to any preceding embodiment, wherein r3 is h c1-c4 alkyl c1-c4 alkoxy halogen or (c0-c4 alkyl)-nr9r11. embodiment 23 [0046] a compound o compound of formula (i), according to any preceding embodiment, wherein r4 is h. embodiment 25 [0048] a compound of formula (i), according to any preceding embodi formula (i), according to any preceding embodiment, wherein r5 is h or methyl. embodiment 27 [0050] a compound of formula (i), according to any preceding embodime embodiment, wherein r4 is h and r5 is h. embodiment 29 [0052] a compound of formula (i), according to any preceding embodiment, wherein r6 is c1-c6 alkyl optionally substituted by one or more halogen atoms -nr19r21 (c0-c4 alkyl)-c6-c14aryl or (c0-c4 alkyl)-3 to 14 membered heterocyclyl wherein the cycloalkyl, (c0-c4 alkyl)-c6-c14 substituents. embodiment 30 [0053] a compound of formula (i), according to any preceding embodiment, wherein r6 is c1-c6 alkyl optionally substituted by one or more c or more halogen atoms -nr19r21 (c0-c4 alkyl)-c6-c10aryl or (c0-c4 alkyl)-5 to 6 membered heterocyclyl wherein the (c0-c4alkyl)-c3-c6cycloalkyl, (c0-c4 alkyl)-c6-c14ary substituents. embodiment 31 [0054] a compound of formula (i), according to any preceding embodiment, wherein r6 is c1-c6 alkyl optionally substituted by c1-c4 alkoxy wherein the (c0-c2alkyl)-c3-c6cycloalkyl, (c0-c2 alkyl)-c6-c10aryl and (c0-c2alkyl)-5 to 6 membered heterocyclyl are each optionally substituted by one or more z substit embodiment, wherein r6 is c1-c6 alkyl optionally substituted by c1-c4 alkoxy (c0-c1alkyl)-cyclohexyl phenyl or (c0-c4 alkyl)-5 to 6 membered heterocyclyl wherein the (c substituted by one or more z substituents. embodiment 33 [0056] a compound of formula (i), according to any one of embodiments 1 to 30, wherein r6 is c1-c4 alkyl opti -ch2-pyrrolidine or -ch2-piperidine wherein phenyl, tetrahydrofuran, pyrrolidine, -ch2-pyrrolidine and -ch2-piperidine are each optionally substituted by one or more z subst 1 to 30, wherein r6 is (c0-c2 alkyl)-5 to 6 membered heterocyclyl, optionally substituted by one, two or three z substituents. embodiment 35 [0058] a compound of form 36 [0059] a compound of formula (i), according to any one of embodiments 1 to 30, wherein r6 is[ftimg=64854340] embodiment 37 [0060] a compound of formula (i), a -o-c6 aryl c1-c4 alkyl optionally substituted by one or more oh, cn or -nr19a2r1a c1-c4 haloalkyl c1-c4 alkoxy optionally substituted by one or more oh, -co2r19a, -nr19a2r (o)r18a (c0-c4 alkyl)-c(o)r19a oxo cn no2 halogen or (c0-c4 alkyl)-4 to 6 membered heterocyclyl wherein the (c0-c4 alkyl)-c6 aryl, -o-c6 aryl and (c0-c4 alkyl)-4 to 6 c1-c4 alkoxy optionally substituted by one or more halogens. embodiment 38 [0061] a compound of formula (i), according to any preceding embodiment, wherein each z haloalkyl c1-c4 alkoxy optionally substituted by one or more oh, c1-c4 alkoxy or -nr19a2r1a (c0-c4 alkyl)-c6 aryl or (c0-c4 alkyl)-4 to 6 membered heterocyclyl wh c1-c4 haloalkyl, or c1-c4 alkoxy optionally substituted by one or more halogens. embodiment 39 [0062] a compound of formula (i), according to any preceding embodim nr19a2r1a c1-c4 haloalkyl c1-c4 alkoxy optionally substituted by one or more oh, c1-c4 alkoxy or -nr19a2r1a (c0-c4 alkyl)-c6 aryl or (c0-c4 alkyl)-4 to 6 membered h halogen, c1-c4 alkyl or c1-c4 haloalkyl. embodiment 40 [0063] a compound of formula (i), according to any preceding embodiment, wherein each za is independently c1- compound of formula (i), according to any one of embodiments 1 to 39, wherein each za is independently fluorine, bromine, chlorine, methyl, methoxy, -ch2nh2,[ftimg=6 embodiment, wherein each z is independently (c0-c4 alkyl)-c6 aryl -o-c6 aryl c1-c4 alkyl optionally substituted by one or more cn or -nr19r21 c1-c4 haloalkyl c1-c4 alkoxy halogen or (c0-c4 alkyl)-4 to 6 membered heterocyclyl wherein the (c0-c4 alkyl)-c6 aryl, -o-c6 aryl and (c0-c4 alkyl)-4 to 6 membered heterocyclyl are each optionally s more halogens. embodiment 43 [0066] a compound of formula (i), according to any preceding embodiment, wherein each z is independently c1-c4 alkyl optionally substitit alkoxy or -nr19r21 cn halogen or (c0-c4 alkyl)-4 to 6 membered heterocyclyl wherein the (c0-c4 alkyl)-4 to 6 membered heterocyclyl is optionally substituted by halogen embodiment 44 [0067] a compound of formula (i), according to any preceding embodiment wherein each z is independently c1-c4 alkoxy, halogen, c1-c4 alkyl or c1-c4 h embodiment, wherein r9 and r11 are each independently h c1-c6 alkyl optionally substituted by c1-c4 alkoxy or oh c1-c6 haloalkyl (c0-c1alkyl)-c3-c6cycloalkyl (c0-c4 alkyl and halogen or (c0-c4 alkyl)-5- to 6-membered heterocyclyl optionally substituted by one or more groups selected from halogen, oxo, c1-c6 alkyl and c(o)c1-c6 alkyl. e wherein r9 and r11 together with the nitrogen atom to which they attached form a 5- to 6-membered heterocyclyl, the heterocyclyl including 0 to 3 further heteroatoms sel selected from oh halogen phenyl 5- to 10-membered heterocyclyl c1-c6 alkyl c1-c6 haloalkyl c1-c6 alkoxy optionally substituted by one or more oh or c1-c4 alkoxy and c substituted by c1-c6 alkyl, c1-c6 haloalkyl or c1-c6 alkoxy. embodiment 47 [0070] a compound of formula (i), according to any preceding embodiment, wherein r15 is h c (c0-c4 alkyl)-3 to 14 membered heterocyclyl group wherein the c3-c10 cycloalkyl, (c1-c4alkyl)-c3-c8 cycloalkyl, (c0-c4 alkyl)-c6-c14aryl and (c0-c4 alkyl)-3 to 14 mem embodiment 48 [0071] a compound of formula (i), according to any preceding embodiment, wherein r15 is h or c1-c4 alkyl. embodiment 49 [0072] a compound of formu embodiment 50 [0073] a compound of formula (i), according to any preceding embodiment, wherein r19 and r21 are each independently c1-c6 alkyl optionally substitute optionally substituted by one or more groups selected from c1-c6 alkyl, c1-c6 alkoxy and halogen or (c0-c4 alkyl)-5- to 6-membered heterocyclyl optionally substituted by [0074] a compound of formula (i), according to any one of embodiments 1 to 49, wherein r19 and r21 together with the nitrogen atom to which they are attached form a n, o and s, the heterocyclyl being optionally substituted by one or more substituents selected from halogen phenyl 5- to 10-membered heterocyclyl c1-c4 alkyl c1-c4 halo wherein the phenyl and heterocyclyl substituent groups are themselves optionally substituted by c1-c6 alkyl, c1-c6 haloalkyl or c1-c6 alkoxy. embodiment 52 [0075] a co c1-c4 alkyl. embodiment 53 [0076] a compound of formula (i), according to any preceding embodiment, wherein r19a and r21a are each independently h c1-c6 alkyl opti aryl optionally substituted by one or more groups selected from c1-c6 alkyl, c1-c6 alkoxy and halogen or (c0-c4 alkyl)-5- to 6-membered heterocyclyl optionally substitute 54 [0077] a compound of formula (i), according to any one of embodiments 1 to 52, wherein r19a and r21a together with the nitrogen atom to which they attached form a from n, o and s, the heterocyclyl being optionally substituted by one or more substituents selected from oh halogen phenyl 5- to 10-membered heterocyclyl c1-c4 alkyl c1 c6alkyl wherein the phenyl and heterocyclyl substituent groups are themselves optionally substituted by c1-c6 alkyl, c1-c6 haloalkyl or c1-c6 alkoxy. embodiment 55 [007 represented by formula ii:[ftimg=64854342] embodiment 56 [0079] a compound of formula (ii), or a pharmaceutically acceptable salt thereof:[ftimg=64854343] wherein or ch [0080] r2 is h c1-c4 alkyl optionally substituted by one or more oh, -nr9r11 or c1-c4 alkoxy c1-c4 haloalkyl c2-c6 alkynyl substituted by one or more halogen, oh, -nr substituted by one or more halogen, -nr9r11 or oh oh cn halogen (c0-c4 alkyl)-nr9r11 (c0-c4 alkyl)-co2r15 (c0-c4 alkyl)-c(o)nr9r11 (c0-c4 alkyl)-c6-c14aryl or (c0-c4 a c4 alkyl)-3 to 14 heterocyclyl are each optionally substituted by one or more za substituents r6 is c1-c6 alkyl optionally substituted by one or more c1-c4 alkoxy c1-c6 halo atoms -nr19r21 (c0-c4 alkyl)-c6-c10aryl or (c0-c4 alkyl)-5 to 6 membered heterocyclyl wherein the (c0-c1alkyl)-c3-c6cycloalkyl, (c0-c4 alkyl)-c6-c14aryl and (c0-c4 alk independently oh c1-c4 alkyl optionally substituted by one or more oh or nh2 c1-c4 haloalkyl c1-c4 alkoxy optionally substituted by one or more oh, c1-c4 alkoxy or -nr19 heterocyclyl is optionally substituted by halogen, c1-c4 alkyl optionally substituted by one or more halogen atoms, or c1-c4 alkoxy optionally substituted by one or more h c4 haloalkyl c1-c4 alkoxy optionally substituted by one or more c1-c4 alkoxy or -nr19r21 cn halogen or (c0-c4 alkyl)-4 to 6 membered heterocyclyl wherein the heterocycl substituted by halogen, c1-c4 alkyl, c1-c4 haloalkyl or c1-c4 alkoxy optionally substituted by one or more halogens r9 and r11 are each independently h c1-c6 alkyl option (c0-c4 alkyl)-c6-c14aryl optionally substituted by one or more groups selected from c1-c6 alkyl, c1-c6 alkoxy and halogen or (c0-c4 alkyl)-5- to 6-membered heterocyclyl c6 alkyl r15 is h or c1-c4 alkyl r19 and r21 are each independently c1-c6 alkyl optionally substituted by one or more c1-c4 alkoxy c1-c6 haloalkyl (c0-c4alkyl)-c3-c6cycloal c1-c6 alkoxy and halogen or (c0-c4 alkyl)-5- to 6-membered heterocyclyl optionally substituted by one or more groups selected from halogen, c1-c6 alkyl and (c0)c1-c6 c4 alkoxy or oh c1-c6 haloalkyl (c0-c1alkyl)-c3-c6cycloalkyl (c0-c4 alkyl)-aryl optionally substituted by one or more groups selected from c1-c6 alkyl, c1-c6 alkoxy and hal selected from halogen, oxo, c1-c6 alkyl and c(o)c1-c6 alkyl. embodiment 57 [0082] a compound of formula (i), according to any one of embodiments 1 to 54, wherein th compound of formula (iii), or a pharmaceutically acceptable salt thereof:[ftimg=64854345] wherein r1 is c1-c4 alkyl, c1-c4 alkoxy, cn or halogen r1a is h, halogen, c1-c4 a oh, -nr9r11 or c1-c4 alkoxy c1-c4 haloalkyl c2-c6 alkynyl substituted by one or more halogen, oh, -nr9r11 or c1-c4 alkoxy c3-c6 cycloalkyl (c1-c4 alkyl)-c3-c6 cycloalkyl c1 alkyl)-nr9r11 (c0-c4 alkyl)-co2r15 (c0-c4 alkyl)-c(o)nr9r11 (c0-c4 alkyl)-c6-c1aaryl or (c0-c4 alkyl)-3 to 14 membered heterocyclyl wherein the c3-c6cycloalkyl, (c0-c4 a more za substituents r6 is c1-c6 alkyl optionally substituted by one or more c1-c4 alkoxy c1-c4 haloalkyl (c0-c1alkyl)-c3-c6cycloalkyl c1-c4alkoxy optionally substituted by heterocyclyl wherein the (c0-c1alkyl)-c3-c6cycloalkyl, (c0-c4 alkyl)-c6-c10aryl and (c0-c4 alkyl)-5 to 6 membered heterocyclyl are each optionally substituted by one or oh or nh2 c1-c4 alkyl c1-c4 alkoxy optionally substituted by one or more oh, c1-c4 alkoxy or -nr19a2r1a (c0-c4 alkyl)-c6 aryl or (c0-c4 alkyl)-4 to 6 c1-c4 haloalkyl or c1-c4 alkoxy optionally substituted by one or more halogens each z is independently c1-c4 alkyl optionally substituted by one or more nh2 c1-c4 alkyl c halogen or (c0-c4 alkyl)-4 to 6 membered heterocyclyl wherein the heterocyclyl is optionally substituted by halogen, c1-c4 alkyl, c1-c4 haloalkyl or c1-c4 alkoxy optionally substituted by one or more c1-c4 alkoxy or oh c1-c6 haloalkyl (c0-c1alkyl)-c3-c6cycloalkyl (c0-c4 alkyl)-c6-c14aryl optionally substituted by one or more groups selected optionally substituted by one or more groups selected from halogen, oxo, c1-c6 alkyl and (c0)c1-c6 alkyl r15 is h or c1-c4 alkyl r19 and r21 are each independently c1-c6 alkyl optionally substituted by one or more groups selected from c1-c6 alkyl, c1-c6 alkoxy and halogen or (c0-c4 alkyl)-5- to 6-membre c(o)c1-c6 alkyl r19a and r21a are each independently h c1-c6 alkyl optionally substituted by one or more c1-c4 alkoxy or oh c1-c6 haloalkyl (c0-c1alkyl)-c3-c6cycloalkyl (c alkoxy and halogen or (c0-c4 alkyl)-5- to 6-membered heterocyclyl optionally substituted by one or more groups selected from halogen, oxo, c1-c6 alkyl and c(o)c1-c6 al embodiment, wherein x, r1, r1a, r2, r3, r4, r5, r6, z, za r15, r18, r19 and r19 are those defined by the embodiments above or by the examples section below. embodiment methylpiperazin-1-yl)benzylcarbamoyl)phenyl)-7-(1-methyl-1h-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamide7-(3-fluoro-4-(2-hydroxyethylcarbamoyl)phenyl)-n-(2-fl carboxamide7-bromo-n-(2-methyl-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide7-(1-methyl-1h-pyrazol-5-yl)-n-(2-methyl (2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)-7-(pyridine-3-yl)imidazo[1,2-a]pyridine-3-carboxamiden-2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylca difluorobenzylicarbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamiden-5-(benzylcarbamoyl)-2-fluorophenyl)-6-(1-methyl-1h-pyr yl) benzylcarbamoyl)phenyl)-7-(pyridine-3-yl)imidazo[1,2-a]pyr idine-3-carboxamiden-5-(3,4-difluorobenzylicarbamoyl)-2-fluorophenyl)-7-(6-(3-(dimethyl amino) propox ethylcarbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-5-yl)imidazo[1,2-a]pyrid ine-3-carboxamide7-(4-(aminomethyl)phenyl)-n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl butoxyethylcarbamoyl)-2-fluorophenyl)-7-(1-(2-morpholinoethyl)-1h-pyrazol-4-yl)imidazo[1,2-a]pyrid ine-3-carboxamiden-5-(5,5-dimethyltetrahydrofuran-2-yl)methyl c carboxamide n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)-7-(6-methoxy pyridine-3-yl)imidazo[1,2-a]pyridine-3-carboxamiden-2-fluoro-5-(2-(4-m 3-carboxamide1-(2-(4-fluoro-3-(7-(pyridine-3-yl)imidazo[1,2-a]pyridine-3-carboxamido)benzamido)ethyl)-2,6-cis-dimethylpiperidinen-5-(2-tert-butoxyethylcarbamoyl)- carboxamiden-(2-methyl-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)-7-(pyridine-3-yl)imidazo[1,2-a]pyridine-3-carboxamide1-methyl-4-(2-((6-methyl-5-(7(1

piperazine-7-(1-methyl-1h-pyrazol-4-yl)-imidazo[1,2-a]pyridine-3-carboxylic acid {5-[2-(2,6-cis-dimethyl-piperidin-1-yl)-ethylcarbamoyl]-2-fluoro-phenyl}-amiden-(5-(2-t
[1,2-a]pyridine-3-carboxamiden-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(6-(2-(pyrrolidin-1-yl)ethoxy) pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide-6-(1
pyrazolo[1,5-a]pyridine-3-carboxamiden-(2-bromo-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamiden-(2-bromo-5-(2-(4-m
difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-hydroxy-3-methyl butyl)imidazo[1,2-a]pyridine-3-carboxamiden-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-flu
difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-(2-(tetrahydro-2h-pyran-4-yl)ethylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamiden-(5-(3,4-difluorobenz
pyridine-3-carboxamide-6-(1-methyl-1h-pyrazol-5-yl)-n-(2-methyl-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carboxamiden-(5-
yl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamiden-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(1-(3-(dimethyl amino)propyl)-1h-pyrazol-4-yl)imidazo[1,2-a]
7-(5-(((tetrahydro-2h-pyran-4-ylamino)methyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide(s)-n-(5-(((5,5-dimethyltetrahydrofuran-2-yl)methyl) carbamoyl)-2-fluor
(r)-n-(5-(((5,5-dimethyltetrahydrofuran-2-yl)methyl) carbamoyl)-2-fluorophenyl)-7-(5-(((2-methoxyethyl) (methyl)amino)methyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-c
yl)methyl)carbamoyl)-2-fluorophenyl) imidazo[1,2-a]pyridine-3-carboxamiden-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(6-(2-(pyrrolidin-1-yl)ethoxy) pyridin-3
7-(6-(2-(pyrrolidin-1-yl) ethoxy)pyridin-3-yl) imidazo[1,2-a]pyridine-3-carboxamiden-(5-(((5,5-dimethyl tetrahydrofuran-2-yl)methyl)carbamoyl)-2-fluorophenyl)-7-(6-(((1
pyrazol-5-yl)-n-(2-methyl-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)pyrazolo[1,5-a]pyridine-3-carboxamiden-(2-bromo-5-(2-(4-methylpiperazin-1-yl)benzyl
carbamoyl)phenyl)pyrazolo[1,5-a]pyridine-3-carboxamiden-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-hydroxy-3-methyl butyl)imidazo[1,2-a]pyridine-
ethylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamiden-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-(2-(tetrahydro-2h-pyran-4-yl)ethylcarb
carbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamiden-(5-(2-(2-dimethylpyrrolidin-1-yl)ethylcarbamoyl)-2-fluorophenyl)-7-(3-
(5-(2-(2,2-dimethylpyrrolidin-1-yl)ethylcarbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-(1-hydroxy-2-methylpropan-2-ylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamid
hydroxy-2-methylpropan-2-ylcarbamoyl)phenyl)pyrazolo[1,5-a]pyridine-3-carboxamiden-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-(3-morpholino pr
yl)ethylcarbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-(1-hydroxy-2-methylpropan-2-ylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide-7-(3-fluoro-4-(2-fluoroethylcarb
pyridine-3-carboxamiden-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)-7-(3-fluoro-5-(2-hydroxy ethylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carb
1h-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carboxamide(s)-n-(2-fluoro-5-(2-(2-methoxy methyl) pyrrolidin-1-yl)ethyl carbamoyl)phenyl)-7-(1-methyl-1h-pyrazol-4-yl)imi
phenyl)-7-(1-methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide(r)-n-(2-fluoro-5-(((2-(2-methoxymethyl) pyrrolidin-1-yl)ethyl) carbamoyl)phenyl)-7-(1-methy
carbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamiden-(2-fluoro-5-(((2-(2,6,6-tetra methylpiperidin-1-yl)ethyl)carbamoyl)phe
(methyl)amino)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamiden-(5-(((2-(2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl
((2-butyl (ethyl)amino)ethyl)carbamoyl)-2-fluoro phenyl)-7-(3-fluoro-4-(((2-hydroxy ethyl)carb amoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide-7-(3-fluoro-4-(((1-hyd
carbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamiden-(5-(((2-(3,3-dimethylmorpholino)ethyl)carbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-((1-hydroxy-2-methylpropan-
methylpropan-2-yl)carbamoyl)phenyl)-n-(2-fluoro-5-(((2-(2-methoxymethyl)pyrrolidin-1-yl)ethyl) carbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamiden-(5-(((3,4-difl
imidazo[1,2-a]pyridine-3-carboxamiden-(5-(((2-(2,2-dimethylpiperidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-
methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carboxamiden-(5-(((2-(2s,3r)-2,3-diethylazetidin-1-yl)ethyl) carbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-4-yl)j
hydroxyethyl) (methypamino)methyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamiden-(5-(3,4-difluorobenzyl)carbamoyl)-2-fluorophenyl)-7-(6-(methyl (phenethyl)a
carbamoyl)-2-fluorophenyl)-7-(6-((methyl(phenethyl)amino)methyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamiden-(5-(3,4-difluoro benzyl)carbamoyl)-2-fluorophe
(cyclohexyl amino)methyl)pyridin-3-yl)-n-(5-(((3,4-difluorobenzyl) carbamoyl)-2-fluoro phenyl)imidazo[1,2-a]pyridine-3-carboxamide andn-(5-(3,4-difluoro benzyl)carb
pyridine-3-carboxamideor a pharmaceutically acceptable salt thereof. embodiment 61 [0163] a compound of formula (i), which is selected from: n-(5-(((2-(2,2-dimethylpyr
3-carboxamide n-(5-(2-(2,6-cis-dimethylpiperidin-1-yl)ethylcarbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamiden-(5-(2-(2,2-d
[1,5-a]pyridine-3-carboxamide-7-(1-methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxylic acid {5-[2-(2,6-cis-dimethyl-piperidin-1-yl)-ethylcarbamoyl]-2-fluoro-ph
4-(1-hydroxy-2-methylpropan-2-ylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamideor a pharmaceutically acceptable salt thereof.[0169] in another embodime
t as the free base or as a pharmaceutically acceptable salt thereof.[0170] as used herein, the term "an optical isomer" or "a stereoisomer" refers to any of the various ster
includes geometric isomers. it is understood that a substituent may be attached at a chiral center of a carbon atom. the term "chiral" refers to molecules which have the p
molecules which are superimposable on their mirror image partner. therefore, the invention includes enantiomers, diastereomers or racemates of the compound. "enantio
mixture of a pair of enantiomers is a "racemic" mixture. the term is used to designate a racemic mixture where appropriate. "diastereoisomers" are stereoisomers that ha
stereochemistry is specified according to the cahn-ingold-prelog r-s system. when a compound is a pure enantiomer the stereochemistry at each chiral carbon may be spe
designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium d line. certain compoun
enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (r)- or (s)-.[0171] depending on the choice of
possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereoisomer mixtures, depending on the
possible isomers, including racemic mixtures, diastereomeric mixtures and optically pure forms. optically active (r)- and (s)-isomers may be prepared using chiral synthons
bond, the substituent may be e or z configuration. if the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. al
"salts" refers to an acid addition or base addition salt of a compound of the invention. "salts" include in particular "pharmaceutical acceptable salts". the term "pharmaceu
compounds of this invention and, which typically are not biologically or otherwise undesirable. in many cases, the compounds of the present invention are capable of formi
similar thereto.[0174] pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, t
chloride/hydrochloride, chlorthephylionate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydriodide/iodide, isethionate, lactate, la
naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonat
inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.[0176] orga
acid, oxalic acid, malic acid, maleic acid, malonic acid, succinic acid, fumaric acid, l-tartaric acid, citric acid, benzoic acid, 4-hydroxybenzoic acid, mandelic acid, methanesul
acid, nicotinic acid, adipic acid, saccharin and the like. pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.[0177] inorganic ba
columns i to xii of the periodic table. in certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copp
salts.[0178] organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring
include isopropylamine, benzathine, cholineate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.[0179] the pharmaceutically acceptable s
chemical methods. generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as n
these compounds with a stoichiometric amount of the appropriate acid. such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.[
acetonitrile is desirable, where practicable. lists of additional suitable salts can be found, e.g., in "remington's pharmaceutical sciences", 20th ed., mack publishing compa
by stahl and wermuth (wiley-vch, weinheim, germany, 2002).[0181] any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled
given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. examples of isotopes that can be incorporated int
phosphorous, fluorine, and chlorine, such as 2h, 3h, 11c, 13c, 14c, 15n, 18f 36cl, 125i respectively. the invention includes various isotopically labeled compounds as defin
which non-radioactive isotopes, such as 2h and 13c are present. such isotopically labelled compounds are useful in metabolic studies (with 14c), reaction kinetic studies (w
tomography (pet) or single-photon emission computed tomography (spect) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. i
isotopically-labeled compounds of formula (i) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those
labeled reagents in place of the non-labeled reagent previously employed.[0182] further, substitution with heavier isotopes, particularly deuterium (i.e., 2h or d) may affo
in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. it is understood that deuterium in this context is regarded as a substituent of a
may be defined by the isotopic enrichment factor. the term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural a
deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5 percent deuterium incorporation at each designa
percent deuterium incorporation), at least 5000 (75 percent deuterium incorporation), at least 5500 (82.5 percent deuterium incorporation), at least 6000 (90 percent deu
percent deuterium incorporation), at least 6600 (99 percent deuterium incorporation), or at least 6633.3 (99.5 percent deuterium incorporation).[0183] pharmaceutically a
crystallization may be isotopically substituted, e.g. d2o, d6-acetone, d6-dmsol.[0184] compounds of the invention, i.e. compounds of formula (i), (ii) or (iii) that contain g
co-crystals with suitable co-crystal formers. these co-crystals may be prepared from compounds of formula (i), (ii) or (iii) by known co-crystal forming procedures. such pro
formula (i), (ii) or (iii) with the co-crystal former under crystallization conditions and isolating co-crystals thereby formed. suitable co-crystal formers include those describe
formula (i), (ii) or (iii).[0185] as used herein, the term "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxi
delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and c
pharmaceutical sciences, 18th ed. mack printing company, 1990, pp. 1289-1329). except insofar as any conventional carrier is incompatible with the active ingredient, its
therapeutically effective amount" of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or me
or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc. in one non-limiting embodiment, the term "a therapeutically e
administered to a subject, is effective to (1) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder or a disease (i) mediated by
pdgfr or (2) reducing or inhibiting the activity of pdgfr. in another non-limiting embodiment, the term "a therapeutically effective amount" refers to the amount of the com
biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of pdgfr.[0187] as used herein, the term "subject" refers to an animal.
male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. in certain embodiments, the subject is a primate. in yet other embod
refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or pro
refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical sym
ameliorating at least one physical parameter including those which may not be discernible by the patient. in yet another embodiment, "treat", "treating" or "treatment" ref
symptom), physiologically, (e.g., stabilization of a physical parameter), or both. in yet another embodiment, "treat", "treating" or "treatment" refers to preventing or dela
subject is "in need of" a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.[0191] as used herein, the term "a," "an,"
claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.[0192] all methods described her
contradicted by context. the use of any and all examples, or exemplary language (e.g. "such as") provided herein is intended merely to better illuminate the invention an
asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (r)-, (s)-
enantiomeric excess, at least 60 percent enantiomeric excess, at least 70 percent enantiomeric excess, at least 80 percent enantiomeric excess, at least 90 percent enan
excess in the (r)- or (s)-configuration. substituents at atoms with unsaturated double bonds may, if possible, be present in cis-(2)- or trans-(e)-form.[0194] accordingly,
isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (anti
on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for exampl
products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically
basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with
toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chro
invention, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization. the compounds of the present inv
(including water) therefore, it is intended that the invention embrace both solvated and unsolvated forms. the term "solvate" refers to a molecular complex of a compound
solvent molecules. such solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and
synthetic schemes [0198] the compounds of the invention may be synthesized by the general synthetic routes below, specific examples of which are described in more de
shown using either method a or method a1. method a is an amide coupling. method a1 is a tbd coupling. this amide formation introduces the r6 moiety. x, r1, r1a, r4, r5
bond at the aniline nitrogen is shown using method b1 and method b2. method b1 and method b2 are aniline amide couplings using acid chlorides. in addition, scheme 2
amide coupling. one of y and y2 is a halogen, such as bromine, and one of y and y2 is hydrogen. x, r1, r1a, r4, r5 and r6 are as defined herein.[ftimg=64854348][0201]
method c or method d. method c is a suzuki reaction to couple aryl group at r2 or r3. method d is a negishi reaction to couple an alkyl group at r2 or r3. r1 cannot be bro
hydrogen. x, r1, r1a, r2, r3, r4, r5 and r6 are as defined herein.[ftimg=64854349][0202] in scheme 4, the formation of the amide bond at the aniline nitrogen is shown u
chlorides. in addition, scheme 2 depicts the formation of an amide bond to introduce the r6 moiety using method a2, which is an amide coupling. one of y and y2 is a hal
herein.[ftimg=64854350][0203] in scheme 5, the introduction of r2 and/or r3 is depicted as a substitution reaction at y or y2 using method c or method d. method c is a
group at r2 or r3. r1 cannot be bromine for this reaction. one of y and y2 is a halogen, such as bromine, and one of y and y2 is hydrogen. x, r1, r1a, r2, r3, r4, r5 and r6
to an ester group is depicted using method e, a grignard addition, to form tertiary alcohol. r1 and r6 are as defined herein.[ftimg=64854352][0205] in scheme 7, the intr
r1, r6, and r21 are as defined herein.[ftimg=64854353] in scheme 8, the introduction of alkoxy moiety is depicted using method g. method g is a nucleophilic displaceme
c4 alkoxy. r1, r6, r18, r19 and r21 are as defined herein.[0206] the invention further includes any variant of the present processes, in which an intermediate product obtai
in which the starting materials are formed in situ under the reaction conditions, or in which the reaction components are used in the form of their salts or optically pure ma
according to methods generally known to those skilled in the art.[0208] within the scope of this text, only a readily removable group that is not a constituent of the partic
group", unless the context indicates otherwise. the protection of functional groups by such protecting groups, the protecting groups themselves, and their cleavage reactio
groups in organic chemistry", plenum press, london and new york 1973, in t. w. greene and p. g. m. wuts, "protective groups in organic synthesis", third edition, wiley, new
london and new york 1981, in "methoden der organischen chemie" (methods of organic chemistry), houben weyl, 4th edition, volume 15/i, georg thieme verlag, stuttgart
proteins), verlag chemie, weinheim, deerfield beach, and basel 1982, and in jochen lehmann, "chemie der kohlenhydrate: monosaccharide and derivate" (chemistry of car
characteristic of protecting groups is that they can be removed readily (i.e. without the occurrence of undesired secondary reactions) for example by solvolysis, reduction,
of compounds of the present invention having at least one salt-forming group may be prepared in a manner known to those skilled in the art. for example, salts of comp

compounds with metal compounds, such as alkali metal salts of suitable organic carboxylic acids, e.g. the sodium salt of 2-ethylhexanoic acid, with organic alkali metal or carbonates, such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with corresponding calcium compounds or with ammonia or a suitable organic ami acid addition salts of compounds of the present invention are obtained in customary manner, e.g. by treating the compounds with an acid or a suitable anion exchange re groups, e.g. a free carboxy group and a free amino group, may be formed, e.g. by the neutralisation of salts, such as acid addition salts, to the isoelectric point, e.g. with compounds in accordance with methods known to those skilled in the art. metal and ammonium salts can be converted, for example, by treatment with suitable acids, an isomers obtainable according to the invention can be separated in a manner known to those skilled in the art into the individual isomers diastereoisomers can be separat chromatographic separation, for example over silica gel or by e.g. medium pressure liquid chromatography over a reversed phase column, and racemates can be separat of the mixture of diastereoisomers so obtainable, for example by means of fractional crystallisation, or by chromatography over optically active column materials.[0212] i e.g. using chromatographic methods, distribution methods, (re-) crystallization, and the like.[0213] the following applies in general to all processes mentioned herein bef reaction conditions that are known to those skilled in the art, including those mentioned specifically, in the absence or, customarily, in the presence of solvents or diluents them, in the absence or presence of catalysts, condensation or neutralizing agents, for example ion exchangers, such as cation exchangers, e.g. in the h+ form, dependi temperature, for example in a temperature range of from about -100 degrees centigrade to about 190 degrees centigrade, including, for example, from approximately -8 degrees centigrade, at room temperature, at from -20 to 40 degrees centigrade or at reflux temperature, under atmospheric pressure or in a closed vessel, where approp atmosphere.[0215] at all stages of the reactions, mixtures of isomers that are formed can be separated into the individual isomers, for example diastereoisomers or ena diastereoisomers, for example analogously to the methods described under "additional process steps".[0216] the solvents from which those solvents that are suitable for water, esters, such as lower alkyl-lower alkanoates, for example ethyl acetate, ethers, such as aliphatic ethers, for example diethyl ether, or cyclic ethers, for example tetr as methanol, ethanol or 1- or 2-propanol, nitriles, such as acetonitrile, halogenated hydrocarbons, such as methylene chloride or chloroform, acid amides, such as dimeth pyridine or n-methylpyrrolidin-2-one, carboxylic acid anhydrides, such as lower alkanico acid anhydrides, for example acetic anhydride, cyclic, linear or branched hydrocarb for example aqueous solutions, unless otherwise indicated in the description of the processes. such solvent mixtures may also be used in working up, for example by chr the form of hydrates, or their crystals may, for example, include the solvent used for crystallization. different crystalline forms may be present.[0218] the invention relate stage of the process is used as starting material and the remaining process steps are carried out, or in which a starting material is formed under the reaction conditions or compound obtainable by the process according to the invention is produced under the process conditions and processed further in situ.[0219] all starting materials, buildi the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (houb the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier. the pharmaceutic administration, parenteral administration, and rectal administration, etc. in addition, the pharmaceutical compositions of the present invention can be made up in a solid f a liquid form (including without limitation solutions, suspensions or emulsions). the pharmaceutical compositions can be subjected to conventional pharmaceutical operati buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc.[0221] typically, the pharmaceutical compositions are dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycineb) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol for ta methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone if desiredd) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent coated or enteric coated according to methods known in the art.[0228] suitable compositions for oral administration include an effective amount of a compound of the inv granules, emulsion, hard or soft capsules, or syrups or elixirs. compositions intended for oral use are prepared according to any method known in the art for the manufact selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palata pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. these excipients are, for example, inert diluents, such as calcium carbonate, sodi agents, for example, corn starch, or alginic acid binding agents, for example, starch, gelatin or acacia and lubricating agents, for example magnesium stearate, stearic ac absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. for example, a time delay material such as glyceryl monostearate or g capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherei paraffin or olive oil.[0229] certain injectable compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emul preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. in addition, they may also contain othe mixing, granulating or coating methods, respectively, and contain about 0.1-75 percent, or contain about 1-50 percent, of the active ingredient.[0230] suitable compositio suitable carrier. carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. for exa containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rat compositions for topical application, e.g., to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for deliv application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like. they are thus particularly suited for use in topical, i tonicity enhancing agents, buffers and preservatives.[0232] as used herein a topical application may also pertain to an inhalation or to an intranasal application. they ma dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurised cont where the inhalable form of the active ingredient is an aerosol composition, the inhalation device may be an aerosol vial provided with a valve adapted to deliver a meter dose inhaler. suitable such aerosol vials and procedures for containing within them aerosol compositions under pressure are well known to those skilled in the art of inhale example as described in ep-a-0642992. where the inhalable form of the active ingredient is a nebulizable aqueous, organic or aqueous/organic dispersion, the inhalation airjet nebulizer, or an ultrasonic nebulizer, which may contain, for example, from 1 to 50 ml, commonly 1 to 10 ml, of the dispersion or a hand-held nebulizer, sometimes as an aerx (aradigm, us) or aerodose (aerogen), or a mechanical device such as a respimat (boehringer ingelheim) nebulizer which allows much smaller nebulized volum ingredient is the finely divided particulate form, the inhalation device may be, for example, a dry powder inhalation device adapted to deliver dry powder from a capsule o powder inhalation (mdpi) device adapted to deliver, for example, 3-25 mg of dry powder comprising a dosage unit of (a) and/or (b) per actuation. the dry powder compos against product performance deterioration due to moisture e.g. magnesium stearate. suitable such dry powder inhalation devices include devices disclosed in u.s. pat. no. device), wo 97/30743 (including the twisthaler device) and wo 05/37353 (including the gyrohaler device).[0234] the invention also includes (a) an agent of the invention i inhalable medicament comprising such a compound in inhalable form together with a pharmaceutically acceptable carrier in inhalable form (c) a pharmaceutical product co inhalation device containing such a compound in inhalable form.[0235] dosages of agents of the invention employed in practising the present invention will of course vary mode of administration. in general, suitable daily dosages for administration by inhalation are of the order of 0.0001 to 30 mg/kg, typically 0.01 to 10 mg per patient, wh present invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention as active ingredients, si compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. an is maintained. accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water such that they can be included in suitable formulary plastics, unit dose containers (e. g., vials), blister packs, and strip packs.[0238] the invention further provides pharmaceutical compositions and dosage forms that compri active ingredient will decompose. such agents, which are referred to herein as "stabilizers," include, but are not limited to, antioxidants such as ascorbic acid, ph buffers, c simultaneously with, or before or after, one or more other therapeutic agent. the compound of the present invention may be administered separately, by the same or diff agents.[0240] another aspect of this invention relates to the fact that the compounds of formula (i), (ii) or (iii) and their pharmaceutically acceptable salts have beneficial to a further aspect of the invention a compound of formula (i), (ii) or (iii) is hereinbefore described as a medicament. the use of compounds of formula (i), (ii) or (iii) in i formula (i), (ii) or (iii) or pharmaceutically acceptable salt thereof is an inhibitor of pdgfr receptor mediated biological activity. we particularly provide a compound of formul disorder.[0242] according to a further aspect of the invention the use of a compound of formula (i) is hereinbefore described in the manufacture of a medicament. more pdgfr receptor mediated biological activity. another aspect of the invention is the use of a compound of formula (i) in the manufacture of a medicament for the treatment that include a therapeutically effective amount of a compound of formula (i), (ii), or (iii), or a pharmaceutical salt thereof and a pharmaceutically acceptable carrier. in cer formulated for intravenous administration, intravitreal administration, intramuscular administration, oral administration, rectal administration, transdermal administration, ophthalmic administration or otic administration. in other embodiments, the pharmaceutical compositions are in the form of a tablet, a pill, a capsule, a liquid, an inhalan drop. in other embodiments, such pharmaceutical compositions further include one or more additional therapeutic agents. use and method of treating [0244] another asp acceptable salt thereof for the treatment of a disorder or disease in a subject by inhibiting c-kit and/or pdgfr kinase activity, and such use include a therapeutically effectiv use of the compound of formula (i), (ii) or (iii) or a pharmaceutically acceptable salt thereof for the treatment of a disorder or disease in a subject by inhibiting c-kit and/ compound of formula (i), (ii) or (iii), wherein the disease or disorder is a mast-cell associated disease, a respiratory disease, an inflammatory disorder, irritable bowel syn fibrosis disease, a dermatological disease, cariac hypertrophy, cancers of the lung or other tissues in which a pdgfr isoform is mutated, overexpressed or activated, pulmo of this aspect, the disease is asthma, allergic rhinitis, pulmonary arterial hypertension (pah), pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, scleroderma, irritable bo ii diabetes.[0246] another aspect provided herein are uses for treating a disease mediated by a kinase in a patient in need therof, and such uses include a therapeutically pdgfr, pdgfr beta, p38, bcr-abl and c-fms and the disease is a mast-cell associated disease, a respiratory disease, an inflammatory disorder, irritable bowel syndrome (i disease, a dermatological disease, pulmonary arterial hypertension (pah) or primary pulmonary hypertension (pph).[0247] in certain embodiments of this aspect, the dis fibrosis, cardiac fibrosis, cardiac hypertrophy, scleroderma, irritable bowel syndrome (ibs), inflammatory bowel disease (ibd), uticaria, dermatosis, type i diabetes or type i (iii), in the manufacture of a medicament for treating a disease or disorder in a patient where modulation of a c-kit and/or pdgfr kinase is implicated.[0249] another aspe and/or pdgfr kinase is implicated, wherein the method includes administering to a system or subject in need of such treatment an effective amount of a compound of for thereby treating the disease or disorder. in such methods, the compound of formula (i), (ii) or (iii), is an inhibitor of c-kit and/or pdgfr kinases. in certain embodiments of human or animal subject. in certain embodiments of such methods, the disease or condition is a metabolic disease, a fibrotic disease, cardiac hypertrophy, a respiratory i certain embodiments of such methods, the disease or condition is asthma, allergic rhinitis, irritable bowel syndrome (ibs), inflammatory bowel disease (ibd), pulmonary urticaria, dermatoses, atopic dermatitis, type i diabetes or type ii diabetes.[0250] in another embodiment the disease is selected from a respiratory disease, an inflam disease, pulmonary arterial hypertension (pah) and primary pulmonary hypertension (pph). in other embodiments the diseases is asthma, pulmonary arterial hypertension pharmaceutical composition and combinations [0251] the pharmaceutical composition or combination of the present invention can be in unit dosage of about 1-1000 mg about 1-150 mg or about 0.5-100 mg, or about 1-50 mg of active ingredients. the therapeutically effective dosage of a compound, the pharmaceutical composition, or th individual condition, the disorder or disease or the severity thereof being treated. a physician, clinician or veterinarian of ordinary skill can readily determine the effective disorder or disease.[0252] the above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkey be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either externally, parenterally, advantageously intravenously, e.g., as a suspension or in a concentrations. a therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1-500 mg/kg, or between about 1-100 m following in vitro and in vivo methods. pharmaceutical use and assay [0254] compounds of formula (i), (ii) or (iii) provided herein were assayed to measure their capacity evaluated using the rat a10 cell proliferation. rat a10 cell proliferation assay [0255] rat a10 cells (atcc) were resuspended in dmem supplemented with 1 percent fbs and 1 50 micro l/well and incubated for 4 hours at 37 degrees centigrade 0.5 micro l of test compound 3-fold serially diluted in dms0 was added to each well. the plates were ret each well and the plates were incubated on the bench for 15 minutes. luminescence was then read using a clipr ccd camera (molecular devices).[0256] data were analysed logistic equation to generate ic50 values for each compound.[0257] compounds of the examples, herein below, generally have pdgfr kb values in the rat a10 cell based a values.table aaxemppdgfr rat(a10) ic50 / micro m1.10.0091.20.0401.40.0101.50.0041.90.0111.100.0451.150.0071.160.0271.190.0741.200.0131.210.0352.10.0032.60.0163.10.0133.20.0153.30.014.10.0126.10.0417 [0258] pdgfr inhibitors, including the compounds of formula (i), (ii) or (iii) are also useful as co-therapeutic agents for use in combination with second agents, such as org isosorbide dinitrate, molsidomine or sin-1, and inhalational no compounds that inhibit the degradation of cyclic guanosine monophosphate (cgmp) and/or cyclic adenosin especially pde 5 inhibitors such as sildenafil, vardenafil and tadalafil no-independent, but haem-dependent stimulators of guanylate cyclase, such as in particular the com independent activators of guanylate cyclase, such as in particular the compounds described in wo 01/19355, wo 01/19776, wo 01/19778, wo 01/19780, wo 02/070462 and (reltran) compounds inhibiting the signal transduction cascade, such as tyrosine kinase and/or serine/threonine kinase inhibitors, in particular imatinib, gefitinib, erlotinib, and preferably etomoxir, dichloroacetate, ranolazine or trimetazidine antithrombotic agents, for example and preferably from the group comprising platelet aggregation in for example and preferably from the group comprising calcium antagonists, angiotensin ii antagonists, ace inhibitors, endothelin antagonists, renin inhibitors, aldosterone antagonists, rho-kinase inhibitors and diuretics and/or active substances that modify lipid metabolism, for example and preferably from the group comprising thyroid rece inhibitors or inhibitors of squalene synthesis, acat inhibitors, cetp inhibitors, mtp inhibitors, ppar-alpha, ppar-gamma and/or ppar-delta agonists, cholesterol absorption in lipoprotein(a) antagonists, particularly in the treatment of pah or diseases and disorders such as those mentioned hereinbefore, e.g., as potentiators of therapeutic activit drugs.[0259] in particular, an embodiment of this invention is a pharmaceutical combination comprising the compounds of formula (i), (ii) or (iii) and a second agent whe of formula (i), (ii) or (iii) may be mixed with a second agent in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or af inflammatory drugs are those with antagonists of chemokine receptors, e.g., ccr-1, ccr-2, ccr-3, ccr-4, ccr-5, ccr-6, ccr-7, ccr-8, ccr-9 and ccr10, cxcr1, cxcr2, cxcr3, cxcr4, cx sch-d takeda antagonists, such as n-[[4-[[[6,7-dihydro-2-(4-methyl-phenyl)-5h-benzo-cyclohepten-8-yl]carbonyl]amino]phenyl]-methyl]tetrahydro-n,n-dimethyl-2h-pyra (particularly claims 18 and 19), wo 00/66558 (particularly claim 8), wo 00/66559 (particularly claim 9), wo 04/018425 and wo 04/026873.[0262] suitable anti-inflammatory dipropionate, fluticasone propionate, ciclesonide or mometasone furoate, or steroids described in wo 02/88167, wo 02/12266, wo 02/100879, wo 02/00679 (especially tho 03/35668, wo 03/48181, wo 03/62259, wo 03/64445, wo 03/72592, wo 04/398827 and wo 04/66920 non-steroidal glucocorticoid receptor agonists, such as those described 03/104195, wo 03/101932, wo 04/05229, wo 04/18429, wo 04/19935 and wo 04/26248 it4d antagonists, such as montelukast and zafirlukast pde4 inhibitors, such as cilo sch-351591 (scherching-plough), aroxyline (almirall prodesfarma), pd189659/pd168787 (parke-davis), awd-12-281 (asta medica), cdc-801 (celgene), selic cc-10004 (celg disclosed in wo 92/19594, wo 93/19749, wo 93/19750, wo 93/19751, wo 98/18796, wo 99/16766, wo 01/13953, wo 03/104204, wo 03/104205, wo 03/39544, wo 04/00081

04/018431, wo 04/018449, wo 04/018450, wo 04/018451, wo 04/018457, wo 04/018465, wo 04/019944, wo 04/019945, wo 04/045607 and wo 04/037805 adenosine a2b such as albuterol (salbutamol), metaproterenol, terbutaline, salmeterol fenoterol, procaterol, and especially, formoterol, carmoterol and pharmaceutically acceptable salts document is incorporated herein by reference, preferably indacaterol and pharmaceutically acceptable salts thereof, as well as compounds (in free or salt or solvate form) 99/64035, usp 2002/0055651, wo 01/42193, wo 01/83462, wo 02/66422, wo 02/70490, wo 02/76933, wo 03/24439, wo 03/42160, wo 03/42164, wo 03/72539, wo 03/912 04/37773, wo 04/37807, wo 04/39762, wo 04/39766, wo 04/45618, wo 04/46083, wo 04/80964, wo 04/108765 and wo 04/108676.[0263] suitable bronchodilatory drugs i bromide, tiotropium salts and chf 4226 (chiesi), and glycopyrrolate, but also those described in ep 424021, u.s. pat. no. 3,714,357, u.s. pat. no. 5,171,744, wo 01/04118 03/87094, wo 04/018422 and wo 04/05285.[0264] suitable dual anti-inflammatory and bronchodilatory drugs include dual beta-2 adrenoceptor agonist/muscarinic antagonist antihistamine drug substances include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexof tefenadine, as well as those disclosed in jp 2004107299, wo 03/099807 and wo 04/026841.[0266] accordingly, the invention includes as a further aspect a combination of [0267] accordingly, the invention includes as a further aspect a combination of pdgfr inhibitor with second agents that are rho-kinase inhibitors. accordingly, the invention antagonists.[0268] accordingly, the invention includes as a further aspect a combination of pdgfr inhibitor with second agents that are ip receptor agonist.[0269] according that are multi-kinase inhibitors, such as imatinib mysilate (gleevec(r)) or nilotinib. imatinib functions as a specific inhibitor of a number of tyrosine kinase enzymes. it occ insulin receptor. imatinib is specific for the tk domain in the abelson proto-oncogene, c-kit and pdgfr-r (platelet-derived growth factor receptor).[0270] accordingly, an emb formula (i), (ii) or (iii), or pharmaceutically salts thereof, and a second agent wherein the second agent is selected from phosphodiesterase v (pdeV) inhibitors, such as sild inflammatory drugs including antagonists of chemokine receptors including corticosteroids such as long-acting corticosteroids beta 2-agonists including ultra-long- such as long-acting muscarinic antagonists dual anti-inflammatory and bronchodilatory drugs including dual beta-2 adrenoceptor agonist/muscarinic antagonists antihista. that induce pulmonary vascular vasodilation agents that are tryptophan hydroxylase 1 (tph1) inhibitors multi-kinase inhibitors such as c-kit inhibitors tyrosine kinase inhibit combination with pi3k inhibitors) lpa-1 inhibitors endothelin antagonists diuretics aldosterone receptor blockers and endothelin receptor blockers. formulation and adminis e.g., orally, e.g., in the form of a tablet or capsule parenterally, e.g., intravenously by inhalation, e.g., in the treatment of inflammatory or obstructive airways disease intr atopic dermatitis topically to the eye, e.g., in the treatment of glaucoma or rectally, e.g., in the treatment of inflammatory bowel disease.[0272] in a further aspect, the in (iii) in free form or in the form of a pharmaceutically acceptable salt, optionally together with a pharmaceutically acceptable adjuvant, diluent or carrier.[0273] the composi antihistamine or anti-tussive drug as hereinbefore described. such compositions may be prepared using conventional diluents or excipients and techniques known in the g administration may take the form of creams, ointments, gels or transdermal delivery systems, e.g., patches. compositions for inhalation may comprise aerosol or other a aerosol formulation, it preferably contains, e.g., a hydro-fluoro-alkane (hfa) propellant, such as hfa134a or hfa227 or a mixture of these, and may contain one or more c surfactants such as oleic acid or sorbitan trioleate, and/or one or more bulking agents, such as lactose. when the composition comprises a dry powder formulation, it prefe optionally together with a diluent or carrier, such as lactose, of the desired particle size distribution and a compound that helps to protect against product performance del formulation, it preferably contains, e.g., the compound of formula (i), (ii) or (iii) either dissolved, or suspended, in a vehicle containing water, a co-solvent, such as ethan further includes: (a) a compound of formula (i)-(iii) in inhalable form, e.g., in an aerosol or other atomisable composition or in inhalable particulate, e.g., micronised, for (c) a pharmaceutical product comprising a compound of formula (i), (ii) or (iii) in inhalable form in association with an inhalation device and (d) an inhalation device cont formula (i), (ii) or (iii) employed in practicing the present invention will of course vary depending, e.g., on the particular condition to be treated, the effect desired and the order of 0.005-10 mg, while for oral administration suitable daily doses are of the order of 0.05-100 mg.[0277] the present invention includes all pharmaceutically acc replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.[0278] hydrogen, such as 2h and 3h, carbon, such as 11c, 13c and 14c, chlorine, such as 36cl, fluorine, such as 18f, iodine, such as 123i and 125i, nitrogen, such as 13n and 15 substitution with heavier isotopes such as deuterium, i.e. 2h, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased circumstances.[0280] isotopically-labeled compounds of formula (i), (ii) or (iii) can generally be prepared by conventional techniques known to those skilled in the art or t an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.[0281] compounds of formula (i), (ii) or (iii) may be prepared by th compounds of the preferred embodiments are synthesized using the methods described herein, or other methods, which are known in the art.[0283] it should be underst phenomenon of tautomerism. as the chemical structures within this specification can only represent one of the possible tautomeric forms, it should be understood that the understood that the invention is not limited to the embodiments set forth herein for illustration, but embraces all such forms thereof as come within the scope of the abov conditions [0286] mass spectra were run on lcms systems using electrospray ionization. these were either agilent 1100 hplc/micromass platform mass spectrometer combi molecular weights.[0287] nmr spectra were run on open access bruker avance 400 nmr spectrometers using icon-nmr. spectra were measured at 298k and were reference are not to be construed as being limitations thereon. temperatures are given in degrees centigrade. if not mentioned otherwise, all evaporations are performed under red of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., ms, ir, nmr. accepted meanings. abbreviations [0289] aq. aqueous br broad d doublet cm dichloromethane dmf n,n-dimethylformamide [0290] dmac dimethylacetamide dmso dime chromatography lc-ms liquid chromatography and mass spectrometry meoh methanol ms mass spectrometry m multiplet min minutes ml milliliter(s) m/z mass to charge (r) pe-ax columns from biotage) rt retention time rt room temperature s singlet scx-2 strong cation exchange (e.g. isolate(r) scx-2 columns from biotage) t triplet tea trie referring to the examples that follow, compounds of the preferred embodiments were synthesized using the methods described herein, or other methods, which are know embodiments may be isolated and purified, where appropriate, using conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation, and suppliers and used without further purification. salts may be prepared from compounds by known salt-forming procedures.[0293] it should be understood that the organic tautomerism. as the chemical structures within this specification can only represent one of the possible tautomeric forms, it should be understood that the preferred embo the analytical hplc conditions are as follows: method 2minlc_v001columnwaters beh c18 100 x 2.1 mm, 1.7 micro mcolumn temp.50 degrees centigrade eluents: h2o, b: percent to 95 percent b in 1.00 min, 0.25 min95 percent b method 2minlc_v002 columnwaters beh c18 50 x 2.1 mm, 1.7 micro mcolumn temperature50 degrees centigra percent b 5 percent to 95 percent b in 1.30 min,0.25 min 95 percent b method 2minlc_v003 columnwaters beh c18 50 x 2.1 mm, 1.7 micro mcolumn temperature50 d ml/mingradient0.25 min 30 percent b 30 percent to 95 percent b in 1.00 min,0.25 min 95 percent b method 10minlc_v003 columnwaters beh c18 50 x 2.1 mm, 1.7 micro mcolumn percent tfflow rate0.8 ml/mingradient0.20 min 5 percent b 5 percent to 95 percent b in 7.80 min, 1.00 min 95 percent b method lowph_v002 [0295] columnphenomenex meoh, both containing 0.1 percent tfflow rate1.0 ml/mingradient5 percent to 95 percent b in 2.0 min, 0.2 min 95 percent b method a [0296] column:acquity hss t3 1.8 mm ammoniumacetateeluent b:acetonitrile + 0.04 percent formic acidgradient:2 percent to 98 percent b in 1.4 min-flow 1.2 ml/min method 10 min lc [0297] columnaglie h2o, c: acetonitrile, both containing 0.1 percent formic acidflow rate0.8 ml/mingradient0.50 min 5 percent c 5 percent to 95 percent c in 6.50 min, 95 percent to 5 percent compounds example 1.1 n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)-7-(1-methyl-1h-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamide [0299] [f phenyl]imidazo[1,2-a]pyridine-3-carboxamide [0300] methyl 3-(7-bromoimidazo[1,2-a]pyridine-3-carboxamido)-4-fluorobenzoate (intermediate 1a)(1.08 g, 2.75 mmol) mmol) in toluene (35 ml) were heated to 80 degrees centigrade for 6 hrs. a further portion of tbd (0.06 g, 0.431 mmol) and (2-(4-methylpiperazin-1-yl)phenyl)methana overnight. tbd (0.06 g, 0.431 mmol) was added and heating continued at 110 degrees centigrade overnight. toluene was removed in vacuo and the resulting solid was par with sodium bicarbonate solution (2x50 ml) and concentrated in vacuo. the resulting oil was dissolved in meoh and purified by chromatography on silica eluting with 0-10 solid was recrystallised from etoac (50 ml) to afford the title compound[0301] lc-ms: rt 0.85 mins ms m/z 567.4 {m+h}+ method 2minlc_v003[0302] 1h nmr (400 mhz, d m), 7.4 (1h, d), 7.35 (1h, d), 7.2 (2h, m), 7.1 (1h, d), 7.0 (1h, t), 4.6 (1h, d), 2.9 (4h, m), 2.4 (3h, t), 2.2 (3h, s). step 2: n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)ben mixture comprising 7-bromo-n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzyl carbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide (step 1) (120 mg, 0.212 mmol), 1 cesium carbonate (69.1 mg, 0.212 mmol) and pdc12(dppf).ch2cl2 adduct (17.33 mg, 0.021 mmol) in dmf (5 ml) under n2 was heated at 85 degrees centigrade for 2 hrs. formed which was removed by filtration and discarded. the organic portion was separated and washed with nahco3, water, dried (mgso4) and concentrated in vacuo. the c product fractions were combined and concentrated in vacuo. the product was dissolved in meoh and passed through a 1 g 2,4,6-trimercaptopotriazine silica column under gra product was triturated with thf (1 percent meoh) followed by ether to afford the title compound[0304] lc-ms: rt 0.80 mins ms m/z 567 {m+h}+ method 2minlc_v003[0305] (1h, s), 7.45-7.3 (5h, m), 7.2 (1h, m), 6.7 (1h, s), 4.75 (2h, s), 4.1 (3h, s), 3.4 (4h, s broad), 3.2 (4h, s broad), 2.95 (3h, s). example 1.2 7-(3-fluoro-4-(2-hydroxyethy a]pyridine-3-carboxamide [0306] [ftimg=64854355][0307] a mixture comprising 7-bromo-n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-hydroxyethylcarbamoyl)phenylboronic acid (48.2 mg, 0.212 mmol), cesium carbonate (69.1 mg, 0.212 mmol) and pdc12(dppf).ch2cl2 adduct (17.33 mg, 0.021 mmol) in (2-hydroxyethylcarbamoyl)phenylboronic acid (48.2 mg, 0.212 mmol), cesium carbonate (69.1 mg, 0.212 mmol) and pdc12(dppf).ch2cl2 adduct (17.33 mg, 0.021 mmol) diluted with etoac and water and the biphasic mixture was filtered. the filtercake was washed with meoh and the filtrate was concentrated under vacuum. purification of the beige solid. the solid was triturated with thf/ether and dried in vacuo at 45 degrees centigrade overnight to afford the title compound[0308] lc-ms: rt 0.81 mins ms m/z 6 8.6 (1h, s), 8.4 (1h, d), 8.1 (1h, s), 8.0 (1h, t), 7.8 (3h, m), 7.6 (1h, d), 7.5-7.2 (4h, m), 7.2 (1h, t), 4.7 (2h, s), 3.75 (2h, t), 3.6 (2h, t), 3.1 (4h, s broad), 3.0 (4h, s b (4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide [0310] [ftimg=64854356][0311] methyl 3-(7-bromoimidazo[1,2-a]pyridine-3-car mmol) in toluene (10 ml) was treated with (2-(4-methylpiperazin-1-yl)phenyl)methanamine (212 mg, 1.030 mmol) and heated at 100 degrees centigrade under nitrogen centigrade for a further 24 hrs. the solvent was removed in vacuo and the residue was partitioned between etoac (50 ml) and sodium bicarbonate solution (50 ml). the or and evaporated to dryness to give a yellow solid. purification by chromatography on silica eluting with 0-20 percent 2m nh3 in meoh/dcm afforded a colourless oil. the oil as a white solid[0312] lc-ms: rt 0.85 mins ms m/z 561.4 {m+h}+ method 2minlc_v003[0313] 1h nmr (400 mhz, dms0-d6) delta 10.1 (s, 1h), 9.4 (d, 1h), 8.9 (t, 1h), 8.5 (m, 1h), 4.6 (d, 2h), 3.1 (t, 4h), 2.4 (s, 3h), 2.3 (s, 3h) step 2 example 1.3 (ii): 7-(1-methyl-1h-pyrazol-5-yl)-n-(2-methyl-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl mixture comprising 7-bromo-n-(2-methyl-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide (step 1) (77.8 mg, 0.125 mmol), cesium carbonate (40.6 mg, 0.125 mmol) in dmf (1 ml) was treated with pdc12(dppf).ch2cl2 adduct (50.9 mg, 0.062 mmol) and heated at 110 degrees centigrade for 1 hr percent 2m nh3 in meoh/dcm afforded a black solid. the solid was dissolved in 7m nh3 in meoh (12 ml) and passed through a 1 g pd scavenger cartridge. the solvent wa 0.98 mins ms m/z 563.5 {m+h}+ method 2minlc_v003[0317] av55760 1h nmr (400 mhz, meod) delta 9.5 (1h, d), 8.55 (1h, s), 8.0 (1h, s), 7.8 (1h, s), 7.7 (1h, dd), 7. 2.7 (4h, s), 2.4 (3h, s) example 1.4 n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)-7-(pyridine-3-yl)imidazo[1,2-a]pyridine-3-carboxamide [0318] [fti benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide (ex 1.1, step 1) (120 mg, 0.212 mmol), pyridine-3-ylboronic acid (33.8 mg, 0.212 mmol), triethylamine (17.33 mg, 0.021 mmol) in dmf (3 ml) were heated at 85 degrees centigrade overnight. a further portion of cesium carbonate (24.34 mg, 0.075 mmol) and pdc12(dppf).c (34.6 mg, 0.212 mmol) and heated continued at 85 degrees centigrade for 26 hrs. a further portion of cesium carbonate (24.34 mg, 0.075 mmol) and pdc12(dppf).ch2cl2 mmol) were added. the reaction was heated at 100 degrees centigrade for 2 hrs. the reaction mixture was diluted with etoac and water and the resulting product which pre washed with sat. nahco3, brine, dried (mgso4) and concentrated in vacuo. the crude residue was combined with the precipitated product and purified by chromatography o eluting with 0.1 percent diethylamine (30-70 percent acetonitrile/water. the product fractions were partitioned between etoac and nahco3. the organic portion was separated mins ms m/z 564/565 {m+h}+ method 10minlc_v003[0321] 1h nmr (400 mhz, cd3od) delta 9.7 (1h, d), 9.1 (1h, d), 8.7 (1h, m), 8.6 (1h, s), 8.4 (1h, m), 8.3 (1h, m), (4h, s broad), 2.5 (3h, t). example 1.5 n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)-7-(1-methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxa benzylcarbamoyl)phenyl)-7-(1-methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide [0323] a mixture comprising 7-bromo-n-(2-fluoro-5-(2-(4-methylpiperazin- 0.177 mmol) and cesium carbonate (230 mg, 0.707 mmol) in dme (2.5 ml) and water (1 ml) under nitrogen was treated with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-diox heated using microwave radiation at 100 degrees centigrade for 1 hr. after cooling to rt, the reaction mixture was partitioned between water (4 ml) and etoac (10 ml)/meo by chromatography on silica eluting with 0-20 percent meoh in dcm followed by trituration of the resulting solid with etoac afforded the title compound[0324] lc-ms: rt 0.89 benzylcarbamoyl)phenyl)-7-(1-methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide hydrochloride [0325] n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarba 0.053 mmol) in meoh (2 ml) was treated with hcl in ether (0.053 ml, 0.053 mmol) and the solution was evaporated to dryness and dried in vacuo overnight to afford the t compounds of the following tabulated examples (table 1) were prepared by a similar methods to that of example 1.1-1.5 from the appropriate starting compounds, the p 1structureex.name[m + h]+/nmr1.6[ftimg=64854360]rt = 3.16 mins ms m/z 505.4 [m + h] method 10 minlc_v003 1h nmr (400 mhz, dms0) delta 10.35 (1h, s), 9.50 (3h, m), 7.18 (1h, m), 4.48 (2h, d), 4.01 (3h, s).n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamide (400 mhz, dms0-d6) delta10.3 (1h, s), 10.0 (1h, s), 9.1 (1h, t), 8.6 (1h, s), 8.2 (1h, m), 7.9 (1h, d), 7.8 (3h, m), 7.5 (1h, t), 7.35 (4h, m), 7.3 (1h, m), 6.7 (1h, s), 4. [1,2-a]pyridine-3-carboxamide1.8[ftimg=64854362]rt = 0.78 mins ms m/z 578.5 [m + h] method 2 minlc_v003 1h nmr (400 mhz, dms0) delta 9.60 (1h, s), 8.93 (1h, 7.36 (1h, d), 7.30 (1h, dd), 7.22 (1h, d), 7.13 (2h, m), 4.73 (2h, d), 3.05 (4h, m), 2.90-2.75 (4h, m), 2.48 (3h, s), 2.39 (3h, s).n-(4-fluoro-2-methyl-5-(2-(4-methylpip [ftimg=64854363]rt 0.92 mins ms m/z 603.6 {m + h}+ method 2 minlc_v003 1h nmr (400 mhz, meod) delta 9.6 (1h, s), 8.6 (1h, d), 7.6 (1h, s), 7.5 (2h, t), 6.6 (1h, s), 3.6 (2h (400 mhz, dms0-d6) delta 10.7 (1h, s), 10.0 (1/2h, m), 9.5 (1h, t), 9 (1h, t), 8.8 (1h, s), 8.2 (1h, m), 8.1 (1h, s), 7.6 (1h, s), 7.5 (2h, t), 6.6 (1h, s), 3.4 (3h, s), 3.6 (2h (2h, d)n-(5-(2-(6-cis-dimethylpiperidin-1-yl)ethylcarbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamide1.11[ftimg=64854365]r (broad 1h, s), 9.5 (1h, d), 9.0 (1h, t), 8.7 (1h, s), 8.25 (1h, d), 8.1 (1h, s), 7.9 (2h, d), 7.6 (1h, d), 7.5-7.4 (3h, m), 7.25-7.2 (2h, m), 7.15 (1h, d), 7.1 (1h, t), 4.6 (2h phenyl)-n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide1.12[ftimg=64854366]rt = 0.83 mins ms m/z 578.5, [m (2h, m), 8.15 (2h, s), 7.97 (1h, s), 7.77 (1h, m), 7.60-7.35 (3h, m), 4.28 (2h, m), 3.55 (4h, m), 3.40 (2h, m), 2.50-2.80 (8h, m), 1.00-1.21 (9h, m).n-(5-(2-tert-butoxy 3-carboxamide1.13[ftimg=64854367]rt = 0.96 mins ms m/z 590.5, [m + h] method 2 minlc_v003 1h nmr (400 mhz, dms0) delta 10.20 (1h, s), 9.38 (1h, s), 8.61 (2h, (1h, m), 3.57 (4h, m), 2.76 (2h, t), 2.52 (2h, m), 2.45 (4h, m), 2.02 (1h, m), 1.70 (3h, m), 1.21 (3h, s), 1.17 (3h, s).n-(5-(5,5-dimethyltetrahydrofuran-2-yl)methyl-ca carboxamide1.14[ftimg=64854368]rt = 1.03 mins ms m/z 594.4, [m + h] method 2 minlc_v003 1h nmr (400 mhz, dms0) delta 10.30(1h, s), 9.50 (1h, s), 9.50 (1h, d), 8.99 (1h, t), 7.52-7.36 (3h, m), 7.27 (1h, m), 7.05 (2h, m), 4.58 (2h, d), 3.32 (3h, s), 2.87 (4h, m), 2.52 (4h, m), 2.23 (3h, s).n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarba [ftimg=64854369]rt 0.89 mins ms m/z 567/568/569 {m + h}+ method 2 minlc_v003 1h nmr (400 mhz, dms0-d6) delta 10.0 (1h, s), 9.9 (1h, m), 9.1 (1h, s), 9.0 (1h, t m), 6.6 (1h, s), 4.6 (2h, d), 4.0 (3h, s), 3.6- 3.0 (8h, m), 2.9 (3h, d).n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)-6-(1-methyl-1h-pyrazol-5-yl)pyr

method 2 minlc_v003 1h nmr (400 mhz, dms0) delta 10.71 (1h, s), 10.01 (1h, t), 9.72 (1h, d), 9.33 (1h, s), 9.05 (1h, m), 8.90 (1h, s), 8.85 (1h, d), 8.70 (1h, m), 8.47 1.70 (2h, m), 1.50 (2h, m), 1.40 and 1.30 (6h, 2 x d).1-(2-(4-fluoro-3-(7-(pyridine-3-yl)imidazo[1,2-a]pyridine-3-carboxamido)benzamido)ethyl)-2,6-cis-dimethylpiperid nmr (400 mhz, meod) delta 9.0 (1h, s), 837 (1h, s), 8.5 (1h, s), 8.4 (1h, d), 8.4 (1h, d), 8.1 (1h, dd), 7.85 (1h, d), 7.75 (1h, m), 7.35 (1h, t), 6.95 (1h, d), 4.4 (2h, t), butoxyethylcarbamoyl)-2-fluorophenyl)-6-(6-(3-(dimethylamino)propoxy)pyridine-3-yl)pyrazolo[1,5-a]pyridine-3-carboxamide.18[ftimg=64854372]rt 0.75 mins m/z 8.6 (1h, dd), 8.5 (1h, s), 8.3 (1h, d), 8.05 (1h, s), 7.95 (1h, d), 7.7 (1h, dd), 7.6 (1h, s), 7.55 (1h, dd), 7.4 (1h, d), 7.35 (1h, d), 7.25 (2h, m), 7.1 (2h, s), 7.05 (1h, d), 6.95 (1h, s), 6.85 (1h, s), 6.75 (1h, s), 6.65 (1h, d), 4.76 (2h, s), 4.04 (3h, s), 3.10 (4h, m), 2.96 (4h, b), 2.66 (3h, s), 2.59 (3h, s)1-methyl-4-(2-((6-methyl-phenyl)piperazin-1-ium chloride example 1.10 n-(5-(2-(2,6-cis-dimethylpiperidin-1-yl)ethylcarbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-5-yl)imidazo[1,2-a]pyridin mmol) was added to a mixture comprising 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole (commercially available) (212 mg, 1.017 mmol), 7-bro 3-carboxamide (intermediate 4c) (500 mg, 0.968 mmol), cs2co3 (1262 mg, 3.87 mmol) in 1,2-dimethoxyethane (10 ml) and water (4.29 ml). the mixture was degassed degrees centigrade for 1 hour. the water was removed by pipette and the organic portion was concentrated in vacuo. the residue was dissolved in meoh and dry loaded on in dcm to afford the title compound. (see table 1 for characterising data).[0330] the citrate salt of n-(5-(2-(2,6-cis-dimethylpiperidin-1-yl)ethylcarbamoyl)-2-fluorophenyl) following procedure: step 1: 3-((7-bromo-imidazo[1,2-a]pyridine-3-carbonyl)-amino)-4-fluoro-benzoic acid methyl ester [0331] to the solution of compound 7-bromoidmid added dropwise socl2 (1.86 kg, 15.6 mol) at 10 degrees centigrade in 30 min. to the resulting mixture warmed to 20 degrees centigrade was added compound methyl 3- temperature went up to 30 degrees centigrade hplc showed the reaction went to completion within 5 min. to the reaction mixture was added water (20 l) over 20 min. the nmr (400 mhz, dms0-d6) delta 3.87 (s, 3h) 7.57 (dd, j=7.28, 2.01 hz, 1h) 7.51 (dd, j=10.16, 8.66 hz, 1h) 7.90 (td, j=4.33, 2.38 hz, 1h) 8.29 (m, 2h) 8.90 (s, 1h) 9.43 (f fluoro-3-[[7-(2-methyl-2h-pyrazol-3-yl)-imidazo[1,2-a]pyridine-3-carbonyl]-amino]-benzoic acid [0333] 3-[[7-bromo-imidazo[1,2-a]pyridine-3-carbonyl]-amino]-4-fluoro dioxaborolan-2-yl)-1h-pyrazole (commercially available) (764 g, 3.67 mol), pdc12(dppf).ch2cl2 (75.0 g, 91.8 mmol) in dioxane (10 l) and aqueous na2co3 (2 n, 4.6 l) wer the filtrate was heated to reflux, to which was added acoh (600 g, 10.0 mol) was added dropwise. during the course of addition solids came out of solution to give pale pin dioxane (20 l) followed by heating to reflux to obtain a solution. the solution was cooled to rt and filtered to provide the title compound as a white solid[0334] 1h nmr (40 7.54 (s, 1h) 7.85 (d, j=2.26 hz, 1h) 7.99 (s, 1h) 8.28 (d, j=6.27 hz, 1h) 8.67 (s, 1h) 9.47 (d, j=7.03 hz, 1h) 10.35 (s, 1h).[0335] rt 5.40 mins ms m/z 380.1 {m+h}+ me [2-(2,6-dimethyl-piperidin-1-yl)-ethylcarbamoyl]-2-fluoro-phenyl)-amide [0336] 4-fluoro-3-[[7-(2-methyl-2h-pyrazol-3-yl)-imidazo[1,2-a]pyridine-3-carbonyl]-amino]-be in dmf (3.2 l) at 25 degrees centigrade were stirred for 1.5 hr. the reaction was monitored by hplc. to the reaction mixture was dropwise added cis 2-(2,6-dimethyl-piperidi reaction mixture was dropwise an aqueous solution of na2co3 (5 percent, 6 l) over 120 min and the resulting solid was collected by filtration and washed with water (5 l). t solution. water (1.5 l) was dropwise added at 70 degrees centigrade and stirred for 30 min. the clear solution was slowly cooled to 25 degrees centigrade over 2 hr. the sol overnight to afford the title compound as a white solid[0337] 1h nmr (400 mhz, dms0-d6) delta 1.03-1.19 (m, 3h) 1.10 (d, j=6.02 hz, 6h) 1.55 (br. s., 1h) 1.50 (d, j=12. (d, j=6.02 hz, 2h) 7.54 (s, 1h) 7.77 (s, 1h) 8.00 (s, 1h) 8.14 (d, 1h) 8.54 (s, 1h) 8.67 (s, 1h) 9.48 (d, 1h) 10.35 (s, 1h).[0338] rt 4.80 mins ms m/z 518.2 {m+h}+ met (1-methyl-1h-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamide citric acid (1:1) [0339] 7-(2-methyl-2h-pyrazol-3-yl)-imidazo[1,2-a]pyridine-3-carboxylic acid [5-[2-(2,6 in ethanol (2300 ml) in a 5000 ml four-necked flask equipped with thermometer, reflux condenser and a nitrogen inlet. the mixture was heated to 55 degrees centigrade added over 1 h and the internal temperature was controlled at 45-50 degrees centigrade the clear solution was stirred at 50 degrees centigrade for 2 h. a crystal seed (1. speed of 8 degrees centigrade /h. the mixture was stirred at 20 degrees centigrade for 60 h. the resulting solid was filtered and the filter cake was washed with acetone (1 compound[0340] 1h nmr (400 mhz, dms0-d6) delta 1.46 (m, 3h) 1.29 (d, j=6.02 hz, 6h) 1.65 (s., 1h) 1.73 (d, 2h) 2.59 (m, 4h) 3.18 (m, 4h) 3.53 (d, 2h) 4.00 (s, 3h) 6 1h) 8.90 (s, 1h) 9.48 (d, 1h) 10.36 (s, 1h). example 1.20 7-(1-methyl-1h-pyrazol-4-yl)-imidazo[1,2-a]pyridine-3-carboxylic acid {5-[2-(2,6-cis-dimethyl-piperidin-1-yl)-e (5-(2-(2,6-cis-dimethylpiperidin-1-yl)ethylcarbamoyl)-2-fluorophenyl) imidazo[1,2-a]pyridine-3-carboxamide (intermediate 4c) (50 mg, 0.097 mmol), 1-methyl-1h-pyrazo dissolved in dme (215 micro l)/water (108 micro l) to form a solution. nitrogen was bubbled though the reaction mixture for 2 minutes. pdc12(dppf).ch2cl2 adduct (3.95 m degrees centigrade for 15 mins. the water was removed and the organic portion was dry loaded onto silica. the crude product was purified by chromatography on silica eluti vacuo. the product was dissolved in meoh and passed through a 1 g 2,4,6-trimercaptotriazine silica. the solvent was removed in vacuo and the residue was triturated with [0343] lc-ms: rt 0.30 mins ms m/z 517{m+h}+ method 2minlc_v003[0344] 1h nmr (400 mhz, dms0) delta 10.4 (1h, s), 10 (1h, d), 9.4 (1h, d), 8.9 (1h, t), 8.7 (1h, s), m), 3.4 (4h, m), 3.3 (2h, m), 3.1 (1h, m), 1.9 (1h, m), 1.7 (2h, m), 1.5 (2h, m), 1.4 (4h, m), 1.3 (2h, d), 1.1 (1h t). example 1.21 6-(1-methyl-1h-pyrazol-5-yl)-n-(2-me carboxamide [0345] [ftimg=64854376][0346] the title compound was prepared from intermediate 1d and (2-(4-methylpiperazin-1-yl)phenyl)methanamine analogously t example 2.1 n-(5-(2-tert-butoxyethylcarbamoyl)-2-fluorophenyl)-7-(6-(3-(dimethylamino)propoxy) pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide [0348] [ftimg=648 pyridine-3-carboxamide (intermediate 2a) (300 mg, 0.629 mmol), n,n-dimethyl-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)propan-1-amine (202 dimethoxyethane (7 ml) and water (3 ml). the mixture was degassed thoroughly refilling with nitrogen and treated with pdc12(dppf).ch2cl2 adduct (25.7 mg, 0.031 mmol). microwave radiation at 100 degrees centigrade for 1 hr. the aqueous was removed by pipette and the organic portion was absorbed onto silica and purified by chromatogr afford the title compound[0350] lc-ms: rt 2.55 mins ms m/z 577.5, {m+h}+ method 10minlc_v003[0351] 1h nmr (400 mhz, dms0) delta 10.25 (1h, s), 9.46 (1h, d), 8.7 (1h, t), 6.95 (1h, d), 4.36 (2h, t), 3.45 (2h, m), 3.35 (2h, m), 2.35 (2h, m), 2.15 (6h, s), 1.87 (2h, m), 1.16 (9h, s). example 2.2 n-(5-(((5,5-dimethyltetrahydrofuran-2- pyridine-3-carboxamide [0352] [ftimg=64854378][0353] the title compound was prepared from commercially available 1-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxabo 0.71 mins ms m/z 586/587 {m+h}+ method 2minlc_v003 example 2.3 n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(1-(3-(dimethyl amino)propyl)-1h-pyrazol-4 prepared from commercially available n,n-dimethyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazol-1-yl)propan-1-amine and intermediate 3a analogously example 2.4 n-(5-(((5,5-dimethyltetrahydrofuran-2-yl)methylcarbamoyl)-2-fluorophenyl)-7-(5-((tetrahydro-2h-pyran-4-ylamino)methyl)pyridin-3-yl)imidazo[1,2-a]pyridine methylcarbamoyl)-2-fluorophenyl)-7-(5-formylpyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide [0359] the title compound was prepared from 5-(4,4,5,5-tetramethyl-1, ms: rt 0.87 mins ms m/z 516/517/518 {m+h}+ method 2minlc_v003 step 2: n-(5-(((5,5-dimethyltetrahydrofuran-2-yl)methylcarbamoyl)-2-fluorophenyl)-7-(5-((tetrahydro suspension of n-(5-(((5,5-dimethyltetrahydrofuran-2-yl)methylcarbamoyl)-2-fluorophenyl)-7-(5-formylpyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (step 1)(98 mg mmol) and 2-picoline borane (24.16 mg, 0.228 mmol) in meoh (2 ml) was heated at 50 degrees centigrade for 3 hrs. the reaction mixture was concentrated under vacuu nahco3 and h2o. the organic portion was dried mgso4 and concentrated in vacuo. the crude product was purified by chromatography on silica eluting with 0-20 percent 2m triturated with etoac/iso-hexane to afford the title compound[0362] lc-ms: rt 0.69 mins ms m/z 601/602 {m+h}+ method 2minlc_v003[0363] the compounds of the follo the appropriate starting compounds, the preparations of which are detailed in the preparation of intermediates section.table 2structureex.namecl.ms/nmr.2.5[ftimg=64854 dimethyltetrahydrofuran-2-yl)methylcarbamoyl)-2-fluorophenyl)-7-(5-(((2-fluoroethyl)amino)methyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide2.6[ftimg=64854 dimethyltetrahydrofuran-2-yl)methylcarbamoyl)-2-fluorophenyl)-7-(5-(((2-methoxyethyl)(methyl)amino)methyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide2.7[fti butylamino)methyl)pyridin-3-yl)-n-(5-(((5,5-dimethyltetrahydrofuran-2-yl)methylcarbamoyl)-2-fluorophenyl)imidazo[1,2-a]pyridine-3-carboxamide example 3.1 n-(5-(3, [1,2-a]pyridine-3-carboxamide hydrochloride [0364] [ftimg=64854384] step 1: 7-(6-chloropyridin-3-yl)-n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)imidazo[1,2-a] difluorobenzylcarbamoyl)-2-fluorophenyl)imidazo[1,2-a]pyridine-3-carboxamide (intermediate 3a) 100 mg, 0.199 mmol, 6-chloropyridin-3-ylboronic acid (31.3 mg, 0.19 was purged with nitrogen and treated with pdc12(dppf).ch2cl2 adduct (8.11 mg, 9.93 micro mol) the resulting mixture was heated using microwave radiation at 100 degree with meoh. purification of the mixture by chromatography on silica eluting with 0-20 percent 2m nh3 in meoh/dcm afforded the title compound[0366] lc-ms: rt 0.75 mins fluorophenyl)-7-(6-(2-(pyrrolidin-1-yl)ethoxy) pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide hydrochloride [0367] a solution of 2-(pyrrolidin-1-yl)ethanol (30.5 mg, 0 for 30 mins and treated with 7-(6-chloropyridin-3-yl)-n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)imidazo[1,2-a]pyridine-3-carboxamide (step 1). the reaction mixt purification of the mixture by chromatography on silica eluting with 0-20 percent (2m nh3 in meoh)/dcm afforded a yellow solid. the solid was dissolved in meoh and treat crude product by chromatography on silica eluting with 2m nh3 in meoh/tbme afforded a solid. the solid was treated again with 2m hcl in diethyl ether and concentrated in 2minlc_30_v003[0369] 1h nmr (400 mhz, dms0-d6) delta10.5 (1h, s), 9.6 (1h, s), 8.8 (2h, d) 8.4 (1h, d), 8.2 (1h, d), 7.9 (1h, m), 7.7 (1h, d), 7.45 (1h, t), 7.4 (1h, m), 3.1 (2h, m), 2.05 (2h, m), 1.95 (2h, m).[0370] the compounds of the following tabulated examples (table 3) were prepared by a similar method to that of example preparation of intermediates section.table 3structureex.namecl.ms/nmr.3.2[ftimg=64854385]lc-ms: rt 0.87 mins ms m/z 589 [m + h]+ method 2 minlc_v003n-(5-(((2-(ter a]pyridine-3-carboxamide3.3[ftimg=64854386]lc-ms: rt 0.71 mins ms m/z 601/602 [m + h]+ method 2 minlc_v003.n-(5-(((5,5-dimethyltetrahydrofuran-2-yl)methyl)carb carboxamide example 4.1 6-(1-methyl-1h-pyrazol-5-yl)-n-(2-methyl-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)pyrazolo[1,5-a]pyridine-3-carboxamide hydro benzylcarbamoyl)phenyl)pyrazolo[1,5-a]pyridine-3-carboxamide (169 mg, 0.301 mmol), 5-(1,5-dimethyl-2,4-dioxa-3-borabicyclo[3.1.0]hexan-3-yl)-1-methyl-1h-pyrazol water (1284 ul) were combined to give a yellow solution. pdc12(dppf).ch2cl2 adduct (6.15 mg, 7.52 micro mol) was added and the mixture was heated using microwave rad 7.52 micro mol) was added and heating continued using microwave radiation at 100 degrees centigrade for 1 hr. 5-(1,5-dimethyl-2,4-dioxa-3-borabicyclo[3.1.0]hexan-3-y mol) and cesium carbonate (392 mg, 1.204 mmol) were added. the mixture was heated using microwave radiation at 100 degrees centigrade for 2 hrs. the product was p second column using 0-15 percent 2m nh3 in meoh/dcm. the resulting residue was dissolved in meoh/dcm, filtered through a glass fibre filter paper and purified by prepa fractions were partitioned between nahco3 and etoac and the organic portion was dried (mgso4) and concentrated to afford a colourless oil. hcl (1 equiv.) in dioxane w 2.66 mins ms m/z 563/564/565 {m+h}+ method 10minlc_v003[0374] 1h nmr (400 mhz, cd3od) delta 8.9 (1h, s), 8.7 (1h, s), 8.4 (1h, d), 7.95 (1h, s), 7.7 (1h, d), 7.65 4.7 (2h, s), 4.0 (3h, s), 3.0 (4h, m), 2.7 (4h, s broad), 2.45 (6h, d). example 5.1 n-(2-bromo-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridi 1-yl)benzylbenzamide [0376] n,1,n1-dimethyl-n2-(propylimino)methylene)ethane-1,2-diamine (0.70 ml, 3.99 mmol) was added to a stirred solution/suspension of 3-a (820 mg, 3.99 mmol) and hobt (140 mg, 1.0 mmol) in dry dcm (20 ml) under argon. after 24 hrs the reaction mixture was diluted with dcm and washed several times wit dcm/diethyl to give a yellow crystalline powder[0377] lcms: rt 0.85 min ms m/z 403.2 {m+h}+ method 2minlc_v003[0378] 1h nmr (400 mhz, cdcl3) delta 6.48 (1h, d), 6. 3.02 (4h, br s), 2.62 (4h, br s), 2.35 (3h, s) step 2: n-(2-bromo-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide [0379] imid portions to a stirred solution of 3-amino-4-bromo-n-(2-(4-methylpiperazin-1-yl)benzyl)benzamide (step 1)(900 mg, 2.23 mmol) in dry pyridine (15 ml). the reaction was treated with a small amount of meoh to dissolve insoluble material then partitioned between aq. nahco3 and dcm. the organic extract was washed with brine, dried over m white solid[0380] lcms: rt 0.78 min ms m/z 549.2 {m+h}+ method 2minlc_v003[0381] 1h nmr (400 mhz, meod) delta 9.52 (1h, s), 8.53 (1h, s), 8.25 (1h, s), 7.85 (1h, 3.0 (4h, br s), 2.67 (4h, br s), 2.37 (3h, s). example 5.2 n-(2-bromo-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)pyrazolo[1,5-a]pyridine-3-carboxamide [038 methylpiperazin-1-yl)benzyl)benzamide (ex 5.1, step 1) and pyrazolo[1,5-a]pyridine-3-carbonyl chloride (commercially available) analogously to example 5.1[0384] lcms dms0) delta 9.90 (1h, s), 9.05 (1h, t), 8.85 (1h, d), 8.79 (1h, s), 8.22 (1h, d), 8.14 (1h, d), 7.84 (1h, d), 7.74 (1h, d), 7.54 (1h, m), 7.23 (2h, m), 7.13 (2h, m), 7.05 difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-hydroxy-3-methyl butyl)imidazo[1,2-a]pyridine-3-carboxamide [0386] [ftimg=64854390] step 1: ethyl 3-(3-(5-(3,4-difluor bromo-n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)imidazo[1,2-a]pyridine-3-carboxamide (intermediate 3a)(1 g, 1.987 mmol), pd2(dba)3 (0.091 g, 0.099 mmol) ml) under nitrogen and the mixture was degassed thoroughly refilling with nitrogen (x3). (3-ethoxy-3-oxopropyl)zinc(ii) bromide (19.87 ml, 9.93 mmol) was added and th absorbed onto silica and purification by chromatography eluting with 0-6 percent meoh in dcm afforded a yellow oil which was triturated with etoac to give the title compou difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-hydroxy-3-methyl butyl)imidazo[1,2-a]pyridine-3-carboxamide [0389] ethyl 3-(3-(5-(3,4-difluorobenzylcarbamoyl)-2-fluor suspended in dry ether and cooled to 0 degrees centigrade methylmagnesium bromide (0.318 ml, 3.0m in ether, 0.953 mmol) was added and the mixture was stirred an and etoac. the organics were separated, dried (mgso4), filtered and evaporated to dryness. the residue was purified by chromatography on silica eluting with 0-10 percent 2minlc_v003[0391] 1h nmr (400 mhz, meod) delta 9.45 (2h, d), 9.08 (1h, t), 8.45 (1h, s), 8.35 (1h, d), 7.75 (1h, m), 7.55 (1h, s), 7.15-7.38 (3h, m), 7.10 (1h, d), 4.5 difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-(2-(piperidin-1-yl)ethylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide hydrochloride [0392] [ftimg=648 [1,2-a]pyridin-7-yl)-2-fluorobenzoate [0393] 7-bromo-n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)imidazo[1,2-a]pyridine-3-carboxamide (intermediate 3a)(500 mg, 1.093 mmol) and cesium carbonate (1295 mg, 3.97 mmol) in water (2 ml)/dme (5 ml) were mixed to give a suspension. the mixture was degassed with nitrogen an using microwave radiation at 100 degrees centigrade for 1 hr and partitioned between etoac and water. the organic portion was separated, dried (mgso4) and concentrate lcms: rt 1.09 min ms m/z 567. {m+h}+ method 2minlc_v003 step 2: n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-(2-(piperidin-1-yl)ethylcarbamoyl) difluorobenzylcarbamoyl)-2-fluorophenylcarbamoyl)imidazo[1,2-a]pyridin-7-yl)-2-fluorobenzoate (step 1)(50 mg, 0.087 mmol), 2-piperidin-1-yl-ethylamine (0.260 mmol) days. the mixture was diluted with water (4 ml) and extracted with dcm using a phase separator. the organic portion was concentrated in vacuo and the residue was dissolv fractions were loaded onto a pre-wetted (meoh) isolate(r) scx-2 cartridge and washed with meoh. the product was eluted with 7m ammonia in meoh. the resulting residue compound as a hydrochloric salt[0395] ls-ms: rt 3.79 mins ms m/z 673 {m+h}+ method 10minlc_v003[0396] 1h nmr (400 mhz, dms0-d6) delta 9.1 (1h, s), 9 (1h, bs), (2h, d), 3.4 (2h, m), 3.2 (2h, s), 2.4 (4h, m), 1.5 (4h, m), 1.4 (2h, m). example 7.2 n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-(2-(tetrahydro-2h [ftimg=64854392][0398] the title compound was prepared analogously to example 7.1 using the appropriate amine in step 2. the hydrochloride salt was obtained by trea yl)ethylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide with 2m hcl (in diethyl ether) and removing the solvent in vacuo[0399] lc-ms: rt 3.49 mins ms m/z 674 [8.25 (2h, m), 7.9 (1h, d), 7.8 (1h, d), 7.7 (1h, t), 7.65 (2h, d), 7.4 (3h, m), 7.2 (1h, m), 4.5 (2h, d), 3.8 (2h, m), 3.3 (3h, m) 3.15 (1h, s), 1.6 (3h, m), 1.5 (2h, m). 1. (1-methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide [0401] [ftimg=64854393] step 1: 4-fluoro-3-(7-(1-methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-car carboxamido)-4-fluorobenzoate (intermediate 1a)(5.41 g, 13.79 mmol), 1-methyl-1h-pyrazol-4-ylboronic acid (1.911 g, 15.17 mmol), pd(dppf)cl2.dcm (1.127 g, 1.379 at 100 degrees centigrade for 4 hrs. 3 equivalents of sodium carbonate were added and the mixture was heated to 100 degrees centigrade for 6 hrs. a further 3 equivale overnight.[0403] the reaction mixture was cooled to 50 degrees centigrade and filtered through glass fiber filter paper. the filtrate was acidified to ph3 and allowed to cool at 45 degrees centigrade to afford the title compound[0404] lc-ms: rt 0.68 mins ms m/z 380/381 {m+h}+ method 2minlc_v003. step 2: n-(5-(((2-(2-dimethylpyrrolidin-carboxamide [0405] a solution of 4-fluoro-3-(7-(1-methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide) benzoic acid (step 1)(6.31 g, 16.63 mmol), 2-(2-dim dmf (36.9 ml) and etoac (2 ml) was treated dropwise with (rt)3p (propylphosphonic anhydride) (50 percent w/w in etoac) (15.88 g, 24.95 mmol). the resulting mixture was with 0.5 m licl, h2o and sat. nahco3. the aqueous layer was back-extracted with 10 percent meoh etoac (62.7 ml) (3x100 ml), the combined organic extracts was dried mg degrees centigrade to afford the title compound[0406] lc-ms: rt 0.59 mins ms m/z 504/505/506 {m+h}+ method 2minlc_v003[0407] further purification was carried out b

meoh. the product was eluted with 2n nh3 in meoh to afford a brown solution which was triturated with etoac to the title compound[0408] 1h nmr (400 mhz, cd3od) delta m), 7.3 (1h, t), 4.0 (3h, s), 3.5 (2h, m), 2.9 (2h, t), 2.7 (2h, t), 1.8 (2h, m), 1.7 (2h, m), 1.0 (6h, s). example 7.4 n-(5-(2-(2,2-dimethylpyrrolidin-1-yl)ethylcarbamoyl)-pyridine-3-carboxamide [0409] [ftimg=64854394] step 1: 7-bromo-n-(5-(2-(2,2-dimethylpyrrolidin-1-yl)ethylcarbamoyl)-2-fluorophenyl)imidazo[1,2-a]pyridine-3-carbox hydrolysis of methyl 3-(7-bromimidazo[1,2-a]pyridine-3-carboxamido)-4-fluorobenzoate (intermediate 1a) using naoh(700 mg, 1.851 mmol), 2-(2,2-dimethylpyrrolidin in etoac (7.284 ml) and dmf (1.28 ml) to give a yellow solution. (rt)3p (propylphosphonic anhydride)(1.620 ml, 2.036 mmol) was added and the mixture was stirred at ro in h2o and sat nahco3. the organic portion was dried mgso4, filtered and concentrated in vacuo. the residue was triturated with etoac/iso-hexane to afford the title compo step 2: methyl 4-(3-(5-(2-(2,2-dimethylpyrrolidin-1-yl)ethylcarbamoyl)-2-fluorophenylcarbamoyl)imidazo[1,2-a]pyridin-7-yl)-2-fluorobenzoate [0412] the title compound dimethylpyrrolidin-1-yl)ethylcarbamoyl)-2-fluorophenyl) imidazo[1,2-a]pyridine-3-carboxamide (step 1) analogously to example 7.3 step 1[0413] lc-ms: rt 0.75 mins ms ethylcarbamoyl)-2-fluorophenyl carbamoyl)imidazo[1,2-a]pyridin-7-yl)-2-fluorobenzoic acid [0414] a mixture comprising methyl 4-(3-(5-(2-(2,2-dimethylpyrrolidin-1-yl)et mg, 0.711 mmol) and sodium hydroxide (142 mg, 3.55 mmol) in meoh (5 ml) was heated at 60 degrees centigrade overnight. the reaction mixture was concentrated and solid precipitate was collected by filtration and dried at 45 degrees centigrade the aqueous portion was concentrated in vacuo and the residue was sonicated in 5 percent precipitate from the first filtration. the combined product were evaporated to dryness and dried at 45 degrees centigrade in the vacuum oven.[0415] lc-ms: rt 0.68 mins m ethylcarbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-((1r,2r)-2-hydroxycyclohexylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide [0416] the title compound was prepa 2-fluorophenylcarbamoyl)imidazo[1,2-a]pyridin-7-yl)-2-fluorobenzoic acid (step 3) analogously to example 7.3 step 2 lc-ms: rt 0.70 mins ms m/z 659/660 {m+h}+ meth 7-(3-fluoro-4-(1-hydroxy-2-methylpropan-2-ylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide [0417] [ftimg=64854395][0418] the title compound was prepared fluorophenylcarbamoyl)imidazo[1,2-a]pyridin-7-yl)-2-fluorobenzoic acid (step 3) and 2-amino-2-methylpropan-1-ol lc-ms: rt 0.69 mins ms m/z 633/634/635 {m+h}+ met methylpyridin-3-yl)-6-(3-fluoro-4-(1-hydroxy-2-methylpropan-2-ylcarbamoyl)phenyl)pyrazolo[1,5-a]pyridine-3-carboxamide [0419] [ftimg=64854396] steps 1, 2 and 3: 4 [1,5-a]pyridin-6-yl)-2-fluorobenzoic acid [0420] the title compound was prepared from intermediate 1e analogously to example 7.4 steps 1, 2 and 3[0421] lc-ms: rt 0.72 ethylcarbamoyl)-2-methylpyridin-3-yl)-6-(3-fluoro-4-(1-hydroxy-2-methylpropan-2-ylcarbamoyl)phenyl)pyrazolo[1,5-a]pyridine-3-carboxamide [0422] a solution of 2-ami ethylcarbamoyl)-2-methylpyridin-3-ylcarbamoyl)pyrazolo[1,5-a]pyridin-6-yl)-2-fluorobenzoic acid (72 mg, 0.129 mmol) and triethylamine (0.054 ml, 0.387 mmol) in dcm the reaction mixture was diluted with dcm and washed with sat nahco3 and h2o. the organic portion was separated, dried mgso4 and concentrated in vacuo. the product wa meoh/dcm. the product fractions were combined and concentrated to afford an orange oil which was triturated with etoac/hexane to afford a pale brown solid.[0423] lc-ms: difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-(3-morpholino propylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide hydrochloride [0424] [ftimg=64854 pyridin-7-yl)-2-fluorobenzoic acid [0425] a solution of methyl 4-(3-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenylcarbamoyl) imidazo[1,2-a]pyridin-7-yl)-2-fluorobenzoa (2874 micro ml) was stirred at rt overnight. the solvent was removed in vacuo and the residue was acidified with 2m hcl to ph 2 and extracted with dcm. the organic extracts rt 0.66 min m/z 563 {m+h}+ method 2minlc_v003 step 2: n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-(3-morpholino propylcarbamoyl)pheny difluorobenzylcarbamoyl)-2-fluorophenyl carbamoyl)imidazo[1,2-a]pyridin-7-yl)-2-fluorobenzoic acid (100 mg, 0.178 mmol), 3-morpholinopropan-1-amine (51.3 mg, 0.3 micro l) was stirred at room temperature overnight. the solvent was removed in vacuo and the residue was partitioned between water and dcm. the organic portion was dri silica eluting with 0-20 percent 2m nh3 in methanol in tbm. the resulting solid was treated with 2m hcl in diethyl ether and concentrated in vacuo to afford the title compc dms0-d6) delta 10.5 (1h, s), 10.4 (1h, bs), 9.5 (1h, d), 9.2 (1h, t), 8.8 (1h, s), 8.6 (1h, bs), 8.3 (1h, s), 8.2 (1h, d), 7.9 (1h, d), 7.8 (1h, m), 7.7 (1h, d), 7.5 (1h, m) m example 8.2 n-(5-(2-(2,6-cis-dimethylpiperidin-1-yl)ethylcarbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-(1-hydroxy-2-methylpropan-2-ylcarbamoyl)phenyl)imidazo[1,2-a]pyrid ethylcarbamoyl)-2-fluorophenyl carbamoyl)imidazo[1,2-a]pyridin-7-yl)-2-fluorobenzoic acid [0431] the title compound was prepared from 7-bromo-n-(5-(2-(2,6-cis-dimet (intermediate 4c) and 3-fluoro-4-(methoxycarbonyl)phenylboronic acid analogously to example 1.20[0432] lcms: rt 0.50 mins ms m/z 294 {m+h}+ method 2minlowph st hydroxy-2-methylpropan-2-ylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide [0433] the title compound was prepared from 4-(3-(5-(2-(2,6-cis-dimethylpiperidin step 1) and 2-amino-2-methylpropan-1-ol analogously to example 8.1, step 2[0434] lcms: rt 0.73 mins ms m/z 647 {m+h}+ method 2minlowph example 8.3 7-(3-fluor phenyl)imidazo[1,2-a]pyridine-3-carboxamide [0435] [ftimg=64854399] step 1: methyl 2-fluoro-4-(3-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenylcarb n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl) benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide (example 1.1 step 1) and 3-fluoro-4-(methoxycarbonyl)phenyl + method 2minlc_v003 step 2 and 3: 7-(3-fluoro-4-(2-fluoroethylcarbamoyl)phenyl)-n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyri 5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenylcarbamoyl)imidazo[1,2-a]pyridin-7-yl)benzoate (step) and 2-fluoroethanamine analogously example 8.1 steps 1 an fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)-7-(3-fluoro-5-(2-hydroxy ethylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide [0440] [ftimg=6485 1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide (example 1.1 step1 and 2-aminoethanol analogously to example 8.2 steps 1 and 2[0442] lc-ms: rt dimethylpyrrolidin-1-yl)ethylcarbamoyl)-2-methylpyridin-3-yl)-6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carboxamide [0443] [ftimg=64854401] step 1: meth [1,5-a]pyridine-3-carboxylic acid (7.71 g, 32.0 mmol) in toluene (80 ml) was treated with thionyl chloride (18.67 ml, 256 mmol) and was heated to 110 degrees centigrad methyl 5-amino-6-methylnicotinate (4.25 g, 25.6 mmol) and oven dried molecular sieves. the reaction mixture was stirred at rt overnight and then treated with meoh (25 and the solid produced was isolated to afford the title compound[0445] lcms: rt 0.91 mins ms m/z 391.4 {m+h}+ method 2minlowph step 2: 6-methyl-5-(6-(1-methyl-1h bromopyrazolo[1,5-a]pyridine-3-carboxamido)-6-methylnicotinate (step 1) (7 g, 17.99 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole (4. dimethoxyethane (60 ml) and water (25.00 ml), the mixture was degassed thoroughly refilling with nitrogen. pdcl2(dppf).ch2cl2 adduct (0.350 g, 0.429 mmol) was added degrees centigrade for 7 hrs and then cooled to 50 degrees centigrade and filtered through glass-fiber paper. the filtrate was acidified to ph 5 by the addition of 2m hcl a the resulting solid was dried in a vacuum oven to afford the title compound[0447] lcms: rt 0.69 mins ms m/z 377.5 {m+h}+ method 2minlowph step 3: n-(5-(2-(2,2-dime [1,5-a]pyridine-3-carboxamide [0448] 6-methyl-5-(6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carboxamido)nicotinic acid (6.6 g, 1.1 equiv) and 2-(2,2-dimet with dipea (8.34 ml, 47.7 mmol) followed by hatu (4.44 g, 11.67 mmol), after string at rt for 90 mins, the mixture was partitioned between water (1 l) and etoac (750 ml) aqueous sodium bicarbonate, 0.5m lithium chloride, brine, dried mgso4, filtered and evaporated to dryness. purification by chromatography on silica eluting with 0-20 per title compound[0449] lcms: rt 0.61 mins ms m/z 501 {m+h}+ method 2minlowph[0450] 1h nmr (400 mhz, dms0) delta 9.75 (1h, s), 9.15 (1h, s), 8.75 (2h, m), 8.58 (1h 2.76 (2h, t), 2.56 (3h, s), 1.69 (2h, m), 1.53 (2h, m) 0.92 (6h, s) [0451] the compounds of the following tabulated examples (table 4) were prepared by a similar metho detailed herein and in the preparation of intermediates section.table 4structureex.name{m + h}+/nmr9.1[ftimg=64854402]rt 0.59 mins ms m/z 520 {m + h}+ method 2 methyl-1h-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide9.2[ftimg=64854403]rt 2.40 mins ms m/z 516.5[m + h] + method 10 minlowphv01n-(2-fluoro-5-((2-(3-pro carboxamide9.3[ftimg=64854404]rt 0.57 mins ms m/z 520/521 {m + h}+ method 2 minlowphv01(r)-n-(2-fluoro-5-((2-(2-(methoxymethyl)pyrrolidin-1-yl)ethyl)carbamoyl rt 2.36 mins: ms m/z 516 {m + h}+ method 10 minlowphv01n-(5-((2-(3,5-dimethylpiperidin-1-yl)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-4-yl)imidazo[method 2 minlowphn-(2-fluoro-5-((2-(2,6,6-tetramethylpiperidin-1-yl)ethyl)carbamoyl)phenyl)-7-(1-methyl-1h-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamide hydr minlc_v003n-(5-(2-(tert-butyl(methyl)amino)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1h-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamidehydrochloride salt9.7ft (2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-6-(1-methyl-1h-pyrazol-5-yl)pyrazolo[1,5-a]pyridine-3-carboxamide hydrochloride salt9.8[ftimg=6485 amino)ethyl)carbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-((2-hydroxy-ethyl)carbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide9.9[ftimg=64854410]lcms: rt 0.79 mins methylpropan-2-yl)carbamoyl)phenyl)-n-(2-fluoro-5-((2-(3-propylpyrrolidin-1-yl)ethyl)carbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide9.10[ftimg=64854411]lcm ethyl)carbamoyl)-2-fluorophenyl)-7-(3-fluoro-4-((1-hydroxy-2-methylpropan-2-yl)carbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide9.11[ftimg=64854412]lcms: rt methylpropan-2-yl)carbamoyl)phenyl)-n-(2-fluoro-5-((2-(2-(methoxymethyl)pyrrolidin-1-yl)ethyl)carbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide9.12[ftimg=648 carbamoyl)-2-fluorophenyl)-7-(6-((2-(dimethylamino)ethyl)carbamoyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide9.13[ftimg=64854414]lcms: rt 0.66 mins ms m/ methylpyridin-3-yl)-6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carboxamide9.14[ftimg=64854415]lc-ms: rt 0.62 mins ms m/z 515.7 {m + h}+ method 2 minl 1h-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carboxamide9.15[ftimg=64854416]lc-ms: rt 0.66 mins ms m/z 518.5 [m + h] + method 2 minlowphv01n-(5-((2-(2,3,3r)-2,3-di pyridine-3-carboxamide example 10.1 n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(6-(((2-hydroxyethyl) (methyl)amino)methyl)pyridin-3-yl)imidazo[1,2-a]pyri difluorobenzyl)-7-(6-formylpyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide [0453] a mixture comprising 7-bromo-n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl) im 1,3,2-dioxaborolan-2-yl)picolininaldehyde (1.375 g, 5.90 mmol) and cesium carbonate (6.99 g, 21.46 mmol) in dme (30 ml) and water (3 ml) was treated with pdcl2(dppf). degrees centigrade for 1 hr. the resulting mixture was concentrated in vacuo and the residue was dissolved in 10 percent trifluoroethanol/chcl3. the organics were washed with 0-30 percent 2m nh3 in meoh/dcm afforded the title product[0454] lc-ms: rt 0.67 mins ms m/z 530/531 {m+h}+ method 2minlc_v003 step 2: n-(5-(3,4-difluorobenz [1,2-a]pyridine-3-carboxamide [0455] a suspension of n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)-7-(6-formylpyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide sieves in etoh (2 ml) was heated at 70 degrees centigrade overnight. the mixture was cooled to 0 degrees centigrade and treated with sodium borohydride (7.15 mg, 0.1 was removed by filtration and the filtrate was concentrated in vacuo. the residue was partitioned between etoac and water. the organic portion was separated, washed with chromatography eluting with 25-50 percent 0.1 percent tfa acetonitrile/water afforded fractions that were combined and diluted with nahco3 and 5 percent trifluoroethanol/ was triturated with etoh/ether to afford the title compound as a white solid[0456] lc-ms: rt 0.74 mins ms m/z 589/590/591 {m+h}+ method 2minlc_v003 example 10.2 n- pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide [0457] [ftimg=64854418][0458] the title compound was prepared analogously to example 10.1 from the appropriate the compounds of the following tabulated examples (table 5) were prepared by a similar methods to that of example 10 from the appropriate starting compounds, the pr 5structureex.name{m + h}+/nmr10.2[ftimg=64854419]lc-ms: rt 0.83 mins ms m/z 649/650 {m + h}+ method 2 minlc_v003.n-(5-((3,4-difluorobenzyl)carbamoyl)-2-fluor carboxamide10.3[ftimg=64854420]lcms: rt 0.71 mins ms m/z 544.5 [m + h] + method an-(5-((3,4-difluorobenzyl)carbamoyl)-2-fluorophenyl)-7-(5-((methylamino)methyl m/z 612.6 [m + h] + method a7-(5-((cyclohexylamino)methyl)pyridin-3-yl)-n-(5-((3,4-difluorobenzyl)carbamoyl)-2-fluoro-phenyl)imidazo[1,2-a]pyridine-3-carboxamide1 difluorobenzyl)carbamoyl)-2-fluorophenyl)-7-(5-(((2-methoxyethyl) (methyl)amino)methyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide preparation of intermediate [0461] [ftimg=64854423] step 1: potassium (z)-2-chloro-1-ethoxy-3-oxoprop-1-en-1-olate [0462] a cooled (0 degrees centigrade) suspension of ethyl 2-chloroacetate (over 3 hrs) with potassium 2-methylpropan-2-olate (18.31 g, 163 mmol) keeping the temperature below 5 degrees centigrade the mixture was concentrated in vacuo an afford the title compound[0463] 1h nmr (400 mhz, d6-dms0) delta 8.95 (1h, s), 3.9 (2h, q), 1.1 (3h, t). step 2: ethyl 7-bromimidazo[1,2-a]pyridine-3-carboxylate [046 3-oxoprop-1-en-1-olate (step 1)(23.4 g, 124 mmol) in ethanol (200 ml) was cooled to 5 degrees centigrade sulfuric acid (7.70 ml, 144 mmol) was added dropwise and th (20.03 ml, 144 mmol) was slowly added and heating continued at 90 degrees centigrade for 18 hrs. after cooling to rt, the mixture was filtered and the solid was partition extracted using etoac. the combined organic extracts were dried (mgso4) and concentrated in vacuo to afford the title compound[0465] 1h nmr (400 mhz, d6-dms0) delta [1,2-a]pyridine-3-carboxylic [0466] ethyl 7-bromimidazo[1,2-a]pyridine-3-carboxylate (step 2)(30.81 g, 114 mmol) in meoh (172 ml) was treated with 2m naoh (172 ml solution was removed in vacuo and the crude material was treated with 2m sodium bisulfate solution to adjust the ph to 6-7. the resulting solid was collected by filtration a after cooling to rt, the suspension was filtered and dried in a vacuum oven at 40 degrees centigrade to afford the title product[0467] lc-ms: rt 0.59 mins ms m/z 243.1 {m fluorobenzoate [0468] a mixture comprising 7-bromimidazo[1,2-a]pyridine-3-carboxylic acid (step 3)(1.8 g, approximately 7.47 mmol) and thionyl chloride (10 ml, 137 and azeotroped with toluene. methyl 3-amino-4-fluorobenzoate (1.263 g, 7.47 mmol) (pre-dried at 45 degrees centigrade) was added followed by pyridine and the mixtu and washed with h2o. the resulting solid was collected by filtration. the filtrate was dried (mgso4) and concentrated in vacuo and triturated with ether to afford cream solid lc-ms: rt 0.97 mins ms m/z 392 {m+h}+ method 2minlc_v003[0470] 1h nmr (400 mhz, dms0-d6) delta 10.3 (1h, s), 9.4 (1h, d), 8.6 (1h, s), 8.3 (1h, m), 8.2 (1h, s), 7. pyridine-3-carboxamido)-4-methylbenzoate [0471] [ftimg=64854424][0472] a mixture comprising 7-bromimidazo[1,2-a]pyridine-3-carboxylic acid (intermediate 1a ste for 2 hrs. the mixture was concentrated in vacuo and azeotroped with toluene. methyl 3-amino-4-methylbenzoate (514 mg, 3.11 mmol) (pre-dried at 45 degrees centigra n2 overnight. the reaction mixture was diluted with etoac and washed with sat. nahco3, brine, h2o, dried (mgso4) and concentrated in vacuo. purification by chromatograp orange solid[0473] lc-ms: rt 0.94 mins ms m/z 390/391/392 {m+h}+ method 2minlc_v003[h274] 1h nmr (400 mhz, dms0-d6) delta 10.0 (1h, s), 9.4 (1h, d), 8.6 (1h, s) intermediate 1c methyl 5-(7-bromimidazo[1,2-a]pyridine-3-carboxamido)-6-methylnicotinate [0475] [ftimg=64854425] step 1: methyl 2-chloro-6-methyl-5-nitronicotina (commercially available)(12.5 g, 63.1 mmol) in chlorobenzene (210 ml) was added dmf (2.442 ml, 31.5 mmol) followed by pocl3 (23.52 ml, 252 mmol). the mixture was vacuo. the residue was cooled in an ice bath, treated with meoh (200 ml, 4944 mmol) and stirred at rt for 16 hrs. the mixture was concentrated in vacuo and the residue w concentrated in vacuo to afford the title compound as a red crystalline solid[0477] lc-ms: rt 1.10 mins ms m/z 230.9 {m+h}+ method 2minlc_v003 step 2: methyl 5-amin was added to a suspension of ammonium formate (18.87 g, 299 mmol) and 10 percent pd(carbon)(0.522 g, 0.491 mmol) in meoh (330 ml) and the mixture was heated washed through with meoh. the solvent was removed in vacuo and the crude product was triturated with etoac to give an orange solid. purification by chromatography on si bromimidazo[1,2-a]pyridine-3-carboxamido)-6-methylnicotinate [0479] the title compound was prepared from 7-bromimidazo[1,2-a]pyridine-3-carboxylic acid (interme [0480] 1h nmr (400 mhz, d6-dms0) delta 10.21 (1h, s), 9.40 (1h, f=7.4, d), 8.83 (1h, s), 8.55 (1h, s), 8.39 (1h, s), 8.13 (1h, f=1.6, d), 7.35 (1h, f=2.0, 7.4, dd), 3.89 (a pyridine-3-carboxamido)nicotinate [0481] [ftimg=64854426] step 1: ethyl 6-(1-methyl-1h-pyrazol-5-yl)pyrazolo[1,5-a]pyridine-3-carboxylate [0482] a mixture compris tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole (1.218 g, 5.85 mmol), cesium carbonate (7.26 g, 22.30 mmol) and pdcl2(dppf).ch2cl2 adduct (91 mg, 0.111 mmol) in for 1 hr. further pdcl2(dppf).ch2cl2 adduct (91 mg, 0.111 mmol) was added and the mixture was heated at 80 degrees centigrade for 1 hr. 1-methyl-5-(4,4,5,5-tetrameth mg, 0.111 mmol) were added and heating continued at 100 degrees centigrade for 3 hrs. the mixture was diluted with 10 percent meoh in etoac (200 ml) and washed wit resulting solid was loaded onto silica and purified by chromatography eluting with 0-100 percent etoac in iso-hexane to afford the title compound[0483] lc-ms: rt 0.92 min pyridine-3-carboxylic acid [0484] the title compound was prepared from ethyl 6-(1-methyl-1h-pyrazol-5-yl)pyrazolo[1,5-a]pyridine-3-carboxylate analogously to intermedi 6-methyl-5-(6-(1-methyl-1h-pyrazol-5-yl)pyrazolo[1,5-a]pyridine-3-carboxamido)nicotinate [0486] 6-(1-methyl-1h-pyrazol-5-yl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (mmol) was added. the reaction mixture was stirred under nitrogen overnight. the mixture was diluted with etoac (200 ml) and washed with sat. aq. nahco3 (200 ml). the a dried mgso4, filtered and concentrated under vacuum to give yellow solid. purification of the solid by chromatography on silica eluting with 0-20 percent 2m nh3 in meoh/t 2minlowph intermediate 1e 5-(6-bromopyrazolo[1,5-a]pyridine-3-carboxamido)-6-methylnicotinic acid [0488] [ftimg=64854427][0489] a solution of methyl 5-(7-bromoi sodium hydroxide (1.028 g, 25.7 mmol) in meoh (20 ml) was heated at 50 degrees centigrade overnight. the mixture was concentrated in vacuo and the residue was diss collected by filtration and dried at 45 degrees centigrade to afford the title compound[0490] lc-ms: rt 0.82 mins ms m/z 376/377 {m+h}+ method 2minlowphv01 interne

carboxamide [0491] [ftimg=64854428] step 1: 3-amino-n-(2-tert-butoxyethyl)-4-fluorobenzamide [0492] a mixture comprising 2-tert-butoxyethanamine (1.2 g, 5.12 m was treated with tbd (0.713 g, 5.12 mmol) and heated at 90 degrees centigrade for 16 hrs. after cooling to rt, the solvent was removed in vacuo and the residue was parti citric acid (x2), nahco3 (sat. aq), brine, dried (mgso4) and concentrated in vacuo. purification of the crude product by chromatography on silica eluting with 0-100 percent 255 [m+h]+ method 2minlc_v003 step 2: 7-bromo-n-(5-(2-tert-butoxyethylcarbamoyl)-2-fluorophenyl)imidazo[1,2-a]pyridine-3-carboxamide [0494] 6-bromoidimadzo[1, toluene (30 ml) and thionyl chloride (1.550 ml, 21.23 mmol) was added. the mixture was heated at 110 degrees centigrade for 3 hrs. the solvent was removed in vacuo a fluorobenzamide (step 1) (900 mg, 3.54 mmol) in pyridine (10 ml). molecular sieves were added the mixture was stirred at rt for 16 hrs. in a separate flask, 6-bromoiimi thionyl chloride (0.969 ml, 13.27 mmol) at 110 degrees centigrade for 3 hrs. the solvent was removed in vacuo and the solid residue was added to the reaction mixture in resulting suspension was removed by filtration. the filtrate was azeotroped with toluene to give a solid, which was triturated with meoh to afford the product. the filtrate wa water. the organic portion was dried (mgso4) and concentrated in vacuo to afford a solid that was triturated with etoac to give the title compound[0495] lc-ms: rt 0.96 min 2-methyl-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl) imidazo[1,2-a]pyridine-3-carboxamide [0496] [ftimg=64854429] step 1: 2-fluoro-4-methyl-5-nitrobenzo cooled to 0 degrees centigrade in an ice salt water bath and treated dropwise with mixture of h2so4 (0.763 ml, 14.31 mmol) and nitric acid (0.65 ml, 14.54 mmol) over 1 (200 ml) and stirred for a further hour. the resulting suspension was collected by filtration, dried in vacuo and collected in etoh, azeotroping to dryness to afford the title c acid (900 mg, 4.52 mmol) in meoh (70 ml) was treated with ammonium formate 1 (425 mg, 22.60 mmol) and pd (carbon) (144 mg, 1.356 mmol). the mixture was dega was filtered through silica and washed with meoh. the filtrate was passed through scx-2 resin (30 g 0.67 mmol/g) eluting with meoh (250 ml) followed by 2m ammonia in residue was purified by recrystallisation from meoh to afford the title compound[0499] lc-ms: rt 0.53 mins ms m/z 170 {m+h}+ method 10minlc_v003 step 5: 5-amino-2-(4-methylpiperazin-1-yl)phenyl)methanamine (413 mg, 2.010 mmol) and 5-amino-2-fluoro-4-methylbenzoic acid (step 2)(340 mg, 2.010 mmol) in dmf (3 ml) was treat degrees centigrade for 24 hrs. the mixture was partitioned between water and etoac. the organic portion was washed with sat. aq. nahco3, 0.5 m lici and brine (each back dryness to give a pink oil. purification by chromatography on silica eluting with 0-20 percent meoh in dcm afforded the title compound[0501] lc-ms: rt 0.73 mins ms m/z 1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide [0502] the title compound was prepared from 5-amino-2-fluoro-4-methyl-n-(2-(4-methylpiperazin-1-fluorophenyl)imidazo[1,2-a]pyridine-3-carboxamide (intermediate 2a step 2)[0503] lc-ms: rt 0.91 mins ms m/z 579.4/582.4 {m+h}+ method 2minlc_v003 intermediate carboxamide [0504] [ftimg=64854430][0505] the title compound was prepared analogously to intermediate 2a by replacing 6-bromoidimadzo[1,2-a]pyridine-3-carboxylic lc-ms: rt 1.13 mins ms m/z 477.1 {m+h}+ method 2minlc_v003. intermediate 3a 7-bromo-n-(5-(3,4-difluorobenzylcarbamoyl)-2-fluorophenyl)imidazo[1,2-a]pyridine-3-c [0508] a mixture comprising methyl 3-amino-4-fluorobenzoate (2 g, 11.82 mmol), (3,4-difluorophenyl)methanamine (2.54 g, 17.74 mmol) and tbd (1.646 g, 11.82 mmol) was purified by chromatography on silica eluting with 0-20 percent 2m nh3 in meoh/dcm to afford the title compound. step 2: 7-bromo-n-(5-(3,4-difluorobenzylcarbamoyl bromoidimadzo[1,2-a]pyridine-3-carboxylic acid (intermediate 1a step 3) (1.4 g, 5.81 mmol) and thionyl chloride (8.48 ml, 116 mmol) was heated at 100 degrees centiga fluorobenzamide (step 1) (1.4 g, 5.00 mmol) and pyridine (16.65 ml) was added and the resulting suspension was stirred at rt for 1 hour. etoac and meoh were added an 0.74 mins ms m/z 503 {m+h}+ method 2minlc_v003 intermediate 4a 6-bromo-n-(2-methyl-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)pyrazolo[1,5-a]pyri 1-yl)benzyl)benzamide [0512] a solution of methyl 3-amino-4-methylbenzoate (commercially available) (1.609 g, 9.74 mmol), tbd (2,3,4,6,7,8-hexahydro-1h-pyrimido [commercially available] (2 g, 9.74 mmol) in toluene (30 ml) was heated at reflux overnight. the reaction mixture was diluted with etoac and washed with sat.nahco3 and was purified by chromatography on silica eluting with a gradient of 0-20 percent 2m nh3 in meoh/dcm to afford the title compound[0513] lc-ms: rt 0.64-0.8 mins ms m/z 3. m), 5.0 (2h, s), 4.5 (2h, dd), 2.9 (4h, m), (4h, m), 2.2 (3h, s), 2.1 (3h, s). step 2: 6-bromo-n-(2-methyl-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)pyrazolo[1 carboxylic acid (commercially available)(196 mg, 0.813 mmol) and thionyl chloride (2 ml, 27.4 mmol) was heated at 60 degrees centigrade for 1 hr and concentrated in v 1) (220 mg, 0.651 mmol) and pyridine (5 ml). the reaction was stirred under nitrogen at room temperature for 2 hrs. the mixture was diluted with 10 percent meoh in eto purified by chromatography on silica eluting with 0-20 percent 2m nh3 in meoh/dcm to afford the title compound[0516] lc-ms: rt 0.95 mins ms m/z 561/563/564 {m+h}+ a]pyridine-3-carboxamide [0517] [ftimg=64854433] step 1: 6-iodoimidazo[1,2-a]pyridine-3-carboxylic acid [0518] the title compound was prepared from 5-iodopyridin-2 and step 3) lc-ms: rt 1.07 mins ms m/z 317 [m+h]+ method 2minlc_v003 step 2: 3-amino-n-benzyl-4-fluorobenzamide [0519] the title compound was prepared from m pyrimidine analogously to 3-amino-4-methyl-n-(2-(4-methylpiperazin-1-yl)benzyl)benzamide (intermediate 4a, step 1)[0520] 1h nmr (400 mhz, dms0-d6) delta 8.9 (1h, fluorophenyl)-6-iodoimidazo[1,2-a]pyridine-3-carboxamide [0521] the title compound was prepared from 6-iodoimidazo[1,2-a]pyridine-3-carboxylic acid (step 1) and 3-a methylpiperazin-1-yl)benzylcarbamoyl)phenyl)pyrazolo[1,5-a]pyridine-3-carboxamide (intermediate 4a)[0522] lc-ms: rt 0.99 mins ms m/z 515/516/517 {m+h}+ method fluorophenyl)imidazo[1,2-a]pyridine-3-carboxamide [0523] [ftimg=64854434] step 1: 3-amino-n-(2-(2,6-cis-dimethylpiperidin-1-yl)ethyl)-4-fluorobenzamide [0524] a m methyl 3-amino-4-fluorobenzoate (3.51 g, 20.75 mmol) in thf (50 ml) was treated with tbd (2.89 g, 20.75 mmol) and stirred at 80 degrees centigrade for 16 hrs. a furthe continued for 24 hrs. the resulting mixture was partitioned between ethyl acetate and aqueous sodium bicarbonate. the mixture was extracted once with ethyl acetate and dryness. purification of the residue by chromatography on silica eluting with 0-20 percent meoh in dcm afforded the title compound[0525] lc-ms: rt 0.71 mins ms m/z 294 ethylcarbamoyl)-2-fluorophenyl)imidazo[1,2-a]pyridine-3-carboxamide [0526] 7-bromoidimadzo[1,2-a]pyridine-3-carboxylic acid (intermediate 1a step 3) (1.150 g, 4.77 the mixture was at 100 degrees centigrade for 2 hrs. the solvent was removed in vacuo and the solid was added to a stirred solution of 3-amino-n-(2-(2,6-cis-dimethyl pi dried molecular sieves. the mixture was stirred at rt under nitrogen atmosphere overnight. the solvent was removed in vacuo and purification of the crude product by chro ms: rt 0.82 mins ms m/z 516{m+h}+ method 2minlc_v003 intermediate 4d 6-bromo-n-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl) pyrazolo[1,5-a]p analogously to interemdiat 4a from the appropriate starting compounds[0530] lc-ms: rt 0.95 mins ms m/z 565/568/569 {m+h}+ method 2minlc_v003 intermediate 4e pyridine-3-carboxamide [0531] [ftimg=64854436] step 1: 5-(azidomethyl)-2,2-dimethyltetrahydrofuran [0532] 5-(bromomethyl)-2,2-dimethyltetrahydrofuran (36 g, 186 degrees centigrade for 4 hrs. the mixture was allowed to cool to rt and partitioned between water (1.51) and ether (2x500 ml). the ether layer was separated and washed (5,5-dimethyltetrahydrofuran-2-yl)methanamine [0533] 5-(azidomethyl)-2,2-dimethyltetrahydrofuran (22 g, 142 mmol) in thf (500 ml) was treated with triphenylphosphin was heated at 80 degrees centigrade for 4 hrs. the mixture was passed through isolate(r) scx-2 resin (200 g 0.67 mmol/g) eluting with meoh (500 ml), dms0 (100 ml), 2 ammonia layer was evaporated to dryness to afford the title compound.[0534] lc-ms: rt 0.63 mins ms m/z 243 {m+h}+ method 2minlc_v002_low mass step 3-4: 7-brom pyridine-3-carboxamide [0535] the title compound was prepared from (5,5-dimethyltetrahydrofuran-2-yl)methan amine (step 2) and methyl 3-amino-4-fluorobenzoate a method 2minlc_v003 intermediate 4f 7-bromo-imidazo[1,2-a]pyridine-3-carboxylic acid {5-[(s)-5,5-dimethyl-tetrahydro-furan-2-ylmethyl]-carbamoyl]-2-fluoro-phenyl}-a intermediate 4e by replacing (5,5-dimethyltetrahydrofuran-2-yl)methanamine (step 3) with (s)-{(s)-5,5-dimethyltetrahydrofuran-2-yl)methanamine[0539] lcms rt 0.87 mins 3-carboxamido)benzoic acid [0540] [ftimg=64854438] step 1: imidazo[1,2-a]pyridine-3-carbonyl chloride [0541] a suspension of imidazo[1,2-a]pyridine-3-carboxylic aci followed by the addition of dmf (0.252 ml, 3.25 mmol). the reaction mixture was stirred at rt overnight. the solvent was removed in vacuo to afford the title compound as m), 7.56 (1h, t). step 2: methyl 4-fluoro-3-(imidazo[1,2-a]pyridine-3-carboxamido)benzoate [0543] a solution of methyl 3-amino-4-fluorobenzoate (5 g, 29.6 mmol) in 29.6 mmol) and the mixture was stirred at rt for 2 days. the mixture was poured into water (30 ml) and a small exotherm was observed. after cooling to rt, the resulting p ms m/z 314.2 {m+h}+ method 2minlc_v003[0544] 1h nmr (400 mhz, dms0-d6) delta 10.30 (1h, s), 9.44 (1h, d), 8.63 (1h, s), 8.34 (1h, dd), 7.83 (1h, m), 7.78 (1h, d), 3-carboxamido)benzoic acid [0545] a suspension of methyl 4-fluoro-3-(imidazo[1,2-a]pyridine-3-carboxamido)benzoate (step 1) (7.2 g, 22.98 mmol) in water (30 ml), t mmol). the reaction mixture was stirred at rt overnight and concentrated in vacuo to remove thf and meoh. the resulting mixture was acidified with 2m hcl to yield a solid t oven at 50 degrees centigrade to afford the title compound as a hydrochloride salt[0546] lc-ms: rt 0.71 mins ms m/z 300.2 {m+h}+ method 2minlc_v003[0547] 1h nmr (dd), 8.00 (1h, d), 7.86 (2h, m), 7.47 (2h, m). intermediate 6a (s)-2-(2-(methoxymethyl)pyrrolidin-1-yl)ethanamine [0548] [ftimg=64854439] step 1: (s)-tert-butyl 2-(2-(methoxymethyl)pyrrolidine (1 g, 8.68 mmol), tert-butyl 2-bromothylcarbamate (1.946 g, 8.68 mmol), triethylamine (1.210 ml, 8.68 mmol) and potassium carbonate (1 mixture was filtered and washed with mecn. purification of the crude product by chromatography on silica eluting with 0-5 percent meoh in dcm afforded the title compoun m), 3.0 (2h, m), 2.9 (1h, m), 2.8 (1h, m), 2.55 (1h, m), 2.3 (1h, m), 2.15 (1h, q), 1.8 (1h, m), 1.65 (2h, m), 1.45 (1h, m), 1.4 (9h, s). step 2: (s)-2-(2-(methoxymeth yl)ethylcarbamate (step 1)(1.89 g, 7.32 mmol) and in meoh (5 ml) and treated with 2m hcl in meoh (10 equivalents) at room temperature over the weekend. the solvent m), 3.25 (1h, m), 3.1 (1h, m), 2.9 (1h, m), 2.8 (2h, m), 2.6 (1h, m), 2.9 (1h, m), 2.8 (2h, m), 2.6 (1h, m), 2.5 (3h, s), 2.4 (1h, m), 2.2 (1h, m), 0.8 (1h, m), 1.7 (2h, m), 1.6 (1h, m).[0553] the intermediat from the appropriate commercially available starting compounds.table 6int.structurename[m + h]+nmr6b[ftimg=64854440]2-(3-propyl- pyrrolidin-1-yl) ethanamine1h n m), 1 (3h, t)6c[ftimg=64854441](s)-2-(2-(methoxy- methyl) pyrrolidin-1-yl) ethanamine1h nmr (400 mhz, cdc13) delta 3.4 (1h, m), 3.38 (3h, s), 3.5 (1h, m), 2.9 (1h, m), [ftimg=64854442](r)-2-(2-(methoxy- methyl) pyrrolidin-1-yl) ethanamine1h nmr (400 mhz, cdc13) delta 3.45 (1h, m), 3.25 (1h, m), 3.1 (1h, m), 2.9 (1h, m), 2.8 (2h, [ftimg=64854443](2-(tert-butyl (methyl) amino) ethanamine trifluoro- acetateh nmr (400 mhz, dms0) delta 8.15 (3h, br), 3.60 (1h, m), 3.30 (2h, m), 3.07 (1h, m), 2.7 (400 mhz), cd3od) delta 3.75-3.42 (4h, m), 3.17 (4h, m), 1.87 (4h, m), 1.70 (2h, m), 1.55-0.82 (6h, m), intermediate 7a 3-(5-carboxy-2-fluorophenylcarbamoyl)-7-(1-t title compound was prepared analogously to 6-methyl-5-(6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carboxamido)nicotinic acid (example 9.0 step 2) from m 1-methyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1h-pyrazole followed hydrolysis of the resulting methyl ester using sodium hydroxide[0556] lc-ms: rt 0.77 min 5-yl)pyrazolo[1,5-a]pyridine-3-carboxamido)nicotinic acid [0557] [ftimg=64854446][0558] the title compound was prepared analogously to 6-methyl-5-(6-(1-methyl-1h-intermediate 1c and 1-methyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1h-pyrazole followed hydrolysis of the resulting methyl ester using sodium hydroxide[055 (7-(3-fluoro-4-(1-hydroxy-2-methylpropan-2-ylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamido)benzoic acid [0560] [ftimg=64854447] steps 1 and 2: 7-(3-fluor 2-ylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide [0561] the title compound was analogously to example 9.0 steps 2 and 3 from (1) intermediate 1a and 4-b fluorophenylcarbamoyl)imidazo[1,2-a]pyridin-7-yl)-2-fluorobenzoic acid (step 1) and 2-amino-2-methylpropan-1-ol [0562] lc-ms: rt 0.91 mins ms m/z 580.4 [m+h]+ me phenyl)imidazo[1,2-a]pyridine-3-carboxamido)benzoic acid [0563] 7-(3-fluoro-4-(1-hydroxy-2-methylpropan-2-ylcarbamoyl)phenyl)-n-(2-fluoro-5-(1-hydroxy-2-methylpr in 1,2-dimethoxyethane (10 ml) and water (10.00 ml) was treated with sodium hydroxide (181 mg, 4.52 mmol) and warmed to 60 degrees centigrade for 1 hr. after cooli in vacuo and the resulting crude product was triturated with water to afford the title compound[0564] lcms: rt 0.92 mins ms m/z 509.4 [m+h]+ method 2minlowph interme (s)-2-((5,5-dimethyltetrahydrofuran-2-yl)methyl)isoindoline-1,3-dione [0566] [ftimg=64854449][0567] to a stirred solution of (s)-5,5-dimethyltetrahydrofuran-2-yl)meth phthalimide (17.40 g, 118 mmol) to give a suspension. the mixture was cooled to 8 degrees centigrade and diad (27.2 ml, 140 mmol) was added dropwise over 30 mins and extracted with etoac (100 ml). the organics were washed with sat. nahco3 (100 ml), brine (100 ml) and dried (mgso4) and concentrated under reduced pressure. purif compound as a white crystalline solid[0568] lc-ms: rt 1.02 mins ms m/z 260 [m+h]+ method 2minlowph step 2: (s)-5,5-dimethyltetrahydrofuran-2-yl)methanamine hydr dione (step 1) (21.9 g, 84 mmol) in etoh (440 ml) was stirred at 60 degrees centigrade under n2 and hydrazine hydrate (4.51 ml, 93 mmol) was added. the mixture was dropwise to adjust ph to ph 1. the slurry was filtered washing with etoh (50 ml) and the filtrate was concentrated in vacuo to a volume of approximately 50 ml.[0570] the washed with thme (100 ml) and the organic phase was extracted with 2m hcl (50 ml). the acidic aqueous layers were combined and basified to ph 10 with 2m naoh (70 ml with brine (200 ml) and dried (mgso4) and filtered. 4m hcl in dioxane (21 ml, 84 mmol) was added slowly and the resulting solution was then concentrated in vacuo to yie solid lc-ms: rt 0.57 mins ms m/z 164.1 [m+h]+ method 2minlowph intermediate 9b (r)-5,5-dimethyltetrahydrofuran-2-yl)methanaminium chloride [0571] [ftimg=64854 (5,5-dimethyltetrahydrofuran-2-yl)methanol [refer bull chem soc japan vol. 45, no. 3, pp. 916-921, 1972 j yoshimura et.al p921] (6.7 g, 51.5 mmol) in pyridine (50 ml) w solvent was removed by evaporation and azeotroping with toluene. the mixture was then partitioned between ethyl acetate and 10 percent aqueous citric acid. the organic organic layers were dried mgso4, filtered and evaporated to dryness to give a dark oil of (r)-5,5-dimethyltetrahydrofuran-2-yl)methyl 4-methylbenzenesulfonate[0573] 1 2.07 (1h, m), 1.85-1.70 (3h, m), 1.18 (6h, s). step 2: (r)-5-(azidomethyl)-2,2-dimethyltetrahydrofuran [0574] (r)-5,5-dimethyltetrahydrofuran-2-yl)methyl 4-methylben 58.5 mmol) at rt overnight then warmed to 70 degrees centigrade for 3 hrs. sodium azide (3.80 g, 58.5 mmol) was added and the mixture was warmed to 100 degrees ce ethyl acetate layer was washed with 0.5 m lithium chloride in water and the organic layers were dried mgso4, filtered and evaporated to dryness to afford the title compou 1.75 (3h, m), 1.30 (3h, s) 1.23 (3h, s) step 3: (r)-5,5-dimethyltetrahydrofuran-2-yl)methanaminium chloride [0575] (r)-5-(azidomethyl)-2,2-dimethyltetrahydrofuran (st triphenylphosphine (12.98 g, 49.5 mmol) and stirred at rt for 20 mins then warmed to 80 degrees centigrade for 4 hrs. solid isolate(r) scx resin was added and stirred at r evaporated to dryness with a cool water bath and vacuum 80 mbar. the oily residue was treated with 2n hcl (aq) and the solid precipitate was removed by filtration. the aq aqueous was basified by the addition of 2n naoh (aq) and was extracted with ethyl acetate (x3). the combined organic layers were dried mgso4, filtered and treated with e nmr (400 mhz, meod) delta 4.17 (1h, m), 3.09 (1h, dd), 2.87 (1h, dd), 2.19 (1h, m), 1.95-1.70 (3h, m), 1.31 (3h, s) 1.27 (3h, s). intermediate 9c (s)-7-bromo-n-(5-((5-carboxamide [0577] [ftimg=64854451][0578] the title compound was prepared from (r)-5,5-dimethyltetrahydrofuran-2-yl)methanaminium chloride (intermediate 9b) an of methyl 3-(7-bromoidimadzo[1,2-a]pyridine-3-carboxamido)-4-fluorobenzoate (intermediate 1a) using naoh) analogously to example 7.4 step 1[0579] lc-ms: rt 0.97 mi diethylazetidin-1-yl)ethanamine [0580] [ftimg=64854452] step 1: (2rs,3rs)-2,3-diethyl-4-oxoazetidine-1-sulfonyl chloride [0581] [ftimg=64854453][0582] chlorosulfonyl dropwise with (e)-hex-3-ene (7.39 ml, 59.4 mmol) in dcm (6 ml). the mixture was stirred at rt for 72 hrs. the reaction mixture was heated over 6 hrs at 40 degrees centig combined organics were washed with water (x1), dried mgso4 and evaporated to dryness to afford the title compound[0583] 1h nmr (400 mhz, cdc3) delta 3.95 (1h, dt), diethylazetidin-2-one [0584] (2rs,3rs)-2,3-diethyl-4-oxoazetidine-1-sulfonyl chloride (step 1) (3.2 g, 14.18 mmol) in acetone (7 ml) was treated with thiophenol (2.92 ml, 2.55 ml) was added dropwise over 30 mins, maintaining the temperature around -30 degrees centigrade after stirring for 30 minutes, water (10 ml) was added slowly an organic layers were dried mgso4, filtered and evaporated to dryness (colorless oil 2.3 g). purification by chromatography on silica eluting with iso-hexane followed by dieth 1.81 (1h, m), 1.72-1.55 (3h, m), 1.03 (3h, t), 0.95 (3h, t). step 3: 2-(2-(2rs,3rs)-2,3-diethyl-4-oxoazetidin-1-yl)acetonitrile [0586] (3rs,4rs)-3,4-diethylazetidin-2-one (ste with lithium bis(trimethylsilyl)amide (0.786 ml, 0.786 mmol) [1 m in thf]. the solution was allowed to warm to 0 degrees centigrade then re-cooled to 0 degrees centigrad overnight. 10 percent aqueous citric acid (30 ml) was added and the mixture was extracted with ether (4x40 ml). the combined organic layers were dried mgso4, filtered a in iso-hexane afforded the title compound 1h nmr (400 mhz, cdc3) delta 4.21 (1h, d), 3.99 (1h, d), 3.32 (1h, dt), 2.71 (1h, dt), 1.81 (1h, m), 1.72-1.55 (3h, m), 1.03 (3 alc13 (3.37 g, 25.3 mmol) in dry ether (140 ml) was added to a stirred suspension of 1m laih4 in ether (25.3 ml, 25.3 mmol) in ether (140 ml). the mixture was heated a 2-(2rs,3rs)-2,3-diethyl-4-oxoazetidin-1-yl)acetonitrile (step 3) (1.4 g, 8.42 mmol) in dry ether (50 ml). stirring was continued at rt for 16 hrs. the reaction mixture was cc stir at rt for 24 hr. the aqueous was separated and the ether layer was retained. the aqueous was stirred with 10 percent trifluoroethanol/dcm (250 ml) for 3 hrs then the l m) for a further 2 hrs. the remaining aqueous was extracted with 10 percent trifluoroethanol/dcm (x3). the combined organic layers were treated with 1m hcl in methanol

(1h, dd), 4.33 (1h, t), 4.12 (1h, dd), 3.87 (1h, m), 3.72-3.46 (3h, m), 2.56 (1h, m), 2.16-1.91 (2h, m), 1.71 (2h, m), 1.05 (3h, t), 0.90 (3h, t).[0589] from the foregoing herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. accordingly, the invention is not limited

Search (12) AND IPC=(C07) (Results 87)
13:

Search (13) AND IPC=(A61) (Results 63)
14:

Search (14) AND PD>1994 (Results 52)
15:

Search TAC=(PDGFR inhibitors) and CPC=(A61K31/444) (Results 0)
16:

Search TAC=(PDGFR inhibitors) (Results 13)
17:

Search TAC=(PDGFR inhibitors) and CPC=(A61K31/444) (Results 0)
18:

Search TAC=(PDGFR) and CPC=(A61K31/444) (Results 6)
19:

Search TAC=(PDGFR) and CPC=(A61K31/4545) (Results 4)
20:

Search TAC=(PDGFR) and CPC=(A61K31/4745) (Results 10)
21:

Search TAC=(PDGFR) and CPC=(A61K31/496) (Results 25)
22:

Search TAC=(PDGFR) and CPC=(A61K31/5377) (Results 26)
23:

Search TAC=(PDGFR) and CPC=(A61K45/06) (Results 122)
24:

Search (24) AND PD>2009 (Results 105)
25:

Search TAC=(PDGFR) and CPC=(C07D471/04) (Results 98)
26:

Title: Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation

Abstract: Source: US6150359A PCT No. PCT/US98/16848 Sec. 371 Date Jan. 26, 2000 Sec. 102(e) Date Jan. 26, 2000 PCT Filed Aug. 13, 1998 PCT Pub. No. WO99/09030 PCT Pub. Date Feb. 25, 1999This invention relates to the inhibition of protein tyrosine kinase (PTK) and cell cycle kinase mediated cellular proliferation. More specifically, this invention relates to naphthyridinones and their use in inhibiting cellular proliferation and PTK or cell cycle kinase enzymatic activity.

Classifications:


International (IPC 8-9): A61K31/4375 A61K31/44 A61K31/444 A61K31/4545 A61K31/496 A61K31/498 A61K31/4985 A61K31/5377 A61P17/06 A61P35/00 A61P43/00 A61P9/08 A61P9/10 C07D471/02 C07D471/04 (Advanced/Invention); A61K31/496 A61P35/00 A61P43/00 C07D471/04 (Advanced/Non-invention)

International (IPC 1-7): A61K31/4375 A61K31/44 A61K31/444 A61K31/4545 A61K31/496 A61K31/5377 A61P17/06 A61P35/00 A61P43/00 A61P9/08 A61P9/10 C07D221/00 C07D471/04 C07D471/04

CPC: C07D471/04

European: C07D471/04

US: 514/234.5 544/127 544/362 546/122



Family:

Publication number	Publication date	Application number	Application date
AT286053 E	20050115	AT19980939941T	19980813
AU199888289 A1	19990308	AU19980088289	19980813
AU742999 B2	20020117	AU19980088289	19980813
BRPI9811956 A	20000815	BR1998PI11956	19980813
BRPI9811956 B1	20100601	BR1998PI11956	19980813
CA2291222 AA	19991125	CA19982291222	19980813
CA2291222 C	20040330	CA19982291222	19980813
DE69828408 D1	20050203	DE19986028408	19980813
DE69828408 T2	20051208	DE19986028408T	19980813
EP1003745 A1	20000531	EP19980939941	19980813
EP1003745 B1	20041229	EP19980939941	19980813
ES2235353 T3	20050701	ES19980939941T	19980813
JP2001515078 T2	20010918	JP20000509710T	19980813
JP4965021 B2	20120704	JP20000509710	19980813
KR20010023089 A	20010326	KR20007001710	20000219
NZ502704 A	20020628	NZ19980502704	19980813
US6150359 A	20001121	US20000463553	20000126
WO9909030 A1	19990225	WO1998US16848	19980813
ZA9807491 A	19990421	ZA19980007491	19980819

Priority:

US19970056746P 19970820 WO1998US16848 19980813 US20000463553 20000126

Probable Assignee: WARNER LAMBERT CO

Assignee(s): (std): BARVIAN MARK ROBERT ; DENNY WILLIAM ALEXANDER ; DOBRUSIN ELLEN MYRA ; HAMBY JAMES MARINO ; SHOWALTER HOWARD DANIEL HOLLIS ; WARNER LAMBERT CO ; THOMPSON ANDREW MARK ; WINTERS ROY THOMAS ; WU ZHIPEI

Assignee(s): WARNER LAMBERT CO LLC ; WARNER LAMBERT COMPANY ; WARNER LAMBERT COMPANY LLC ; WARNER LAMBERT CO LLC MORRIS PLAINS ; WARNER LAMBERT COMPANYLLC

Inventor(s): (std): BARVIAN MARK ROBERT ; BARVIAN ROBERT ; DENNY ALEXANDER ; DENNY WILLIAM ALEXANDER ; DOBRUSIN ELLEN MYRA ; DOBRUSIN MYRA ; HAMBY JAMES MARINO ; HAMBY MARINO ; SHOWALTER DANIEL ; SHOWALTER HOWARD DANIEL ; SHOWALTER HOWARD DANIEL HOLLIS ; THOMPSON ANDREW MARK ; THOMPSON MARK ; WINTERS ROY THOMAS ; WINTERS THOMAS ; WU ZHIPEI

Inventor(s): ZHIPEI WU ; WILLIAM ALEXANDER DENNY ; HOWARD DANIEL HOLLIS SHOWALTER ; JAMES MARINO HAMBY ; MARK ROBERT BARVIAN ; ROY THOMAS WINTERS ; ELLEN MYRA DOBRUSIN ; ANDREW MARK THOMPSON

Designated states: AL AM AT AU AZ BA BB BE BF BG BJ BR BY CA CF CG CH CI CM CN CU CY CZ DE DK EE ES FI FR GA GB GE GH GM GN GR GW HR HU ID IE IL IS IT JP KE KG KR KZ LC LI LK LR LS LT LU LV MC MD MG MK ML MN MR MW MX NE NL NO NZ PL PT RO RU SD SE SG SI SK SL SN SZ TD TG TJ TM TR TT UA UG US UZ VN YU ZW

Title: Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors

Abstract: Source: US2003004351A Compounds of formula (I): wherein X is N, CH, CCF₃, or C(C1-12 aliphatic); R₄ is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R₇-sulfonyl, R₇ sulfonyl-C1-12 aliphatic, R₇-aminosulfonyl, R₇-aminosulfonyl-C1-12 aliphatic, R₇-sulfonylamino, R₇-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R₈)1-3-Arylamino, (R₈)1-3-Arylsulfonyl, (R₈)1-3-Aryl-aminosulfonyl, (R₈)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R₅ is hydorgen; and further wherein R₄ and R₅ are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.

Classifications:

International (IPC 8-9): A61K31/18 A61K31/40 A61K31/403 A61K31/404 A61K31/405 A61K31/407 A61K31/41 A61K31/415 A61K31/416 A61K31/417 A61K31/419 A61K31/42 A61K31/422 A61K31/424 A61K31/425 A61K31/429 A61K31/433 A61K31/437 A61K31/44 A61K31/442 A61K31/443 A61K31/4439 A61K31/505 A61K31/506 A61K31/5377 A61P13/12 A61P17/06 A61P17/14 A61P25/00 A61P27/02 A61P29/00 A61P3/10 A61P35/00 A61P39/00 A61P43/00 A61P7/00 A61P9/00 A61P9/10 C07D209/24 C07D209/34 C07D209/40 C07D401/06 C07D401/10 C07D401/12 C07D403/04 C07D403/12 C07D405/12 C07D413/04 C07D417/12 C07D471/04 C07D487/04 C07D491/04 C07D491/056 C07D498/04 C07D498/06 C07D513/04 C07D521/00 (Advanced/Invention); A61K31/403 A61K31/407 A61K31/415 A61K31/416 A61K31/419 A61K31/422 A61K31/424 A61K31/429 A61K31/433 A61K31/442 A61K31/506 A61P25/00 A61P29/00 A61P35/00 A61P43/00 A61P7/00 A61P9/00 C07D209/40 (Advanced/Non-invention)

International (IPC 1-7): A61K31/18 A61K31/40 A61K31/404 A61K31/405 A61K31/407 A61K31/415 A61K31/416 A61K31/417 A61K31/419 A61K31/42 A61K31/422 A61K31/424 A61K31/429 A61K31/433 A61K31/435 A61K31/437 A61K31/4439 A61K31/495 A61K31/506 A61K31/5377 A61P13/12 A61P17/06 A61P17/14 A61P25/00 A61P27/02 A61P29/00 A61P3/10 A61P35/00 A61P39/00 A61P43/00 A61P7/00 A61P9/00 A61P9/10 C0729/56 C0741/02 C0743/02 C07D209/00 C07D209/24 C07D209/34 C07D209/40 C07D401/06 C07D401/10 C07D401/12 C07D403/04 C07D403/12 C07D405/12 C07D413/04 C07D417/12 C07D471/04 C07D487/02 C07D487/04 C07D487/04 C07D491/04 C07D491/056 C07D498/04 C07D498/06 C07D513/04

CPC: C07D209/34 C07D209/40 C07D231/12 C07D233/56 C07D249/08 C07D401/06 C07D401/12 C07D403/04 C07D403/12 C07D405/12 C07D413/04 C07D471/04 C07D487/04 C07D491/04 C07D513/04

European: C07D209/34 C07D209/40 C07D231/12 C07D233/56 C07D249/08 C07D401/06 C07D401/12 C07D403/04 C07D403/12 C07D405/12 C07D413/04 C07D471/04 C07D487/04 C07D491/04 C07D498/04 C07D513/04

US: 291/365 291/366 514/272 514/291 514/338 514/365 514/366 514/414 514/419 514/426 544/111 544/333 546/200 546/200P 546/256 546/270.1 546/277.1 546/277.7 546/277.700P 546/278.1 546/80 548/122 548/126 548/150 548/151 548/361.1 548/361.100S 548/432 548/432S 548/452 548/483 548/484 548/486 548/486S



Family:

Publication number	Publication date	Application number	Application date
AR015432 AA	20010502	AR1998P104424	19980904
AT267170 E	20040615	AT19980951342T	19980903
AU199897407 A1	19990412	AU19980097407	19980903
AU747506 B2	20020516	AU19980097407	19980903
BRPI9812048 A	20000926	BR1998PI12048	19980903
CA2302572 AA	20000302	CA19982302572	19980903
CN1278794 A	20010103	CN19988010937	19980903
CO4960633 A1	20000925	CO19980050493	19980903
DE69824014 D1	20040624	DE19986024014	19980903
DE69824014 T2	20050512	DE19986024014T	19980903
EE200000117 A	20001215	EE20000000117	19980903
EP1009738 A1	20000621	EP19980951342	19980903
EP1009738 B1	20040519	EP19980951342	19980903
ES2221211 T3	20041216	ES19980951342T	19980903
GB9718913 A0	19971112	GB19970018913	19970905
HU0004490 AB	20010328	HU20000004490	19980903
HU0004490 AC	20021028	HU20000004490	19980903
JP2001517652 T2	20011009	JP20000512809T	19980903
KR20010023695 A	20010326	KR20007002348	20000304
MA26542 A1	20041220	MA19980025240	19980902
PE107699 A1	19991124	PE19980000818	19980902
PL338991 A1	20001204	PL19980338991	19980903
TR200001174 T2	20000821	TR20000001174T	19980903
TW520358 B	20030211	TW19980113993	19980825
US2003004351 AA	20030102	US20010924431	20010808
US2003069430 AA	20030410	US20010999331	20011130
US6369086 BA	20020409	US19990262351	19990304
US6387919 BA	20020514	US20000486960	20000606
US6541503 BB	20030401	US20010924431	20010808
US7105529 BB	20060912	US20010999331	20011130
WO9915500 A1	19990401	WO1998EP05559	19980903
ZA9808078 A	20000322	ZA19980008078	19980903

Priority:

GB19970018913 19970905	WO1998EP05559 19980903	US19990262351 19990304
US20010924431 20010808	US20000486960 20000606	US20010999331 20011130

Probable Assignee: SMITHKLINE BEECHAM CORP

Assignee(s): (std): GLAXO WELLCOME INC ; HARRIS PHILIP ANTHONY ; KUYPER LEE FREDERICK ; LUZZIO MICHAEL JOSEPH ; VEAL JAMES MARVIN ; WALKER DUNCAN HERRICK ; SMITHKLINE BEECHAM CORP ; HUNTER ROBERT NEIL III ; LACKEY KAREY ELIZABETH ; DAVIS STEPHEN THOMAS ; DICKERSON SCOTT HOWARD ; FRYE STEPHEN VERNON ; GLAXO GROUP LTD

Assignee(s): GLAXO GROUP LTD GREENFORD ; GLAXO GROUP LTD GREENFORD MIDDLESEX ; LACKEY KAREN ELIZABETH ; HUNTER ROBERT NEIL

Inventor(s): (std): DAVIS STEPHEN THOMAS ; DAVIS STEPHEN THOMAS DAVIS STEPHEN THOMAS ; DICKERSON SCOTT HOWARD ; DICKERSON SCOTT HOWARD DICKERSON SCOTT HOWARD ; DUNCAN HERRICK WALKER ; FRYE STEPHEN VERNON ; FRYE STEPHEN VERNON FRYE STEPHEN VERNON ; HARRIS PHILIP ANTHONY ; HARRIS PHILIP ANTHONY HARRIS PHILIP ANTHONY ; HARRIS PHILIP ANTONY ; HUNTER III ; HUNTER III ROBERT NEIL ; HUNTER ROBERT NEIL ; HUNTER ROBERT NEIL AND ; HUNTER ROBERT NEIL III ; HUNTER ROBERT NEIL III HUNTER ROBERT NEIL III ; III ROBERT NEIL HUNTER ; JAMES MARVIN VEAL ; KAREN ELIZABETH LACKEY ; KAREY ELIZABETH LACKEY ; KUYPER LEE FREDERICK ; KUYPER LEE FREDERICK KUYPER LEE FREDERICK ; LACKEY ELIZABETH KAREN ; LACKEY KAREN ELISABETH ; LACKEY KAREN ELIZABETH ; LACKEY KAREY ELIZABETH ; LACKEY KAREY ELIZABETH LACKEY KAREY ELIZABETH ; LEE FREDERICK KUYPER ; LUZZIO MICHAEL JOSEPH ; LUZZIO MICHAEL JOSEPH LUZZIO MICHAEL JOSEPH ; MARVIN VEAL JAMES ; MICHAEL JOSEPH LUZZIO ; PHILIP ANTHONY HARRIS ; FRYE S V ; DICKERSON S H ; DAVIS S T ; ROBERT NEIL HUNTER III ; S H DICKERSON ; S T DAVIS ; S V FRYE ; SCOTT HOWARD DICKERSON ; STEPHEN THOMAS DAVIS ; STEPHEN VERNON FRYE ; VEAL JAMES MARVIN ; VEAL JAMES MARVIN VEAL JAMES MARVIN ; WALKER DUNCAN HERRICK ; WALKER DUNCAN HERRICK WALKER DUNCAN HERRICK

Inventor(s): III ROBERT NEIL ; HUNTER ; ELIZABETH LACKEY KAREN
Agent(s): JENNIFER L
Designated states: AL AM AT AU AZ BA BB BE BF BG BJ BR BY CA CF CG CH CI CM CN CU CY CZ DE DK EE ES FI FR GA GB GE GH GM GN GR
GW HR HU ID IE IL IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MC MD MG MK ML MN MR MW MX NE NL NO NZ PL PT
RO RU SD SE SG SI SK SL SN SZ TD TG TJ TM TR TT UA UG US UZ VN YU ZW

Title: Heteroaromatic compounds and their use in medicine.

Abstract: Source: ZA9809249A Compounds of formula (I) where R¹ is optionally substituted phenyl or an optionally substituted phenyl or an optionally substituted heterocyclic ring selected from pyrrole, furan, thiophene, pyrazole or indole are useful as protein kinase inhibitors in diseases characterized by cellular proliferation.

Classifications:


International (IPC 8-9): A61K31/34 A61K31/40 A61K31/435 C07D405/14 C07D409/14 C07D471/04 (Advanced/Invention)

International (IPC 1-7): A61K31/40 A61K31/435 C07D209/00 C07D209/02 C07D221/00 C07D221/02 C07D471/04

CPC: C07D471/04

European: C07D471/04

PatBase - W09921859_R1



Family:

Publication number	Publication date	Application number	Application date
AR017311 AA	20010905	AR1998P105023	19981008
AU199911510 A1	19990517	AU19990011510	19981008
GB9721437 A0	19971210	GB19970021437	19971010
MA26550 A1	20041220	MA19980025280	19981006
PE120199 A1	19991215	PE19980000949	19981007
WO9921859 A1	19990506	WO1998EP06357	19981008
ZA9809249 A	20000410	ZA19980009249	19981009

Priority:

GB19970021437 19971010 WO1998EP06357 19981008

Probable Assignee: GLAXO GROUP LTD

Assignee(s): (std): GLAXO GROUP LTD ; GLENNON KIMBERLY CAROLINE ; LACKEY KAREN ELIZABETH ; PEEL MICHAEL ROBERT ; CHEUNG MUI

Assignee(s): GLAXO GROUP LIMITED

Inventor(s): (std): CHEUNG MUI ; GLENNON KIMBERLY CAROLINE ; KAREN ELIZABETH LACKEY ; KIMBERLY CAROLINE GLENNON ; LACKEY KAREN ELISABETH ; LACKEY KAREN ELIZABETH ; MICHAEL ROBERT PEEL ; MUI CHEUNG ; PEEL MICHAEL ROBERT

Designated states: AL AM AT AU AZ BA BB BE BF BG BJ BR BY CA CF CG CH CI CM CN CU CY CZ DE DK EE ES FI FR GA GB GD GE GH GM GN GR GW HR HU ID IE IL IS IT JP KE KG KP KR KZ LC LK LR LS LT LU LV MC MD MG MK ML MN MR MW MX NE NL NO NZ PL PT RO RU SD SE SG SI SK SL SN SZ TD TG TJ TM TR TT UA UG US UZ VN YU ZW

Title: HETEROCYCLIC COMPOUNDS

Abstract: Source: US2002147205A The present invention relates to substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. Specifically, the invention relates to quinazoline derivatives useful in treating disorders mediated by protein tyrosine kinase activity, in particular erbB-2 and/or EGFR activity.

FDA Data:

Application numberActive ingredient**Proprietary name****Applicant****Date of approval**022059 LAPATINIB DITOSYLATE TYKERB
NOVARTIS PHARMS CORP Mar 13, 2007022059 LAPATINIB DITOSYLATE TYKERB SMITHKLINE BEECHAM Mar 13, 2007

Classifications:

International (IPC 8-9): A01N43/54 A01N43/90 A61K31/44 A61K31/47 A61K31/4709 A61K31/505 A61K31/517 A61K31/519 A61K31/73 A61P17/00 A61P17/06 A61P29/00 A61P31/10 A61P35/00 A61P43/00 A61P9/00 A61P9/10 C07D221/00 C07D239/00 C07D239/72 C07D239/86 C07D239/94 C07D401/12 C07D403/12 C07D405/00 C07D405/02 C07D405/04 C07D405/14 C07D417/00 C07D417/04 C07D417/14 C07D471/00 C07D471/04 (Advanced/Invention); A61K31/47 A61K31/4709 A61K31/505 A61K31/517 A61K31/519 C07D221/00 C07D239/00 (Advanced/Non-invention); A61K31/00 A61P35/00 C07D221/00 C07D239/00 C07D405/00 C07D417/00 C07D471/00 (Core/Invention)

International (IPC 1-7): A01N43/54 A61K31/435 A61K31/44 A61K31/47 A61K31/4709 A61K31/505 A61K31/517 A61K31/519 A61K31/73 A61P17/06 A61P29/00 A61P31/00 A61P35/00 A61P37/00 A61P43/00 A61P9/00 A61P9/10 C07D211/00 C07D221/00 C07D233/00 C07D239/00 C07D239/72 C07D239/94 C07D401/00 C07D401/12 C07D403/12 C07D405/00 C07D405/04 C07D405/10 C07D405/14 C07D417/00 C07D417/04 C07D417/10 C07D417/14 C07D45/02 C07D471/00 C07D471/04 C07D487/00 C07D487/02


CPC: C07D405/04 C07D239/94 C07D405/14 C07D411/04 C07D417/04 C07D417/14 C07D471/04

European: C07D239/94 C07D405/04 C07D405/14 C07D411/04 C07D417/04 C07D417/14 C07D471/04

US: 514/258 514/259 514/264.11 514/264.110P 514/266.1 514/266.2 514/266.200S 514/266.21 514/266.210S 514/266.24 514/266.240P 544/279 544/279S 544/283 544/283P 544/284 544/284S 544/293 544/293S

Family:

Publication number	Publication date	Application number	Application date
AP1446 A	20050719	AP20000001861	19990108
AP200001861 A0	20000930	AP20000001861	19990108
AR066982 AB	20090923	AR2008P102516	20080612
AT270670 E	20040715	AT19990902522T	19990108
AT322491 E	20060415	AT19990076761T	19990108
AT417847 E	20090115	AT19990076762T	19990108
AU199922783 A1	19990726	AU19990022783	19990108
AU2010276460 AA	20110217	AU20100276460	20101217
AU749549 B2	20020627	AU19990022783	19990108
AU749549 C	20030320	AU19990022783	19990108
BG104668 A	20010430	BG20000104668	20000807
BG64825 B1	20060531	BG20000104668	20000807
BRPI9906904 A	20001017	BR1999PI06904	19990108
BRPI9906904 B1	20110503	BR1999PI06904	19990108
CA2317589 AA	20000706	CA19992317589	19990108
CA2317589 C	20070807	CA19992317589	19990108
CN1134438 C	20040114	CN19998003887	19990108
CN1292788 A	20010425	CN19998003887	19990108
CO4820390 A1	19990728	CO19990001037	19990108
CY1108859 T1	20140702	CY20091100253T	20090306
CZ20002587 A3	20010516	CZ20000002587	19990108
CZ298047 B6	20070606	CZ20000002587	19990108
DE122008000048 I1	20090102	DE200812000048	19990108
DE69918528 D1	20040812	DE19996018528	19990108
DE69918528 T2	20050728	DE19996018528T	19990108
DE69930773 D1	20060518	DE19996030773	19990108
DE69930773 T2	20060928	DE19996030773T	19990108
DE69940128 D1	20090129	DE19996040128	19990108
DK1047694 T3	20041108	DK19990902522T	19990108
DK1454907 T3	20090309	DK19990076762T	19990108
DK1460072 T3	20060731	DK19990076761T	19990108
EA002455 B1	20020425	EA20000000637	19990108
EE04616 B1	20060417	EE20000000411	19990108
EE200000411 A	20011217	EE20000000411	19990108
EG24743 A	20100714	EG19990000026	19990111
EP1047694 A1	20001102	EP19990902522	19990108
EP1047694 B1	20040707	EP19990902522	19990108
EP1454907 A1	20040908	EP20040076762	19990108
EP1454907 B1	20081217	EP20040076762	19990108
EP1460072 A1	20040922	EP20040076761	19990108
EP1460072 B1	20060405	EP20040076761	19990108
ES2221354 T3	20041216	ES19990902522T	19990108
ES2262087 T3	20061116	ES20040076761T	19990108
ES2319119 T3	20090504	ES20040076762T	19990108
GB9800569 A0	19980311	GB19980000569	19980112
HK1031883 A1	20050304	HK20010102589	20010411
HR20000469 A2	20010630	HR20000000469	20000712
HR20000469 B1	20070531	HR20000000469	20000712
HR20060387 A2	20080229	HR20060000387	20061110
HU0100941 AB	20010928	HU20010000941	19990108
HU0100941 AC	20020930	HU20010000941	19990108
HU227593 B1	20110928	HU20010000941	19990108
IL137041 A0	20010614	IL19990137041	19990108
IL137041 A1	20061005	IL20000137041	20000627
IS2276 B	20070915	IS20000005549	20000627
IS5549 A	20000627	IS20000005549	20000627
JP2002326990 A2	20021115	JP20020092102	20020328



JP2002500225 T2	20020108	JP20000527545T	19990108
JP3390741 B2	20030331	JP20000527545T	19990108
LU91475 A9	20080910	LU20080091475	20081110
LU91475 I2	20080910	LU20080091475	20081110
MA26596 A1	20041220	MA19990025422	19990108
NL300360 I1	20081103	NL20080300360	20080912
NL300360 I2	20090202	NL20080300360	20080912
NO20003561 A	20000911	NO20000003561	20000711
NO20003561 A0	20000711	NO20000003561	20000711
NO316176 B1	20031222	NO20000003561	20000711
NZ505456 A	20030630	NZ19990505456	19990108
OA11444 A	20040429	OA20001000202	20000707
PL192746 B1	20061229	PL19990341595	19990108
PL341595 A1	20010423	PL19990341595	19990108
PT1047694 T	20041130	PT19990902522T	19990108
PT1454907 T	20090218	PT20040076762T	19990108
PT1460072 T	20060731	PT20040076761T	19990108
RS49779 B	20080605	YU20000000448	19980112
SI1047694 T1	20050228	SI19990030663T	19990108
SI1454907 T1	20090430	SI19990031027T	19990108
SI1460072 T1	20060831	SI19990030902T	19990108
SK200001050 A5	20010806	SK20000001050	19990108
SK285405 B6	20070104	SK20000001050	19990108
TR200002015 T2	20010122	TR20000002015T	19990108
TW477788 B	20020301	TW19990100388	19990112
UA66827 C2	20001215	UA20000704012	19990108
US2002147205 AA	20021010	US20020071358	20020208
US2003176451 AA	20030918	US20030342810	20030115
US2005130996 AA	20050616	US20050050033	20050203
US2007015775 AA	20070118	US20060532926	20060919
US2007238875 AA	20071011	US20070752582	20070523
US2010120804 AA	20100513	US20100691784	20100122
US6713485 BB	20040330	US20020071358	20020208
US6727256 BA	20040427	US20000582746	20000630
US7109333 BB	20060919	US20050050033	20050203
US8513262 BB	20130820	US20100691784	20100122
WO9935146 A1	19990715	WO1999EP00048	19990108
ZA9900172 A	20000711	ZA19990000172	19990111

Priority:

GB19980000569 19980112	EP19990902522 19990108	EP20040076762 19990108
EP20040076761 19990108	JP20000527545 19990108	WO1999EP00048 19990108
US20020071358 20020208	US20000582746 20000630	US20030342810 20030115
US20060532926 20060919	US20050050033 20050203	US20070752582 20070523
US20100691784 20100122		

Probable Assignee: GLAXOSMITHKLINE LLC

Assignee(s): (std): CARTER MALCOLM C ; CARTER MALCOLM CLIVE ; CARTER MALCOM C ; CARTER MALCOM CLIVE ; COCKERILL GEORGE S ; GLAXO GROUP LTD ; GLAXO WELLCOME HOUSE ; COCKERILL GEORGE STUART ; GUNTRIP STEPHEN B ; LACKEY KAREN E ; SMITH KATHRYN J ; SMITHKLINE BEECHAM CORP ; SMITH KATHRYN JANE ; GUNTRIP STEPHEN BARRY ; LACKEY KAREN ELIZABETH ; GLAXOSMITHKLINE LLC ; DAINIPPON PHARMACEUTICAL CO LTD

Assignee(s): GLAXO WELCOME INC ; GLAXO GROUP LTD980 GREAT WEST ROADMIDDLESEXTW8 9SGSGREENFORDGB ; SMITHKLINE BEECHAM (CORK) LTD ; GLAXOSMITHKLINE LLC400 - 2711 CENTERVILLE ROADCORPORATION SERVICE COMPANYWILMINGTONDE19808US ; LEO OSPREY LTD ; NOVARTIS AG ; SMITHKLINE BEECHAM CORK LTD ; SMITHKLINE BEECHAM LTD ; GLAXO GROUP GREENFORD LTD ; GLAXO GROUP LTD GREENFORD ; GLAXO WELLCOME INC ; GLAXO GROUP GREENFORD MIDDLESEX LTD

Inventor(s): (std): CARTER M C ; CARTER MALCOLM ; CARTER MALCOLM C ; CARTER MALCOLM CL IVE ; CARTER MALCOLM CLIVE ; CARTER MALCOM C ; CARTER MALCOM CLIVE ; CARTER MALCOME CLIVE ; CLIVE CARTER MALCOLM ; COCKERILL G S ; COCKERILL GEORGE ; COCKERILL GEORGE S ; COCKERILL GEORGE STUART ; GUNTRIP S B ; GUNTRIP STEPHEN ; GUNTRIP STEPHEN B ; GUNTRIP STEPHEN BARRY ; GEORGE STUART COCKERILL ; KAREN ELIZABETH LACKEY ; LACKEY KAREN ; LACKEY KAREN E ; LACKEY KAREN ELIZABETH ; SMITH KATHRYN ; SMITH KATHRYN J ; SMITH KATHRYN JANE ; MALCOLM CLIVE CARTER ; KATHRYN JANE SMITH ; STEPHEN BARRY GUNTRIP

Inventor(s): CARTER ; LACKEY ; MALCOM CLIVE CARTER ; MC CARTER ; S B GUNTRIP ; SB GUNTRIP ; SMITH ; SMITH KATHRYN JANE GLAXOSMITHKLINE ; SMITH KATHRYN JANEGB ; ELIZABETH LACKEY KAREN ; CARTER MALCOM ; STEPHEN B GUNTRIP ; LACKEY KAREN ELIZABETH GLAXOSMITHKLINE ; LACKEY KAREN ELIZABETHUS ; M C CARTER ; KATHRYN J SMITH ; GS COCKERILL ; GUNTRIP ; GUNTRIP STEPHEN BARRY GLAXOSMITHKLINE ; GUNTRIP STEPHEN BARRYGB ; KAREN E LACKEY ; COCKERILL GEORGE STUARTGB ; G S COCKERILL ; COCKERILL ; CARTER MALCOLM CLIVEGB

Agent(s): REED MICHAEL ANTONY ET AL; DAVID J LEVY CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE; DAVID J LEVY CORPORATE INTELLECTUAL PROPERTY GLAXOSMITHKLINE; GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY MAI B475; GLAXOSMITHKLINE CORPORATE INTELLECTUAL PROPERTY MAI B475; GLAXOSMITHKLINE CORPORATE INTELLECTUAL PROPERTY MAI B482; JOHN L; J SCOTT

Designated states: AL AM AT AU AZ BA BB BE BF BG BJ BR BY CA CF CG CH CI CM CN CU CY CZ DE DK EE ES FI FR GA GB GD GE GH GM GN GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MC MD MG MK ML MN MR MW MX NE NL NO NZ PL PT RO RU SD SE SG SI SK SL SN SZ TD TG TJ TM TR TT UA UG US UZ VN YU ZW

This family is part of an extended family. Please click here to view the extended family.

Title: 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE

Abstract: The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Classifications:

International (IPC 8-9): A61K31/403 A61K31/404 A61K31/437 A61K31/4427 A61K31/443 A61K31/4433 A61K31/4439 A61K31/496 A61K31/5377 A61P17/06 A61P19/02 A61P29/00 A61P35/00 A61P37/00 A61P43/00 A61P9/00 C07D209/04 C07D209/34 C07D401/10 C07D403/06 C07D405/06 C07D409/10 C07D409/14 C07D413/12 C07D471/04 (Advanced/Invention); A61K31/403 A61K31/4427 A61K31/496 A61P29/00 A61P35/00 A61P37/00 A61P43/00 A61P9/00 (Advanced/Non-invention)

International (IPC 1-7): A61K31/404 A61K31/405 A61K31/437 A61K31/4439 A61K31/496 A61K31/5377 A61P17/06 A61P19/02 A61P29/00 A61P35/00 A61P37/00 A61P43/00 A61P9/00 C07D209/34 C07D401/10 C07D403/06 C07D405/06 C07D409/10 C07D471/04

CPC: C07D401/10 C07D209/34 C07D403/06 C07D405/06 C07D409/10 C07D471/04

European: C07D209/34 C07D401/10 C07D403/06 C07D405/06 C07D409/10 C07D471/04

Family:

Publication number	Publication date	Application number	Application date
AU199954684 A1	20000228	AU19990054684	19990804
AU199954684 A5	20000228	AU19990054684	19990804
CA2383623 AA	20011129	CA19992383623	19990804
JP2002522452 T2	20020723	JP20000563824T	19990804
WO0008202 A2	20000217	WO1999US17845	19990804
WO0008202 A3	20000518	WO1999US17845	19990804
WO0008202 C2	20000727	WO1999US17845	19990804

Priority:

US19980129256 19980804

US19980095470P 19980805

US19980102178P 19980928

US19990116107P 19990115

WO1999US17845 19990804

Probable Assignee: SUGEN INC

Assignee(s): (std): LIANG CONGXIN ; MILLER TODD ANTHONY ; NEMATALLA ASAAD ; NGUYEN ANH THI ; SUGEN INC ; SUN LI ; TANG PENG CHO ; TRAN NGOC MY

Inventor(s): (std): LIANG CONGXIN ; MILLER TODD ANTHONY ; NEMATALLA ASAAD ; NGUYEN ANH THI ; SUN LI ; TANG PENG CHO ; TRAN NGOC MY

Inventor(s): TODD ANTHONY MILLER ; PENG CHO TANG ; NGOC MY TRAN ; ANH THI NGUYEN ; ASAAD NEMATALLA ; CONGXIN LIANG ; LI SUN

Designated states: AL AM AT AU AZ BA BB BE BF BG BJ BR BY CA CF CG CH CI CM CN CU CY CZ DE DK EE ES FI FR GA GB GD GE GH GM GN GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LK LR LS LT LU LV MC MD MG MK ML MN MR MW MX NE NL NO NZ PL PT RO RU SD SE SG SI SK SL SN SZ TD TG TJ TM TR TT UA UG US UZ VN YU ZW

Title: SUBSTITUTED AZA-OXINDOLE DERIVATIVES

Abstract: Source: US2004072836A Substituted aza-oxindole derivatives useful as cyclin dependent kinase II inhibitors, for preventing/reducing the severity of epithelial cytotoxicity side-effects (e.g., alopecia, plantar-palmar syndrome, mucositis) induced by chemopotherapy and/or radiation therapy in a patient receiving such therapy.

Classifications:

International (IPC 8-9): A61K31/437 A61K31/4709 A61P1/16 A61P13/12 A61P17/06 A61P17/14 A61P17/16 A61P25/28 A61P27/02 A61P29/00 A61P3/10 A61P31/04 A61P31/12 A61P35/00 A61P37/06 A61P43/00 A61P7/00 A61P7/04 A61P9/10 A61P9/14 C07B61/00 C07D471/04 C07D471/14 C07D513/04 C07D513/14 (Advanced/Invention); A61K31/4709 A61P29/00 A61P35/00 A61P43/00 A61P7/00 C07B61/00 (Advanced/Non-invention); A61K31/4353 A61K31/4709 A61P1/00 A61P13/00 A61P17/00 A61P25/00 A61P27/00 A61P29/00 A61P3/00 A61P31/00 A61P35/00 A61P37/00 A61P43/00 A61P7/00 A61P9/00 C07D471/00 C07D513/00 (Core/Invention); C07B61/00 (Core/Non-invention)

International (IPC 1-7): A61K31/33 A61K31/38 A61K31/407 A61K31/429 A61K31/4365 A61K31/437 A61K31/4709 A61K31/498 A61K31/519 A61P1/16 A61P13/12 A61P17/06 A61P17/14 A61P17/16 A61P25/28 A61P27/02 A61P29/00 A61P3/10 A61P31/04 A61P31/12 A61P35/00 A61P37/06 A61P43/00 A61P7/00 A61P9/10 A61P9/14 C07D209/00 C07D209/56 C07D221/00 C07D221/06 C07D471/00 C07D471/02 C07D471/04 C07D471/14 C07D487/02 C07D513/00 C07D513/14

CPC: C07D471/04 C07D471/14 C07D513/04 C07D513/14 C40B40/00

European: C07D471/04 C07D471/14 C07D513/04 C07D513/14 M40B40/00

US: 514/183 514/229.2 514/249 514/265.1 514/265.100S 514/293 514/299 514/300 514/300S 514/366 514/411 514/412 514/418 514/426 514/430 544/111 544/179 544/180 544/242 544/281 544/281S 544/301 544/336 544/35 544/350 544/350S 544/359 544/368 544/59 544/61 544/98 546/112 546/113 546/113S 546/151 546/79 546/83 548/427 548/430 548/431 548/452 548/453 548/465 548/486 548/490

Family:

Publication number	Publication date	Application number	Application date
AT240328 E	20030515	AT20000917713T	20000303
AU200038645 A5	20001004	AU20000038645	20000303
DE60002714 D1	20030618	DE20006002714	20000303
DE60002714 T2	20040318	DE20006002714T	20000303
EP1180105 A2	20020220	EP20000917713	20000303
EP1180105 B1	20030514	EP20000917713	20000303
ES2199156 T3	20040216	ES20000917713T	20000303
GB9904995 A0	19990428	GB19990004995	19990304
JP2003502280 T2	20030121	JP20000605588T	20000303
US2004072836 AA	20040415	US20030669400	20030923
US6624171 BA	20030923	US20010914393	20010828
US6815439 BB	20041109	US20030669400	20030923
WO0055159 A2	20000921	WO2000US05583	20000303
WO0055159 A3	20011129	WO2000US05583	20000303

Priority:

GB19990004995 19990304 WO2000US05583 20000303 US20010914393 20010828
US20030669400 20030923

Probable Assignee: SMITHKLINE BEECHAM CORP


Assignee(s): (std): HARRIS PHILIP ANTHONY ; KUYPER LEE FREDERICK ; LACKEY KAREN ELIZABETH ; VEAL JAMES MARVIN ; SMITHKLINE BEECHAM CORP ; GLAXO GROUP LTD

Assignee(s): GLAXO GROUP LTD GREENFORD ; GLAXO WELLCOME INC

Inventor(s): (std): HARRIS PHILIP ANTHONY ; KUYPER LEE FREDERICK ; LACKEY KAREN ELIZABETH ; VEAL JAMES MARVIN ; VEAL MARVIN ; LACKEY ELIZABETH ; KUYPER FREDERICK ; HARRIS ANTHONY

Inventor(s): KAREN ELIZABETH LACKEY ; JAMES MARVIN VEAL ; PHILIP ANTHONY HARRIS ; LEE FREDERICK KUYPER

Designated states: AE AL AM AT AU AZ BA BB BE BF BG BJ BR BY CA CF CG CH CI CM CN CR CU CY CZ DE DK DM EE ES FI FR GA GB GD GE GH GM GN GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX NE NL NO NZ PL PT RO RU SD SE SG SI SK SL SN SZ TD TG TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW



Title: 3-(Anilinomethylene)oxindoles

Abstract: Source: US2002099071A Compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, D, X, Y and Z have the meaning as defined in the claims exhibit protein tyrosine kinase and protein serin/threonine kinase inhibitory activity.

Classifications:

International (IPC 8-9): A61K31/404 A61K31/4155 A61K31/4188 A61K31/4192 A61K31/422 A61K31/429 A61K31/4353 A61K31/437 A61K31/4439 A61K31/444 A61K31/454 A61K31/4745 A61K31/4985 A61K31/5377 A61K31/663 A61P1/00 A61P1/16 A61P11/00 A61P13/12 A61P17/00 A61P17/06 A61P17/14 A61P17/16 A61P19/02 A61P25/28 A61P29/00 A61P3/10 A61P31/10 A61P31/12 A61P35/00 A61P37/06 A61P43/00 A61P7/00 A61P9/00 A61P9/08 A61P9/10 C07D209/34 C07D209/38 C07D401/12 C07D403/12 C07D405/04 C07D405/12 C07D405/14 C07D409/04 C07D409/14 C07D471/02 C07D471/04 C07D487/04 C07D513/04 C07F9/40 C07F9/6561 (Advanced/Invention); A61K31/4155 A61K31/4192 A61K31/422 A61K31/429 A61K31/4985 A61P1/00 A61P11/00 A61P17/00 A61P29/00 A61P35/00 A61P43/00 A61P7/00 A61P9/00 (Advanced/Non-invention)

International (IPC 1-7): A61K31/40 A61K31/41 A61K31/415

A61K31/4155 A61K31/4188 A61K31/4192 A61K31/422 A61K31/425 A61K31/426 A61K31/429 A61K31/437 A61K31/4375 A61K31/4439 A61K31/454 A61K31/47 A61K31/4745 A61K31/4985 A61K31/5377 A61K31/74 A61P1/00 A61P1/16 A61P11/00 A61P13/12 A61P17/00 A61P17/06 A61P17/14 A61P17/16 A61P19/02 A61P25/28 A61P29/00 A61P3/10 A61P35/00 A61P43/00 A61P7/00 A61P9/00 A61P9/08 A61P9/10 C07D209/00 C07D209/34 C07D209/38 C07D209/40 C07D221/00 C07D235/00 C07D253/00 C07D277/00 C07D401/04 C07D401/12 C07D403/12 C07D405/04 C07D405/12 C07D405/14 C07D409/04 C07D413/14 C07D471/02 C07D471/04 C07D471/06 C07D487/04 C07D487/06 C07D513/02 C07D513/04 C07D513/06 C07M9/00

CPC: C07D209/34 C07D401/12 C07D403/12 C07D405/04 C07D405/14 C07D409/04 C07D471/04 C07D487/04 C07D513/04 C07F9/6561

European: C07D209/34 C07D401/12 C07D403/12 C07D405/04 C07D405/14 C07D409/04 C07D471/04 C07D487/04 C07D513/04 C07F9/6561

US: 424/78.17 424/78.170P 514/232.5 514/235.2 514/290 514/292 514/300 514/338 514/339 514/345 514/359 514/366 514/374 514/384 514/387 514/418 514/81 54/62.3 544/124 544/144 546/113 546/113S 546/151 546/23 546/268.4 546/277.7 546/84 548/151 548/236 548/259 548/302.1 548/483

Family:

Publication number	Publication date	Application number	Application date
AU200035050 A5	20001009	AU20000035050	20000228
EP1165514 A1	20020102	EP20000913643	20000228
GB9904933 A0	19990428	GB19990004933	19990304
JP2002540097 T2	20021126	JP20000606572T	20000228
JP3824866 B2	20060920	JP20000606572T	20000228
US2002099071 AA	20020725	US20010966318	20010927
US2004191210 AA	20040930	US20030742435	20031219
US6350747 BA	20020226	US20000514528	20000228
US6498176 BA	20021224	US20010914063	20010822
US6818632 BB	20041116	US20010966318	20010927
US7129253 BB	20061031	US20030742435	20031219
WO0056710 A1	20000928	WO2000US05057	20000228

Priority:

GB19990004933 19990304 US20000514528 20000228 WO2000US05057 20000228
US20010914063 20010822 US20010966318 20010927 US20030742435 20031219

Probable Assignee: SMITHKLINE BEECHAM CORP

Assignee(s): (std): GLAXO GROUP LTD ; GLAXO WELLCOME INC ; GLENNON KIMBERLEY CAROLINE ; KUYPER LEE FREDERICK ; LACKEY KAREN ELIZABETH ; MCNUTT ROBERT WALTON JR ; SMITHKLINE BEECHAM CORP ; SMITHKLINEBEECHAM CORP


Assignee(s): MCNUTT ROBERT WALTON

Inventor(s): (std): GLENNON KIMBERLEY CAROLINE ; GLENNON KIMBERLY CAROLINE ; KUYPER LEE FREDERICK ; LACKEY KAREN ELIZABETH ; MCNUTT JR ROBERT WALTON ; MCNUTT ROBERT WALTON ; MCNUTT ROBERT WALTON JR

Inventor(s): ROBERT WALTON MCNUTT ; LEE FREDERICK KUYPER ; KIMBERLEY CAROLINE GLENNON ; KAREN ELIZABETH LACKEY ; MCNUTT ; JR ROBERT WALTON

Agent(s): JENNIFER L

Designated states: AE AL AM AT AU AZ BA BB BE BF BG BJ BR BY CA CF CG CH CI CM CN CR CU CY CZ DE DK DM EE ES FI FR GA GB GD GE GH GM GN GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX NE NL NO NZ PL PT RO RU SD SE SG SI SK SL SN SZ TD TG TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW



Title: KINASE INHIBITORS AS THERAPEUTIC AGENTS

Abstract: Source: US7071199B The present application is directed to a compound of Formula (I) as defined herein which are useful as kinase inhibitors.

Classifications:


International (IPC 8-9): A61K31/4353 A61K31/437 A61K31/5025 A61K31/519 A61K31/55 A61K31/551 A61K38/00 A61P1/18 A61P15/00 A61P17/02 A61P17/06 A61P19/02 A61P27/02 A61P29/00 A61P3/10 A61P31/12 A61P31/18 A61P33/02 A61P35/00 A61P35/02 A61P37/02 A61P7/06 A61P9/00 A61P9/10 C07D209/00 C07D221/00 C07D231/00 C07D237/00 C07D239/00 C07D243/00 C07D471/04 C07D487/04 C07D491/04 C07D498/04 C07F9/6561 (Advanced/Invention); A61K31/5025 A61K31/519 A61K31/55 A61K38/00 A61P15/00 A61P29/00 A61P35/00 A61P9/00 C07D209/00 C07D221/00 C07D231/00 C07D237/00 C07D239/00 C07D243/00 C07D471/04 C07D487/04 (Advanced/Non-invention); A61K31/00 A61K31/4353 A61K31/5025 A61K31/519 A61K31/55 A61K38/00 A61P1/00 A61P15/00 A61P17/00 A61P19/00 A61P27/00 A61P29/00 A61P3/00 A61P31/00 A61P33/00 A61P35/00 A61P37/00 A61P7/00 A61P9/00 C07D209/00 C07D221/00 C07D231/00 C07D237/00 C07D239/00 C07D243/00 C07D471/04 C07D487/04 C07D491/04 C07D498/04 C07F9/6561 (Core/Invention)

International (IPC 1-7): A61K31/4353 A61K31/437 A61K31/5025 A61K31/519 A61K31/55 A61K31/551 A61K31/551A61P35/00 A61K38/00 A61P1/18 A61P15/00 A61P17/02 A61P17/06 A61P19/02 A61P27/02 A61P29/00 A61P3/10 A61P31/12 A61P31/18 A61P33/02 A61P35/00 A61P35/02 A61P37/00 A61P37/02 A61P7/06 A61P9/00 A61P9/10 C07D209/00 C07D221/00 C07D231/00 C07D237/00 C07D239/00 C07D243/00 C07D471/04 C07D471/04C07D491/04 C07D487/04 C07D491/04 C07D498/04 C07D498/04A61K31/519 C07F9/6561 C07M7/00

CPC: C07D471/04 C07D487/04 C07F9/6561

European: C07D471/04 C07D487/04 C07F9/6561

US: 514/258 514/260.1 514/263.2 544/280



Family:

Publication number	Publication date	Application number	Application date
AR029766 AA	20030716	AR2000P104887	20000918
AT380814 E	20071215	AT20000963510T	20000915
AU200074914 A5	20010417	AU20000074914	20000915
BG106585 A	20030331	BG20020106585	20020405
BRPI0014075 A	20020716	BR2000PI14075	20000915
CA2385769 AA	20020315	CA20002385769	20000915
CN1390220 A	20030108	CN20008015776	20000915
CY1107886 T1	20130619	CY20081100173T	20080214
CZ20020934 A3	20020717	CZ20020000934	20000915
DE60037455 D1	20080124	DE20006037455	20000915
DE60037455 T2	20081127	DE20006037455T	20000915
DK1268481 T3	20080505	DK20000963510T	20000915
EP1268481 A2	20030102	EP20000963510	20000915
EP1268481 B1	20071212	EP20000963510	20000915
ES2299434 T3	20080601	ES20000963510T	20000915
HU0303363 AB	20040728	HU20030003363	20000915
IL148719 A0	20020912	IL20000148719	20000915
JP2003509427 T2	20030311	JP20010523405T	20000915
KR20020063854 A	20020805	KR20027003507	20020315
MXPA02002938 A1	20041206	MX2002PA02938	20020314
NO20021329 A	20020521	NO20020001329	20020318
NO20021329 A0	20020318	NO20020001329	20020318
NZ517759 A	20040430	NZ20000517759	20000915
PL354241 A1	20031229	PL20000354241	20000915
PT1268481 T	20080319	PT20000963510T	20000915
SI1268481 T1	20080630	SI20000030979T	20000915
SK200200379 A5	20030911	SK20020000379	20000915
TR200201506 T2	20021021	TR20020001506T	20000915
US7071199 BA	20060704	US20000663320	20000915
WO0119828 A2	20010322	WO2000US25357	20000915
WO0119828 A3	20011004	WO2000US25357	20000915
ZA200202122 A	20030827	ZA20020002122	20020314

Priority:
US19990154618P 19990917 WO2000US25357 20000915 US20000663320 20000915
EP20000963510 20000915

Probable Assignee: ABBVIE DEUTSCHLAND GMBH AND CO KG

Assignee(s): (std): ABBOTT GMBH AND COKG ; BASF AG ; HIRST GAVIN C ; RAFFERTY PAUL ; RITTER KURT ; CALDERWOOD DAVID ; TWIGGER HELEN L ; ST GALLAY STEPHEN ; ABBOTT GMBH AND CCO KG ; ABBOTT GMBH AND CO ; ABBOTT GMBH AND CO KG ; ABBOTT AG

Assignee(s): ABBVIE DEUTSCHLAND GMBH AND CO KG ; ABBOTT GMBH ; BASF AKTIENGESELLSCHAFT

Inventor(s): (std): CALDERWOOD DAVID ; CALDERWOOD DAVID J ; DAVID CALDERWOOD ; GAVIN C HIRST ; GC HIRST ; HELEN L TWIGGER ; HIRST G C ; HIRST GAVIN C ; HL TEVIGE ; KURT RITTER ; P RAPHITI ; PAUL RAFFERTY ; RAFFERTY PAUL ; RAPHITI P ; RITTER KURT ; ST GALLAY STEPHEN ; STEPHEN ST GALLAY ; TEVIGE H L ; TWIGGER HELEN ; TWIGGER HELEN L ; TWIGGER HELEN LOUISE ; GALLAY STEPHEN ST ; COLDERWOOD DAVID ; HIRST GAVIN

Inventor(s): H L TEVIGE ; G C HIRST ; STGALLAY STEPHEN ; ST ; HELEN TWIGGER

Agent(s): GAYLE B; JOHN D


Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BY BZ CA CF CG CH CI CM CN CR CU CY CZ DE DK DM DZ EE ES FI FR GA GB GD GE GH GM GN GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NE NL NO NZ PL PT RO RU SD SE SG SI SK SL SN SZ TD TG TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Title: 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors

Abstract: Source: US2002183319A This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Particular 4-substituted 7-aza-indolin-2-ones disclosed herein are of Formula 1 and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R₁, R₂, R₃, R₄, X, Y, and Z are defined herein. The invention further relates to pharmaceutical compositions and dosage forms comprising compounds of Formula 1 and to methods of their use for the treatment and/or prevention of diseases such as, but not limited to, cancer.

Classifications:

International (IPC 8-9): A61K31/407 A61K31/437 A61K31/519 A61K31/5377 A61P1/00 A61P1/18 A61P11/00 A61P11/06 A61P13/00 A61P15/00 A61P19/00 A61P25/00 A61P3/00 A61P35/00 A61P37/08 A61P43/00 A61P5/00 A61P9/00 C07D471/04 C07D487/04 (Advanced/Invention); A61K31/519 A61P1/00 A61P11/00 A61P13/00 A61P15/00 A61P19/00 A61P25/00 A61P3/00 A61P35/00 A61P43/00 A61P5/00 A61P9/00 (Advanced/Non-invention)
International (IPC 1-7): A61K31/407 A61K31/437 A61K31/4745 A61K31/496 A61K31/519 A61K31/5377 A61P1/00 A61P1/18 A61P11/00 A61P11/06 A61P13/00 A61P15/00 A61P19/00 A61P25/00 A61P3/00 A61P35/00 A61P37/08 A61P43/00 A61P5/00 A61P9/00 C07D471/02 C07D471/04 C07D487/04 C07D491/02
CPC: C07D471/04 C07D487/04
European: C07D471/04 C07D487/04
US: 514/234.2 514/234.5 514/234.500P 514/252.16 514/252.160S 514/253.04 514/253.040S 514/265.1 514/265.100S 514/300 514/300S 544/117 544/117S 544/127 544/127S 544/280 544/280S 544/281 544/281S 544/362 544/362S 546/113 546/113S



Family:

Publication number	Publication date	Application number	Application date
AR029423 AA	20030625	AR2000P106848	20001221
AT299881 E	20050815	AT20000990229T	20001221
AU200127282 A5	20010703	AU20010027282	20001221
CA2395520 AA	20020621	CA20002395520	20001221
CO5271715 A1	20030430	CO20000097184	20001221
DE60021423 D1	20050825	DE20006021423	20001221
DE60021423 T2	20060413	DE20006021423T	20001221
EP1244672 A1	20021002	EP20000990229	20001221
EP1244672 B1	20050720	EP20000990229	20001221
ES2245955 T3	20060201	ES20000990229T	20001221
JP2003518123 T2	20030603	JP20010547106T	20001221
US2002183319 AA	20021205	US20000741737	20001221
US2004053924 AA	20040318	US20030622787	20030721
US6610688 BB	20030826	US20000741737	20001221
US6908930 BB	20050621	US20030622787	20030721
WO0146196 A1	20010628	WO2000US34259	20001221

Priority:

US19990171288P 19991221 WO2000US34259 20001221 US20000741737 20001221
US20030622787 20030721

Probable Assignee: SUGEN INC

Assignee(s): (std): CUI JINGRONG ; HIRTH KLAUS PETER ; LIANG CONGXIN ; MCMAHON GERALD ; SUGEN INC ; SUN LI ; TANG PENG CHO ; WEI CHUNG CHEN

Inventor(s): (std): WEI CHUNG CHEN ; WEI CHEN ; TANG PENG CHO ; TANG CHO ; SUN LI ; MCMAHON GERALD ; LIANG CONGXIN ; HIRTH PETER ; HIRTH KLAUS PETER ; CUI JINGRONG

Inventor(s): CHUNG CHEN WEI ; CHUNG WEI CHEN ; CONGXIN LIANG ; GERALD MCMAHON ; JINGRONG CUI ; KLAUS PETER HIRTH ; LI SUN ; PENG CHO TANG

Agent(s): RICHARDSON PETER C ; ZIELINSKI BRYAN C ; LIPTAK VINCENT P ; PETER C ; VINCENT P ; BRYAN C

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BY BZ CA CF CG CH CI CM CN CR CU CY CZ DE DK DM DZ EE ES FI FR GA GB GD GE GH GM GN GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NE NL NO NZ PL PT RO RU SD SE SG SI SK SL SN SZ TD TG TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Title: 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS

Abstract: Compounds of Formula (I), having the structure or a pharmaceutically salt thereof are useful as antineoplastic agents and in the treatment of osteoporosis and polycystic kidney disease.

Classifications:

International (IPC 8-9): A61K31/4706 A61K31/4709 A61K31/496 A61K31/5377 A61K31/541 A61P1/00 A61P1/02 A61P1/16 A61P1/18 A61P11/00 A61P11/04 A61P13/08 A61P13/10 A61P13/12 A61P15/00 A61P17/00 A61P19/02 A61P19/10 A61P29/00 A61P31/00 A61P31/12 A61P35/00 A61P37/04 A61P37/06 A61P43/00 A61P9/00 C07D215/54 C07D221/00 C07D401/04 C07D401/06 C07D401/10 C07D401/12 C07D401/14 C07D405/04 C07D405/12 C07D405/14 C07D409/04 C07D409/14 C07D413/10 C07D413/14 C07D417/06 C07D471/04 (Advanced/Invention); C07D221/00 (Advanced/Non-invention)
International (IPC 1-7): A61K31/4706 A61K31/4709 A61K31/496 A61K31/5377 A61K31/541 A61P1/00 A61P1/02 A61P1/16 A61P1/18 A61P11/00 A61P11/04 A61P13/08 A61P13/10 A61P13/12 A61P15/00 A61P17/00 A61P19/02 A61P19/10 A61P29/00 A61P31/00 A61P31/12 A61P35/00 A61P37/04 A61P37/06 A61P43/00 A61P9/00 C07D215/54 C07D221/00 C07D401/04 C07D401/06 C07D401/10 C07D401/12 C07D401/14 C07D405/04 C07D405/12 C07D405/14 C07D409/04 C07D409/14 C07D413/10 C07D413/14 C07D417/06 C07D471/04

CPC: C07D215/54 C07D401/04 C07D401/06 C07D401/10 C07D401/12 C07D401/14 C07D405/04 C07D405/12 C07D405/14 C07D409/04

European: C07D215/54 C07D401/04 C07D401/06 C07D401/10 C07D401/12 C07D401/14 C07D405/04 C07D405/12 C07D405/14 C07D409/04 C07D409/14 C07D471/04



Family:

Publication number	Publication date	Application number	Application date
AR035851 AA	20040721	AR2001P101423	20010326
AT371647 E	20070915	AT20010924407T	20010328
AU2001251063 AA	20011008	AU20010251063	20010328
BRPI0109650 A	20030422	BR2001PI09650	20010328
CA2404662 AA	20020930	CA20012404662	20010328
CN100439340 C	20081203	CN20018007202	20010328
CN1419545 A	20030521	CN20018007202	20010328
DE60130200 D1	20071011	DE20016030200	20010328
DE60130200 T2	20080313	DE20016030200T	20010328
DK1268431 T3	20071210	DK20010924407T	20010328
EP1268431 A1	20030102	EP20010924407	20010328
EP1268431 B1	20070829	EP20010924407	20010328
ES2291311 T3	20080301	ES20010924407T	20010328
JP2003528857 T2	20030930	JP20010570624T	20010328
MXPA02009439 A1	20030224	MX2002PA09439	20020926
TWI297007 B	20080521	TW20010107407	20010328
WO0172711 A1	20011004	WO2001US09966	20010328

Priority:

US20000535843 20000328 WO2001US09966 20010328

Probable Assignee: AMERICAN HOME PROD

Assignee(s): (std): WYETH ; WYETH CO ; WYETH CORP ; AMERICAN HOME PROD ; WYETH LLC

Assignee(s): YE FEI ; YAMASHITA AYAKO ; ZHANG NAN ; AMERICAN HOME PRODUCTS CORP ; BERGER DAN MAARTEN ; BOSCHELLI DIANE HARRIS ; BOSCHELLI FRANK CHARLES ; POWELL DENNIS WILLIAM ; WU BIQI ; TSOU HWEI RU ; WISSNER ALLAN ; OVERBEEK KLUMPERS ELSEBE GERALDINE ; WANG YANONG ; DEMORIN FRENEL FILS

Inventor(s): (std): ALLAN WISSNER ; AYAKO YAMASHITA ; BERGER DAN ; BERGER DAN MAARTEN ; BIQI WU ; BOSCHELLI D H ; BOSCHELLI DIANE ; BOSCHELLI DIANE HARRIS ; BOSCHELLI F C ; BOSCHELLI FRANK ; BOSCHELLI FRANK CHARLES ; DAN MAARTEN BERGER ; DEMORIN FRENEL ; DEMORIN FRENEL FILS ; DENNIS WILLIAM POWELL ; DH BOSCHELLI ; DIANE HARRIS BOSCHELLI ; ELSEBE GERALDINE OVERBEEK KLUMPERS ; NAN ZHANG ; OVERBEEK KLUMPERS ELSEBE ; OVERBEEK KLUMPERS ELSEBE GERAL ; OVERBEEK KLUMPERS ELSEBE GERALDINE ; POWELL DENNIS ; POWELL DENNIS WILLIAM ; TSOU HWEI RU ; WANG YANONG ; WISSNER ALLAN ; WU BIQI ; YAMASHITA AYAKO ; YANONG WANG ; YE FEI ; YE FEY ; ZHANG NAN ; FRANK CHARLES BOSCHELLI ; FRENEL FILS DEMORIN ; HWEI RU TSOU ; FC BOSCHELLI ; FEI YE

Inventor(s): FEY YE ; HWEI-RU TSOU ; ELSEBE GERALDINE OVERBEEK-KLUMPERS ; F C BOSCHELLI ; D H BOSCHELLI

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EE ES FI FR GA GB GD GE GH GM GN GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NE NL NO NZ PL PT RO RU SD SE SG SI SK SL SN SZ TD TG TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

Title: FUSED PYRAZOLE DERIVATIVES BIENG PROTEIN KINASE INHIBITORS

Abstract: Source: US2004053942A Compounds of Formula (I): salts or solvates or physiologically functional derivatives thereof, wherein Z is CH or N, and R<1>, (R<2>, and R<4>are various substituent groups, are protein kinase inhibitors.

Classifications:


International (IPC 8-9): A61K31/437 A61K31/444 A61K31/506 A61K31/5377 A61K31/55 A61P1/04 A61P11/00 A61P11/06 A61P13/12 A61P17/04 A61P17/06 A61P19/02 A61P19/10 A61P25/00 A61P25/08 A61P25/16 A61P25/28 A61P29/00 A61P3/00 A61P31/04 A61P31/08 A61P31/18 A61P33/06 A61P35/00 A61P37/06 A61P39/02 A61P43/00 A61P7/00 A61P7/02 A61P9/04 A61P9/10 C07D221/00 C07D231/00 C07D471/04 (Advanced/Invention); C07D221/00 C07D231/00 C07D471/04 C07F5/02 (Advanced/Non-invention); A61K31/4427 A61K31/506 A61K31/5375 A61K31/55 A61P1/00 A61P11/00 A61P13/00 A61P17/00 A61P19/00 A61P25/00 A61P29/00 A61P3/00 A61P31/00 A61P33/00 A61P35/00 A61P37/00 A61P39/00 A61P43/00 A61P7/00 A61P9/00 C07D221/00 C07D231/00 C07D471/00 (Core/Invention); A61K A61P C07D (Subclass/Invention)

International (IPC 1-7): A61K A61K31/415 A61K31/437 A61K31/444 A61K31/4745 A61K31/506 A61K31/5377 A61K31/55 A61P A61P1/04 A61P11/00 A61P11/06 A61P13/12 A61P17/04 A61P17/06 A61P19/02 A61P19/10 A61P25/00 A61P25/08 A61P25/16 A61P25/28 A61P29/00 A61P3/10 A61P31/04 A61P31/08 A61P31/18 A61P33/06 A61P35/00 A61P37/06 A61P39/02 A61P43/00 A61P7/00 A61P7/02 A61P9/04 A61P9/10 C07D221/00 C07D231/00 C07D401/04 C07D403/04 C07D409/04 C07D471/02 C07D471/04

CPC: C07D471/04

European: C07D471/04

US: 514/235.8 514/252.18 514/256 514/274 514/275 514/303 514/303S 540/601 544/122 544/315 544/316 544/331 544/333 544/333S 546/113 546/113S



Family:

Publication number	Publication date	Application number	Application date
AR034261 AA	20040218	AR2001P104007	20010822
AT318814 E	20060315	AT20010960928T	20010822
AU2001282318 AA	20020304	AU20010282318	20010822
AU200182318 A5	20020304	AU20010082318	20010822
BRPI0113448 A	20030617	BR2001PI13448	20010822
CA2420024 AA	20030218	CA20012420024	20010822
CN1798747 A	20060705	CN20018017742	20010822
DE60117568 D1	20060427	DE20016017568	20010822
DE60117568 T2	20060824	DE20016017568T	20010822
EP1311507 A1	20030521	EP20010960928	20010822
EP1311507 B1	20060301	EP20010960928	20010822
ES2259331 T3	20061001	ES20010960928T	20010822
GB200020556 A0	20001011	GB20000020556	20000822
GB200020576 A0	20001011	GB20000020576	20000822
HU0400757 AB	20040728	HU20040000757	20010822
IL154402 A0	20030917	IL20010154402	20010822
IN00168KN2003 A	20100430	IN2003KN00168	20030211
JP2004506736 T2	20040304	JP20020521460T	20010822
KR20030040419 A	20030522	KR20037002634	20030222
MXPA03001593 A1	20030604	MX2003PA01593	20030221
NO20030779 A	20030407	NO20030000779	20030219
NO20030779 A0	20030219	NO20030000779	20030219
PE05062002 A1	20020709	PE20010000842	20010821
PL362130 A1	20041018	PL20010362130	20010822
US2004053942 AA	20040318	US20030362146	20030707
US7166597 BB	20070123	US20010362146	20010822
UY26899 A1	20020322	UY20010026899	20010822
WO0216359 A1	20020228	WO2001GB03783	20010822
ZA200301318 A	20040622	ZA20030001318	20030218

Priority:

GB20000020556 20000822 GB20000020576 20000822 WO2001GB03783 20010822

Probable Assignee: SMITHKLINE BEECHAM CORP

Assignee(s): (std): GLAXO GROUP LTD ; BALDWIN IAN ROBERT ; CHEUNG MUI ; COCKERILL STUART ; FLACK STEPHEN ; HARRIS PHILIP ANTHONY ; JUNG DAVID KENDALL ; PECKHAM GREGORY ; PEEL MICHAEL ROBERT ; STANFORD JENNIFER BADIANG ; STEVENS KIRK ; VEAL JAMES MARVIN ; ALBERTI MICHAEL JOHN

Assignee(s): BADIANG JENNIFER ; BADIANG JENNIFER GABRIEL ; BALDWIN IAN ; SMITHKLINE BEECHAM CORP ; HARRIS PHILIP ; VEAL JAMES ; JUNG DAVID ; PEEL MICHAEL ; GLAXO GROUP LTD GREENFORD ; GLAXO GROUP GREENFORD LTD ; GLAXO GROUP LIMITED GREENFORD ; GLAXO GROUP LIMITED

Inventor(s): (std): ANT ALBERTI MICHAEL JOHN BALDW ; BADIANG JENNIFER ; BADIANG JENNIFER GABRIEL ; BALDWIN IAN ; BALDWIN IAN ROBERT ; BALDWIN ROBERT ; CHEUNG MUI ; COCKERILL STUART ; ALBERTI JOHN ; ALBERTI MICHAEL JOHN ; HARRIS ANTHONY ; HARRIS PHILIP ; HARRIS PHILIP ANTHONY ; JUNG DAVID ; JUNG DAVID KENDALL ; JUNG KENDALL ; PECKHAM GREGORY ; PEEL MICHAEL ; PEEL MICHAEL ROBERT ; PEEL ROBERT ; PELL MICHAEL ROBERT ; FLACK STEPHEN ; STANFORD BADIANG ; STANFORD JENNIFER BADIANG ; STANFORD JENNIFER BAIANG ; STEVENS KIRK ; VEAL JAMES ; VEAL JAMES MARVIN ; VEAL MARVIN

Inventor(s): JENNIFER BADIANG STANFORD ; ALBERTI MICHAEL JOHN BALDWIN IAN ROBERT CHEUNG ; STUART COCKERILL ; STEPHEN FLACK ; STANFORD JENNIFER ; GREGORY PECKHAM ; PHILIP ANTHONY HARRIS ; KIRK STEVENS ; MICHAEL JOHN ALBERTI ; MICHAEL ROBERT PEEL ; MUI CHEUNG ; PECKAM GREGORY ; IAN ROBERT BALDWIN ; JAMES MARVIN VEAL ; JENNIFER BAIANG STANFORD ; JENNIFER GABRIEL BADIANG ; ALBERTI MICHAEL JOHN BALDWIN IAN ROBERT CHEUNG MUI ; ALBERTI MICHAEL ; DAVID KENDALL JUNG

Agent(s): LORIE ANN

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NE NL NO NZ PH PL PT RO RU SD SE SG SI SK SL SN SZ TD TG TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Title: 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors

Abstract: Source: US2003092917A The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Classifications:

International (IPC 8-9): C07D403/06 A61K31/404 A61K31/405 A61K31/416 A61K31/4166 A61K31/4178 A61K31/4192 A61K31/437 A61K31/537 A61K31/5377 A61K31/541 A61K35/00 A61P17/06 A61P19/02 A61P29/00 A61P3/10 A61P35/00 A61P9/00 C07D207/34 C07D209/04 C07D209/34 C07D249/02 C07D249/08 C07D257/04 C07D279/12 C07D401/14 C07D403/02 C07D403/08 C07D403/14 C07D407/14 C07D413/14 C07D417/04 C07D417/06 C07D471/04 (Advanced/Invention); C07D207/34 C07D209/34 C07D295/088 C07D403/06 C07D413/14 (Advanced/Non-invention); A61K31/00 A61K31/403 A61K31/416 A61K31/4164 A61K31/4353 A61K31/537 A61K31/5375 A61K31/541 A61P17/00 A61P19/00 A61P29/00 A61P3/00 A61P35/00 A61P9/00 C07D401/00 C07D403/00 C07D413/00 C07D471/00 (Core/Invention); A61K A61P C07D (Subclass/Invention)

International (IPC 1-7): A61K1/4166 A61K1/5377 A61K31/4015 A61K31/404 A61K31/405 A61K31/41 A61K31/4166 A61K31/4178 A61K31/437 A61K31/5375 A61K31/5377 A61K31/541 A61K31/7404 A61P17/06 A61P19/02 A61P29/00 A61P3/10 A61P35/00 A61P9/00 C0743/02 C0743/14 C07D207/34 C07D401/14 C07D403/02 C07D403/04 C07D403/06 C07D403/08 C07D403/14 C07D407/14 C07D413/02 C07D413/14 C07D417/02 C07D43/02 C07D471/04 C07D471/14


CPC: C07D403/06 C07D403/14 C07D471/04

European: C07D403/06 C07D403/14 C07D471/04

US: 514/232.8 514/232.800P 514/235.2 514/359 514/359S 514/414 514/414S 544/144 544/144P 544/144S 544/58.2 546/117 546/177 548/181 548/181P 548/215 548/215S 548/229 548/229S 548/236 548/253 548/255 548/255S 548/259 548/261 548/266.2 548/266.200S 548/311.1 548/311.100S 548/312.1 548/312.100S 548/465 548/465S 548/468 548/468P

Family:

Publication number	Publication date	Application number	Application date
AP1718 A	20070130	AP20030002836	20020215
AP200302836 A0	20030930	AP20030002836	20020215
AR041247 AA	20050511	AR2003P103313	20030912
AR042586 AA	20050629	AR2002P100509	20020214
AT307128 E	20051115	AT20020714897T	20020215
AU2002247133 AA	20020904	AU20020247133	20020215
AU2002247133 BB	20070830	AU20020247133	20020215
AU2003216282 AA	20030909	AU20030216282	20030214
BG108098 A	20051230	BG20030108098	20030815
BRPI0207494 A	20040427	BR2002PI07494	20020215
BRPI0307721 A	20050125	BR2003PI07721	20030214
CA2438314 AA	20030813	CA20022438314	20020215
CA2438314 C	20120807	CA20022438314	20020215
CA2475455 AA	20040804	CA20032475455	20030214
CN100338059 C	20070919	CN20028006680	20020215
CN1308326 C	20070404	CN20038003988	20030214
CN1529704 A	20040915	CN20028006680	20020215
CN1671693 A	20050921	CN20038003988	20030214
CR7056 A	20040202	CR20030007056	20030814
CZ20032414 A3	20040414	CZ20030002414	20020215
DE60206736 D1	20060302	DE20026006736	20020215
DE60206736 T2	20060803	DE20026006736T	20020215
DK1370554 T3	20060206	DK20020714897T	20020215
EA007186 B1	20060825	EA20030000793	20020215
ECSPO34734 A	20031028	EC2003SP04734	20030815
EE200300385 A	20040216	EE20030000385	20020215
EP1370554 A1	20031217	EP20020714897	20020215
EP1370554 B1	20051019	EP20020714897	20020215
EP1476443 A2	20041117	EP20030742760	20030214
ES2251580 T3	20060501	ES20020714897T	20020215
GE20053600 B	20050810	GE20020005287	20020215
HK1059621 A1	20060630	HK20040102229	20040325
HK1059621 A3	20040709	HK20040102229	20040325
HK1065545 A3	20050225	HK20040108435	20041028
HK1078075 A1	20070713	HK20050109991	20051109
HK1078075 A3	20060303	HK20050109991	20051109
HR20030657 A2	20051031	HR20030000657	20030814
HR20030657 B1	20061031	HR20030000657	20030814
HU0303146 AB	20031229	HU20030003146	20020215
HU0303146 AC	20070828	HU20030003146	20020215
IL157418 A0	20040328	IL20020157418	20020215
IL157418 A1	20110331	IL20030157418	20030814
IL163219 A0	20051120	IL20040163219	20040726
IN01291DN2003 A	20090403	IN2003DN01291	20030813
IN02019DN2004 A	20070810	IN2004DN02019	20040714
IN233480 B	20090327	IN2004DN02019	20040714
IN243939 B	20101119	IN2003DN01291	20030813
IS2411 B	20081015	IS20030006913	20030814
IS6913 A	20030814	IS20030006913	20030814
JP2004522776 T2	20040729	JP20020565978T	20020215
JP2005528344 T2	20050922	JP20030569632T	20030214
JP3677501 B2	20050803	JP20020565978T	20020215
KR100657110 B1	20061212	KR20047012598	20030214
KR20040081203 A	20040920	KR20047012598	20030214
MA26997 A1	20041220	MA20030027282	20030815
MXPA03007367 A1	20050725	MX2003PA07367	20030815
MXPA04006992 A1	20041110	MX2004PA06992	20040719
MY126235 A	20060929	MY20020000528	20020215
NO20033608 A	20031014	NO20030003608	20030814
NO20033608 A0	20030814	NO20030003608	20030814
NO326604 B1	20090119	NO20030003608	20030814
NZ527572 A	20050729	NZ20020527572	20020215



OA12834 A	20060915	OA20031000211	20020215
PE10062002 A1	20021108	PE20020000134	20020215
PL364176 A1	20041213	PL20020364176	20020215
PL372302 A1	20050711	PL20030372302	20030214
RS51026 B	20101031	YU20030000717	20020215
RS70904 A	20061027	YU20040000709	20030214
RU2004124711 A	20060120	RU20040124711	20030214
RU2299209 C2	20070520	RU20040124711	20030214
SI1370554 T1	20060430	SI20020030238T	20020215
SK200301133 A5	20040406	SK20030001133	20020215
TNSN03055 A1	20050409	TN2003SN00055	20030708
TW200410958 A	20040701	TW20030125614	20030917
TWI289560 B	20071111	TW20030125614	20030917
TWI324155 B	20100501	TW20020102595	20020215
UA75635 C2	20031015	UA20030807745	20020215
US2003092917 AA	20030515	US20020076140	20020215
US2003229229 AA	20031211	US20030367008	20030214
US2004102510 AA	20040527	US20030656907	20030908
US2005171357 AA	20050804	US20050095433	20050330
US2007027149 AA	20070201	US20060511981	20060828
US2008045709 AA	20080221	US20070779807	20070718
US6653308 BB	20031125	US20020076140	20020215
US7119209 BB	20061010	US20030367008	20030214
US7179910 BB	20070220	US20030656907	20030908
US7256189 BB	20070814	US20060511981	20060828
US7582756 BB	20090901	US20070779807	20070718
VN5630 A1	20060626	VN20030000712	20020215
WO02066463 A1	20020829	WO2002US04407	20020215
WO03070725 A2	20030828	WO2003US04520	20030214
WO03070725 A3	20040115	WO2003US04520	20030214
YU71703 A	20060525	YU20030000717	20020215
ZA200306335 A	20041115	ZA20030006335	20030814
ZA200405615 A	20050627	ZA20040005615	20040714

Priority:

US20010268683P 20010215	US20010312361P 20010815	US20020076140 20020215
EP20020714897 20020215	US20030367008 20030214	US20030656907 20030908
US20050095433 20050330	US20060511981 20060828	US20070779807 20070718
WO2003US04520 20030214	US20020411732P 20020918	WO2002US04407 20020215

Probable Assignee: UPJOHN CO

Assignee(s): (std):	GUAN HUIPING ; HERRINTON PAUL MATTHEW ; JIN QINGWU ; LIANG CONGXIN ; MAURAGIS MICHAEL A ; SUGEN INC ; SUGEN ; MAY PAUL D ; PHARMACIA AND UP JOHN CO ; PHARMACIA AND UPJOHN CO LLC ; SUGEN CO LTD ; AGOURON PHARMA ; FARMATSIJA EHND APDZHON KOMPAN ; PHARMACIA AND UPJOHN CO LLC KALA ; PHARMACIA AND UPJOHN COMPANY LLC ; PHARMACIA AND UP JOHN COMPANY ; SUGEN INC SUGEN INC ; PHARMACIA AND UPJOHN COMPANY PHA ; UPJOHN CO ; SUN LI ; TANG PENG CHO ; WEI CHUNG CHEN ; VOJKOVSKY TOMAS ; SUGEN PHARMACIA AND UPJOHN COMPA ; SUGEN INK
Assignee(s):	SUGEN PHARMACIA AND UPJOHN COMPANY ; SUGEN PHARMACIA AND UPJOHN CO ; PHARMACIA AND UPJOHN COMPANY ; PHARMACIA AND UPJOHN CO KALAMAZOO ; PHARMACIA AND UPJOHN COMPANY PHARMACIA AND UPJOHN COMPANY ; SUGEN CO ; PHARMACIA AND UPJOHN CO ; PHARMACIA AND UPJOHN COMPANY PHARMACIA AND UPJOHN ; FARMATSIJA EHND APDZHON KOMPANI ; AGOURON PHARMACEUTICALS INC ; E AEN OE I AND C AND AE AND AND BE ; PHARMACIA AND UPJOHN CO LLC KALAMAZOO
Inventor(s): (std):	CHUNG CHEN WEI ; CONGXIN LIANG ; DZIN Kvingvu ; Errinton Paul Matthew ; Guan H ; Guan Huiping ; HERRINTON PAUL M ; HERRINTON PAUL MATTEW ; HERRINTON PAUL MATTHEW ; HUIPING GUAN ; JIN QINGWU ; JIN QING WU ; JIN QINGWU ; JIN QINGWU ALAN ; JIN QINGWU MAURAGIS MICHAEL A ; HERRINGTON PAUL ; HERRINGTON PAUL MATTHEW ; HERRINTON MATTHEW ; CHAEL A ; JUN QINGWU ; LI SUN ; LIANG C ; LIANG CONGXIN ; MARGARIS MICHAEL ; MAURAGIS A ; MAURAGIS MAJKL A ; MAURAGIS MICHAEL ; MAURAGIS MICHAEL A ; MAY PAUL ; MAY PAUL D ; MEHJ POL D ; SUN CONNIE L ; SUN CONNIE LI ; SUN H GUAN C LIANG L ; SUN L ; SUN LI ; TANG CHO ; TANG CHO PENG ; TANG PENG ; TANG PENG CHO ; TOMAS VOJKOVSKY ; VOJKOVSKY CZ TOMAS ; VOJKOVSKY THOMAS ; VOJKOVSKY TOMAS ; WEI CHEN ; WEI CHEN CHUNG ; WEI CHUNG ; WEI CHUNG C ; WEI CHUNG CHEN ; PAUL MATTHEW HARRINGTON ; PAUL MATTHEW HERRINGTON ; PAUL MATTHEW HERRINTON ; PENG CHO TANG ; QINGWU JIN ; QUINGWU JIN ; MICHAEL A MAURAGIS ; PAUL D MAY
Inventor(s):	PAUL DENNIS MAY ; MICHAEL ANTHONY MAURAGIS ; C LIANG ; QUINGWU JUN ; SUN CONNIE ; L SUN ; CHEN WEI CHUNG ; HERRINTON PAUL ; JIN QINGWU MAURAGIS MICHAEL A MAY PAUL D ; H GUAN ; H GUAN C LIANG L SUN
Agent(s):	AGOURON PHARMACEUTICALS INC; PFIZER INC; STEPHEN D; PETER; BRYAN C; YE; BURROUS BETH A; ENGELMANN JOHN H
Designated states:	AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NE NL NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL SN SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

This family is part of an extended family. Please click here to view the extended family.

Title: Bicyclic protein kinase inhibitors

Abstract: Source: US2002156083A The present invention relates to novel 3-hetero-arylidene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Classifications:

International (IPC 8-9): A61P35/00 C07D209/34 C07D471/04 (Advanced/Invention)

International (IPC 1-7): A61K31/4745 A61K31/495 A61K31/4985 A61K31/5025 A61K31/519 A61P35/00 C07D409/00 C07D471/00 C07D471/02 C07D487/00 C07D498/02

CPC: C07D209/34 C07D471/04

European: C07D209/34 C07D471/04

US: 514/249 514/264.1 514/265.1 514/300 514/300S 514/80 544/236 544/236S 544/238 544/280 544/280S 544/350 544/350S 546/113 546/113S

Family:

Publication number	Publication date	Application number	Application date
US2002156083 AA	20021024	US20010819698	20010329
US6683082 BB	20040127	US20010819698	20010329

Priority:

US19970045838P 19970507 US19970059677P 19970919 US19980074621 19980507
US20010819698 20010329

Probable Assignee: SUGEN INC

Assignee(s): (std): SUGEN INC ; SUN LI ; TANG PENG CHO

Assignee(s): MCMAHON GERALD

Inventor(s): (std): MCMAHON GERALD ; SUN LI ; TANG PENG CHO

This family is part of an extended family. Please click here to view the extended family.

Title: 3-HETEROARYLIDENE-2-INDOLINONE PROTEIN KINASE INHIBITORS

Abstract: Source: US6486185B The present invention relates to novel 3-heteroarylidene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Classifications:
International (IPC 8-9): A61P35/00 C07D209/34 C07D471/04 (Advanced/Invention)
International (IPC 1-7): A61K31/41 A61K31/415 C07D403/06 C07D403/14
CPC: C07D209/34 C07D471/04
European: C07D209/34 C07D471/04
US: 514/359 514/361 514/397 548/125 548/143 548/202 548/250

Family:

Publication number	Publication date	Application number	Application date
US6486185 BA	20021126	US19980191458	19981112

Priority:
US19970045838P 19970507 US19970059677P 19970919 US19980074621 19980507
US19980191458 19981112

Probable Assignee: SUGEN INC
Assignee(s): (std): SUGEN INC
Inventor(s): (std): MCMAHON GERALD ; SUN LI ; TANG PENG CHO

This family is part of an extended family. Please click here to view the extended family.

Title: 3-Methylidenyl-2-indolinone modulators of protein kinase

Abstract: Source: US6531502B The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Classifications:

International (IPC 8-9): C07D209/34 C07D401/10 C07D403/06 C07D405/06 C07D409/10 C07D471/04 C12N9/12 (Advanced/Invention)

International (IPC 1-7): A61K31/4015 C07D209/12 C07D209/14

CPC: C07D401/10 C07D209/34 C07D403/06 C07D405/06 C07D409/10 C07D471/04 C07K2319/00 C12N9/1205

European: C07D209/34 C07D401/10 C07D403/06 C07D405/06 C07D409/10 C07D471/04 C12N9/12C M07K319/00 M07K319/00E M12N203/02 M12N207/00 M12N213/00 M12N215/00

US: 514/414 514/418 548/455 548/468 548/486

Family:

Publication number	Publication date	Application number	Application date
US6531502 BA	20030311	US20010762198	20010205

Priority:

US19980072023P 19980121 US19980095470P 19980805 US19980102178P 19980928
WO1999US17845 19990804 US20010762198 20010205

Probable Assignee: SUGEN INC

Assignee(s): (std): SUGEN INC

Inventor(s): (std): LIANG CONGXIN ; MILLER TODD ANTHONY ; NEMATALLA ASAAD ; NGUYEN ANH THI ; SUN LI ; TANG PEN CHO ; TRAN NGOC MY

Title: BENZIMIDAZOLES

Abstract: Source: US2004048868A The invention is directed to physiologically active compounds of the general formula (I_x) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I_x), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Classifications:

International (IPC 8-9): A61K31/416 A61K31/4184 A61K31/4188 A61K31/42 A61K31/437 A61K31/4439 A61K31/454 A61K31/496 A61K31/4985 A61K31/5377 A61P1/04 A61P11/00 A61P11/02 A61P11/06 A61P17/00 A61P17/06 A61P19/00 A61P19/02 A61P19/10 A61P21/00 A61P25/00 A61P25/16 A61P25/18 A61P25/24 A61P25/28 A61P27/02 A61P29/00 A61P3/04 A61P3/10 A61P31/04 A61P31/12 A61P33/00 A61P35/00 A61P37/02 A61P37/06 A61P37/08 A61P39/02 A61P43/00 A61P7/00 A61P9/00 A61P9/04 A61P9/10 C07D235/04 C07D235/06 C07D235/18 C07D401/14 C07D403/02 C07D403/04 C07D403/14 C07D405/14 C07D407/14 C07D409/14 C07D413/04 C07D413/14 C07D43/02 C07D471/00 C07D487/04 C07D491/04 C07D491/056 C07D521/00 (Advanced/Invention); C07D231/56 C07D235/06 C07D239/72 C07D295/00 C07D307/52 C07D319/18 C07D333/10 (Advanced/Non-invention); A61K31/4164 A61K31/42 A61K31/4353 A61K31/4427 A61K31/4523 A61K31/496 A61K31/4985 A61K31/5375 A61P1/00 A61P11/00 A61P17/00 A61P19/00 A61P21/00 A61P25/00 A61P27/00 A61P29/00 A61P3/00 A61P31/00 A61P33/00 A61P35/00 A61P37/00 A61P39/00 A61P43/00 A61P7/00 A61P9/00 C07D401/00 C07D403/00 C07D405/00 C07D409/00 C07D413/00 C07D471/00 C07D487/00 C07D491/00 C07D521/00 (Core/Invention)

International (IPC 1-7): A61K31/33 A61K31/415 A61K31/416 A61K31/4184 A61K31/4188 A61K31/42 A61K31/437 A61K31/4439 A61K31/454 A61K31/4745 A61K31/496 A61K31/498 A61K31/4985 A61K31/503 A61K31/522 A61K31/5377 A61P1/04 A61P11/00 A61P11/02 A61P11/06 A61P17/00 A61P17/06 A61P19/00 A61P19/02 A61P19/10 A61P21/00 A61P25/00 A61P25/16 A61P25/18 A61P25/24 A61P25/28 A61P27/02 A61P29/00 A61P3/04 A61P3/10 A61P31/04 A61P31/12 A61P33/00 A61P35/00 A61P37/02 A61P37/06 A61P37/08 A61P39/02 A61P43/00 A61P7/00 A61P9/00 A61P9/04 A61P9/10 C07D C07D207/00 C07D211/00 C07D211/40 C07D213/38 C07D231/00 C07D231/38 C07D235/00 C07D235/04 C07D235/06 C07D277/00 C07D295/04 C07D309/06 C07D317/00 C07D319/00 C07D395/00 C07D401/14 C07D403/04 C07D403/14 C07D405/14 C07D407/14 C07D409/14 C07D413/04 C07D413/14 C07D471/04 C07D487/00 C07D487/04 C07D491/04 C07D491/056 C07D513/04 **CPC:** C07D231/12 C07D233/56 C07D249/08 C07D401/14 C07D403/04 C07D403/14 C07D405/14 C07D409/14 C07D413/04 C07D413/14 C07D471/04 C07D487/04 C07D491/04

European: C07D231/12 C07D233/56 C07D249/08 C07D401/14 C07D403/04 C07D403/14 C07D405/14 C07D409/14 C07D413/04 C07D413/14 C07D471/04 C07D487/04 C07D491/04

US: 514/183 514/248 514/248S 514/249 514/254.06 514/254.060P 514/263.34 514/263.340S 514/303 514/303S 514/359 514/385 514/387 514/393 514/394 514/394S 514/396 514/397 514/406 544/236 544/236S 544/269 544/269S 544/276 544/276S 544/277 544/277S 544/35 544/350 544/350S 544/370 544/370S 546/116 546/116S 548/100 548/300.1 548/300.7 548/303.1 548/304.7 548/305.1 548/306.1 548/306.100S 548/360.1 548/364.1

Family:

Publication number	Publication date	Application number	Application date
AR037032 AA	20041020	AR2002P104061	20021025
AU2002334217 AA	20030506	AU20020334217	20021024
AU2002334217 BB	20080703	AU20020334217	20021024
BRPI0213562 A	20040831	BR2002P113562	20021024
CA2465247 AA	20040426	CA20022465247	20021024
CA2465247 C	20100518	CA20022465247	20021024
EP1441725 A1	20040804	EP20020801954	20021024
FR2831537 A1	20030502	FR20010013868	20011026
FR2831537 B1	20080229	FR20010013868	20011026
GB200206893 A0	20020501	GB20020006893	20020322
GB200206895 A0	20020501	GB20020006895	20020322
GT200200219 A	20030711	GT20020000219	20021025
HN2002000311 A	20071214	HN20020000311	20021024
IL161576 A0	20040927	IL20020161576	20021024
JO2339 B	20060628	JO20020000108	20021027
JP2005509633 T2	20050414	JP20030537632T	20021024
JP5039268 B2	20121003	JP20030537632	20021024
MXPA04003954 A1	20041129	MX2004PA03954	20040426
PA8557101 A1	20031210	PA20020085571	20021025
PE06122003 A1	20030903	PE20020001052	20021025
SV2008001369 A	20080326	SV20020001369	20021025
US2004048868 AA	20040311	US20020279834	20021024
US2006014756 AA	20060119	US20050029064	20050104
US6897208 BB	20050524	US20020279834	20021024
US8288425 BB	20121016	US20050029064	20050104
UY27516 A1	20030430	UY20020027516	20021025
WO03035065 A1	20030501	WO2002GB04763	20021024

Priority:

FR20010013868 20011026	GB20020006893 20020322	GB20020006895 20020322
US20020395060P 20020711	US20020395151P 20020711	US20020279834 20021024
WO2002GB04763 20021024	US20050029064 20050104	

Probable Assignee: AVENTISUB LLC

Assignee(s): (std): EDWARDS MICHAEL LOUIS ; GILLESPIY TIMOTHY ALAN ; EDLIN CHRISTOPHER DAVID ; MORLEY ANDREW DAVID ; GARDNER CHARLES J ; PEDGRIFT BRIAN ; GAUZY LAURENCE ; LE BRUN ALAIN ; MAJID TAHIR NEDEEM ; READER JOHN C ; PAYNE LLOYD J ; KHAN NAWAZ M ; EDWARDS MICHAEL L ; GILLESPIY TIMOTHY A ; MAJID TAHIR N ; MORLEY ANDREW D ; EDLIN CHRISTOPHER D ; AVENTIS PHARMA LTD ; AVENTIS PHARMA SA ; COX PAUL JOSEPH ; DEPRETS STEPHANIE DANIELE ; BOUCHARD HERVE ; BABIN DIDIER ; CHERRY MICHAEL ; DEPRETS STEPHANIE D ; COX PAUL J ; AMENDOLA SHELLEY ; AVENTIS PHARMA INC

Assignee(s): AVENTIS PHARMA LIMITED ; AVENTISUB LLC ; AVENTIS PHARMACEUTICALS INC

Inventor(s): (std): AMENDOLA SHELLEY ; BABIN DIDIER ; BRUN ALAIN LE ; BRUNET ALAIN ; CHERRY MICHAEL ; CHRISTOPHER DAVID MORLEY ; COX JOSEPH PAUL ; COX PAUL J ; COX PAUL JOSEPH ; DEPRETS STEPHANIE D ; DEPRETS STEPHANIE DANIELE ; EDLIN CHRISTOPHER D ; EDLIN CHRISTOPHER DAVID ; EDWARDS MICHAEL L ; EDWARDS MICHAEL LOUIS ; GARDNER CHARLES J ; GAUZY LAURENCE ; GAUZY LAZO LAURENCE ; GILLESPIY TIMOTHY A ; GILLESPIY TIMOTHY ALAN ; KHAN NAWAZ M ; LAURENE GAUZY ; LE BRUN ALAIN ; LLOYD J PAYNE ; MAJID TAHIR ; MAJID TAHIR N ; MAJID TAHIR NADIM ; MAJID TAHIR NEDEEM ; MICHAEL CHERRY ; READER JOHN C ; STEPHANE DANIELE DEPERTS ; BOUCHARD HERVE ; BABIN FABIENNE ; TIMOTHY ALAN GILLESPIY ; MORLEY ANDREW D ; MORLEY ANDREW DAVID ; PAYNE LLOYD J ; PEDGRIFT BRIAN ; SHELLEY AMENDOLA ; NAWAZ M KHAN ; MICHAEL LOUIS EDWARDS ; MAJID TAHIR NADEEM ; JOHN C READER ; HERVE BOUCHARD ; ESWARDS MICHAEL LOUIS ; EDLIN CHRISTOPHER DAVID ; DIDIER BABIN ; CHARLES J GARDNER ; BRIAN PEDGRIFT ; ANDREW DAVID MORLEY ; ALAIN LE BRUN

Inventor(s): ALAIN BRUNET ; CHRISTOPHER DAVID EDLIN ; CHRISTOPHER DAVID EDLIN ; LLOYD J PAYNE ; LAURENCE GAUZY ; MICHAEL LOUIS ESWARDS ; PAUL JOSEPH COX ; READER JOHN ; PAYNE LLOYD ; TAHIR NEDEEM MAJID ; TAHIR NADEEM MAJID ; STEPHANIE DANIELE DEPRETS ; MORLEY ANDREW ; JOSEPH PAUL COX ; KHAN NAWAZ ; GILLESPIY TIMOTHY ; GARDNER CHARLES ; EDWARDS MICHAEL ; EDLIN CHRISTOPHER ; DEPRETS STEPHANIE ; COX PAUL


Agent(s): ROSS J OEHLER AVENTIS PHARMACEUTICALS INC; DARKES PAUL; WANG GEORGE; PARKER III RAYMOND S; BRIAN R

Designated states: AE AG AL AM AU AZ BA BB BE BF BG BJ BR BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD



Title: KINASE INHIBITORS

Abstract: Source: US2005004140A A compound of the general formula:



Family:

Publication number	Publication date	Application number	Application date
AT457025 E	20100215	AT20030722065T	20030523
AU2002002514 A0	20020613	AU2002PS02514	20020523
AU2003229370 AA	20031212	AU20030229370	20030523
AU2003229370 BB	20090226	AU20030229370	20030523
CA2486187 AA	20041116	CA20032486187	20030523
CA2486187 C	20130219	CA20032486187	20030523
CN1671696 A	20050921	CN20038017452	20030523
CN1671696 B	20101208	CN20038017452	20030523
DE60331187 D1	20100325	DE20036031187	20030523
EP1511742 A1	20050309	EP20030722065	20030523
EP1511742 A4	20060705	EP20030722065	20030523
EP1511742 B1	20100203	EP20030722065	20030523
GB200318343 A0	20030910	GB20030018343	20030523
GB2398781 A1	20040901	GB20030018343	20030523
GB2398781 B2	20050202	GB20030018343	20030523
IL165262 A0	20051218	IL20030165262	20030523
IL165262 A1	20111031	IL20040165262	20041116
IN01743KN2004 A	20060602	IN2004KN01743	20041117
JP2005535597 T2	20051124	JP20040507468T	20030523
JP4772325 B2	20110914	JP20040507468T	20030523
KR101169964 B1	20120806	KR20047018880	20030523
KR20050016425 A	20050221	KR20047018880	20030523
NZ537156 A	20070629	NZ20030537156	20030523
US2005004140 AA	20050106	US20030472156	20030523
US2006241112 AA	20061026	US20060397973	20060404
US2006270687 AA	20061130	US20060397982	20060404
US2007161635 AA	20070712	US20070711957	20070227
US7259179 BB	20070821	US20030472156	20030523
US7511047 BB	20090331	US20060397982	20060404
US7598272 BB	20091006	US20060397973	20060404
WO03099811 A1	20031204	WO2003AU00628	20030523
ZA200409346 A	20060222	ZA20040009346	20041119

Priority:

AU2002PS02514 20020523	US20020398998P 20020726	US20030472156 20030523
AU20030229370 20030523	WO2003AU00628 20030523	US20030472156 20030919
US20060397982 20060404	US20060397973 20060404	US20070711957 20070227

Probable Assignee: YM BIOSCIENCES AUSTRALIA PTY LTD

Assignee(s): (std): BU XIANYONG ; BURNS CHRISTOPHER J ; BURNS CHRISTOPHER JOHN ; CYTOPIA PTY LTD ; CYTOPIA RES PTY LTD ; WILKS ANDREW F ; WILKS ANDREW FREDERICK ; WILKS ANDREW FREDRICK ; YM BIO SCIENCE AUSTRALIA PRIVATE CO LTD ; YM BIOSCIENCES AUSTRALIA PTY LTD ; YM BIOSCIENCES AUSTRALIA PTY

Assignee(s): YM BIO SCIENCE AUSTRALIA PRIVATE CO ; CYTOPIA RESEARCH PTY LTD

Inventor(s): (std): ANDREW FREDERICK WILKS ; ANDREW FREDRICK WILKS ; BU XIANYONG ; BURNS CHRISTOPHER ; BURNS CHRISTOPHER J ; BURNS CHRISTOPHER JOHN ; CHRISTOPHER JOHN BURNS ; FREDERICK WILKS ANDREW ; JOHN BURNS CHRISTOPHER ; WILKS ANDREW ; WILKS ANDREW F ; WILKS ANDREW FREDERICK ; WILKS ANDREW FREDRICK ; XIANYONG BU

Agent(s): CAMPBELL PATRICK JOHN HENRY; MORRISON AND FOERSTER LLP

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NE NI NL NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL SN SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

This family is part of an extended family. Please click here to view the extended family.

Title: 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE

Abstract: Source: US2004024010A The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Classifications:

International (IPC 8-9): C07D209/34 C07D401/10 C07D403/06 C07D405/06 C07D409/10 C07D471/04 C12N9/12 (Advanced/Invention)

International (IPC 1-7): A61K31/40 A61K31/404 A61K31/44 A61K31/4745 A61K31/535 C07D209/34 C07D413/00 C07D471/02

CPC: C07D401/10 C07D209/34 C07D403/06 C07D405/06 C07D409/10 C07D471/04 C07K2319/00 C12N9/1205

European: C07D209/34 C07D401/10 C07D403/06 C07D405/06 C07D409/10 C07D471/04 C12N9/12C M07K319/00 M07K319/00E M12N203/02 M12N207/00 M12N213/00 M12N215/00

US: 514/235.5 514/300 514/343 514/414 514/414S 514/418 514/418S 544/144 546/113 546/113S 546/278.4 548/457 548/457S 548/465 548/465S 548/484 548/484S 548/486

Family:

Publication number	Publication date	Application number	Application date
US2004024010 AA	20040205	US20030383690	20030310
US6855730 BB	20050215	US20030383690	20030310

Priority:

US19980095470P 19980805 US20030383690 20030310 US20010762198 20010205
US19980102178P 19980928 US19990116107P 19990115

Probable Assignee: SUGEN INC

Assignee(s): (std): SUGEN INC


Inventor(s): (std): LIANG CONGXIN ; MILLER TODD ANTHONY ; NEMATALLA ASAAD ; NGUYEN ANH THI ; SUN LI ; TANG PEN CHO ; TRAN NGOC MY

Title: 3-PYRROL-PYRIDOPYRAZOLES AND 3-PYRROLYL-INDAZOLES AS NOVEL KINASE INHIBITORS

Abstract: Source: US2004092546A Compounds of Formula I are useful as mediators of protein kinases and have activity as cell proliferation inhibitors: where X, R1-R7 and R9 are as defined herein.

Classifications:

International (IPC 8-9): A61K31/40 A61K31/416 A61K31/437 A61K31/4439 A61K31/444 A61K31/4545 A61K31/496 A61K31/535 A61K31/5377 A61P1/16 A61P13/08 A61P13/12 A61P17/00 A61P17/06 A61P19/02 A61P27/02 A61P29/00 A61P3/10 A61P31/10 A61P31/18 A61P35/00 A61P35/02 A61P35/04 A61P43/00 A61P9/10 A61P9/14 C07D207/04 C07D401/14 C07D403/04 C07D413/14 C07D471/04 H01M2/02 (Advanced/Invention); A61K31/416 A61K31/4353 A61K31/4427 A61K31/4523 A61K31/496 A61K31/535 A61K31/5375 A61P1/00 A61P13/00 A61P17/00 A61P19/00 A61P27/00 A61P29/00 A61P3/00 A61P31/00 A61P35/00 A61P43/00 A61P9/00 C07D401/00 C07D403/00 C07D471/00 H01M2/02 (Core/Invention) **International (IPC 1-7):** A61K31/40 A61K31/416 A61K31/437 A61K31/4439 A61K31/4745 A61K31/5377 C0743/04 C07D207/04 C07D401/14 C07D403/04 C07D413/14 C07D471/02 C07D471/04 **CPC:** A61K31/416 A61K31/437 A61K31/5377 C07D401/14 C07D403/04 C07D471/04 **European:** A61K31/416 A61K31/437 A61K31/5377 C07D401/14 C07D403/04 C07D471/04 G09F3/04 H01M2/02E12 H01M2/02E8 T01M2/02B7 Y02E60/12 **US:** 428/204P 514/234.2 514/253.04 514/303 514/406 514/406S 544/127 544/362 546/119 546/119S 548/361.1 548/361.100S



Family:

Publication number	Publication date	Application number	Application date
AU2003259749 AA	20040225	AU20030259749	20030812
BRPI0313396 A	20050628	BR2003PI13396	20030812
CA2495216 AA	20050210	CA20032495216	20030812
EP1545515 A1	20050629	EP20030785178	20030812
JP2006501217 T2	20060112	JP20040528019T	20030812
MXPA05001688 A1	20050419	MX2005PA01688	20050211
US2004092546 AA	20040513	US20030638468	20030812
US7186716 BB	20070306	US20030638468	20030812
WO04014368 A1	20040219	WO2003US25096	20030812

Priority:

US20020402547P 20020812	US20020406334P 20020828	US20030449552P 20030225
US20030638468 20030812	WO2003US25096 20030812	US20030445552P 20030206

Probable Assignee: SUGEN INC

Assignee(s): (std): HUANG PING ; SUGEN INC ; WEI CHUNG CHEN ; XIA YI

Inventor(s): (std): HUANG PING ; WEI CHUNG CHEN ; XIA YI ; YI XIA ; PING HUANG ; CHUNG CHEN WEI

Agent(s): VINCENT P; BRYAN C


Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NE NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: BENZIMIDAZOLE QUINOLINONES AND USES THEREOF

Abstract: Source: US2004092535A Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.

Classifications:

International (IPC 8-9): A01N43/40 A61K31/4184 A61K31/435 A61K31/4353 A61K31/4375 A61K31/439 A61K31/47 A61K31/4709 A61K31/4745 A61K31/496 A61K31/497 A61K31/4985 A61K31/513 A61K31/52 A61K31/5377 A61K31/541 A61K31/551 A61K31/553 A61K47/26 A61K6/00 A61K9/00 A61K9/08 A61K9/10 A61K9/20 A61K9/48 A61P19/00 A61P25/00 A61P25/28 A61P3/10 A61P35/00 A61P35/02 A61P37/02 A61P43/00 A61P9/00 C07C51/41 C07C59/08 C07D C07D215/42 C07D241/04 C07D295/12 C07D401/04 C07D401/14 C07D403/04 C07D403/14 C07D405/14 C07D409/14 C07D413/14 C07D417/14 C07D453/00 C07D453/02 C07D453/06 C07D471/04 C07D471/14 C07D487/04 C07D487/08 C07D487/10 C07D498/10 C07D519/00 G01N30/72 G01N30/88 G01N33/573 (Advanced/Invention); A61K31/4184 A61K31/4353 A61K31/4375 A61K31/496 A61K31/5377 A61K31/541 A61K31/551 A61K31/553 A61P19/00 A61P35/00 A61P43/00 C07B61/00 C07D401/04 C07D403/06 C07D471/04 C07D487/04 C07D487/10 C07D498/10 C07D519/00 C12N9/99 (Advanced/Non-invention); A61K31/00 A61K31/435 A61P35/00 C07D401/00 (Core/Invention); A61K31/496 (Core/Non-invention); A61K A61P C07D (Subclass/Invention)
International (IPC 1-7): A61K A61K0/00 A61K31/395 A61K31/4184 A61K31/435 A61K31/4375 A61K31/47 A61K31/4709 A61K31/496 A61K31/4995 A61K31/52 A61K9/08 A61K9/20 A61K9/48 A61P35/00 A61P35/02 B01J8/06 C01B3/38 C07D C07D0/00 C07D215/42 C07D241/04 C07D401/04 C07D401/14 C07D403/04 C07D403/14 C07D43/14 C07D471/04 G01N21/33 G01N30/00
CPC: A61K9/0019 A61K31/52 A61K47/26 C07D453/06 C07D471/04 C07D401/04 A61K31/4375 A61K31/4709 A61K31/496 A61K31/5377 A61K31/541 C07D401/14 C07D405/14 C07D409/14 C07D413/14 C07D453/02 C07C51/412 C07C59/08
European: A61K31/4375 A61K31/4709 A61K31/496 A61K31/52 A61K31/5377 A61K31/541 A61K47/26 A61K9/00M5 C07D401/04 C07D401/14 C07D405/14 C07D409/14 C07D413/14 C07D453/02 C07D453/06 C07D471/04 C07D487/08
US: 514/235.8 514/235.800P 514/253.07 514/253.07P 514/253.070S 514/255.02 514/263.22 514/263.220P 514/303 514/303S 514/312 514/312S 514/313 514/314 544/363 544/363P 544/363S 546/157 546/157S



Family:

Publication number	Publication date	Application number	Application date
AR045404 AA	20051026	AR2003P104190	20031113
AU2003288899 AA	20040311	AU20030288899	20030819
AU2003288899 BB	20090903	AU20030288899	20030819
AU2003290699 AA	20040603	AU20030290699	20031112
AU2003290699 BB	20090827	AU20030290699	20031112
AU2004288692 AA	20050526	AU20040288692	20041105
AU2004288692 BB	20110217	AU20040288692	20041105
AU2004288709 AA	20050526	AU20040288709	20041105
AU2004288709 BB	20110106	AU20040288709	20041105
AU2004289672 AA	20050526	AU20040289672	20041105
AU2004289672 BB	20100624	AU20040289672	20041105
AU2004289672 CA	20101202	AU20040289672	20041105
AU2009238373 AA	20091217	AU20090238373	20091120
AU2009238373 BB	20111103	AU20090238373	20091120
AU2011202249 AA	20110602	AU20110202249	20110516
AU2011202249 BB	20130221	AU20110202249	20110516
BRPI0313743 A	20050705	BR2003PI13743	20030819
BRPI0316229 A	20051004	BR2003PI16229	20031112
BRPI0416143 A	20070102	BR2004PI16143	20041105
CA2496164 AA	20050218	CA20032496164	20030819
CA2496164 C	20101109	CA20032496164	20030819
CA2501932 AA	20050411	CA20032501932	20031112
CA2501932 C	20140311	CA20032501932	20031112
CA2543820 AA	20060426	CA20042543820	20041105
CA2543820 C	20120710	CA20042543820	20041105
CA2544186 AA	20060428	CA20042544186	20041105
CA2544492 AA	20060502	CA20042544492	20041105
CA2544492 C	20130129	CA20042544492	20041105
CN100377709 C	20080402	CN200380103178	20031112
CN100526312 C	20090812	CN20038024565	20030819
CN101160308 A	20080409	CN200480037126	20041105
CN101160308 B	20110525	CN200480037126	20041105
CN102225926 A	20111026	CN201110096325	20041105
CN1692112 A	20051102	CN20038024565	20030819
CN1711088 A	20051221	CN200380103178	20031112
CN1878766 A	20061213	CN200480032837	20041105
CN1878766 B	20110817	CN200480032837	20041105
CN1976706 A	20070606	CN200480032700	20041105
CN1976706 B	20120118	CN200480032700	20041105
EA012621 B1	20091030	EA20060000928	20041105
EA2006000928 A1	20071026	EA20060000928	20041105
EP1539754 A2	20050615	EP20030781286	20030819
EP1539754 A4	20090225	EP20030781286	20030819
EP1565187 A2	20050824	EP20030783281	20031112
EP1565187 A4	20100217	EP20030783281	20031112
EP1682529 A2	20060726	EP20040810468	20041105

EP1682529 A4 20100630 EP20040810468 20041105
EP1692085 A2 20060823 EP20040810419 20041105
EP1692085 A4 20101013 EP20040810419 20041105
EP1699421 A2 20060913 EP20040816941 20041105
EP1699421 A4 20100217 EP20040816941 20041105
EP1699421 B1 20140521 EP20040816941 20041105
EP2573079 A2 20130327 EP20120186782 20030819
EP2573079 A3 20150311 EP20120186782 20030819
EP2762475 A1 20140806 EP20140165975 20041105
ES2486240 T3 20140818 ES20040816941T 20041105
HK1085205 A1 20100604 HK20060105175 20060502
HK1085205 A3 20060818 HK20060105175 20060502
HK1086575 A3 20060922 HK20060108679 20060804
HK1087401 A3 20061013 HK20060109532 20060828
IL167469 A1 20110927 IL20050167469 20050316
IL174471 A0 20060801 IL20060174471 20060321
IL174471 A0 20060801 IL20060174471 20060322
IL174471 A1 20130627 IL20060174471 20060322
IL174767 A0 20060820 IL20060174767 20060404
IL175385 A0 20080413 IL20060175385 20060502
IL175385 A1 20120628 IL20060175385 20060502
IL217114 A0 20120131 IL20110217114 20111221
IL217114 A1 20150430 IL20110217114 20111221
IL219818 A0 20120628 IL20120219818 20120516
IN00484KN2005 A 20060106 IN2005KN00484 20050323
IN00793KN2005 A 20060303 IN2005KN00793 20050503
IN01358KN2006 A 20070504 IN2006KN01358 20060522
IN01574KN2006 A 20070504 IN2006KN01574 20060607
IN217454 B 20080328 IN2005KN00484 20050323
IN253308 B 20120713 IN2006KN01574 20060607
JP2006503919 T2 20060202 JP20050501762T 20030819
JP2006511616 T2 20060406 JP20050507133T 20031112
JP2007510665 T2 20070426 JP20060538512T 20041105
JP2007510668 T2 20070426 JP20060538526T 20041105
JP2007522098 T2 20070809 JP20060538509T 20041105
JP2011042687 A2 20110303 JP20100258402 20101118
JP2011046716 A2 20110310 JP20100208650 20100916
JP2011162563 A2 20110825 JP20110118515 20110526
JP2014037428 A2 20140227 JP20130220838 20131024
JP4613130 B2 20110112 JP20050501762T 20030819
JP4724665 B2 20110713 JP20060538526T 20041105
JP4823914 B2 20111124 JP20060538512T 20041105
JP4890255 B2 20120307 JP20060538509T 20041105
JP5214768 B2 20130619 JP20110118515 20110526
KR101167573 B1 20120730 KR20067011003 20041105
KR101224410 B1 20130123 KR20067007021 20041105
KR20050037585 A 20050422 KR20057003112 20050223
KR20050075005 A 20050719 KR20057008597 20050513
KR20060111520 A 20061027 KR20067009999 20060523
KR20070011231 A 20070124 KR20067007021 20041105
KR20070011241 A 20070124 KR20067011003 20041105
KR20110108404 A 20111005 KR20117019525 20110823
MXPA05004754 A1 20050802 MX2005PA04754 20050503
MXPA06004194 A1 20060628 MX2006PA04194 20060412
MY144045 A 20110729 MY20030004345 20031113
NO20052760 A 20050720 NO20050002760 20050607
NO20052760 A0 20050607 NO20050002760 20050607
NO332772 B1 20130114 NO20050002760 20050607
NZ539425 A 20071130 NZ20030539425 20031112
SG148864 A1 20090129 SG20070003449 20031112
SI1699421 T1 20140930 SI20040032176T 20041105
TH96041 A 20090618 TH20031004283 20031113
TW200413349 A 20040801 TW20030123171 20030822
TW200418483 A 20041001 TW20030131830 20031113
TW200526604 A 20050816 TW20040133800 20041105
TWI335817 B 20110111 TW20030131830 20031113
TWI345567 B 20110721 TW20030123171 20030822
TWI347940 B 20110901 TW20040133800 20041105
US2004092535 AA 20040513 US20030644055 20030819
US2004220196 AA 20041104 US20030706328 20031112
US2005137399 AA 20050623 US20040982757 20041105
US2005203101 AA 20050915 US20040839793 20040505
US2005209247 AA 20050922 US20040982543 20041105
US2005256157 AA 20051117 US20050041191 20050121
US2005261307 AA 20051124 US20040983174 20041105
US2009181979 AA 20090716 US20090398130 20090304
US2009281100 AA 20091112 US20080317493 20081223
US2012277434 AA 20121101 US20120539872 20120702
US2013018058 AA 20130117 US20110309879 20111202
US2013338171 AA 20131219 US20130956463 20130801
US2014303182 AA 20141009 US20140215437 20140317
US7470709 BB 20081230 US20030644055 20030819
US7825132 BB 20101102 US20040983174 20041105
US7838527 BB 20101123 US20030706328 20031112
WO04018419 A2 20040304 WO2003US25990 20030819
WO04018419 A3 20040603 WO2003US25990 20030819
WO04018419 B1 20040729 WO2003US25990 20030819
WO04043389 A2 20040527 WO2003US35806 20031112
WO04043389 A3 20040805 WO2003US35806 20031112
WO04043389 B1 20040916 WO2003US35806 20031112
WO05046589 A2 20050526 WO2004US36941 20041105

WO05046589 A3	20071122	WO2004US36941	20041105
WO05046590 A2	20050526	WO2004US37051	20041105
WO05046590 A3	20051020	WO2004US37051	20041105
WO05047244 A2	20050526	WO2004US36956	20041105
WO05047244 A3	20061221	WO2004US36956	20041105
ZA200603598 A	20080430	ZA20060003598	20060505

Priority:

US20020405729P	20020823	US20020426204P	20021113	US20020426107P	20021113
US20030460369P	20030403	US20020426226P	20021113	US20020426282P	20021113
US20020428210P	20021121	US20030460328P	20030403	US20030460493P	20030403
US20030706328	20031112	WO2003US25990	20030819	WO2003US35806	20031112
US20030644055	20030819	US20030460327P	20030403	US20030478916P	20030616
US20030484048P	20030701	AU20030290699	20031112	JP20050507133	20031112
EP20030781286	20030819	US20030517915P	20031107	US20030517915P	20031007
US20040839793	20040505	WO2004US37051	20041105	WO2004US36941	20041105
WO2004US36956	20041105	US20080317493	20081223	US20040983174	20041105
US200500041191	20050121	US20040538984P	20040123	AU20090238373	20091120
US20030426282P	20031113	US20040982757	20041105	JP20060538526	20041105
AU20040288692	20041105	AU20110202249	20110516	JP20060538509	20041105
US20120539872	20120702	US20110309879	20111202	US20090398130	20090304
US20040982543	20041105	US20030526425P	20031202	US20030526426P	20031202
US20040546017P	20040219	JP20100208650	20031112	EP20040816941	20041105
US20130956463	20130801	US20140215437	20140317		

Probable Assignee: NOVARTIS AG

Assignee(s): (std): BARSANTI PAUL A ; BUSSIERE DIRKSEN ; CAI SHAOPEI ; CHIRON CORP ; CHOU JOYCE ; HANNAH ALISON ; HAROLDSSEN PETER ; HARRISON STEPHEN D ; HEISE CARLA C ; JANSEN JOHANNA M ; JAZAN ELISA ; MACHAJEWSKI TIMOTHY D ; MCBRIDE CHRISTOPHER ; MCCREA WILLIAM R ; NG SIMON ; NI ZHI JIE ; HARWOOD ERIC ; NOVARTIS VACCINES AND DIAGNOST ; NOVARTIS VACCINES AND DIAGNOSTIC ; MCCREA JR WILLIAM R ; NOVARTIS AG ; MACHAJEWSKI TIMOTHY ; PECCHI SABINA ; PFISTER KEITH ; RAMURTHY SAVITHRI ; RENHOWE PAUL A ; SHAFER CYNTHIA M ; SILVER JOEL B ; WAGMAN ALLAN ; WEISMANN MARION ; SAMARA EMIL ; SHANG XIAO ; VORA JAYESH ; ZHU SHUGUANG ; WIESMANN MARION ; RYCKMAN DAVID ; WAYMAN KELLY ; TESCONI MARC S ; OKHAMAFE AUGUSTUS O ; PFISTER KEITH B ; WAGMAN ALLAN S ; OKHAMAFE AUGUSTUS ; OKHAMATE AUGUSTUS

Assignee(s): NOVARTIS VACCINES AND DIAGNOSTICS INC WAS KNOW AS CHIRON CORPORATION.. ; NOVARTIS VACCINES AND DIAGNOSTICS INC WAS KNOW AS ; NOVARTIS VACCINES AND DIAGNOSTICS S R L ; NOVARTIS VACCINES AND DIAGNOSTICS INC

Inventor(s): (std): ALLAN WAGMAN ; AUGUSTUS O OKHAMAFE ; BARSANTI PAUL A ; BRAMMEIER NATHAN M ; BUSSIERE DIRKSEN ; CAI SHAOPEI ; ALISON HANNAH ; ALLAN S WAGMAN ; CARLA C HEISE ; CARLA HEISE ; CHOU JOYCE ; CHRISTOPHER MCBRIDE ; CYNTHIA M SHAFER ; DAVID RYCKMAN ; DIRKSEN BUSSIERE ; ELISA JAZAN ; EMIL SAMARA ; ERIC HARWOOD ; GESNER THOMAS G ; HANNAH ALISON ; HANNAH ALISON HARWOOD ERIC HAR ; HARRISON STEPHEN ; HARRISON STEPHEN D ; HARWOOD ERIC ; HAROLDSSEN PETER ; HEISE CARLA ; HEISE CARLA C ; JANSEN JOHANNA M ; JAYESH VORA ; JAZAN ELISA ; JOANNA M JANSEN ; JOHANNA M JANSEN ; JOYCE CHOU ; KEITH B PFISTER ; JOEL B SILVER ; KEITH PFISTER ; LE VINCENT P ; MACHAJEWSKI TIM ; MACHAJEWSKI TIMOTHY ; MACHAJEWSKI TIMOTHY D ; MARC S TESCONI ; MARION WEISMANN ; MARION WIESMANN ; MC BRIDE CHRISTOPHER ; MC CREA WILLIAM R ; MCBRIDE CHRISTOPHER ; MICHAJEWSKI TIMOTHY D ; NG SIMON ; NI ZHI JIE ; NI ZHI JIE Z J ; OKHAM CAI SHAOPEI CHOU JOYCE H ; OKHAMAFE AUGUSTUS ; OKHAMAFE AUGUSTUS O ; MCCREA JR WILLIAM R ; MCCREA WILLIAM R ; MCCREA WILLIAM R JR ; OKHAMATE AUGUSTUS ; PAUL A BARSANTI ; PAUL A RENHOWE ; PECCHI SABINA ; PETER HAROLDSSEN ; PFISTER KEITH ; PFISTER KEITH B ; RAMURTHY SAVITHRI ; RENHOWE PAUL A ; RYCKMAN DAVID ; SABINA PECCHI ; SAMARA EMIL ; SAVITHRI RAMURTHY ; SHAFER CYNTHIA M ; SHANG XIAO ; SHAOPEI CAI ; SHUGUANG ZHU ; SILVER JOEL B ; SIMON NG ; STEPHEN D HARRISON ; TESCONI MARC ; TESCONI MARC S ; TIM MACHAJEWSKI ; TIMOTHY D MACHAJEWSKI ; TIMOTHY MACHAJEWSKI ; VORA JAYESH ; VORA MACHAJEWSKI TIM HEISE CAR ; WAGMAN ALLAN ; WAGMAN ALLAN S ; WAYMAN KELLY ; WEISMANN MARION ; WIESMANN MARION ; WILLIAM R MCCREA ; WILLIAM R MCCREA JR ; XIAO SHANG ; ZHI JIE NI ; ZHOU YASHEEN ; ZHU SHUGUANG

Inventor(s): ZHI-JIE NI ; RAMURTHY SAVITRI ; MCCREA WILLIAM RJR ; MCBRIDGE CHRISTOPHER ; MACHAJEWSKI TIMOTHYD ; MACHAJEWSKI TIM HEISE CARLA HANNAH ALISON ; MACHAJEWSKI TIM HEISE CARLA HANNAH ALISON HARWOODE ; KELLY WAYMAN ; HESIE CARLA C ; HANNAH ALISON HARWOOD ERIC HAROLDSSEN PETER ; HANNAH ALISON HARWOOD ERIC HAROLDSSEN PETER HEISE C ; HANNAH ALISON HARWOOD ERIC HAROLDSSEN PETER HEISE CARLA MACHAJEWSKI TIMOTHY SAMARA EMIL SHANG XIAO VORA JAYESH ZHU SHUGUANG ; CHAU JOYCE ; CAI SHAOPEI CHOU JOYCE HARWOOD ERIC ; CAI SHAOPEI CHOU JOYCE HARWOOD ERIC MACHAJEWSKI TI ; CAI SHAOPEI CHOU JOYCE HARWOOD ERIC MACHAJEWSKI TIMOTHY RYCKMAN DAVID SHANG XIAO ZHU SHUGUANG OKHAMAFE AUGUSTUS O ; 1 BARSANTI PAUL A ; 10 NG SIMON ; 11 NI ZHI JIE ; 12 PECCHI SABINA ; 13 PFISTER KEITH ; 14 RAMURTHY SAVITRI ; 15 RENHOWE PAUL A ; 16 SHAFER CYNTHIA M ; 17 SILVER JOEL B ; 18 WAGMAN ALLAN ; 19 WIESMANN MARION ; 2 BUSSIERE DIRKSEN ; 20 WAYMAN KELLY ; 3 HARRISON STEPHEN D ; 4 HEISE CARLA C ; 5 JANSEN JOHANNA M ; 6 JAZAN ELISA ; 7 MACHAJEWSKI TIMOTHY D ; 8 MCBRIDE CHRISTOPHER ; 9 MCCREA WILLIAM R

Agent(s): GRUBER MARKUS; RUDGE SEWKIAN; CHIRON INTELLECTUAL PROPERTY R440 CORP; FOLEY AND LARDNER LLP; MEARA JOSEPH P; JOSEPH P; FRIEDRICHSSEN BERNARD P

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NA NE NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

This family is part of an extended family. Please click here to view the extended family.

Title: BICYCLIC PROTEIN KINASE INHIBITORS

Abstract: Source: US2004106618A The present invention relates to novel 3-heteroarylidene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Classifications:

International (IPC 8-9): A61K31/503 A61K31/519 A61P35/00 C07D209/34 C07D471/04 C07D487/02 (Advanced/Invention)

International (IPC 1-7): A61K31/498 A61K31/503 A61K31/519 C07D487/02

CPC: C07D209/34 C07D471/04

European: C07D209/34 C07D471/04

US: 514/248 514/249 514/249S 514/252.04 514/265.1 514/265.100S 544/236 544/236S 544/281 544/281S 544/35 544/350 544/350S

Family:

Publication number	Publication date	Application number	Application date
US2004106618 AA	20040603	US20030725267	20031202
US7189721 BB	20070313	US20030725267	20031202

Priority:

US19970045838P 19970507 US19970059677P 19970919 US19980074621 19980507
US20010819698 20010329 US20030725267 20031202

Probable Assignee: SUGEN INC

Assignee(s): (std): SUGEN INC

Inventor(s): (std): MCMAHON GERALD ; SUN LI ; TANG PENG CHO

Agent(s): VINCENT P; BRYAN C

This family is part of an extended family. Please click here to view the extended family.

Title: BICYCLIC PROTEIN KINASE INHIBITORS

Abstract: Source: US2004106630A The present invention relates to novel 3-heteroarylidene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Classifications:

International (IPC 8-9): A61P35/00 C07D209/34 C07D471/04 (Advanced/Invention)

International (IPC 1-7): A61K31/519 C07D471/02 C07D487/02

CPC: C07D209/34 C07D471/04

European: C07D209/34 C07D471/04

US: 514/248 514/248S 514/249 514/249S 514/265.1 514/265.100P 514/300 514/300S 514/418 514/418S 544/236 544/236S 544/28 544/280 544/280S 544/35 544/350 544/350S 546/113 546/113S 548/484 548/484S

Family:

Publication number	Publication date	Application number	Application date
US2004106630 AA	20040603	US20030725079	20031202

Priority:

US19970045838P 19970507	US19970059677P 19970919	US19980074621 19980507
US20010819698 20010329	US20030725079 20031202	

Probable Assignee: SUGEN INC

Assignee(s): (std): SUGEN INC

Inventor(s): (std): MCMAHON GERALD ; SUN LI ; TANG PENG CHO

Title: MODULATION OF PROTEIN FUNCTIONALITIES

Abstract: Source: US2004171075A New methods for the rational identification of molecules capable of interacting with specific naturally occurring proteins are provided, in order to yield new pharmacologically important compounds and treatment modalities. Broadly, the method comprises the steps of identifying a switch control ligand forming a part of a particular protein of interest, and also identifying a complementary switch control pocket forming a part of the protein and which interacts with said switch control ligand. The ligand interacts in vivo with the pocket to regulate the conformation and biological activity of the protein such that the protein assumes a first conformation and a first biological activity upon the ligand-pocket interaction, and assumes a second, different conformation and biological activity in the absence of the ligand-pocket interaction. Next, respective samples of said protein in the first and second conformations are provided, and these are screened against one or more candidate molecules by contacting the molecules and the samples. Thereupon, small molecules which bind with the protein at the region of the pocket may be identified. Novel protein-modulator adducts and methods of altering protein activity are also provided.

Classifications:

International (IPC 8-9): A61B5/055 A61K31/17 A61K31/4035 A61K31/41 A61K31/415 A61K31/4152 A61K31/4155 A61K31/416 A61K31/4178 A61K31/4184 A61K31/4196 A61K31/42 A61K31/422 A61K31/426 A61K31/427 A61K31/43 A61K31/433 A61K31/435 A61K31/439 A61K31/44 A61K31/4406 A61K31/4439 A61K31/444 A61K31/445 A61K31/454 A61K31/47 A61K31/4709 A61K31/4725 A61K31/4745 A61K31/495 A61K31/496 A61K31/4965 A61K31/497 A61K31/498 A61K31/505 A61K31/506 A61K31/517 A61K31/519 A61K31/53 A61K31/535 A61K31/5377 A61K31/54 A61K31/541 A61K31/55 A61K31/553 A61K39/395 A61P1/00 A61P11/00 A61P17/00 A61P19/00 A61P25/00 A61P27/02 A61P29/00 A61P31/04 A61P33/00 A61P35/02 A61P37/00 A61P39/00 A61P43/00 A61P7/00 A61P7/06 A61P7/08 A61P9/00 A61P9/08 A61P9/10 C07C237/06 C07C243/22 C07C257/06 C07C271/50 C07C275/28 C07D209/46 C07D215/16 C07D217/22 C07D221/22 C07D231/14 C07D231/38 C07D231/40 C07D233/00 C07D237/04 C07D239/02 C07D239/42 C07D249/12 C07D261/00 C07D263/06 C07D263/48 C07D275/03 C07D285/06 C07D285/10 C07D295/10 C07D401/00 C07D401/02 C07D401/04 C07D401/10 C07D401/12 C07D401/14 C07D403/02 C07D403/04 C07D403/10 C07D403/12 C07D403/14 C07D409/02 C07D409/04 C07D409/14 C07D413/02 C07D413/10 C07D413/12 C07D413/14 C07D417/02 C07D417/04 C07D417/10 C07D417/12 C07D417/14 C07D471/04 C07D471/08 C07K1/00 C07K1/107 C07K14/00 C07K7/06 C12N9/00 C12N9/10 C12N9/12 C12N9/16 C12N9/48 C12N9/64 C12N9/96 C12N9/99 C12Q1/42 C12Q1/48 G01N21/19 G01N21/64 G01N23/20 G01N27/447 G01N33/15 G01N33/48 G01N33/483 G01N33/50 G01N33/53 G01N33/68 G01R33/465 G06F19/00 G06G7/58 G09B1/00 G09B19/02 (Advanced/Invention); A61K31/41 A61K31/415 A61K31/4155 A61K31/42 A61K31/422 A61K31/425 A61K31/433 A61K31/53 A61K31/5377 A61P29/00 C07D215/38 C07D249/12 C07D263/06 C07D285/06 C07D413/10 C07K17/00 C07K7/04 C12N15/09 C12N9/10 C12N9/12 (Advanced/Non-invention); A61B5/055 A61K31/17 A61K31/403 A61K31/41 A61K31/415 A61K31/4152 A61K31/4155 A61K31/416 A61K31/4164 A61K31/4196 A61K31/42 A61K31/422 A61K31/427 A61K31/43 A61K31/433 A61K31/439 A61K31/44 A61K31/4406 A61K31/4427 A61K31/445 A61K31/47 A61K31/4709 A61K31/472 A61K31/496 A61K31/4965 A61K31/498 A61K31/505 A61K31/506 A61K31/517 A61K31/519 A61K31/535 A61K31/5375 A61K31/541 A61K31/55 A61K39/395 A61P1/00 A61P11/00 A61P15/00 A61P17/00 A61P19/00 A61P25/00 A61P27/00 A61P29/00 A61P31/00 A61P35/00 A61P37/00 A61P43/00 A61P7/00 A61P9/00 C07D209/00 C07D215/00 C07D217/00 C07D231/00 C07D233/00 C07D239/00 C07D249/00 C07D261/00 C07D263/00 C07D275/00 C07D285/00 C07D295/00 C07D401/00 C07D403/00 C07D409/00 C07D413/00 C07D417/00 C07K1/00 C07K7/00 C12N9/12 C12N9/96 C12N9/99 C12Q1/42 C12Q1/48 G01N21/19 G01N21/64 G01N23/20 G01N27/447 G01N33/15 G01N33/48 G01N33/483 G01N33/50 G01N33/53 G01N33/68 G01R33/44 G06F19/00 G09B1/00 G09B19/02 (Core/Invention); A61K31/41 A61K31/415 A61K31/42 A61K31/422 A61K31/425 A61K31/53 A61K31/5375 C07D215/00 C07D263/00 C12N15/09 C12N9/10 C12N9/12 (Core/Non-invention); A61B A61K C12N C12Q (Subclass/Invention)


International (IPC 1-7): A61B5/055 A61B5/055 A61K A61K0/00 A61K31/4152 A61K31/4155 A61K31/4184 A61K31/426 A61K31/433 A61K31/44 A61K31/4439 A61K31/444 A61K31/4745 A61K31/496 A61K31/505 A61K31/506 A61K31/517 A61K31/53 A61K31/5377 A61P29/00 C07D221/22 C07D231/14 C07D231/40 C07D237/04 C07D249/12 C07D285/10 C07D403/02 C07D403/12 C07D413/10 C07D413/12 C07D413/14 C07D417/10 C07D417/14 C07K7/04 C12N C12Q1/42 C12Q1/48 C12Q1/68 G01N33/48 G01N33/50 G01N33/53 G06F19/00 G09B1/00 G09B19/02 **CPC:** C07D209/46 C07D231/38 C07D231/40 C07D401/04 C07D401/10 C07D401/12 C07D401/14 C07D403/04 C07D403/12 C07D403/14 C07D405/12 C07D409/04 C07D409/12 C07D409/14 C07D413/10 C07D413/12 C07D417/04 C07D417/12 C07D417/14 C07D471/04 C07D471/10 C07D487/04 C12Q1/485 A61K31/4184 A61K31/426 A61K31/4745 A61K31/496 A61K31/517 A61K31/53 A61K31/5377 C07C271/56 C07C2101/10 C07D285/10 C07D413/14 C07K14/4702 C12N9/1205 C07D239/42 C07D295/10 A61K31/415 A61K31/422 A61K31/4406 C07D453/06 G09B1/00 G09B19/02 A61K31/506 A61K31/535 A61K31/54

European: A61K31/415 A61K31/4184 A61K31/422 A61K31/426 A61K31/4406 A61K31/4745 A61K31/496 A61K31/506 A61K31/517 A61K31/53 A61K31/535 A61K31/5377 A61K31/54 C07C271/56 C07D209/46 C07D231/38 C07D231/40 C07D239/42 C07D285/10 C07D295/10 C07D401/04 C07D401/10 C07D401/12 C07D401/14 C07D403/04 C07D403/12 C07D403/14 C07D405/12 C07D409/04 C07D409/12 C07D409/14 C07D413/10 C07D413/12 C07D413/14 C07D417/04 C07D417/10 C07D417/12 C07D417/14 C07D471/04 C07D471/10 C07D487/04 C12Q1/48B M07C101/10

US: 435/184 435/184S 435/188 435/188P 435/193 435/193S 435/194 435/194P 435/194S 435/196 435/196S 435/212 435/212S 435/7.1 435/7.100P 514/211.01 514/211.010P 514/212.07 514/212.070P 514/217.01 514/217.010S 514/227.8 514/227.800P 514/227.800S 514/232.8 514/232.800S 514/234.2 514/234.200S 514/235.2 514/235.200P 514/235.5 514/235.500P 514/236.5 514/236.500S 514/237.5 514/237.500P 514/241 514/241S 514/242 514/242S 514/249 514/249S 514/252.18 514/252.180S 514/252.19 514/252.190S 514/253.04 514/253.05 514/253.050S 514/253.06 514/253.060S 514/253.07 514/253.070S 514/254.05 514/254.050S 514/255.01 514/255.010S 514/255.02 514/255.020S 514/256 514/256S 514/264.1 514/264.100S 514/264.11 514/264.110P 514/266.1 514/266.100S 514/266.2 514/266.200S 514/266.23 514/266.230S 514/269 514/269S 514/275 514/275S 514/299 514/299S 514/302 514/302S 514/303 514/303S 514/309 514/309S 514/310 514/310S 514/312 514/312S 514/313 514/313S 514/314 514/314S 514/317 514/317S 514/322 514/322S 514/323 514/323S 514/327 514/327S 514/340 514/340S 514/341 514/341S 514/345 514/359 514/361 514/361S 514/362 514/362S 514/365 514/365S 514/370 514/370S 514/371 514/371S 514/372 514/373 514/373S 514/374 514/374S 514/375 514/375S 514/376 514/376S 514/377 514/378 514/384 514/384S 514/385 514/386 514/389 514/389S 514/394 514/394S 514/395 514/395S 514/396 514/396S 514/397 514/397S 514/403 514/404 514/404S 514/406 514/406S 514/407 514/407S 514/414 514/414S 514/418 514/418S 514/422 514/422S 514/425 514/425S 530/402 530/402S 540/523 540/523S 540/529 540/529S 544/114 544/120 544/120S 544/125 544/125S 544/128 544/128S 544/132 544/132S 544/140 544/140S 544/183 544/183S 544/273 544/279S 544/284 544/284S 544/295 544/295S 544/314 544/314S 544/322 544/322S 544/327 544/327S 544/328 544/328S 544/330 544/330S 544/331 544/331S 544/363 544/363S 544/368 544/368S 544/373 544/373S 544/58.2 544/58.200S 544/58.6 544/58.600S 544/60 544/60S 546/141 546/141S 546/143 546/143S 546/153 546/153S 546/159 546/162 546/162S 546/167 546/167S 546/178 546/178S 546/183 546/183S 546/198 546/198S 546/199 546/199S 546/275.4 546/275.400S 548/127 548/127S 548/130 548/130S 548/134 548/135 548/135S 548/212 548/230 548/230S 548/233 548/244 548/263.2 548/263.200S 548/263.4 548/263.400S 548/263.6 548/263.600S 548/300.1 548/311.1 548/315.7 548/364.1 548/364.100S 548/365.1 548/365.100S 548/371.7 548/371.700S 548/376.1 702/19 702/19S

Family:

Publication number	Publication date	Application number	Application date
AU2003303593 AA	20040729	AU20030303593	20031226
AU2003303593 BB	20080904	AU20030303593	20031226
AU2003303639 AA	20040729	AU20030303639	20031226
AU2003303641 AA	20040729	AU20030303641	20031226
AU2005270132 AA	20060209	AU20050270132	20050630
AU2005321946 AA	20060706	AU20050321946	20051223
AU2005321946 BB	20120816	AU20050321946	20051223
AU2005325676 AA	20060803	AU20050325676	20051223
AU2006268201 AA	20070118	AU20060268201	20060710
BRPI0317863 A	20051206	BR2003PI17863	20031226
BRPI0317872 A	20051206	BR2003PI17872	20031226
BRPI0317880 A	20051213	BR2003PI17880	20031226
CA2511840 AA	20050627	CA20032511840	20031226
CA2511873 AA	20050627	CA20032511873	20031226



CA2513627 AA	20050627	CA20032513627	20031226
CA2573124 AA	20070108	CA20052573124	20050630
CA2592116 AA	20070622	CA20052592116	20051223
CA2592118 AA	20070622	CA20052592118	20051223
CA2614341 AA	20080104	CA20062614341	20060710
CN1756747 A	20060405	CN200380110050	20031226
CN1756849 A	20060405	CN200380110049	20031226
CN1791596 A	20060621	CN200380110048	20031226
EP1585734 A2	20051019	EP20030808576	20031226
EP1585734 A4	20070919	EP20030808576	20031226
EP1585827 A2	20051019	EP20030808577	20031226
EP1590344 A2	20051102	EP20030814980	20031226
EP1590344 A4	20070829	EP20030814980	20031226
EP1773784 A2	20070418	EP20050768204	20050630
EP1835934 A2	20070926	EP20050855777	20051223
EP1835934 A4	20100728	EP20050855777	20051223
EP1836173 A2	20070926	EP20050857260	20051223
EP1836173 A4	20090708	EP20050857260	20051223
EP1907411 A2	20080409	EP20060786910	20060710
EP1907411 A4	20100317	EP20060786910	20060710
IN01427CN2005 A	20070223	IN2005CN01427	20050627
IN01433CN2005 A	20070302	IN2005CN01433	20050628
IN01438CN2005 A	20070302	IN2005CN01438	20050628
IN229368 B	20090320	IN2005CN01433	20050628
IN229712 B	20090327	IN2005CN01438	20050628
IN237750 B	20100115	IN2005CN01427	20050627
JP2006514691 T2	20060511	JP20050508625T	20031226
JP2006517654 T2	20060727	JP20050508626T	20031226
JP2006519765 T2	20060831	JP20050508623T	20031226
JP2008505900 T2	20080228	JP20070520362T	20050630
JP2008525498 T2	20080717	JP20070548595T	20051223
JP2008525502 T2	20080717	JP20070548611T	20051223
JP2009503440 T2	20090129	JP20080521537T	20060710
JP5197016 B2	20130515	JP20070548595T	20051223
MXPA05007236 A1	20060427	MX2005PA07236	20050630
MXPA05007237 A1	20071115	MX2005PA07237	20050630
MXPA05007238 A1	20060427	MX2005PA07238	20050630
TH68447 A	20050429	TH20031004987	20031230
TH70433 A	20050907	TH20031004989	20031230
TW200427672 A	20041216	TW20030137451	20031230
TW200505455 A	20050216	TW20030137441	20031230
TW200506066 A	20050216	TW20030137443	20031230
US2004171075 AA	20040902	US20030746545	20031224
US2004176395 AA	20040909	US20030746607	20031224
US2004180906 AA	20040916	US20030746460	20031224
US2005288286 AA	20051229	US20040886329	20040706
US2007037808 AA	20070215	US20060450840	20060609
US2007078121 AA	20070405	US20050318399	20051223
US2007191336 AA	20070816	US20040022395	20041223
US2008045531 AA	20080221	US20050224750	20050912
US2008045706 AA	20080221	US20050224749	20050912
US2008064688 AA	20080313	US20060336708	20060120
US2008113967 AA	20080515	US20070963740	20071221
US2008132506 AA	20080605	US20060450853	20060609
US2008187978 AA	20080807	US20060337245	20060120
US2008220497 AA	20080911	US20050178834	20050711
US2008299639 AA	20081204	US20060450850	20060609
US2009069310 AA	20090312	US20060450852	20060609
US2009075986 AA	20090319	US20060450849	20060609
US2009105230 AA	20090423	US20060450842	20060609
US2009137021 AA	20090528	US20060450851	20060609
US2009312349 AA	20091217	US20050721026	20051223
US7144911 BB	20061205	US20030746460	20031224
US7202257 BB	20070410	US20040886329	20040706
US7279576 BB	20071009	US20030746607	20031224
US7342037 BB	20080311	US20060450840	20060609
US7531566 BB	20090512	US20060336708	20060120
US7666895 BB	20100223	US20060450850	20060609
US7737283 BB	20100615	US20060450849	20060609
US8163756 BB	20120424	US20070963740	20071221
WO04060305 A2	20040722	WO2003US41425	20031226
WO04060305 A3	20050210	WO2003US41425	20031226
WO04060306 A2	20040722	WO2003US41449	20031226
WO04060306 A3	20050728	WO2003US41449	20031226
WO04061084 A2	20040722	WO2003US41450	20031226
WO04061084 A3	20041104	WO2003US41450	20031226
WO04061084 C1	20041209	WO2003US41450	20031226
WO05024755 A2	20050317	WO2004US11922	20040415
WO05024755 A3	20050421	WO2004US11922	20040415
WO06014290 A2	20060209	WO2005US23100	20050630
WO06014290 A3	20060427	WO2005US23100	20050630
WO06071940 A2	20060706	WO2005US47270	20051223
WO06071940 A3	20090423	WO2005US47270	20051223
WO06081034 A2	20060803	WO2005US47597	20051223
WO06081034 A3	20061123	WO2005US47597	20051223
WO07008917 A2	20070118	WO2006US26920	20060710
WO07008917 A3	20090416	WO2006US26920	20060710
ZA200505266 A	20070425	ZA20050005266	20031226
ZA200505268 A	20070425	ZA20050005268	20031228

Priority:

US20020437304	20021231	US20020437487	20021231	US20020437415	20021231
US20020437487P	20021231	US20020437403P	20021231	US20020437415P	20021231
WO2003US41450	20031226	WO2003US41449	20031226	US20030463804P	20030418
US20030746607	20031224	US20030746460	20031224	US20030746545	20031224
US20020437304P	20021231	US20030437804P	20030103	US20040886329	20040706
WO2005US23100	20050630	US20050318399	20051223	US20040022395	20041223
WO2005US47270	20051223	WO2005US47597	20051223	US20050224750	20050912
US20050224749	20050912	US20060336708	20060120	US20040638987P	20041223
US20040639087P	20041223	US20040638986P	20041223	US20040638968P	20041223
US20050721026	20051223	WO2003US41425	20031226	US20050178834	20050711
US20060541370	20060221	US20060450840	20060609	US20070963740	20071221
US20060450853	20060609	US20060337245	20060120	US20060450850	20060609
US20060450852	20060609	US20060450849	20060609	US20060450842	20060609
US20060450851	20060609	WO2006US26920	20060710		

Probable Assignee: DECIPHERA PHARMACEUTICALS LLC

Assignee(s): (std): DECIPHERA PHARMACEUTICALS INC ; DECIPHERA PHARMACEUTICALS LLC ; FLYNN DANIEL L ; PETRILLO PETER A ; PETILLO PETER A

Assignee(s): M S DECIPHERA PHARMACEUTICALS LLC ; DECIPHERA PHARMACEUTICALS LLC4950 RESEARCH PARK WAYLAWRENCEKS66047US ; BRIGHTSTAR ASSOCIATES LLC

Inventor(s): (std): DANIEL L FLYNN ; DAVID L FLYNN ; FLYNN DAVID L ; PETER A PETILLO ; PETER A PETRILLO ; FLYNN DANIEL L ; FLYNN DANIEL L PETILLO PETER A ; PETILLO PETER A ; PETRILLO PETER A

Inventor(s): PETILLO PETER AUS ; PETRILLO PETER ; FLYNN DANIEL LUS ; PETILLO PETER ; FLYNN DANIEL

Agent(s): UEXKUPELL AND STOLBERG; HOVEY WILLIAMS LLP; WILMERHALE/DECIPHERA PHARMACEUTICALS; WILMERHALE DECIPHERA PHARMACEUTICALS; WILMER CUTLER PICKERING HALE AND DORR LLP; COOLEY LLP; SKOCH GREGORY J

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS

Abstract: Source: US2005009786A The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.


Classifications:

International (IPC 8-9): A61K31/135 A61K31/15 A61K31/185 A61K31/19 A61K31/192 A61K31/195 A61K31/196 A61K31/197 A61K31/198 A61K31/216 A61K31/34 A61K31/341 A61K31/343 A61K31/352 A61K31/381 A61K31/396 A61K31/397 A61K31/40 A61K31/401 A61K31/4025 A61K31/4035 A61K31/404 A61K31/41 A61K31/416 A61K31/4184 A61K31/421 A61K31/422 A61K31/423 A61K31/4245 A61K31/427 A61K31/428 A61K31/435 A61K31/4365 A61K31/437 A61K31/44 A61K31/4406 A61K31/4409 A61K31/4418 A61K31/4427 A61K31/445 A61K31/4453 A61K31/451 A61K31/452 A61K31/4535 A61K31/47 A61K31/472 A61K31/4725 A61K31/495 A61K31/52 A61K31/66 A61K31/675 A61P1/04 A61P1/16 A61P11/00 A61P11/02 A61P11/06 A61P13/12 A61P15/00 A61P17/00 A61P17/04 A61P17/06 A61P17/08 A61P17/14 A61P19/00 A61P19/02 A61P21/04 A61P25/00 A61P25/28 A61P27/02 A61P27/14 A61P27/16 A61P29/00 A61P31/10 A61P31/00 A61P31/04 A61P31/12 A61P31/18 A61P35/00 A61P35/02 A61P37/00 A61P37/02 A61P37/06 A61P37/08 A61P39/02 A61P43/00 A61P51/14 A61P7/04 A61P7/06 A61P9/00 A61P9/04 A61P9/10 C07C C07C207/00 C07C211/27 C07C251/40 C07C251/48 C07C251/50 C07C251/52 C07C251/54 C07C251/60 C07C251/62 C07C317/32 C07C317/36 C07C323/29 C07C323/32 C07C323/63 C07D205/00 C07D205/04 C07D205/12 C07D207/04 C07D207/06 C07D207/12 C07D207/16 C07D209/04 C07D209/44 C07D211/28 C07D211/32 C07D211/34 C07D211/60 C07D213/04 C07D213/30 C07D213/42 C07D213/53 C07D213/55 C07D213/61 C07D213/64 C07D217/00 C07D217/02 C07D217/04 C07D217/12 C07D217/14 C07D217/16 C07D217/18 C07D217/24 C07D231/56 C07D235/18 C07D241/04 C07D261/20 C07D263/56 C07D263/57 C07D263/58 C07D277/64 C07D277/66 C07D295/06 C07D295/08 C07D295/096 C07D307/02 C07D307/10 C07D307/12 C07D307/34 C07D307/40 C07D307/42 C07D307/52 C07D307/54 C07D307/79 C07D311/30 C07D333/04 C07D333/12 C07D333/16 C07D333/20 C07D333/22 C07D333/24 C07D333/50 C07D333/54 C07D333/56 C07D333/58 C07D333/60 C07D333/62 C07D333/64 C07D333/68 C07D401/06 C07D403/06 C07D405/06 C07D409/02 C07D409/06 C07D409/10 C07D413/04 C07D413/06 C07D413/10 C07D417/04 C07D471/04 C07D473/00 C07D493/04 C07D495/02 C07D495/04 C07D498/04 C07D513/04 C07F9/22 C07F9/28 (Advanced/Invention); A61K31/135 A61K31/397 A61K31/445 A61P37/06 C07D241/04 (Advanced/Non-invention); A61K31/00 A61K31/185 A61K31/343 A61K31/352 A61K31/381 A61K31/396 A61K31/397 A61K31/401 A61K31/403 A61K31/41 A61K31/416 A61K31/4164 A61K31/423 A61K31/427 A61K31/428 A61K31/4353 A61K31/4523 A61K31/472 A61K31/519 A61K31/66 A61K31/675 A61P1/00 A61P11/00 A61P13/00 A61P17/00 A61P19/00 A61P21/00 A61P25/00 A61P27/00 A61P29/00 A61P3/00 A61P31/00 A61P35/00 A61P37/00 A61P39/00 A61P43/00 A61P5/00 A61P7/00 A61P9/00 C07C323/00 C07D205/00 C07D207/00 C07D209/00 C07D211/00 C07D217/00 C07D231/00 C07D235/00 C07D241/00 C07D261/00 C07D263/00 C07D277/00 C07D307/00 C07D311/00 C07D333/00 C07D403/00 C07D405/00 C07D409/00 C07D413/00 C07D417/00 C07D471/00 C07D473/00 C07D493/00 C07D495/00 C07D498/00 C07D513/00 C07F9/00 (Core/Invention); C07D241/00 (Core/Non-invention); A61K A61P C07C C07D (Subclass/Invention)

International (IPC 1-7): A61K0/00 A61K31/135 A61K31/15 A61K31/185 A61K31/19 A61K31/195 A61K31/216 A61K31/341 A61K31/343 A61K31/352 A61K31/381 A61K31/397 A61K31/40 A61K31/4035 A61K31/41 A61K31/416 A61K31/4184 A61K31/423 A61K31/428 A61K31/4365 A61K31/44 A61K31/4427 A61K31/445 A61K31/47 A61K31/4725 A61K31/495 A61K31/66 A61K31/675 A61P1/00 A61P13/00 A61P15/00 A61P17/00 A61P19/00 A61P21/00 A61P25/00 A61P27/00 A61P29/00 A61P3/00 A61P31/00 A61P35/00 A61P37/06 C07C251/48 C07C251/52 C07C251/54 C07C323/63 C07D205/04 C07D207/12 C07D207/16 C07D209/44 C07D211/28 C07D211/32 C07D211/60 C07D213/30 C07D213/61 C07D213/64 C07D217/14 C07D221/00 C07D231/56 C07D235/18 C07D241/04 C07D263/52 C07D263/57 C07D263/58 C07D277/66 C07D295/073 C07D307/42 C07D307/52 C07D307/79 C07D309/04 C07D311/30 C07D317/52 C07D333/00 C07D333/16 C07D333/22 C07D333/54 C07D333/60 C07D333/62 C07D333/64 C07D401/06 C07D403/06 C07D405/06 C07D409/06 C07D409/10 C07D413/06 C07D413/10 C07D495/04 C07F9/22 C07F9/28 **CPC:** C07C251/48 C07C251/52 C07C251/54 C07C2101/02 C07C2101/08 C07D207/16 C07D211/60 C07D213/30 C07D213/53 C07D213/61 C07D217/04 C07D295/06 C07D307/10 C07D307/12 C07D307/52 C07D333/12 C07D333/16 C07D333/22 C07D333/54 C07D333/60 C07D333/62 C07D333/64 C07D401/06 C07D403/06 C07D405/06 C07D409/06 C07D409/10 C07D413/06 C07D413/10 C07D471/04 C07D473/00 C07D513/04 **European:** C07C251/48 C07C251/52 C07C251/54 C07C317/32 C07C323/32 C07D205/04 C07D207/16 C07D209/44 C07D211/60 C07D213/30 C07D213/53 C07D213/61 C07D217/04 C07D217/16 C07D217/24 C07D231/56 C07D261/20 C07D263/57 C07D263/58 C07D277/66 C07D295/06 C07D307/10 C07D307/12 C07D307/52 C07D311/28 C07D333/12 C07D333/16 C07D333/22 C07D333/54 C07D333/56 C07D333/58 C07D333/62 C07D403/06 C07D405/06 C07D409/06 C07D413/06 C07D413/10 C07D417/04 C07D471/04 C07D473/00 C07D495/04 C07D498/04 C07D513/04 M07C101/02 M07C101/08 M07C101/14 **US:** 514/114 514/210.01 514/210.17 514/210.170P 514/210.21 514/252.12 514/252.120S 514/301 514/307 514/307S 514/317 514/317S 514/324 514/330 514/330S 514/34 514/340 514/357 514/357S 514/367 514/375 514/381 514/381S 514/403 514/412 514/423 514/423S 514/438 514/438S 514/443 514/456 514/464 514/471 514/471S 514/553 514/553S 514/561 514/561S 514/562 514/562S 514/570 514/570S 514/79 514/79P 514/8 514/80 514/89 514/89S 544/337 544/337S 546/114 546/139 546/147 546/147S 546/213 546/22 546/22S 546/245 546/245S 546/268.4 546/335 546/335S 548/112 548/112S 548/152 548/217 548/252 548/252S 548/360.1 548/452 548/531 548/531S 548/950 548/953 548/953S 549/396 549/462 549/496 549/496S 549/57 549/58 549/77 549/77S 562/102 562/111 562/11S 562/21 562/21S 562/41 562/42 562/426 562/426S 562/42S 562/435 562/435S 562/44 562/440 562/440S 562/44S 562/553

Family:

Publication number	Publication date	Application number	Application date
AR044402 AA	20050914	AR2004P101735	20040519
AR044403 A	20050914	AR2004P101736	20040519
AT537825 E	20120115	AT20040752678T	20040519
AU2004240637 AA	20041202	AU20040240637	20040519
AU2004240649 AA	20041202	AU20040240649	20040519
AU2004249664 AA	20041229	AU20040249664	20040519
AU2004251146 AA	20050106	AU20040251146	20040519
AU2008203087 AA	20080807	AU20080203087	20080711
AU2008203088 AA	20080807	AU20080203088	20080711
AU2009200338 AA	20090219	AU20090200338	20090130
AU2009200338 BB	20111117	AU20090200338	20090130
AU2009200362 AA	20090219	AU20090200362	20090202
AU2009200362 BB	20111201	AU20090200362	20090202
BRPI0410439 A	20060606	BR2004PI10439	20040519
BRPI0410454 A	20060613	BR2004PI10454	20040519
BRPI0410741 A	20060627	BR2004PI10741	20040519
BRPI0410746 A	20060627	BR2004PI10746	20040519
CA2524027 AA	20051027	CA20042524027	20040519
CA2524027 C	20130319	CA20042524027	20040519
CA2524047 AA	20051027	CA20042524047	20040519
CA2524047 C	20130618	CA20042524047	20040519
CA2524048 AA	20051027	CA20042524048	20040519
CA2524048 C	20130625	CA20042524048	20040519
CA2524054 AA	20051027	CA20042524054	20040519
CA2524054 C	20120424	CA20042524054	20040519
CL11192004 A1	20050415	CL20040001119	20040519



CL11202004 A1 20050415 CL20040001120 20040519
CL2004001119 A1 20050415 CL20040001119 20040519
CL2004001120 A1 20050415 CL20040001120 20040519
CN102174042 A 20110907 CN201110063282 20040519
CN102174042 B 20130918 CN201110063282 20040519
CN102875413 A 20130116 CN201210323749 20040519
CN1787817 A 20060614 CN200480013194 20040519
CN1787817 B 20110907 CN200480013194 20040519
CN1791395 A 20060621 CN200480013248 20040519
CN1791395 B 20120926 CN200480013248 20040519
CN1791592 A 20060621 CN200480013950 20040519
CN1791592 B 20120704 CN200480013950 20040519
CN1816544 A 20060809 CN200480018860 20040519
CN1816544 B 20110608 CN200480018860 20040519
DK1638551 T3 20120402 DK20040752678T 20040519
ECSPO56148 A 20060419 EC2005SP06148 20051110
EP1628967 A1 20060301 EP20040752679 20040519
EP1628967 A4 20110427 EP20040752679 20040519
EP1628967 B1 20140409 EP20040752679 20040519
EP1633336 A2 20060315 EP20040752597 20040519
EP1633336 A4 20081029 EP20040752597 20040519
EP1638551 A2 20060329 EP20040752678 20040519
EP1638551 A4 20081231 EP20040752678 20040519
EP1638551 B1 20111221 EP20040752678 20040519
EP1644367 A1 20060412 EP20040752676 20040519
EP1644367 A4 20081231 EP20040752676 20040519
EP2514743 A1 20121024 EP20110183758 20040519
EP2644195 A1 20131002 EP20130173514 20040519
ES2379169 T3 20120423 ES20040752678T 20040519
ES2467160 T3 20140612 ES20040752679T 20040519
HK1087929 A3 20061027 HK20060108361 20060727
HK1090559 A1 20120713 HK20060111346 20061017
HK1090559 A3 20061229 HK20060111346 20061017
HK1090639 A1 20130412 HK20060111345 20061017
HK1090639 A3 20061229 HK20060111345 20061017
HK1093490 A3 20070302 HK20060111247 20061012
IL171683 A0 20060312 IL20050171683 20051031
IL171683 A1 20140731 IL20050171683 20051031
IN00599CN2009 A 20090605 IN2009CN00599 20090202
IN01045CN2009 A 20090605 IN2009CN01045 20090224
IN01047CN2009 A 20090529 IN2009CN01047 20090225
IN01064CN2009 A 20090529 IN2009CN01064 20090225
IN03049CN2005 A 20070914 IN2005CN03049 20051118
IN03053CN2005 A 20070914 IN2005CN03053 20051118
IN03054CN2005 A 20070914 IN2005CN03054 20051118
IN03060CN2005 A 20070914 IN2005CN03060 20051118
IN234286 B 20090612 IN2005CN03053 20051118
IN234287 B 20090612 IN2005CN03060 20051118
IN234288 B 20090612 IN2005CN03054 20051118
IN234776 B 20090717 IN2005CN03049 20051118
IS8153 A 20051128 IS20050008153 20051128
JP2006528698 T2 20061221 JP20060533220T 20040519
JP2006528987 T2 20061228 JP20060533219T 20040519
JP2007501860 T2 20070201 JP20060533218T 20040519
JP2007503468 T2 20070222 JP20060533199T 20040519
JP2011012069 A2 20110120 JP20100185021 20100820
JP4575920 B2 20101104 JP20060533219T 20040519
JP4700616 B2 20110615 JP20060533199T 20040519
JP4728962 B2 20110720 JP20060533218T 20040519
JP4944613 B2 20120606 JP20060533220T 20040519
KR101118779 B1 20120320 KR20057022058 20040519
KR20060017797 A 20060227 KR20057022058 20040519
MA27807 A1 20060301 MA20050028608 20051115
MXPA05012459 A1 20060222 MX2005PA12459 20051118
MXPA05012460 A1 20060525 MX2005PA12460 20051118
MXPA05012461 A1 20060222 MX2005PA12461 20051118
MXPA05012462 A1 20060222 MX2005PA12462 20051118
MY150088 A 20131129 MY20040001871 20040518
NO20055837 A 20060217 NO20050005837 20051208
NO20055837 A0 20051208 NO20050005837 20051208
NO334457 B1 20140310 NO20050005837 20051208
NZ543241 A 20090531 NZ20040543241 20040519
PE01582005 A1 20050512 PE20040000514 20040519
PE06262005 A1 20050923 PE20040000513 20040519
PT1638551 T 20120328 PT20040752678T 20040519
RU2005139526 A 20060727 RU20050139526 20040519
RU2009132108 A 20110310 RU20090132108 20090826
RU2405768 C2 20101210 RU20050139526 20040519
SI1638551 T1 20120430 SI20040031832T 20040519
TH71665 A 20051103 TH20041001723 20040514
TH71666 A 20051103 TH20041001724 20040514
TW200505428 A 20050216 TW20040114151 20040519
TW200505442 A 20050216 TW20040114152 20040519
TWI355931 B 20120111 TW20040114151 20040519
US2005009786 AA 20050113 US20040849450 20040519
US2005014724 AA 20050120 US20040849079 20040519
US2005014725 AA 20050120 US20040849458 20040519
US2005014728 AA 20050120 US20040849323 20040519
US2009036423 AA 20090205 US20080024992 20080201
US2009131400 AA 20090521 US20080180479 20080725
US7060697 BB 20060613 US20040849079 20040519

US7417065 BB	20080826	US20040849458	20040519
US7462629 BB	20081209	US20040849450	20040519
US7750021 BB	20100706	US20080180479	20080725
US7939519 BB	20110510	US20080024992	20080201
WO04103306 A2	20041202	WO2004US15603	20040519
WO04103306 A3	20050303	WO2004US15603	20040519
WO04103309 A2	20041202	WO2004US15701	20040519
WO04103309 A3	20050303	WO2004US15701	20040519
WO04113330 A1	20041229	WO2004US15699	20040519
WO04113330 C1	20060330	WO2004US15699	20040519
WO05000833 A1	20050106	WO2004US15702	20040519
ZA200508203 A	20070228	ZA20050008203	20051011

Priority:

US20030471931P	20030519	US20030471931	20030519	US20040561968P	20040414
US20030471931	20030519	US20030471931	20030519	US20030471931	20030519
US20040471931P	20040414	US20040562183P	20040414	US20040849450	20040519
US20040849079	20040519	US20040849458	20040519	US20040849323	20040519
WO2004US15603	20040519	US20040562182P	20040414	WO2004US15701	20040519
WO2004US15699	20040519	WO2004US15702	20040519	AU20040240637	20040519
AU20080203087	20080711	AU20040240649	20040519	AU20080203088	20080711
US20080024992	20080201	AU20040249664	20040519	AU20040251146	20040519
US20080180479	20080725	JP20060533199	20040519	EP20040752678	20040519
EP20040752597	20040519	RU20050139526	20051219	EP20040752679	20040519
AU20090200362	20090202	AU20090200338	20090130		

Probable Assignee: IRM LLC

Assignee(s): (std): IRM LLC ; PAN SHIFENG ; GRAY NATHANAEL S ; MI YUAN ; MARSILJE THOMAS H ; JIANG TAO ; LU WENSHUO ; AJRM LLK ; FAN YI ; GAO WENQI ; IRM LLC A DELAWARE LTD LIABILI ; GENOMICS INST OF THE NOVARTIS RES FOUNDATION ; NOVARTIS AG ; YUAN MI

Assignee(s): GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDA ; GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION ; IRM LLC A DELAWARE LIMITED LIABILITY COMPANY ; IRM LLC OF HURST HOLME ; IRM LLC ; MI YUAN ; GENOMICS INST OF NOVARTIS RESEARCH FOUNDATION ; IRM LLC A DELAWARE LIABILITY CO LTD

Inventor(s): (std): FAN YI ; GAO VEHN TSI ; GAO WENGI ; GAO WENQI ; GRAY NATHANAEL ; GRAY NATHANAEL S ; GRAY NATHANAEL SCHIANDER ; GRAY NATHANEL S ; GREJ NATANAEHL S ; I FAN ; JIANG TAO ; LU WENSHUO ; MARSILJE THOMAS ; MARSILJE THOMAS H ; SHIFENG MARSILJE THOMAS H GRAY ; TAO MI YUAN PAN SHIFENG GRAY N ; WENQI GRAY NATHANAEL S PAN SHI ; YI PAN SHIFENG GAO WENQI GRAY ; YUAN MI ; YI FAN ; WENSHUO LU ; WENQI GAO ; THOMAS H MARSILJE ; TAO JIANG ; SHIFENG PAN ; NATHANAEL S GRAY ; MI YUAN ; MI JUAN ; PAN SHIFEN ; PAN SHIFENG ; FAN YI GAO WENQI JIANG TAO MI

Inventor(s): PAN SHIFENG GAO WENQI GRAY NATHANAEL S ; PAN SHIFENG GAO WENQI GRAY NATHANAEL S MI YUAN FAN ; PAN' SHIFEN ; MI JUAN' ; MI YUAN PAN SHIFENG GRAY NATHANAEL S ; MI YUAN PAN SHIFENG GRAY NATHANAEL S GAO WENQI FAN ; MI YUNA ; PAN SHI FENG ; FAN YI GAO WENQI JIANG TAO MI YUAN PAN SHIFENGPAN SHIFENG GRAY NATHANAEL S ; FAN YI GAO WENQI JIANG TAO MI YUAN PAN SHIFENG GRAY NATHANAEL S ; FAN YI GAO WENQI JIANG TAO MI YUAN PAN SHIFENG ; FAN YI GAO WENQI JIANG TAO MI YUAN PAN ; MARSILJE THOMAS H GRAY NATHANAEL S JIANG TAO LUWEN ; I. FAN' ; GREJ NATANAEHL' S. ; GRAY NATHANEL ; GAO VEHN'TSI ; GAO WEN QI

Agent(s): AECHTER BERND; HILLEBRAND DIRK; HUTCHISON JOHN ROBERT; TER MEER STEINMEISTER AND PARTNER; GENOMICS INST OF NOVARTIS RESEARCH FOUNDATION; NOVARTIS,CORPORATE INTELLECTUAL PROPERTY; NOVARTIS CORPORATE INTELLECTUAL PROPERTY; GENOMICS INSTITUTE OF THE,NOVARTIS RESEARCH FOUNDATION; SCOTT W; REID SCOTT W; PHIL D; D; KAREN; JENNIFER CHIN; COZETTE M

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NA NE NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: INHIBITORS OF AKT ACTIVITY

Abstract: Source: US2008255143A Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.


Classifications:

International (IPC 8-9): A01N43/42 A01N43/54 A61K31/437 A61K31/44 A61K31/4439 A61K31/4545 A61K31/496 A61K31/4965 A61K31/497 A61K31/505 A61K31/506 A61K31/5377 A61K31/551 A61P19/02 A61P35/00 A61P43/00 C07D401/00 C07D403/00 C07D405/00 C07D409/00 C07D411/00 C07D413/00 C07D471/04 (Advanced/Invention); A61K31/4965 C07D471/04 (Advanced/Non-invention); A01N43/34 A01N43/48 A61K31/4353 A61K31/44 A61K31/4427 A61K31/4523 A61K31/496 A61K31/4965 A61K31/505 A61K31/506 A61K31/5375 A61K31/551 A61P19/00 A61P35/00 A61P43/00 C07D401/00 C07D403/00 C07D405/00 C07D409/00 C07D411/00 C07D413/00 C07D471/00 (Core/Invention); A01N A61K C07D (Subclass/Invention)

International (IPC 1-7): A01N41/42 A01N43/42 A01N43/54 A61K31/4188 A61K31/437 A61K31/44 A61K31/4965 A61K31/505 A61P19/02 A61P35/00 C07D213/00 C07D235/00 C07D271/08 C07D401/00 C07D403/00 C07D405/00 C07D409/00 C07D411/00 C07D413/00 C07D471/04

CPC: C07D471/04
European: C07D471/04

US: 514/253.04 514/253.040P 514/303 514/303S 544/362 544/362S 546/118 546/118S



Family:

Publication number	Publication date	Application number	Application date
AR045134 AA	20051019	AR2004P102668	20040727
AU2004261214 AA	20050210	AU20040261214	20040728
BRPI0412993 A	20061003	BR2004P112993	20040728
CA2534038 AA	20060127	CA20042534038	20040728
CN1859912 A	20061108	CN200480028355	20040728
CO5640140 A2	20060531	CO20060007246	20060126
EP1653961 A1	20060510	EP20040779406	20040728
EP1653961 A4	20090401	EP20040779406	20040728
HK1090297 A3	20061222	HK20060111079	20061009
IL173174 A0	20060611	IL20060173174	20060116
IN00264DN2006 A	20070810	IN2006DN00264	20060116
IS8322 A	20060222	IS20060008322	20060222
JP2007500709 T2	20070118	JP20060522030T	20040728
KR20060066714 A	20060616	KR20067002022	20060127
MA27933 A1	20060601	MA20060028757	20060127
MXPA06001134 A1	20060411	MX2006PA01134	20060127
NO20060985 A	20060419	NO20060000985	20060228
RU2006106193 A	20060827	RU20060106193	20040728
TH73842 A	20051222	TH20041002856	20040726
TW200523262 A	20050716	TW20040122340	20040727
US2008255143 AA	20081016	US20040565329	20040728
WO05011700 A1	20050210	WO2004US24340	20040728
ZA200600466 A	20070530	ZA20060000466	20060117

Priority:

US20030490851P	20030729	US20030490851	20030729	US20030491055P	20030730
US20030493101P	20030806	US20030494752P	20030813	US20030507014P	20030929
US20030530847P	20031218	WO2004US24340	20040728	US20040565329	20040728
WO2004US24340	20040729				

Probable Assignee: SMITHKLINE BEECHAM CORP

Assignee(s): (std): HEERDING DIRK A ; LEBER JACK DALE ; SMITHKLINE BEECHAM CORP ; SAFONOV IGOR ; YAMASHITA DENNIS S ; SMITHKLINE BEECHAM PLC ; CLARK TAMMY J ; DREWRY DAVID H

Assignee(s): GLAXOSMITHKLINE LLC

Inventor(s): (std): CLARK TAMMY J ; DAVID DREWRY H ; DAVID H DREWRY ; DENNIS S YAMASHITA ; DIRK A HEERDING ; DIRK HEERDING A ; DREWRY DAVID H ; DREWRY DAVID HAROLD ; HEERDING DIRK ; HEERDING DIRK A ; HEERDING DIRK A CLARK TAMMY J ; IGOR SAFONOV ; JACK DALE LEBER ; LEBER JACK D ; LEBER JACK DALE ; SAFONOV IGOR ; TAMMY CLARK J ; TAMMY J CLARK ; YAMASHITA DENNIS ; YAMASHITA DENNIS S ; SHINJI YAMASHITA DENNIS ; DALE LEBER JACK


Inventor(s): YAMASHITA DENNIS SHINJI ; HEERDING DIRK A CLARK TAMMY J DREWRY DAVID H LEBER

Agent(s): SMITHKLINE BEECHAM CORPORATE INTELLECTUAL PROPERTY US UW2220 CORP

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NA NE NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Title: GEOMETRICALLY RESTRICTED 3-CYCLOPENTYLIDENE-1,3-DIHYDROINDOL-2-ONES AS POTENT PROTEIN TYROSINE KINASE INHIBITORS

Abstract: Source: US2005038066A The present invention relates to certain sulfonamido-substituted geometrically restricted indolinones of the



formula:

•
• wherein R₁ -R₁₂ and X are variables defined herein. The sulfonamido-substituted geometrically restricted indolinones of the preferred embodiments of the present invention modulate the activity of protein kinases ("PKs"). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Classifications:

International (IPC 8-9): A61K31/404 A61K31/405 A61K31/4745 A61P17/06 A61P19/02 A61P19/04 A61P29/00 A61P3/10 A61P35/00 A61P37/00 A61P37/06 A61P43/00 A61P9/00 A61P9/10 C07D209/34 C07D209/42 C07D209/52 C07D209/94 C07D403/04 C07D403/06 C07D403/10 C07D403/14 C07D471/02 C07D471/04 C09B7/02 C09B7/04 C09B71/02 C09B71/04 (Advanced/Invention); C07D (Subclass/Invention)


International (IPC 1-7): A61K31/404 A61K31/4745 C07D403/04 C07D43/02 C07D471/02

CPC: C07D209/34 C07D209/42 C07D403/06 C07D403/14 C07D471/04

European: C07D209/34 C07D209/42 C07D403/06 C07D403/14 C07D471/04

US: 514/300 514/414 514/414S 546/113 546/113S 548/455 548/455S 548/457 548/459

PatBase - US2005038066_A1



Family:

Publication number	Publication date	Application number	Application date
BRPI0413281 A	20061010	BR2004PI13281	20040805
CA2534509 AA	20060201	CA20042534509	20040805
EP1653946 A2	20060510	EP20040778023	20040805
EP1653946 A4	20070404	EP20040778023	20040805
JP2007501229 T2	20070125	JP20060522567T	20040805
US2005038066 AA	20050217	US20040911637	20040805
US7105562 BB	20060912	US20040911637	20040805
WO05016875 A2	20050224	WO2004US22310	20040805
WO05016875 A3	20050728	WO2004US22310	20040805

Priority:

US20030492782P 20030806 US20040911637 20040805 WO2004US22310 20040805

Probable Assignee: SUGEN INC

Assignee(s): (std): CUI JINGRONG ; SUGEN INC ; TANG PENG CHO ; WEI CHUNG CHEN ; ZHANG FANG JIE

Inventor(s): (std): ZHANG FANG JIE ; WEI CHUNG CHEN ; TANG PENG CHO ; PENG CHO TANG ; JINGRONG CUI ; FANG JIE ZHANG ; CUI JINGRONG ; CHUNG CHEN WEI

Inventor(s): TANG PENG

Agent(s): FOLEY AND LARDNER SUITE 500; VINCENT P; BRYAN C

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NA NE NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof

Abstract: Source: US2005085531A Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed.

Classifications:


International (IPC 8-9): A61K31/33 A61K31/381 A61K31/4025 A61K31/4035 A61K31/404 A61K31/41 A61K31/4155 A61K31/4196 A61K31/422 A61K31/4245 A61K31/427 A61K31/429 A61K31/4365 A61K31/437 A61K31/439 A61K31/4439 A61K31/4535 A61K31/455 A61K31/4709 A61K31/4745 A61K31/496 A61K31/515 A61K31/519 A61K31/53 A61K31/5377 A61K31/541 A61K31/55 A61P1/04 A61P11/06 A61P13/12 A61P17/00 A61P17/02 A61P17/06 A61P17/08 A61P19/02 A61P21/04 A61P25/00 A61P25/16 A61P25/28 A61P27/02 A61P27/06 A61P29/00 A61P3/00 A61P3/04 A61P3/10 A61P31/00 A61P31/04 A61P31/10 A61P31/12 A61P35/00 A61P35/02 A61P37/00 A61P37/06 A61P37/08 A61P43/00 A61P9/00 A61P9/10 A61P9/14 C07D249/02 C07D333/36 C07D333/38 C07D333/40 C07D333/50 C07D333/66 C07D333/68 C07D333/78 C07D333/80 C07D409/04 C07D409/12 C07D409/14 C07D413/12 C07D417/12 C07D471/04 C07D487/04 C07D493/08 C07D495/04 C07D495/18 C07D513/04 C07D513/12 (Advanced/Invention)

International (IPC 1-7): A61K31/33 A61K31/381 A61P25/28 A61P29/00 A61P29/00 A61P31/0 A61P35/00 A61P35/00 C07D333/36 C07D333/38 C07D333/40 C07D333/68 C07D409/04 C07D409/12 C07D409/14 C07D413/12 C07D417/12 C07D487/04 C07D49/02 C07D495/04 C07D495/18 C07D513/04

CPC: C07D249/02 C07D333/36 C07D333/38 C07D333/66 C07D333/68 C07D333/78 C07D333/80 C07D409/04 C07D409/12 C07D409/14 C07D413/12 C07D417/12 C07D471/04 C07D487/04 C07D495/04 C07D513/04

European: C07D249/02 C07D333/36 C07D333/38 C07D333/66 C07D333/68 C07D333/78 C07D333/80 C07D409/04 C07D409/12 C07D409/14 C07D413/12 C07D417/12 C07D471/04 C07D487/04 C07D495/04 C07D495/18 C07D513/04

US: 514/444 514/447 514/447S 549/59 549/59S 549/61 549/61S 549/65 549/65S



Family:

Publication number	Publication date	Application number	Application date
EP1670791 A2	20060621	EP20040794006	20041001
JP2007507530 T2	20070329	JP20060534167T	20041001
US2005085531 AA	20050421	US20040957570	20040930
WO05033102 A2	20050414	WO2004US32448	20041001
WO05033102 A3	20050728	WO2004US32448	20041001

Priority:
US20030508393P 20031003 US20040957570 20040930 WO2004US32448 20041001

Probable Assignee: AGRIUS GROUP LLC

Assignee(s): (std): HODGE CARL NICHOLAS ; JANZEN WILLIAM P ; WILLIAMS KEVIN PETER ; AMPHORA DISCOVERY CORP ; CHEATHAM LYNN A

Assignee(s): HODGE CARL N ; AGRIUS GROUP LLC ; WILLIAMS KEVIN P ; SQUARE ; SQUARE 1 BANK

Inventor(s): (std): CHEATHAM LYNN A ; HODGE CARL N ; HODGE CARL NICHOLAS ; JANZEN WILLIAM P ; WILLIAMS KEVIN P ; WILLIAMS KEVIN PETER

Agent(s): FINNEGAN HENDERSON FARABOW GARRETT AND DUNNER, LLP

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NA NE NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: Compounds and compositions as protein kinase inhibitors

Abstract: Source: US2005187230A The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGFbeta, SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2beta kinases.

Classifications:
International (IPC 8-9): A61K31/4375 A61K31/44 A61K31/444 A61K31/47 A61K31/4704 A61K31/4706 A61K31/4745 A61K31/496 A61K31/497 A61K31/501 A61K31/513 A61K31/519 A61K31/5377 A61P11/00 A61P11/06 A61P17/06 A61P19/02 A61P29/00 A61P35/00 A61P35/02 A61P37/02 A61P37/06 A61P43/00 A61P7/02 A61P9/08 A61P9/10 C07D215/16 C07D215/24 C07D215/38 C07D251/38 C07D471/00 C07D471/02 C07D471/04 (Advanced/Invention); C07D215/24 (Advanced/Non-invention); A61K (Subclass/Invention)
International (IPC 1-7): A61K A61K31/44 A61K31/47 A61K31/4706 A61K31/4745 A61K31/514 A61K31/519 C07D215/16 C07D471/00 C07D471/02
CPC: C07D471/04
European: C07D471/04
US: 514/264.1 514/264.100 514/299 514/300 514/312 544/224 544/279 546/123 546/153 546/157

PatBase - CA2542105_C

(I)

Family:

Publication number	Publication date	Application number	Application date
AU2004279427 AA	20050421	AU20040279427	20041008
AU2004279427 BB	20080703	AU20040279427	20041008
BRPI0415210 A	20061205	BR2004PI15210	20041008
CA2542105 AA	20060407	CA20042542105	20041008
CA2542105 C	20110802	CA20042542105	20041008
CN1863774 A	20061115	CN200480029422	20041008
CN1863774 B	20101215	CN200480029422	20041008
EP1673343 A2	20060628	EP20040794382	20041008
EP1673343 A4	20080910	EP20040794382	20041008
IN01179CN2006 A	20070817	IN2006CN01179	20060405
JP2007508310 T2	20070405	JP20060534312T	20041008
JP4758349 B2	20110824	JP20060534312T	20041008
MXPA06003996 A1	20060705	MX2006PA03996	20060407
US2005187230 AA	20050825	US20040961646	20041008
US7449582 BB	20081111	US20040961646	20041008
WO05034869 A2	20050421	WO2004US33009	20041008
WO05034869 A3	20050707	WO2004US33009	20041008

Priority:

US20030509572 20031008 US20030509572P 20031008 WO2004US33009 20041008

US20040961646 20041008

Probable Assignee: IRM LLC

Assignee(s): (std): CHOPIUK GREG ; DING QIANG ; GRAY NATHANAEL SCHIANDER ; IRM LLC ; JIANG JIQING ; XIE YONGPING ; YOU SHULI ; LIU YI ; STEENSMA RUO ; WANG XING ; SIM TAEBO

Inventor(s): (std): GRAY NATHANAEL S ; GREG CHOPIUK ; JIQING JIANG ; NATHANAEL SCHIANDER GRAY ; QIANG DING ; RUO STEENSMA ; SHULI YOU ; TAEBO SIM ; XING WANG ; YI LIU ; YONGPING XIE ; YOU SHULI ; XIE YONGPING ; WANG XING ; STEENSMA RUO ; SIM TAEBO ; LIU YI ; JIANG JIQING ; GRAY NATHANAEL SCHIANDER ; DING QIANG ; CHOPIUK GREG ; WA DING QIANG XIE YONGPING GRA

Inventor(s): DING QIANG XIE YONGPING GRAY NATHANAEL S YOU SHULI ; DING QIANG XIE YONGPING GRAY NATHANAEL S

Agent(s): GENOMICS INSTITUTE OF THE, NOVARTIS RESEARCH FOUNDATION; REID SCOTT W; GENOMICS INST OF NOVARTIS RESEARCH FOUNDATION; SCOTT W

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NA NE NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: Pyridopyrimidinones

Abstract: Source: US2007099910A The invention relates to compounds of formula (I) wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, X and X' have the designations cited in patent claim 1. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumours.

Classifications:


International (IPC 8-9): A61K31/519 A61K31/5355 A61K31/5377 A61K31/541 A61P1/16 A61P13/12 A61P15/00 A61P17/00 A61P17/06 A61P19/02 A61P19/08 A61P25/28 A61P27/02 A61P29/00 A61P3/10 A61P35/00 A61P37/02 A61P37/06 A61P37/08 A61P43/00 A61P9/00 A61P9/10 C07D413/12 C07D471/04 C07D487/02 (Advanced/Invention); A61P35/00 (Advanced/Non-invention); A61K31/519 A61P1/00 A61P13/00 A61P15/00 A61P17/00 A61P19/00 A61P25/00 A61P27/00 A61P29/00 A61P3/00 A61P35/00 A61P37/00 A61P43/00 A61P9/00 C07D471/00 (Core/Invention)

International (IPC 1-7): A61K31/519 A61P35/00 C07D221/00 C07D239/00 C07D471/04

CPC: C07D471/04

European: C07D471/04

US: 514/227.8 514/227.800P 514/232.8 514/234.2 514/234.5 514/234.500S 514/252.16 514/252.160S 514/264.11 514/264.110S 544/117 544/120 544/120S 544/279 544/279S 544/60 544/60S



Family:

Publication number	Publication date	Application number	Application date
AR046929 AA	20060104	AR2004P104173	20041112
AT443704 E	20091015	AT20040790407T	20041014
AU2004288727 AA	20050526	AU20040288727	20041014
CA2545558 AA	20060511	CA20042545558	20041014
DE10352979 A1	20050609	DE20031052979	20031113
DE502004010131 D1	20091105	DE200450010131T	20041014
EP1682548 A1	20060726	EP20040790407	20041014
EP1682548 B1	20090923	EP20040790407	20041014
ES2332319 T3	20100202	ES20040790407T	20041014
JP2007510679 T2	20070426	JP20060538680T	20041014
US2007099910 AA	20070503	US20040579222	20041014
US7547695 BB	20090616	US20040579222	20041014
WO05047283 A1	20050526	WO2004EP11549	20041014

Priority:
DE20031052979 20031113 WO2004EP11549 20041014

Probable Assignee: MERCK PATENT GMBH

Assignee(s): (std): MERCK PATENT GMBH ; STAEHLE WOLFGANG ; RAUTENBERG WILFRIED ; MITJANS FRANCESC ; ROSELL VIVES ELISABET ; SOLER RIERA MARTA ; ACKERMANN KARL AUGUST ; ADAN JAUME ; CRASSIER HELENE ; HOELZEMANN GUENTER ; JONCZYK ALFRED

Assignee(s): MERCK PATENT GES MIT BESCHRAENKTER HAFTUNG ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUN ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG

Inventor(s): (std): CRASSIER HELENE ; HOELZEMANN GUENTER ; HOELZEMANN GUENTER DR ; HOELZEMANN GUENTHER ; HOLZEMANN GUNTER ; JONCZYK ALFRED ; JONCZYK ALFRED DR ; MITJANS FRANCESC ; RAUTENBERG WILFRIED ; RAUTENBERG WILFRIED DR ; RIERA MARTA SOLER ; ROSELL VIVES ELISABET ; SOLER MARTA ; SOLER RIERA MARTA ; STAEHLE WOLFGANG ; STAEHLE WOLFGANG DR ; STAHL WOLFGANG ; ACKERMANN KARL AUGUST ; ADAN JAUME

Inventor(s): ALFRED JONCZYK ; WILFRIED RAUTENBERG ; WOLFGANG STAHL ; KARL AUGUST ACKERMANN ; MARTA SOLER RIERA ; JAUME ADAN ; DR HOELZEMANN GUENTER ; DR JONCZYK ALFRED ; DR RAUTENBERG WILFRIED ; DR STAEHLE WOLFGANG ; ELISABET ROSELL VIVES ; FRANCESC MITJANS ; GUNTER HOLZEMANN ; HELENE CRASSIER

Agent(s): RONALD J KAMIS BAKER AND DANIELS; ARENT FOX LLP

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NA NE NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: AMIDE DERIVATIVES AS ABL MODULATORS

Abstract: Source: US2005148605A The invention provides methods and compositions for treating conditions mediated by abl wherein derivatives of amide compounds are employed. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects.

Classifications:
International (IPC 8-9): A61K31/17 A61K31/23 A61K31/235 A61K31/38 A61K31/381 A61K31/41 A61K31/415 A61K31/4155 A61K31/4162 A61K31/4188 A61K31/42 A61K31/422 A61K31/4245 A61K31/426 A61K31/428 A61K31/429 A61K31/43 A61K31/433 A61K31/437 A61K31/4375 A61K31/44 A61K31/4402 A61K31/4406 A61K31/4409 A61K31/4453 A61K31/47 A61K31/4709 A61K31/4725 A61K31/4745 A61K31/49 A61K31/495 A61K31/496 A61K31/4965 A61K31/497 A61K31/50 A61K31/501 A61K31/502 A61K31/5025 A61K31/503 A61K31/506 A61K31/51 A61K31/513 A61K31/517 A61K31/519 A61K31/52 A61K31/53 A61K31/5375 A61K31/5377 A61K31/54 A61K31/541 A61P11/00 A61P11/08 A61P35/00 A61P35/02 A61P43/00 A61P9/10 C07D211/16 C07D211/22 C07D213/75 C07D215/14 C07D215/38 C07D217/16 C07D221/04 C07D231/12 C07D231/40 C07D237/28 C07D239/26 C07D241/12 C07D261/06 C07D261/08 C07D261/14 C07D261/18 C07D277/20 C07D277/32 C07D277/46 C07D277/48 C07D277/82 C07D295/20 C07D403/04 C07D403/12 C07D405/12 C07D413/00 C07D413/02 C07D413/04 C07D413/12 C07D413/14 C07D417/12 C07D417/14 C07D455/02 C07D471/04 C07D471/06 C07D473/10 C07D473/34 C07D487/04 C07D495/04 C07D513/04 C07D513/14 (Advanced/Invention); A61K31/422 A61K31/426 A61K31/429 A61K31/4353 A61K31/4375 A61K31/4402 A61K31/4412 A61K31/443 A61K31/47 A61P29/00 A61P35/02 A61P35/04 A61P9/00 C07D231/50 C07D285/06 C07D285/14 C07D333/38 C07D333/68 C07D405/04 C07D409/04 C07D498/04 (Advanced/Non-invention); A61K31/38 A61K31/41 A61K31/43 A61K31/49 A61K31/50 A61K31/51 A61K31/54 (Core/Invention); C07D405/00 (Core/Non-invention); A61K (Subclass/Invention)
International (IPC 1-7): A61K31/415 A61K31/42 A61K31/47 A61K31/4709 A61K31/4745 A61K31/503 A61K31/517 A61K31/519 A61K31/52 C07D215/38 C07D233/64 C07D261/06 C07D413/00 C07D413/02 C07D473/10 C07D487/04
CPIC: A61K31/42 C07D231/12 C07D231/40 C07D261/08 C07D261/14 C07D261/18 C07D277/46 C07D277/82 C07D405/12 C07D413/04 C07D413/12 C07D413/14 C07D417/12 C07D417/14 C07D471/04 C07D471/06 C07D487/04 C07D495/04 C07D513/04
European: A61K31/42 C07D231/12 C07D231/40 C07D261/08 C07D261/14 C07D261/18 C07D277/46 C07D277/82 C07D405/12 C07D413/04 C07D413/12 C07D413/14 C07D417/12 C07D417/14 C07D471/04 C07D471/06 C07D487/04 C07D495/04 C07D513/04
US: 514/232.2 514/235.2 514/235.200S 514/248 514/255.05 514/256 514/263.2 514/263.200P 514/263.200S 514/265.1 514/265.100S 514/266.2 514/266.200P 514/266.200S 514/266.23 514/266.230S 514/270 514/272 514/274 514/294 514/299 514/300 514/300S 514/303 514/307 514/314 514/314S 514/340 514/365 514/366 514/378 514/378S 544/122 544/234 544/234S 544/236 544/238 544/277 544/277S 544/284 544/284S 544/300 544/310 544/316 544/321 544/328 544/405 546/112 546/122 546/122S 546/123 546/135 546/145 546/169 546/169S 546/272.1 546/94 548/151 548/204 548/245 548/245S 548/246 548/247

Family:

Publication number	Publication date	Application number	Application date
AU2004291147 AA	20050602	AU20040291147	20041115
CA2545711 AA	20060511	CA20042545711	20041115
EP1684762 A2	20060802	EP20040811122	20041115
EP1684762 A4	20090617	EP20040811122	20041115
JP2007512255 T2	20070517	JP20060539991T	20041115
US2005148605 AA	20050707	US20040989745	20041115
US2005165024 AA	20050728	US20040989824	20041115
US2005165031 AA	20050728	US20040989814	20041115
US2005165074 AA	20050728	US20040990007	20041115
US2005171171 AA	20050804	US20040989766	20041115
US2005171172 AA	20050804	US20040989823	20041115
US2005192314 AA	20050901	US20040990195	20041115
US2005197371 AA	20050908	US20040990194	20041115
US2005261315 AA	20051124	US20040989623	20041115
US2005267182 AA	20051201	US20040989717	20041115
US2010173917 AA	20100708	US20100714331	20100226
US7750160 BB	20100706	US20040989824	20041115
US7767670 BB	20100803	US20040989623	20041115
WO05048948 A2	20050602	WO2004US38288	20041115
WO05048948 A3	20050728	WO2004US38288	20041115
WO05048953 A2	20050602	WO2004US38433	20041115
WO05048953 A3	20060223	WO2004US38433	20041115

Priority:
US20030520273P 20031113 US20030527094P 20031203 US20030531243P 20031218
US20040989623 20041115 WO2004US38288 20041115 US20040989717 20041115
US20040989766 20041115 US20030531082P 20031218 US20040990194 20041115
US20100714331 20100226 US20040989823 20041115 US20040990007 20041115
US20040989814 20041115 US20040989824 20041115 US20040990195 20041115
US20040989745 20041115

Probable Assignee: AMBIT BIOSCIENCES CORP
Assignee(s): (std): AMBIT BIOSCIENCES CORP ; ANDILIY LAI G ; GROTZFELD ROBERT M ; LAI ANDILIY G ; MILANOV ZDRAVKO V ; PATEL HITESH K ; MEHTA SHAMAL A ; LOCKHART DAVID J
Assignee(s): HORIZON TECHNOLOGY FUNDING CO ; HORIZON TECHNOLOGY FUNDING CO LLC
Inventor(s): (std): ANDILIY LAI G ; GROTZFELD ROBERT M ; LAI ANDILIY G ; LAI ANDILLY G ; LOCKHART DAVID J ; PATEL HITESH K ; PATEL HITEST K ; ZDRAVKO V MILANOV ; SHAMAL A MEHTA ; ROBERT M GROTZFELD ; HITESH K PATEL ; DAVID J LOCKHART ; ANDILIY G LAI ; MEHTA SHAMAL A ; MILANOV ZDRAVKO V ; MILANOV ZDRAVKOE V
Inventor(s): PATEL HITESH ; MILANOV ZDRAVKO ; MEHTA SHAMAL ; LOCKHART DAVID ; LAI ANDILIY ; GROTZFELD ROBERT
Agent(s): WILSON SONSINI GOODRICH AND ROSATI ; JONES DAY
Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NA NE NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Abstract: Source: US2005209269A Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

Classifications:
International (IPC 8-9): A61K31/437 A61K31/44 A61K31/4545 A61K31/496 A61K45/00 A61P11/00 A61P13/08 A61P13/12 A61P15/00 A61P17/00 A61P17/06 A61P17/14 A61P19/00 A61P19/02 A61P19/04 A61P21/00 A61P25/00 A61P25/28 A61P31/12 A61P31/18 A61P35/00 A61P35/02 A61P35/04 A61P37/00 A61P37/06 A61P43/00 A61P5/00 A61P9/10 A61P9/14 C07D471/02 C07D471/04 C07D498/02 C12N9/99 C40B40/04 (Advanced/Invention);
A61K31/437 A61K31/4545 A61K31/496 A61P13/08 A61P13/12 A61P17/06 A61P19/02 A61P19/04 A61P25/28 A61P31/12 A61P31/18 A61P35/00 A61P35/02 A61P35/04 A61P37/00 A61P43/00 A61P9/10 (Advanced/Non-invention);
A61K31/4353 A61K31/4523 A61K31/496 A61P13/00 A61P17/00 A61P19/00 A61P25/00 A61P31/00 A61P35/00 A61P37/00 A61P43/00 A61P9/00 C07D471/00 (Core/Invention)
International (IPC 1-7): A61K31/437 A61K31/4745 A61P35/00 C07D471/02 C07D471/04
CPC: C07D471/04
European: C07D471/04
US: 435/184 435/184S 506/15 506/15S 514/300 546/112 546/113 546/113S

Family:

Publication number	Publication date	Application number	Application date
AT447571 E	20091115	AT20040804268T	20041223
BRPI0418179 A	20070427	BR2004PI18179	20041223
CA2550686 AA	20060620	CA20042550686	20041223
DE602004023971 D1	20091217	DE200460023971T	20041223
EP1704147 A1	20060927	EP20040804268	20041223
EP1704147 B1	20091104	EP20040804268	20041223
ES2333437 T3	20100222	ES20040804268T	20041223
GB200330042 A0	20040128	GB20030030042	20031224
HK1097522 A3	20070629	HK20070102492	20070306
JP2007516997 T2	20070628	JP20060546079T	20041223
JP2012121892 A2	20120628	JP20120010439	20120120
JP5053643 B2	20121017	JP20060546079T	20041223
US2005209269 AA	20050922	US20040020794	20041223
US2011136857 AA	20110609	US20110026789	20110214
US7888508 BB	20110215	US20040020794	20041223
US8198298 BB	20120612	US20110026789	20110214
WO05063747 A1	20050714	WO2004EP14676	20041223

Priority:
GB20030030042 20031224 WO2004EP14676 20041223 US20040020794 20041223
US20110026789 20110214 JP20060546079 20041223

Probable Assignee: PFIZER ITALIA SRL

Assignee(s): (std): BOYD EDWARD ANDREW ; BRASCA MARIA GABRIELLA ; BROOKFIELD FREDERICK ARTHUR ; D ANELLO MATTEO ; GIORDANO PATRIZIA ; LARARD JONATHAN ANTHONY ; MARTINA KATIA ; PHARMACIA ITALIA SPA ; SALOM BARBARA ; TRIGG WILLIAM JOHN ; TESEI DANIA ; PHARMACIA AND ITALIA S P A ; PFIZER ITALIA S R L ; PFIZER ITALIA SRL

Assignee(s): PHARMACIA ITALIA S P A ; PHARMACIA AND ITALIA SPA

Inventor(s): (std): BARBARA SALOM ; BOYD EDWARD ; BOYD EDWARD A ; BOYD EDWARD ANDREW ; BRASCA MARIA ; BRASCA MARIA G ; BRASCA MARIA GABRIELLA ; BROOKFIELD FREDERICK ; BROOKFIELD FREDERICK A ; BROOKFIELD FREDERICK ARTHUR ; D ANELLO MATTEO ; ANELLO MATTEO D ; DANIA TESEI ; EDWARD ANDREW BOYD ; FREDERICK ARTHUR BROOKFIELD ; GIORDANO PATRIZIA ; KATIA MARTINA ; LARARD JONATHAN ; LARARD JONATHAN A ; LARARD JONATHAN ANTHONY ; JONATHAN ANTHONY LARARD ; MARIA GABRIELLA BRASCA ; MARTINA KATIA ; PATRIZIA GIORDANO ; SALOM BARBARA ; TESEI DANIA ; TRIGG WILLIAM ; TRIGG WILLIAM J ; TRIGG WILLIAM JOHN ; MATTEO D ANELLO ; WILLIAM JOHN TRIGG

Inventor(s): TRIGG WILLIAM JOHN EVOTEC OAI ; D'ANELLO MATTEO

Agent(s): MODIANO MICAELA NADIA; SCULLY SCOTT MURPHY AND PRESSER PC

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NA NE NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Abstract: Source: US2005256151A Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

Classifications:
International (IPC 8-9): A61K31/437 A61K31/44 A61K31/445 A61K31/496 A61K31/497 A61K31/50 A61K31/5377 A61K31/541 A61K31/551 A61P11/00 A61P13/08 A61P15/08 A61P17/00 A61P17/06 A61P17/14 A61P19/02 A61P25/00 A61P25/28 A61P29/00 A61P31/12 A61P35/00 A61P35/04 A61P37/00 A61P37/06 A61P43/00 A61P9/10 C07D471/02 C07D471/04 C40B40/04 (Advanced/Invention); A61K31/437 A61K31/496 A61K31/5377 A61K31/551 A61P25/28 A61P31/12 A61P35/00 A61P37/00 A61P37/06 A61P43/00 (Advanced/Non-invention); A61K31/4353 A61K31/496 A61K31/5375 A61K31/551 A61P25/00 A61P31/00 A61P35/00 A61P37/00 A61P43/00 C07D471/00 (Core/Invention)
International (IPC 1-7): A61K31/437 A61K31/4745 C07D471/02 C07D471/04 G01N33/53
CPC: C07D471/04
European: C07D471/04
US: 435/7.1 435/7.100S 506/15 506/15P 514/231.5 514/233.8 514/234.5 514/234.500S 514/235.5 514/252.13 514/253.04 514/253.040S 514/300 514/300S 514/319 546/113 546/113S

Family:

Publication number	Publication date	Application number	Application date
AT458736 E	20100315	AT20040816308T	20041223
BRPI0418184 A	20070427	BR2004PI18184	20041223
CA2549898 AA	20060615	CA20042549898	20041223
CA2549898 C	20140527	CA20042549898	20041223
DE602004025741 D1	20100408	DE200460025741T	20041223
EP1701956 A1	20060920	EP20040816308	20041223
EP1701956 B1	20100224	EP20040816308	20041223
ES2339456 T3	20100520	ES20040816308T	20041223
GB200330043 A0	20040128	GB20030030043	20031224
HK1097521 A3	20070629	HK20070102491	20070306
JP2007534653 T2	20071129	JP20060546078T	20041223
JP2012121891 A2	20120628	JP20120010428	20120120
JP5053642 B2	20121017	JP20060546078T	20041223
US2005256151 AA	20051117	US20040020793	20041223
US2010210476 AA	20100819	US20100766230	20100423
US7728140 BB	20100601	US20040020793	20041223
US8106069 BB	20120131	US20100766230	20100423
WO05063746 A1	20050714	WO2004EP14674	20041223

Priority:
GB20030030043 20031224 WO2004EP14674 20041223 US20040020793 20041223
US20100766230 20100423 JP20060546078 20041223

Probable Assignee: PFIZER ITALIA SRL

Assignee(s): (std): ANGELUCCI FRANCESCO ; BOYD EDWARD ANDREW ; BRASCA MARIA GABRIELLA ; BROOKFIELD FREDERICK ARTHUR ; D ANELLO MATTEO ; GIORDANO PATRIZIA ; LARARD JONATHAN ANTHONY ; PHARMACIA ITALIA SPA ; SALOM BARBARA ; MARTINA KATIA ; TRIGG WILLIAM JOHN ; PFIZER ITALIA S R L ; PFIZER ITALIA SRL

Assignee(s): PHARMACIA ITALIA S P A

Inventor(s): (std): BARBARA SALOM ; BOYD EDWARD ; BOYD EDWARD A ; BOYD EDWARD ANDREW ; BRASCA MARIA ; BRASCA MARIA G ; BRASCA MARIA GABRIELA ; BRASCA MARIA GABRIELLA ; BROOKFIELD FREDERICK ; BROOKFIELD FREDERICK A ; BROOKFIELD FREDERICK ARTHUR ; D ANELLO MATTEO ; ANELLO MATTEO D ; ANGELUCCI FRANCESCO ; EDWARD ANDREW BOYD ; FRANCESCO ANGELUCCI ; FREDERICK ARTHUR BROOKFIELD ; GIORDANO PATRIZIA ; KATIA MARTINA ; LARARD JONATHAN ; LARARD JONATHAN A ; LARARD JONATHAN ANTHONY ; JONATHAN ANTHONY LARARD ; MARIA GABRIELA BRASCA ; MARTINA KATIA ; PATRIZIA GIORDANO ; SALOM BARBARA ; TRIGG WILLIAM ; TRIGG WILLIAM J ; TRIGG WILLIAM JOHN ; MATTEO D ANELLO ; WILLIAM JOHN TRIGG

Inventor(s): TRIGG WILLIAM JOHN EVOTEC OAI ; D'ANELLO MATTEO

Agent(s): MODIANO MICAELA NADIA; SCULLY SCOTT MURPHY AND PRESSER PC

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NA NE NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

Abstract: Source: US2007225306A The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and c-Met kinases.

Classifications:


International (IPC 8-9): A61K31/519 A61K31/5377 A61K31/541 A61P11/08 A61P17/06 A61P17/12 A61P35/00 A61P35/02 A61P43/00 A61P7/02 A61P9/10 C07D471/04 C07D487/04 (Advanced/Invention); A61P35/00 A61P37/06 (Advanced/Non-invention); A61K31/519 C07D471/00 C07D487/00 (Core/Invention)

International (IPC 1-7): A61K31/519 C07D471/04 C07D487/04

CPC: C07D471/04 C07D487/04

European: C07D471/04 C07D487/04

US: 514/264.1 514/264.100P 514/264.11 514/264.110S 514/265.1 514/265.100S 544/279 544/279S 544/280 544/280S



Family:

Publication number	Publication date	Application number	Application date
AU2005214352 AA	20050901	AU20050214352	20050214
AU2005214352 BB	20091112	AU20050214352	20050214
BRPI0507668 A	20070717	BR2005PI07668	20050214
CA2553785 AA	20060714	CA20052553785	20050214
CA2553785 C	20110208	CA20052553785	20050214
CN1918158 A	20070221	CN200580004895	20050214
CN1918158 B	20110302	CN200580004895	20050214
DK1713806 T3	20130805	DK20050713510T	20050214
EP1713806 A1	20061025	EP20050713510	20050214
EP1713806 A4	20091111	EP20050713510	20050214
EP1713806 B1	20130508	EP20050713510	20050214
ES2424642 T3	20131007	ES20050713510T	20050214
IN02987CN2006 A	20070608	IN2006CN02987	20060814
JP2007522241 T2	20070809	JP20060553321T	20050214
JP4989233 B2	20120801	JP20060553321T	20050214
PT1713806 T	20130827	PT20050713510T	20050214
US2007225306 AA	20070927	US20050589099	20050214
US7968557 BB	20110628	US20050589099	20050214
WO05080393 A1	20050901	WO2005US04630	20050214

Priority:

US20040544944P 20040214 US20040544944 20040214 WO2005US04630 20050214

US20050589099 20050214 EP20050713510 20050214

Probable Assignee: NOVARTIS AG

Assignee(s): (std): CHOI HA SOON ; GRAY NATHANAEL SCHIANDER ; GU XIANG JU ; HE XIAOHUI ; HE YUN ; IRM LLC ; WANG ZHICHENG ; JIANG TAO ; LIU YI ; RICHMOND WENDY ; SIM TAEBO ; YANG KUNYONG ; NOVARTIS AG

Assignee(s): NOVARTIS INT PHARMACEUTICAL LTD

Inventor(s): (std): GRAY NATHANAEL SCHIANDER ; GU XIANG JU ; HA SOON CHOI ; HE XIAOHUI ; HE YUN ; JIANG TAO ; JIANG TOA ; KUNYONG YANG ; LIU YI ; NATHANAEL SCHIANDER GRAY ; RICHMOND WENDY ; RICHMOND WINDY ; SCHIANDER GRAY NATHANAEL ; SIM TAEBO ; TAEBO SIM ; TAO JIANG ; WANG ZHICHENG ; WENDY RICHMOND ; XIANG JU GU ; XIAOHUI HE ; YANG KUNYONG ; YI CHOI HA SOON WANG ZHICHENG ; YI LIU ; YUN HE ; ZHICHENG WANG ; CHOI HA SOON ; GAY NATHANAEL S


Inventor(s): GAY NATHANAEL SHIANDER ; CHOI HA SOON WANG ZHICHENG GRAY NATHANAEL ; CHOI HA SOON WANG ZHICHENG GRAY NATHANAEL SCHIANDE ; GAY NATHANAEL

Agent(s): DYER JAMES; GENOMICS INSTITUTE OF THE, NOVARTIS RESEARCH FOUNDATION; GENOMICS INST OF NOVARTIS RESEARCH FOUNDATION; NOVARTIS AG; SCOTT W

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NA NE NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS

Abstract: Source: US2006235031A Compounds of the formula



Classifications:

International (IPC 8-9): A01N43/58 A01N43/60 A01N43/64 A01N43/90 A61K31/437 A61K31/4375 A61K31/495 A61K31/4965 A61K31/4985 A61K31/50 A61K31/5025 A61K31/517 A61K31/519 A61K31/52 A61K31/53 A61K31/5377 A61K31/541 A61K31/551 A61P1/04 A61P1/16 A61P11/00 A61P11/06 A61P13/12 A61P15/00 A61P15/08 A61P17/02 A61P17/06 A61P19/02 A61P25/00 A61P27/02 A61P27/06 A61P27/10 A61P29/00 A61P31/00 A61P31/04 A61P31/12 A61P31/18 A61P31/22 A61P33/02 A61P35/00 A61P35/02 A61P35/04 A61P37/02 A61P37/04 A61P37/06 A61P37/08 A61P43/00 A61P51/14 A61P7/02 A61P7/06 A61P9/00 A61P9/08 A61P9/10 C07D401/04 C07D471/00 C07D471/04 C07D487/00 C07D487/04 C07D491/00 C07D495/00 C07D497/00 C07F5/02 (Advanced/Invention); A61K31/4985 A61K31/5377 A61K31/541 A61K31/551 A61P1/04 A61P1/16 A61P11/00 A61P11/06 A61P13/12 A61P15/00 A61P15/08 A61P17/02 A61P17/06 A61P19/02 A61P25/00 A61P27/02 A61P27/06 A61P27/10 A61P29/00 A61P31/04 A61P31/12 A61P31/18 A61P31/22 A61P33/02 A61P35/00 A61P35/02 A61P37/02 A61P37/04 A61P37/06 A61P43/00 A61P51/14 A61P7/02 A61P7/06 A61P9/00 A61P9/08 A61P9/10 C07D487/04 (Advanced/Non-invention); A61K31/00 A61K36/00 A61P11/00 A61P17/00 A61P25/00 A61P35/00 C07D471/00 C07D487/00 (Core/Invention); A61K31/4985 A61P35/00 C07D487/04 (Core/Non-invention); A61K A61P C07D (Subclass/Invention)

International (IPC 1-7): A61K31/437 A61K31/4985 A61K31/5025 A61K31/519 A61K31/53 A61P11/06 A61P17/06 A61P25/00 A61P35/00 C07D471/04 C07D487/04

CPC: C07F5/025 C07D471/04 C07D487/04

European: C07D471/04 C07D487/04

US: 514/210.21 514/210.210P 514/218 514/218S 514/233.2 514/233.200S 514/243 514/243S 514/249 514/249S 514/255.05 514/262.1 514/263.2 514/263.200P 514/265.1 514/265.100S 540/575 540/575S 544/117 544/117S 544/184 544/184S 544/262 544/268 544/268S 544/280 544/280S 544/284 544/284S 544/350 544/350P 544/350S 544/62 544/62P 546/13 546/13S

Family:

Publication number	Publication date	Application number	Application date
AP200603795 A0	20061031	AP20060003795	20050331
AP2139 A	20100821	AP20060003795	20050331
AR048518 AA	20060503	AR2005P101277	20050331
AT433979 E	20090715	AT20050742128T	20050331
AU2005230818 AA	20051020	AU20050230818	20050331
AU2005230818 BB	20101125	AU20050230818	20050331
BRPI0509576 A	20070529	BR2005PI09576	20050331
CA2561950 AA	20061002	CA20052561950	20050331
CA2561950 C	20100420	CA20052561950	20050331
CN102924458 A	20130213	CN201210370045	20050331
CN102924458 B	20141105	CN201210370045	20050331
CN1960993 A	20070509	CN200580017980	20050331
CY1109372 T1	20140702	CY20091100959T	20090917
DE602005014964 D1	20090730	DE200560014964T	20050331
DK1740591 T3	20091026	DK20050742128T	20050331
EA012873 B1	20091230	EA20060001850	20050331
EA200601850 A1	20070427	EA20060001850	20050331
EP1740591 A1	20070110	EP20050742128	20050331
EP1740591 B1	20090617	EP20050742128	20050331
EP2168968 A1	20100331	EP20090156987	20050331
EP2305682 A1	20110406	EP20100185075	20050331
EP2308879 A1	20110413	EP20100185046	20050331
ES2328833 T3	20091118	ES20050742128T	20050331
HK1100040 A1	20100212	HK20070107395	20070710
HK1100040 A3	20070831	HK20070107395	20070710
HK1159077 A3	20120727	HK20110110774	20111012
HR20090495 T1	20091031	HR20090000495	20090916
IL178419 A0	20070211	IL20060178419	20061003
IL178419 A1	20120830	IL20060178419	20061003
IN04036CN2006 A	20070615	IN2006CN04036	20061102
IN255405 B	20130222	IN2006CN04036	20061102
JP2007531754 T2	20071108	JP20070506493T	20050331
JP2009197013 A2	20090903	JP20090102856	20090421
JP4330659 B2	20090916	JP20090102856	20090421
JP4832426 B2	20111207	JP20070506493T	20050331
KR101079272 B1	20111103	KR20067022653	20050331
KR20070008669 A	20070117	KR20067022653	20061030
MXPA06011423 A1	20070123	MX2006PA11423	20061002
MY143225 A	20110331	MY20050001468	20050331
NO20064895 A	20061219	NO20060004895	20061026
PT1740591 T	20090924	PT20050742128T	20050331
RU2006138624 A	20080510	RU20060138624	20050331
RU2379308 C2	20100120	RU20060138624	20050331
SG163576 A1	20100830	SG20100004876	20050331
SI1740591 T1	20091231	SI20050030783T	20050331
TW200604199 A	20060201	TW20050110343	20050331

TW201134828 A	20111016	TW20110123371	20050331
TWI378934 B	20121211	TW20050110343	20050331
UA89493 C2	20100210	UA20060101523	20050331
US2006235031 AA	20061019	US20050095162	20050331
US2009118499 AA	20090507	US20080244947	20081003
US2009325928 AA	20091231	US20090540047	20090812
US2012077979 AA	20120329	US20110308694	20111201
US2012196847 AA	20120802	US20120446629	20120413
US2013190496 AA	20130725	US20130739442	20130111
US7534797 BB	20090519	US20050095162	20050331
US7820662 BB	20101026	US20080244947	20081003
US8101613 BB	20120124	US20090540047	20090812
US8367826 BB	20130205	US20110308694	20111201
US8653268 BB	20140218	US20130739442	20130111
US8735405 BB	20140527	US20120446629	20120413
VN7676 A1	20090625	VN20060001754	20050331
WO05097800 A1	20051020	WO2005US10606	20050331

Priority:

US20040559250 20040402	US20040559250P 20040402	US20050095162 20050331
US20080244947 20081003	JP20070506493 20050331	US20090540047 20090812
EP20050742128 20050331	WO2005US10606 20050331	EP20090156987 20050331
US20110308694 20111201	US20120446629 20120413	US20130739442 20130111


Probable Assignee: OSI PHARMACEUTICALS LLC

Assignee(s): (std):	ARNOLD LEE D ; CESARIO CARA ; COATE HEATHER ; CREW ANDREW P ; CREW ANDREW PHILIP ; DONG HANQING ; OSI PHARM INC ; FOREMAN KENNETH ; HONDA AYAKO ; LAUFER RADOSLAW ; LI AN HU ; MULVIHILL KRISTEN MICHELLE ; MULVIHILL MARK JOSEPH ; NIGRO ANTHONY ; MULVIHILL KRISTEN M ; MULVIHILL MARK J ; OSI FARMAS JUTIKALZ INK ; NIGRO ANTHONY I ; PANICKER BIJOY ; STEINIG ARNO G ; SUN YINGCHUAN ; WENG QINGHUA ; WERNER DOUGLAS S ; WYLE MICHAEL J ; ZHANG TAO ; WENG QINGUA ; OSI PHARMACEUTICALS ; OSI PHARMACEUTICALS LLC ; STEINIG AMO G ; WENG QUINGHUA
Assignee(s):	OSI PHARMACEUTICALS INC
Inventor(s): (std):	ARNOL D LI D ; ARNOLD LEE ; ARNOLD LEE D ; ARNOLD LEE D COATE HEATHER CRE ; CESARIO CARA ; CHZHAN TAO ; COATE HEATHER ; CREW ANDREW ; CREW ANDREW P ; CREW ANDREW PHILIP ; CREW ANDREW PHILLIP ; DONG HAN QING ; ARNOLD LEE DANIEL ; DONG HANQING ; DUN KHAN TSIN ; FOREMAN KENNETH ; FORMAN KENNET ; HONDA AYAKO ; KHONDA AJAKO ; KOUT KHITER ; LAUFER RADOSLAV ; LAUFER RADOSLAW ; KRJU EHNDRJU FILIP ; LI AN HU ; LI AN KHU ; MALVIKHILL MARK DZHOZEF ; MICHAEL WYLE ; MULVIHILL KRISTEN ; MULVIHILL KRISTEN M ; MULVIHILL KRISTEN MICHELLE ; MULVIHILL MARK ; MULVIHILL MARK J ; MULVIHILL MARK JOSEPH ; NAJGRO EHNTONI ; NIGRO ANTHONY ; NIGRO ANTHONY I ; NIGRO ANTHONY INNOCENZO ; PANICKER BIJOY ; PANIKER BIDZHOJ ; WENG QING HUA ; WENG QINGHUA ; WENG QINGUA ; WENG QUINGHUA ; WERNER DOUGLAS ; WERNER DOUGLAS S ; WYLE MICHAEL ; WYLE MICHAEL J ; YINGCHUAN HANG TAO CESARIO CAR ; ZHANG TAO ; YINGCHUAN SUN ; TAO ZHANG ; STEINIG AMO G ; RADOSLOW LAUFER ; QINGHUA WENG ; PHILIP CREW ANDREW ; MULVIHILL KRISTEN MICHELE ; MICHELLE MULVIHILL KRISTEN ; MALVIKHILL KRISTEN MISHEL ; SESARIO KARA ; SHTAJNIG ARNO G ; STEINIG ARNO ; STEINIG ARNO G ; SUN INCHUAN ; KENNETH FOREMAN ; JOSEPH MULVIHILL MARK ; INNOCENZO NIGRO ANTHONY ; HEATHER COATE ; HANQING DONG ; CARA CESARIO ; BIJOY PANICKER ; AYAKO HONDA ; AN HU LI ; SUN YING CHUAN ; SUN YINGCHUAAN ; SUN YINGCHUAN ; UAJL MAJKL DZH ; VEHN TSINKHUA ; VERNER DUGLAS S ; LAUFER RADOSAW ; DONG HANGING
Inventor(s):	ANTHONY INNOCENZO NIGRO ; WYLE J MICHAEL ; SUN' INCHUAN' ; MALVIKHILL KRISTEN MISHEL' ; LAUFER RADOSLOW ; RADOSLAW LAUFER ; MARK JOSEPH MULVIHILL ; MICHAEL J WYLE ; LI AN'-KHU ; LAIFER RADOSLAW ; LEE D ARNOLD ; KRISTEN MICHELLE MULVIHILL ; HANG TAO CESARIO CARA SUN YINGCHUAN ; DUN KHAN'TSIN ; DOUGLAS S WERNER ; ARNOL'D LI D. ; DONG HAN QUING ; ARNOLD LEE D COATE HEATHER CREW ANDREW P DONG HANQ ; ANDREW PHILIP CREW ; ANTHONY NIGRO ; ARNO G STEINIG
Agent(s):	BLAKEY ALISON JANE; HAILE ALISON VICTORIA; KIM T NGUYEN SUITE 110; OSI PHARMACEUTICALS INC; ASTELLAS US LLC; GUYAN
Designated states:	AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NA NE NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: SULFONAMIDES

Abstract: Source: US2007244135A Compounds of the formula (I), in which R⁶, R⁷, R⁸, R⁹ and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.

(I)



Classifications:

International (IPC 8-9): A61K31/497 A61K31/519 A61P1/16 A61P13/08 A61P13/10

A61P13/12 A61P15/00 A61P17/00 A61P17/02 A61P17/06 A61P19/00 A61P19/02 A61P19/08 A61P25/00 A61P27/02 A61P29/00 A61P3/00 A61P3/10 A61P35/00 A61P35/02 A61P37/02 A61P37/04 A61P37/06 A61P37/08 A61P43/00 A61P7/02 A61P9/00 A61P9/08 A61P9/10 C07D471/04 (Advanced/Invention); A61K31/519 A61P1/16 A61P13/08 A61P13/10 A61P13/12 A61P15/00 A61P17/00 A61P17/02 A61P17/06 A61P19/00 A61P19/02 A61P19/08 A61P25/00 A61P27/02 A61P29/00 A61P3/00 A61P3/10 A61P35/00 A61P35/02 A61P37/02 A61P37/04 A61P37/06 A61P37/08 A61P43/00 A61P7/02 A61P9/00 A61P9/08 A61P9/10 (Advanced/Non-invention);

A61K31/519 A61P1/00 A61P13/00 A61P15/00 A61P17/00 A61P19/00 A61P25/00 A61P27/00 A61P29/00 A61P3/00 A61P35/00 A61P37/00 A61P43/00 A61P7/00 A61P9/00 C07D471/00 (Core/Invention)

International (IPC 1-7): A61K31/519 A61P35/00 C07D221/00 C07D239/00 C07D471/04

CPC: C07D471/04

European: C07D471/04

US: 514/234.2 514/248 514/255.05 514/264.1 514/264.11 514/264.110P 544/119 544/235 544/238 544/279 544/279S 544/329 546/288

Family:

Publication number	Publication date	Application number	Application date
AR052302 A1	20070314	AR2005P101483	20050415
AR052302 AA	20070314	AR2005P101483	20050415
AU2005238135 AA	20051110	AU20050238135	20050317
AU2005238135 BB	20110310	AU20050238135	20050317
CA2563558 AA	20061013	CA20052563558	20050317
DE102004018198 A1	20051103	DE200410018198	20040415
EP1737858 A1	20070103	EP20050716154	20050317
JP2007532590 T2	20071115	JP20070507683T	20050317
JP4891227 B2	20120307	JP20070507683T	20050317
US2007244135 AA	20071018	US20050578375	20050317
US7528139 BB	20090505	US20050578375	20050317
WO05105797 A1	20051110	WO2005EP02849	20050317

Priority:

DE200410018198 20040415 WO2005EP02849 20050317

Probable Assignee: MERCK PATENT GMBH

Assignee(s): (std): CRASSIER HELENE ; HOELZEMANN GUENTER ; JONCZYK ALFRED ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUN ; MERCK PATENT GMBH ; STAEHLE WOLFGANG ; RAUTENBERG WILFRIED

Assignee(s): MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG ; MERCK PATENT GES MIT BESCHRAENKTER HAFTUNG ; MERCK PATENT GES MIT BESCHRAENKTER HAFTUNG

Inventor(s): (std): HOELZEMANN GUENTER ; JONCZYK ALFRED ; RAUTENBERG WILFRIED ; STAEHLE WOLFGANG ; CRASSIER HELENE


Inventor(s): GUENTER HOELZEMANN ; HELENE CRASSIER ; ALFRED JONCZYK ; WILFRIED RAUTENBERG ; WOLFGANG STAEHLE

Agent(s): MILLEN WHITE ZELANO AND BRANIGAN PC

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NA NE NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES

Abstract: Source: US2009215799A The present invention relates to heterocyclic substituted bisarylurea derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.



Classifications:

International (IPC 8-9): A61K31/4192 A61K31/435 A61K31/44 A61K31/4439 A61K31/519 A61P1/04 A61P11/06 A61P13/08 A61P13/12 A61P15/00 A61P17/06 A61P19/02 A61P19/04 A61P25/28 A61P29/00 A61P31/04 A61P31/16 A61P31/18 A61P35/00 A61P35/02 A61P37/06 A61P43/00 A61P9/00 A61P9/10 C07D401/12 C07D401/14 C07D403/12 C07D413/12 C07D471/04 C07D471/10 (Advanced/Invention); A61K31/435 A61K31/4439 A61K31/519 A61P1/04 A61P11/06 A61P13/08 A61P13/12 A61P15/00 A61P17/06 A61P19/02 A61P19/04 A61P25/28 A61P29/00 A61P31/04 A61P31/16 A61P31/18 A61P35/00 A61P35/02 A61P37/06 A61P43/00 A61P9/00 A61P9/10 C07D401/14 C07D403/12 C07D471/04 (Advanced/Non-invention); A61K31/00 A61K31/435 A61K31/4427 A61K31/519 A61P1/00 A61P11/00 A61P13/00 A61P15/00 A61P17/00 A61P19/00 A61P25/00 A61P29/00 A61P31/00 A61P35/00 A61P37/00 A61P43/00 A61P9/00 C07D401/00 C07D403/00 C07D413/00 C07D471/00 (Core/Invention); A61K A61P C07D (Subclass/Invention)

International (IPC 1-7): A61K31/435 A61P35/00 C07D401/12 C07D403/12 C07D413/12 C07D417/12 C07D471/04 C07D471/10

CPC: C07D401/12 C07D403/12 C07D413/12 C07D471/04 C07D471/10

European: C07D401/12 C07D403/12 C07D413/12 C07D471/04 C07D471/10

US: 514/264.1 514/264.100P 514/340 514/340S 514/395 514/395S 544/279 544/279S 546/272.4 546/272.400S 548/255 548/255S

Family:

Publication number	Publication date	Application number	Application date
AR054212 AA	20070613	AR2005P104286	20051013
AU2005293839 AA	20060420	AU20050293839	20051006
AU2005293839 BB	20120823	AU20050293839	20051006
BRPI0515991 A	20080819	BR2005PI15991	20051006
CA2584185 AA	20070411	CA20052584185	20051006
CA2584185 C	20140715	CA20052584185	20051006
CN101039932 A	20070919	CN200580035117	20051006
EP1799669 A1	20070627	EP20050789864	20051006
IN01680KN2007 A	20070727	IN2007KN01680	20070511
JP2008515943 T2	20080515	JP20070536047T	20051006
JP5089392 B2	20121205	JP20070536047T	20051006
KR20070062998 A	20070618	KR20077008364	20070412
MX2007004248 A1	20070612	MX20070004248	20070410
US2009215799 AA	20090827	US20050577270	20051006
US8003657 BB	20110823	US20050577270	20051006
WO06040056 A1	20060420	WO2005EP10744	20051006
ZA200703835 A	20081126	ZA20070003835	20070511

Priority:

EP20040024369 20041013 EP20050016845 20050803 WO2005EP10744 20051006
EP20050789864 20051006

Probable Assignee: MERCK PATENT GMBH

Assignee(s): (std): BUCHSTALLER HANS PETER ; BURGDORF LARS THORE ; GREINER HARTMUT ; HOELZEMANN GUENTER ; JONCZYK ALFRED ; MERCK PATENT GMBH ; STIEBER FRANK ; RAUTENBERG WILFRIED

Assignee(s): MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG ; MERCK PATENT GES MIT BESCHRAENKTER HAFTUNGFRANKFURTER STRASSE 250D-64293DARMSTADTDE ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUN ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG ; MERCK PATENT GES MIT BESCHRAENKTER HAFTUNG


Inventor(s): (std): BUCHSTALLER HANS PETER ; BURGDORF LARS THORE ; GREINER HARTMUT ; HOELZEMANN GUENTER ; JONCZYK ALFRED ; RAUTENBE STIEBER FRANK JONCZYK ; RAUTENBERG WILFRIED ; WILFRIED RAUTENBERG ; THORE BURGDORF LARS ; HARTMUT GREINER ; HANS PETER BUCHSTALLER ; GUENTER HOELZEMANN ; FRANK STIEBER ; ALFRED JONCZYK ; STIEBER FRANK

Inventor(s): STIEBER FRANK JONCZYK ALFRED HOELZEMANN ; STIEBER FRANKDE ; STIEBER FRANK JONCZYK ALFRED HOELZEMANN GUENTER BUCHSTALLER HANS PETER BURGDORF LARS THORE RAUTENBERG WILFRIED GREINER HARTMUT ; LARS THORE BURGDORF ; RAUTENBERG WILFRIEDDE ; JONCZYK ALFREDDE ; HOELZEMANN GUENTERDE ; GREINER HARTMUTDE ; BURGDORF LARS THOREDE ; BUCHSTALLER HANS PETERDE ; BURGDORF LARS

Agent(s): ARENT FOX LLP; PERKINS COIE LLP

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU IE IL IN IS IT JP KE KG KM KP KR KZ LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: N,N'-DIPHENYLUREA DERIVATIVES WHICH ARE SUITABLE AS KINASE INHIBITORS



Abstract: Source: US2008114026A

the formula (I), in which R^{1a} , R^{1c} , R^{2a} , R^{2b} , R^3 and R^5 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.

Classifications:

International (IPC 8-9): A61K31/437 A61K31/4745 A61K45/00 A61P13/08 A61P15/08

A61P17/00 A61P17/06 A61P19/02 A61P27/02 A61P29/00 A61P3/10 A61P35/00

A61P35/02 A61P37/02 A61P43/00 A61P9/10 C07D471/02

C07D471/04 (Advanced/Invention);

A61K31/437 A61P13/08 A61P15/08 A61P17/00 A61P17/06 A61P19/02 A61P27/02

A61P29/00 A61P3/10 A61P35/00 A61P35/02 A61P37/02 A61P43/00

A61P9/10 (Advanced/Non-invention);

A61K31/4353 A61K45/00 A61P13/00 A61P15/00 A61P17/00 A61P19/00 A61P27/00


A61P29/00 A61P3/00 A61P35/00 A61P37/00 A61P43/00 A61P9/00

C07D471/00 (Core/Invention)

CPC: C07D471/04

European: C07D471/04

US: 514/303 546/118 546/119 546/119S



Family:

Publication number	Publication date	Application number	Application date
AT384723 E	20080215	AT20050789235T	20051004
AU2005293821 AA	20060420	AU20050293821	20051004
AU2005293821 BB	20110512	AU20050293821	20051004
CA2584179 AA	20070411	CA20052584179	20051004
CA2584179 C	20130129	CA20052584179	20051004
DE502005002697 D1	20080313	DE200550002697T	20051004
EP1799679 A1	20070627	EP20050789235	20051004
EP1799679 B1	20080123	EP20050789235	20051004
ES2300054 T3	20080601	ES20050789235T	20051004
JP2008515942 T2	20080515	JP20070536040T	20051004
JP5065034 B2	20121031	JP20070536040T	20051004
US2008114026 AA	20080515	US20050665113	20051004
US8097727 BB	20120117	US20050665113	20051004
WO06040039 A1	20060420	WO2005EP10660	20051004

Priority:

EP20040024367 20041013 WO2005EP10660 20051004 EP20050789235 20051004

Probable Assignee: MERCK PATENT GMBH

Assignee(s): (std): HOELZEMANN GUENTER ; MERCK PATENT GMBH ; STAEHLE WOLFGANG ; RAUTENBERG WILFRIED

Assignee(s): MERCK PATENT GES MIT BESCHRAENKTER HAFTUNG ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUN ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG

Inventor(s): (std): HOELZEMANN GUENTER ; RAUTENBERG WILFRIED ; STAEHLE WOLFGANG

Inventor(s): WILFRIED RAUTENBERG ; WOLFGANG STAEHLE ; GUENTER HOELZEMANN

Agent(s): BAKER AND DANIELS LLP; PERKINS COIE LLP

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KM KP KR KZ LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: Phenylurea Derivatives As Inhibitors Of Tyrosine Kinases For The Treatment Of Tumour Diseases

Abstract: Source: US2008207682A Compounds of the formula (I), in which R^{1a}-R^{1e}, R^{2a}, R^{2b}, R³, R⁴ and X have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.


Classifications:

International (IPC 8-9): A61K31/437 A61K45/00 A61P17/00 A61P17/06 A61P19/02 A61P19/08 A61P27/02 A61P29/00 A61P35/00 A61P35/02 A61P35/04 A61P43/00 A61P9/00 A61P9/10 C07D471/04 (Advanced/Invention); A61K31/4353 A61K45/00 A61P17/00 A61P19/00 A61P27/00 A61P29/00 A61P35/00 A61P43/00 A61P9/00 C07D471/00 (Core/Invention)

CPC: C07D471/04

European: C07D471/04

US: 514/303 546/118 546/118S



Family:

Publication number	Publication date	Application number	Application date
AT512146 E	20110615	AT20050787382T	20050916
AU2005297531 AA	20060427	AU20050297531	20050916
AU2005297531 BB	20110623	AU20050297531	20050916
CA2584170 AA	20070411	CA20052584170	20050916
CA2584170 C	20130820	CA20052584170	20050916
EP1809628 A1	20070725	EP20050787382	20050916
EP1809628 B1	20110608	EP20050787382	20050916
ES2365858 T3	20111011	ES20050787382T	20050916
JP2008515935 T2	20080515	JP20070536015T	20050916
US2008207682 AA	20080828	US20050665183	20050916
US7696224 BB	20100413	US20050665183	20050916
WO06042599 A1	20060427	WO2005EP09983	20050916

Priority:

EP20040024368 20041013 WO2005EP09983 20050916 EP20050787382 20050916

Probable Assignee: MERCK PATENT GMBH

Assignee(s): (std): HOELZEMANN GUENTER ; MERCK PATENT GMBH ; RAUTENBERG WILFRIED ; STAEHLE WOLFGANG

Assignee(s): MERCK PATENT GES MIT BESCHRAENKTER HAFTUNG ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUN ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG

Inventor(s): (std): HOELZEMANN GUENTER ; RAUTENBERG WILFRIED ; STAEHLE WOLFGANG ; WOLFGANG STAEHLE ; WILFRIED RAUTENBERG ; GUENTER HOELZEMANN


Agent(s): BAKER AND DANIELS LLP; ARENT FOX LLP

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KM KP KR KZ LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: 4-AMINO-5-OXO-8-PHENYL-5H-PYRIDO(2,3-D) PYRIMIDINE DERIVATIVES AS TYROSINE KINASE AND RAF KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS

Abstract: Source: US2008146560A Compounds of the formula (I), in which R⁶, R⁷, R⁸, R⁹, Het¹, X and X' have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours

(I)



Classifications:

International (IPC 8-9): A01N43/58 A01N43/60 A61K31/495 A61K31/4985 A61K31/50 A61K31/519 A61K31/535 A61K31/5377 A61P13/08 A61P15/08 A61P17/00 A61P17/06 A61P19/00 A61P19/02 A61P19/08 A61P27/02 A61P27/16 A61P29/00 A61P35/00 A61P35/02 A61P35/04 A61P37/06 A61P37/08 A61P43/00 A61P9/00 C07C275/28 C07D401/14 C07D413/00 C07D413/14 C07D471/00 C07D471/04

C07D487/00 (Advanced/Invention);

A61K31/519 A61K31/5375 A61P13/00 A61P15/00 A61P17/00 A61P19/00 A61P27/00 A61P29/00 A61P35/00 A61P37/00 A61P43/00 A61P9/00 C07C275/00 C07D471/00 (Core/Invention)

International (IPC 1-7): A61K31/519 A61K31/519 A61P35/00 A61P35/00 A61P35/02 A61P35/02 C07D471/04 C07D471/04

CPC: C07D471/04

European: C07D471/04

US: 514/234.2 514/234.200P 514/249 514/249S 544/122 544/122S 544/279 544/279S

Family:

Publication number	Publication date	Application number	Application date
AR051623 AA	20070124	AR2005P104687	20051109
AT428712 E	20090515	AT20050800485T	20051020
AU2005304087 AA	20060518	AU20050304087	20051020
AU2005304087 BB	20110616	AU20050304087	20051020
CA2587609 AA	20070508	CA20052587609	20051020
DE102004054215 A1	20060511	DE200410054215	20041110
DE502005007105 D1	20090528	DE200550007105T	20051020
EP1809630 A1	20070725	EP20050800485	20051020
EP1809630 B1	20090415	EP20050800485	20051020
ES2323537 T3	20090720	ES20050800485T	20051020
JP2008519780 T2	20080612	JP20070540524T	20051020
US2008146560 AA	20080619	US20050667173	20051020
US7745434 BB	20100629	US20050667173	20051020
WO06050800 A1	20060518	WO2005EP11304	20051020

Priority:

DE200410054215 20041110 WO2005EP11304 20051020

Probable Assignee: MERCK PATENT GMBH

Assignee(s): (std): ACKERMANN KARL AUGUST ; ADAN JAUME ; CASES CLAUDIA ; CRASSIER HELENE ; GRASSIER HELENE ; HOELZEMANN GUENTER ; MERCK PATENT GMBH ; JONCZYK ALFRED ; RAUTENBERG WILFRIED ; TARRASON GEMA ; ROSELL VIVES ELISABET ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUN


Assignee(s): MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG ; MERCK PATENT GES MIT BESCHRAENKTER HAFTUNG

Inventor(s): (std): ACKERMANN KARL AUGUST ; ADAN JAUME ; CASES CLAUDIA ; CRASSIER HELENE ; GRASSIER HELENE ; HOELZEMANN GUENTER ; JONCZYK ALFRED ; RAUTENBERG WILFRIED ; ROSELL VIVES ELISABET ; TARRASON GEMA

Inventor(s): WILFRIED RAUTENBERG ; KARL AUGUST ACKERMANN ; JAUME ADAN ; GUENTER HOELZEMANN ; HELENE CRASSIER ; ELISABET ROSELL VIVES ; GEMA TARRASON ; CLAUDIA CASES ; ALFRED JONCZYK

Agent(s): BAKER AND DANIELS LLP; ARENT FOX LLP


Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KM KP KR KZ LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW



Title: N,N'-DIPHENYLUREA DERIVATIVES SUITABLE AS KINASE INHIBITORS

Abstract: Source: US2007293488A Compounds of the formula (I), in which R¹, R³ and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.

(I)

**Classifications:**

International (IPC 8-9): A61K31/519 A61K31/5355 A61K31/5377 A61P13/08 A61P15/08 A61P17/02 A61P17/06 A61P19/02 A61P19/08 A61P27/02 A61P29/00 A61P35/00 A61P35/02 A61P37/00 A61P37/02 A61P37/04 A61P37/08 A61P43/00 A61P7/02 A61P9/10 C07D413/12 C07D413/14 C07D471/04

C07D491/04 (Advanced/Invention);


A61K31/519 A61K31/5375 A61P13/00 A61P15/00 A61P17/00 A61P19/00 A61P27/00 A61P29/00 A61P35/00 A61P37/00 A61P43/00 C07D471/00 (Core/Invention)

International (IPC 1-7): A61K31/519 A61K31/519 A61P35/00 A61P35/00 C07D471/04 C07D471/04

CPC: C07D471/04

European: C07D471/04

US: 514/234.2 514/234.200P 514/264.11 514/264.110S 544/122 544/122S 544/279 544/279S

**Family:**

Publication number	Publication date	Application number	Application date
AR054988 AA	20070801	AR2005P104688	20051109
AU2005304066 AA	20060518	AU20050304066	20051012
AU2005304066 BB	20110721	AU20050304066	20051012
CA2586929 AA	20070508	CA20052586929	20051012
DE102004054216 A1	20060511	DE200410054216	20041110
EP1809629 A1	20070725	EP20050791308	20051012
EP1809629 B1	20120613	EP20050791308	20051012
JP2008519778 T2	20080612	JP20070540514T	20051012
US2007293488 AA	20071220	US20050667132	20051012
US7846927 BB	20101207	US20050667132	20051012
WO06050779 A1	20060518	WO2005EP10957	20051012

Priority:

DE200410054216 20041110 WO2005EP10957 20051012

Probable Assignee: MERCK PATENT GMBH

Assignee(s): (std): CRASSIER HELENE ; HOELZEMANN GUENTER ; JONCZYK ALFRED ; MERCK PATENT GMBH ; RAUTENBERG WILFRIED

Assignee(s): MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG ; MERCK PATENT GES MIT BESCHRAENKTER HAFTUNG ; MERCK PATENT GES MIT BESCHRAENKTER HAFTUNG ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG

Inventor(s): (std): ALFRED JONCZYK ; GUENTER HOELZEMANN ; HELENE CRASSIER ; WILFRIED RAUTENBERG ; RAUTENBERG WILFRIED ; JONCZYK ALFRED ; HOELZEMANN GUENTER ; CRASSIER HELENE


Agent(s): BAKER AND DANIELS LLP; PERKINS COIE LLP

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KM KP KR KZ LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE

Abstract: Source: US2007259910A Compounds of formula (I):

Formula (I)



defined in the description, and to salts thereof, to compositions containing them, to the process for preparing them, and to their use as medicinal products, in particular as anticancer agents.

Classifications:

International (IPC 8-9): A61K31/00 A61K31/4025 A61K31/404 A61K31/4045 A61K31/405 A61K31/407 A61K31/4155 A61K31/42 A61K31/422 A61K31/437 A61K31/44 A61K31/4439 A61K31/4745 A61K31/496 A61K31/5377 A61P17/06 A61P19/02 A61P27/02 A61P29/00 A61P31/10 A61P31/00 A61P35/00 A61P43/00 A61P9/00 C07D209/04 C07D209/10 C07D209/12 C07D209/14 C07D209/30 C07D209/42 C07D213/34 C07D295/00 C07D401/00 C07D401/04 C07D401/12 C07D403/12 C07D405/12 C07D409/12 C07D413/12 C07D413/02 C07D471/02 C07D471/04 (Advanced/Invention); A61K31/404 C07B61/00 C07D209/42 C07D471/04 (Advanced/Non-invention); A61K31/4025 A61K31/403 A61K31/404 A61K31/407 A61K31/4155 A61K31/42 A61K31/422 A61K31/4353 A61K31/44 A61K31/4427 A61K31/496 A61K31/5375 A61P17/00 A61P19/00 A61P27/00 A61P29/00 A61P3/00 A61P35/00 A61P43/00 A61P9/00 C07D209/00 C07D213/00 C07D295/00 C07D401/00 C07D403/00 C07D405/00 C07D409/00 C07D413/00 C07D413/12 C07D471/00 (Core/Invention); C07B61/00 (Core/Non-invention); C07D (Subclass/Invention)

International (IPC 1-7): A61K31/4025 A61K31/4025 A61K31/403 A61K31/403 A61K31/404 A61K31/404 A61K31/407 A61K31/422 A61K31/422 A61K31/4427 A61K31/4427 A61P35/00 C07D209/00 C07D209/12 C07D209/14 C07D209/42 C07D209/42 C07D221/00 C07D401/04 C07D403/12 C07D403/12 C07D413/12 C07D413/12 C07D471/04

CPC: C07D209/42 C07D401/04 C07D401/12 C07D403/12 C07D413/12 C07D471/04

European: C07D209/42 C07D401/04 C07D401/12 C07D403/12 C07D413/12 C07D471/04

US: 514/300 514/415 514/419 514/419S 546/113 546/113S 548/469 548/492 548/492S

Family:

Publication number	Publication date	Application number	Application date
AR052257 AA	20070307	AR2005P105076	20051205
AU2005313253 AA	20060615	AU20050313253	20051202
BRPI0515811 A	20080805	BR2005PI15811	20051202
CA2586991 AA	20070508	CA20052586991	20051202
CN101098868 A	20080102	CN200580046174	20051202
CR9115 A	20071023	CR20070009115	20070509
EA012613 B1	20091030	EA20070001227	20051202
EA200701227 A1	20071026	EA20070001227	20051202
EP1841762 A1	20071010	EP20050824445	20051202
FR2878849 A1	20060609	FR20040012966	20041206
FR2878849 B1	20080912	FR20040012966	20041206
GT200500357 A	20070109	GT20050000357	20051206
HK1116487 A3	20081224	HK20080106897	20080620
IL183438 A0	20070920	IL20070183438	20070527
JP2008532926 T2	20080821	JP20070543884T	20051202
KR20070100277 A	20071010	KR20077015482	20070705
MA29026 B1	20071101	MA20070029913	20070517
MX2007006764 A1	20070815	MX20070006764	20070606
NO20073015 A	20070828	NO20070003015	20070613
PA8654701 A1	20060703	PA20050086547	20051206
SV2006002319 A	20060707	SV20050002319	20051206
TH80525 A	20061019	TH20051005693	20051202
TW200634007 A	20061001	TW20050142712	20051205
US2007259910 AA	20071108	US20070757613	20070604
US7566736 BB	20090728	US20070757613	20070604
UY29248 A1	20060630	UY20050029248	20051206
WO06061493 A1	20060615	WO2005FR03003	20051202

Priority:
FR20040012966 20041206 US20050650465P 20050207 WO2005FR03003 20051202
US20070757613 20070604

Probable Assignee: AVENTIS PHARMA SA

Assignee(s): (std): BACQUE ERIC ; HALLEY FRANK ; SOUAILLE CATHERINE ; TABART MICHEL ; VIVIANI FABRICE ; RONAN BAPTISTE ; LETALLEC JEAN PHILIPPE ; FILOCHE ROMME BRUNO ; AVENTIS PHARMA S A ; AVENTIS PHARMA SA ; AVENTIS PHARMA SA SA

Assignee(s): AVENTIS PHARMA SA SOCIETE ANONYME ; AVENTIS PHARMA SOC ANONYME SA

Inventor(s): (std): BACQUE ERIC ; BAPTISTE RONAN ; BRUNO FILOCHE ROMME ; BRUNO ROMME ; CATHERINE SOUAILLE ; ERIC BACQUE ; FABRICE VIVIANI ; FILOCHE ROMME BRUNO ; FRANCK HALLEY ; FRANK HALLEY ; HALLEY FRANK ; JEAN PHILIPPE LETALLEC ; LETALLEC JEAN PHILIPPE ; MICHAEL TABART ; MICHEL TABART ; RONAN BAPTISTE ; SOUAILLE CATHERINE ; SOUAILLE CATHRINE ; TABART MICHEL ; VIVIANI FABRICE ; SQUAILLE CATHERINE

Inventor(s): TABART MICHAEL

Agent(s): ANDREA Q RYAN SANOFI AVENTIS US LLC; KELLY L


Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LC LI LK LR LS LT LU

Title: PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS

Abstract: Source: US2008319005A The invention relates to compounds of the formula (I) wherein the moieties R1, R2, R3, R9, R10 and Q and X, Y and Z are as defined in the specification, and salts thereof, as well as their use, methods of use for them and method of their synthesis, and the like. The compounds are protein kinase inhibitors and can, inter alia, be used in the treatment of various proliferative diseases.

Classifications:

International (IPC 8-9): A61K31/41 A61K31/4164 A61K31/4184 A61K31/4188 A61K31/437 A61K31/44 A61K31/454 A61K31/454 A61K31/496 A61K31/497 A61K31/52 A61K31/5377 A61P1/04 A61P1/16 A61P11/06 A61P13/08 A61P13/12 A61P17/02 A61P17/04 A61P17/06 A61P19/02 A61P27/02 A61P27/06 A61P29/00 A61P35/00 A61P35/02 A61P37/06 A61P43/00 A61P7/02 A61P9/10 A61P9/14 C07D235/04 C07D235/06 C07D235/08 C07D237/28 C07D401/12 C07D403/12 C07D413/06 C07D471/00 C07D471/02 C07D471/04 C07D473/00 C07D487/04 (Advanced/Invention); A61K31/4184 A61K31/437 A61K31/454 A61K31/496 A61K31/52 A61K31/5377 A61P1/04 A61P1/16 A61P11/06 A61P13/08 A61P13/12 A61P17/02 A61P17/04 A61P17/06 A61P19/02 A61P27/02 A61P27/06 A61P29/00 A61P35/00 A61P35/02 A61P37/06 A61P43/00 A61P7/02 A61P9/10 A61P9/14 C07D471/04 C07D487/04 (Advanced/Non-invention); A61K31/41 A61K31/4164 A61P35/00 C07D235/00 C07D401/00 C07D403/00 C07D471/00 C07D473/00 C07D487/00 (Core/Invention)
International (IPC 1-7): A61K31/4184 A61K31/4188 A61P35/00 A61P35/02 C07D235/04 C07D471/04
CP: C07D235/06 C07D401/12 C07D403/12 C07D471/04 C07D473/00
European: C07D235/06 C07D401/12 C07D403/12 C07D471/04 C07D473/00
US: 514/253.04 514/253.040P 514/303 514/303S 514/394 514/394S 544/362 544/362S 546/118 546/118S 548/304.4 548/304.400S



Family:

Publication number	Publication date	Application number	Application date
AR055774 AA	20070905	AR2006P101463	20060412
AT501142 E	20110315	AT20060724286T	20060412
AU2006233688 AA	20061019	AU20060233688	20060412
BRPI0610568 A2	20100629	BR2006PI10568	20060412
CA2603941 AA	20071005	CA20062603941	20060412
CN101198607 A	20080611	CN200680021434	20060412
DE602006020559 D1	20110421	DE200660020559T	20060412
EP1874770 A1	20080109	EP20060724286	20060412
EP1874770 B1	20110309	EP20060724286	20060412
ES2362907 T3	20110714	ES20060724286T	20060412
GB200507575 A0	20050518	GB20050007575	20050414
GT200600143 A	20061124	GT20060000143	20060407
IN07670DN2007 A	20071102	IN2007DN07670	20071005
JP2008538356 T2	20081023	JP20080505810T	20060412
JP4870150 B2	20120208	JP20080505810T	20060412
KR100931103 B1	20091210	KR20077026369	20060412
KR20080002958 A	20080104	KR20077026369	20060412
MX2007012712 A1	20080114	MX20070012712	20071012
PE13052006 A1	20061230	PE20060000397	20060417
PT1874770 T	20110601	PT20060724286T	20060412
RU2007141767 A	20090520	RU20070141767	20060412
TW200714589 A	20070416	TW20060113188	20060413
US2008319005 AA	20081225	US20060914895	20060412
US2012184561 AA	20120719	US20110182182	20110713
US8030311 BB	20111004	US20060914895	20060412
WO06108640 A1	20061019	WO2006EP03380	20060412

Priority:
GB20050007575 20050414 WO2006EP03380 20060412 WO2006EP03380 20071113
US20070914895 20071119 US20110182182 20110713

Probable Assignee: NOVARTIS AG

Assignee(s): (std): BOLD GUIDO ; FURET PASCAL ; GUAGNANO VITO ; MCCARTHY CLIVE ; NOVARTIS AG ; NOVARTIS INT AG ; NOVARTIS PHARMA GMBH ; VAUPEL ANDREA ; NOVARTIS PHARMA AG

Inventor(s): (std): FURET PASCAL ; GUAGNANO VITA ; GUAGNANO VITO ; MCCARTHY CLIVE ; MCCARTHY CLIVE ; VAUPEL ANDREA ; VITO GUAGNANO ; PASCAL FURET ; GUIDO BOLD ; CLIVE MCCARTHY ; ANDREA VAUPEL ; PASCAL FURET DR ; BOLD GUIDO ; BOLD GUIDO DR

Inventor(s): CLIVE MCCARTHY ; DR GUIDO BOLD ; MCCARTHY CLIVE NOVARTIS AG

Agent(s): ROTH PETER RICHARD ET AL; ROTH PETER RICHARD; NOVARTIS, CORPORATE INTELLECTUAL PROPERTY; NOVARTIS CORPORATE INTELLECTUAL PROPERTY

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: INHIBITORS OF AKT ACTIVITY

Abstract: Source: US2008318947A Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

Classifications:


International (IPC 8-9): A01N43/42 A61K31/437 A61K31/44 A61K31/444 A61K31/4545 A61K31/4725 A61K31/4738 A61K31/4745 A61K31/5377 A61K45/00 A61P19/02 A61P35/00 A61P43/00 C07D471/02 C07D471/04 C07D491/02 C07D498/02 C07D513/02 C07D515/02 (Advanced/Invention); A01N43/34 A61K31/4353 A61K31/44 A61K31/4427 A61K31/4523 A61K31/472 A61K31/4738 A61K31/5375 A61K45/00 A61P19/00 A61P35/00 A61P43/00 C07D471/00 C07D471/04 C07D491/00 C07D498/00 C07D513/00 C07D515/00 (Core/Invention)

International (IPC 1-7): A61K31/437 A61K31/437 A61P19/02 A61P19/02 A61P35/00 A61P35/00 C07D471/04 C07D471/04

CPC: C07D471/04

European: C07D471/04

US: 514/234.2 514/303 544/127 546/118



Family:

Publication number	Publication date	Application number	Application date
AR053364 AA	20070502	AR2006P101532	20060418
EP1874768 A2	20080109	EP20060758426	20060420
JP2008536938 T2	20080911	JP20080507851T	20060420
PE13782006 A1	20061203	PE20060000405	20060418
TH82181 A	20070104	TH20061001761	20060418
TW200716110 A	20070501	TW20060113711	20060418
US2008318947 AA	20081225	US20060911892	20060420
WO06113837 A2	20061026	WO2006US14807	20060420
WO06113837 A3	20070830	WO2006US14807	20060420

Priority:
US20050673120P 20050420 WO2006US14807 20060420 US20060911892 20060420

Probable Assignee: SMITHKLINE BEECHAM CORP

Assignee(s): (std): HEERDING DIRK A ; ROUSE MEAGAN B ; SEEFELD MARK ANDREW ; SMITHKLINE BEECHAM ; SMITHKLINE BEECHAM CORP

Assignee(s): GLAXOSMITHKLINE LLC

Inventor(s): (std): HEERDING DIRK A ; ROUSE MEAGAN B ; SEEFELD MARK ANDREW

Agent(s): SEWELL RICHARD CHARLES ET AL; SMITHKLINE BEECHAM CORPORATE INTELLECTUAL PROPERTY US UW2220 CORP

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS

Abstract: Source: US2008234276A The invention relates to novel heterocyclic triazines which are useful as hypoxic selective cytotoxic agents that mediate and/or inhibit cell proliferation, for example, through the activity of protein kinases. The invention is further related to pharmaceutical compositions containing such compounds and compositions, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation by administering effective amounts of such compounds.

Classifications:

International (IPC 8-9): A61K31/437 A61K31/4545 A61K31/47 A61K31/4709 A61K31/496 A61K31/4965 A61K31/498 A61K31/4985 A61K31/51 A61K31/517 A61K31/53 A61K31/5377 A61K31/551 A61K45/00 A61P35/00 A61P43/00 A61P9/00 C07D215/40 C07D215/48 C07D215/60 C07D239/94 C07D241/20 C07D241/54 C07D243/08 C07D253/06 C07D253/08 C07D253/10 C07D401/04 C07D401/10 C07D401/12 C07D401/14 C07D403/12 C07D403/14 C07D413/10 C07D417/10 C07D471/04 C07D487/04 C12N9/99 (Advanced/Invention); C07D401/04 C07D401/12 (Advanced/Non-invention); A61K31/4353 A61K31/4523 A61K31/47 A61K31/4709 A61K31/496 A61K31/4965 A61K31/498 A61K31/4985 A61K31/51 A61K31/517 A61K31/53 A61K31/5375 A61K31/551 A61K45/00 A61P35/00 A61P43/00 A61P9/00 C07D215/00 C07D239/00 C07D241/00 C07D253/00 C07D401/00 C07D403/00 C07D471/00 C07D487/00 (Core/Invention); C07D401/00 (Core/Non-invention)
CPC: C07D239/76 C07D215/48 C07D215/60 C07D239/94 C07D241/20 C07D241/54 C07D253/07 C07D401/04 C07D401/10 C07D401/12 C07D401/14 C07D403/12 C07D403/14 C07D471/04 C07D487/04
European: C07D215/48 C07D215/60 C07D239/76 C07D239/94 C07D241/20 C07D241/54 C07D253/07 C07D401/04 C07D401/10 C07D401/12 C07D401/14 C07D403/12 C07D403/14 C07D471/04 C07D487/04
US: 435/184 435/184S 514/218 514/234.2 514/234.200S 514/243 514/249 514/249S 514/313 514/313S 540/575 540/575S 544/118 544/118S 544/183 544/183S 544/350 544/350S 546/162 546/162S

Family:

Publication number	Publication date	Application number	Application date
EP1846392 A2	20071024	EP20060779878	20060201
EP1858883 A2	20071128	EP20060765560	20060201
GB200501999 A0	20050309	GB20050001999	20050201
JP2008528679 T2	20080731	JP20070553748T	20060201
JP2008538546 T2	20081030	JP20070553746T	20060201
US2008234276 AA	20080925	US20060815159	20060201
US2010048540 AA	20100225	US20060815168	20060201
WO06120573 A2	20061116	WO20061B01657	20060201
WO06120573 A3	20070510	WO20061B01657	20060201
WO06131835 A2	20061214	WO20061B01981	20060201
WO06131835 A3	20070510	WO20061B01981	20060201

Priority:

GB20050001999	20050201	GB20050501999	20050201	US20050678202P	20050506
WO20061B01981	20060201	WO20061B01657	20060201	US20060815159	20060201

Probable Assignee: SENTINEL ONCOLOGY LTD

Assignee(s): (std): BOYLE BOB ; SENTINEL ONCOLOGY LTD ; TRAVERS STUART

Assignee(s): SENTINEL ONCOLOGY LIMITED

Inventor(s): (std): BOYLE BOB ; BOYLE ROBERT GEORGE ; TRAVERS STUART


Agent(s): HESLIN ROTHENBERG FARLEY AND MESITI PC

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

Abstract: Source: US2009118273A The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Abl, Bcr-Abl, Bmx, BTK, b-RAF, c RAF, CSK, cSRC, Fes, FGFR3, Flt3, IKKa, IKK beta, JNK1a1, JNK2a2, Lck, Met, MKK4, MKK6, p70S6K, PAK2, PDGFRa, PKA, PKCa, PKD2, ROCK-II, Ros, Rsk1, SAPK2a, SAPK2 beta, SAPK3, SAPK4, SGK, Syk, Tie2 and TrkB kinases.

Classifications:
International (IPC 8-9): A61K31/519 A61P29/00 A61K31/407 A61K31/4184 A61K31/496 A61K31/4985 A61K31/5377 A61K35/00 A61P35/00 A61P35/02 A61P37/06 A61P43/00 A61P9/10 C07D233/20 C07D233/34 C07D403/14 C07D413/14 C07D471/04 C07D487/04 C07D487/14 (Advanced/Invention); A61K31/519 C07D487/04 (Advanced/Non-invention); A61K31/519 A61P29/00 A61P35/00 C07D471/00 (Core/Invention); A61P (Subclass/Invention)
International (IPC 1-7): A61K31/519 A61P25/00 A61P35/00 A61P37/00 C07D471/04
CPC: C07D471/04
European: C07D471/04
US: 514/232.8 514/234.2 514/234.200P 514/252.16 514/252.160S 514/265.1 514/265.100S 544/117 544/117S 544/122 544/280 544/280S 544/357 544/357S



Family:

Publication number	Publication date	Application number	Application date
AR056346 AA	20071003	AR2006P101900	20060511
AT492545 E	20110115	AT20060752481T	20060510
AU2006247757 AA	20061123	AU20060247757	20060510
AU2006247757 BB	20090827	AU20060247757	20060510
BRPI0610278 A2	20100608	BR2006PI10278	20060510
CA2607299 AA	20071106	CA20062607299	20060510
CA2607299 C	20130507	CA20062607299	20060510
CN101175753 A	20080507	CN200680016132	20060510
CN101175753 B	20110323	CN200680016132	20060510
DE602006019088 D1	20110203	DE200660019088T	20060510
EP1891066 A2	20080227	EP20060752481	20060510
EP1891066 B1	20101222	EP20060752481	20060510
ES2358344 T3	20110509	ES20060752481T	20060510
GT200600197 A	20070328	GT20060000197	20060510
IN08398DN2007 A	20080704	IN2007DN08398	20071031
IN259789 B	20140328	IN2007DN08398	20071031
JP2008540556 T2	20081120	JP20080511323T	20060510
JP5016593 B2	20120905	JP20080511323T	20060510
KR20080025039 A	20080319	KR20077026230	20071112
MX2007014066 A1	20080211	MX20070014066	20071109
PE13662006 A1	20070105	PE20060000501	20060511
RU2007145935 A	20090620	RU20070145935	20060510
RU2411242 C2	20110210	RU20070145935	20060510
TW200726766 A	20070716	TW20060116981	20060512
US2009118273 AA	20090507	US20060914308	20060510
US8183248 BB	20120522	US20060914308	20060510
WO06124462 A2	20061123	WO2006US18096	20060510
WO06124462 A3	20070104	WO2006US18096	20060510

Priority:
US20050680684P 20050513 US20050680684 20050513 WO2006US18096 20060510
US20060914308 20060510

Probable Assignee: IRM LLC
Assignee(s): (std): AJRM LLK ; GRAY NATHANAEL SCHIANDER ; IRM LLC ; SIM TAEBO ; REN PINGDA ; NAGLE ADAIT ; YOU SHULI ; LIU YI ; IRM LLC A DELAWARE LTD LIABILITY
Assignee(s): IRM LLC A DELAWARE LIABILITY CO LTD ; IRM LLC A DELAWARE LIMITED LIABILITY COMPANY
Inventor(s): (std): PINGDA REN ; REN PINGDA ; SCHIANDER GRAY NATHANAEL ; SHULI YOU ; SIM TAEBO ; TAEBO SIM ; YI LIU ; YOU SHULI ; SIM TAEHBO ; SIM TAE BO ; ADAIT NAGLE ; GRAY NATHANAEL ; GRAY NATHANAEL SCHIANDER ; LIU YI ; NAGLE ADAIT ; REHN PINDA ; JU SHULI ; I LJU ; GREJ NATANAEL SHIANDER
Inventor(s): NATHANAEL GRAY ; NATHANAEL SCHIANDER GRAY ; REN PING DA ; REHN' PINDA
Agent(s): ROTH PETER RICHARD ET AL; CASLEY CHRISTOPHER STUART; NOVARTIS CORPORATE INTELLECTUAL PROPERTY; CHIHANG AMY; GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION; GENOMICS INST OF NOVARTIS RESEARCH FOUNDATION
Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY

Abstract: Source: US2006270702A Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, and prodrugs thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicles chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one chemical entity as a single active agent or administering such at least one chemical entity in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one chemical entity under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.

Classifications:
International (IPC 8-9): A61K31/437 A61K31/4439 A61K31/444 A61K31/4709 A61K31/4745 A61P17/06 A61P19/02 A61P27/02 A61P29/00 A61P35/00 C07D215/38 C07D401/06 C07D403/02 C07D471/02 C07D471/04 (Advanced/Invention)
CPC: C07D401/06 C07D471/04
European: C07D401/06 C07D471/04
US: 514/300 514/314 514/314S 514/338 514/338S 514/339 546/113 546/113S 546/167 546/176 546/176S 546/273.4 546/273.400S

Family:

Publication number	Publication date	Application number	Application date
US2006270702 AA	20061130	US20060415419	20060502
US2010286190 AA	20101111	US20100840246	20100720
US7777040 BB	20100817	US20060415419	20060502
US8222421 BB	20120717	US20100840246	20100720
WO07024294 A2	20070301	WO2006US16916	20060502
WO07024294 A3	20070531	WO2006US16916	20060502

Priority:
US20050677758P 20050503 US20050677530P 20050503 US20060415419 20060502
US20100840246 20100720

Probable Assignee: GILEAD CONNECTICUT INC

Assignee(s): (std): BLOMGREN PETER ; BLOMGREN PETER A ; BRITTELLI DAVID ; BRITTELLI DAVID R ; CGI PHARMACEUTICALS INC ; DANCA MIHAELA D ; MITCHELL SCOTT A ; ZHICHKIN PAVEL ; VOSS MATTHEW E ; DANCA MIHAELA DIANA ; GILEAD CONNECTICUT INC

Inventor(s): (std): BLOMGREN PETER ; BLOMGREN PETER A ; BRITTELLI DAVID ; BRITTELLI DAVID R ; DANCA MIHAELA D ; DANCA MIHAELA DIANA ; MITCHELL SCOTT A ; VOSS MATTHEW E ; ZHICHKIN PAVEL

Inventor(s): VOSS MATTHEW ; MITCHELL SCOTT ; DANCA MIHAELA

Agent(s): FINNEGAN HENDERSON FARABOW GARRETT AND DUNNER, LLP; FINNEGAN HENDERSON FARABOW GARRETT AND DUNNER LLP; MORRISON AND FOERSTER LLP

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Title: DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK

Abstract: Source: US2008058340A This invention concerns N-(2-arylamino) aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.


Classifications:

International (IPC 8-9): A01K31/18 A01N41/06 A61K A61K31/18 A61K31/185 A61K31/195 A61K31/34 A61K31/341 A61K31/381 A61K31/40 A61K31/415 A61K31/416 A61K31/4162 A61K31/4164 A61K31/4184 A61K31/42 A61K31/423 A61K31/426 A61K31/433 A61K31/4353 A61K31/4355 A61K31/437 A61K31/44 A61K31/4406 A61K31/4412 A61K31/4465 A61K31/47 A61K31/495 A61K31/4965 A61K31/501 A61K31/502 A61K31/5025 A61K31/517 A61K31/519 A61K31/56 A61K31/63 A61K31/685 A61K31/7068 A61K31/7076 A61K31/7088 A61K39/395 A61K45/00 A61K45/06 A61K47/02 A61K47/12 A61K47/20 A61K47/38 A61K48/00 A61K9/14 A61K9/20 A61K9/28 A61K9/48 A61P1/04 A61P17/00 A61P17/06 A61P19/02 A61P25/00 A61P25/28 A61P27/02 A61P29/00 A61P3/00 A61P3/10 A61P31/00 A61P31/04 A61P35/00 A61P35/02 A61P37/00 A61P37/02 A61P43/00 A61P9/00 A61P9/10 C07C C07C303/36 C07C303/42 C07C303/44 C07C307/00 C07C307/06 C07C311/00 C07C311/08 C07C311/09 C07C311/10 C07C311/13 C07C311/14 C07C311/21 C07C311/25 C07C311/28 C07C311/29 C07C311/36 C07D207/36 C07D213/42 C07D215/38 C07D231/18 C07D231/56 C07D233/84 C07D235/02 C07D235/08 C07D235/14 C07D237/26 C07D237/28 C07D239/74 C07D261/10 C07D261/20 C07D277/36 C07D277/54 C07D295/13 C07D307/64 C07D333/34 C07D333/38 C07D401/04 C07D417/04 C07D471/04 C07D487/04 C07D498/04 C12N5/02 C12N9/99 (Advanced/Invention); A61K31/18 A61P1/16 A61P11/00 A61P13/12 A61P17/00 A61P17/02 A61P19/02 A61P21/00 A61P29/00 A61P35/00 A61P35/02 A61P37/02 C07C311/08 C07C311/14 C07C311/28 (Advanced/Non-invention); A01N41/00 A61K31/00 A61K31/18 A61K31/185 A61K31/341 A61K31/381 A61K31/40 A61K31/415 A61K31/416 A61K31/4162 A61K31/4164 A61K31/42 A61K31/423 A61K31/426 A61K31/433 A61K31/4353 A61K31/44 A61K31/47 A61K31/495 A61K31/5025 A61K31/517 A61K31/519 A61K31/63 A61K39/395 A61K47/38 A61P1/00 A61P17/00 A61P19/00 A61P27/00 A61P29/00 A61P3/00 A61P31/00 A61P35/00 A61P37/00 A61P9/00 C07C307/00 C07C311/00 C07D207/00 C07D215/00 C07D231/00 C07D233/00 C07D235/00 C07D239/00 C07D261/00 C07D277/00 C07D295/00 C07D307/00 C07D333/00 C07D417/00 C07D487/00 C07D498/00 (Core/Invention); A61K31/18 C07C311/14 (Core/Non-invention); A01N A61K A61P C07C C07D (Subclass/Invention)

International (IPC 1-7): A01N41/06 A61K31/18 A61K31/416 A61K31/423 A61P35/00 C07D231/56 C07D235/14 C07D239/74 C07D261/20 **CP:** A61K31/381 A61K31/40 A61K31/4409 A61K31/496 C07D277/54 C07D333/38 C07D417/04 A61K9/146 A61K9/4858 A61K9/4866 A61K47/02 A61K47/20 A61K47/38 C07D231/56 C07D235/14 C07D239/74 C07D261/20 C07D471/04 A61K45/06 A61K31/352 A61K47/3 A61K9/14 A61K9/48 A61K31/1 A61K47/0 A61K47/2 C07B2200/07 C07C311/09 C07C311/21 C07C311/29 C07C311/32 C07C2101/04 C07C2101/08 C07C2101/14 C07D207/36 C07D211/54 C07D213/38 C07D231/12 C07D285/04 C07D333/34 C07C303/44 C07D295/13 C07D213/42 A61K31/34 A61K31/426 A61K31/42 A61K31/4164 A61K31/495 A61K31/18 A61K31/415 A61K31/433 A61K31/4406 C07C311/08 C07C311/28 C07D231/18 C07D233/84 C07D261/10 C07D277/36 C07D307/64 C07B2200/13 C07C2101/02 **European:** A61K31/18 A61K31/352 A61K31/381 A61K31/40 A61K31/415 A61K31/433 A61K31/4406 A61K31/4409 A61K31/496 A61K45/06 A61K47/02 A61K47/20 A61K47/38 A61K9/14H6 A61K9/48H4 A61K9/48H6 C07C311/08 C07C311/09 C07C311/14 C07C311/21 C07C311/29 C07C311/32 C07D207/36 C07D211/54 C07D213/38 C07D231/12 C07D231/18 C07D231/56 C07D233/84 C07D235/14 C07D239/74 C07D261/10 C07D261/20 C07D277/36 C07D277/54 C07D285/04 C07D307/64 C07D333/34 C07D333/38 C07D417/04 C07D471/04 M07B200/07 M07B200/13 M07C101/02 M07C101/04 M07C101/08 M07C101/14 **US:** 424/474 424/474P 435/184 435/184S 435/375 435/375S 514/171 514/171S 514/248 514/249 514/249S 514/252.02 514/252.020P 514/252.12 514/252.120P 514/259.3 514/266.1 514/266.100S 514/300 514/300S 514/302 514/303 514/311 514/311S 514/327 514/327S 514/346 514/357 514/357S 514/361 514/361S 514/369 514/369S 514/379 514/379S 514/380 514/380S 514/393 514/393S 514/394 514/398 514/398S 514/406 514/407 514/407S 514/423 514/423S 514/424 514/424S 514/445 514/445S 514/45 514/471 514/471S 514/49 514/600 514/601 514/601S 514/602 514/604 514/604S 514/605 514/605S 514/709 514/77 544/235 544/235S 544/236 544/238 544/238S 544/281 544/283 544/283S 544/398 544/398S 546/115 546/118 546/118S 546/119 546/119S 546/121 546/121S 546/171 546/171S 548/128 548/128S 548/184 548/184S 548/185 548/185S 548/241 548/241S 548/243 548/243S 548/304.4 548/309.7 548/309.700S 548/323.5 548/323.500S 548/361.1 548/370.1 548/370.100S 548/534 548/534S 549/479 549/479S 549/65 549/65S 564/79 564/80 564/80S 564/84 564/86 564/89 564/89S 564/92 564/92S 564/97 564/97S 564/99 564/99S 600/1

Family:

Publication number	Publication date	Application number	Application date
AP201005134 A0	20100228	AP20100005134	20080728
AP2817 A	20131231	AP20100005134	20080728
AU2006272837 AA	20070201	AU20060272837	20060721
AU2006272837 BB	20120823	AU20060272837	20060721
AU2008206045 AA	20080724	AU20080206045	20080118
AU2008282338 AA	20090205	AU20080282338	20080728
AU2008282338 BB	20150212	AU20080282338	20080728
AU2009236325 AA	20091022	AU20090236325	20090414
AU2015200390 AA	20150219	AU20150200390	20150128
BRPI0815659 A2	20140930	BR2008PI15659	20080728
CA2618218 AA	20080207	CA20062618218	20060721
CA2675358 AA	20090713	CA20082675358	20080118
CA2693390 AA	20100118	CA20082693390	20080728
CA2694646 AA	20100126	CA20082694646	20080728
CA2720671 AA	20091022	CA20092720671	20090414
CN101495118 A	20090729	CN200680034935	20060721
CN101495118 B	20120905	CN200680034935	20060721
CN101663279 A	20100303	CN200880007510	20080118
CN101808516 A	20100818	CN200880108829	20080728
CN101808516 B	20130828	CN200880108829	20080728
CN102131771 A	20110720	CN200980118067	20090414
CN103479604 A	20140101	CN201310317815	20080728
CO6210813 A2	20101020	CO20090074929	20090717
CO6331425 A2	20111020	CO20100128068	20101014
CO6470808 A2	20120629	CO20100009526	20100129
CR10939 A	20091113	CR20090010939	20090717
CR11244 A	20100520	CR20100011244	20100129
CR11731 A	20110608	CR20100011731	20101014
DK1912636 T3	20140721	DK20060788078T	20060721
DOP20090181 A	20100430	DO20090000181	20090722
DOP20100045 A	20101031	DO20100000045	20100129
DOP20100304 A	20111015	DO20100000304	20101014
EA020624 B1	20141230	EA20100000268	20080728
EA200900959 A1	20100226	EA20090000959	20080118
EA201000268 A1	20100830	EA20100000268	20080728
EA201001639 A1	20110630	EA20100001639	20090414
EA201400552 A1	20140930	EA20140000552	20080728
ECSP099525 A	20091130	EC2009SP09525	20090717
ECSP10010548 A	20101130	EC2010SP10548	20101014
ECSP100548 A	20101130	EC2010SP00548	20101014
ECSP109910 A	20100430	EC2010SP09910	20100129



EP1912636 A2	20080423	EP20060788078	20060721
EP1912636 A4	20091118	EP20060788078	20060721
EP1912636 B1	20140625	EP20060788078	20060721
EP2121620 A1	20091125	EP20080727965	20080118
EP2121620 B1	20150617	EP20080727965	20080118
EP2175885 A1	20100421	EP20080782470	20080728
EP2175885 A4	20101201	EP20080782470	20080728
EP2184984 A1	20100519	EP20080796733	20080728
EP2184984 A4	20130724	EP20080796733	20080728
EP2291350 A2	20110309	EP20090732683	20090414
EP2291350 A4	20120919	EP20090732683	20090414
ES2481402 T3	20140730	ES20060788078T	20060721
HK1134436 A1	20130614	HK20100100120	20100107
HK1147396 A1	20140516	HK20110101625	20110218
HK1157738 A3	20120706	HK20110112088	20111109
HN2010000203 A	20121119	HN20100000203	20100129
HN2010002097 A	20130610	HN20100002097	20101014
IL189201 A0	20090211	IL20080189201	20080203
IL189201 A1	20140528	IL20080189201	20080203
IL199727 A0	20100415	IL20090199727	20090707
IL203296 A0	20101031	IL20100203296	20100113
IL208284 A0	20101230	IL20100208284	20100921
IN00614DN2010 A	20111014	IN2010DN00614	20100128
IN00861CN2008 A	20081128	IN2008CN00861	20080220
IN04579DN2009 A	20100514	IN2009DN04579	20090714
IN07650DN2010 A	20110909	IN2010DN07650	20101029
JP2010516698 T2	20100520	JP20090546558T	20080118
JP2010535232 T2	20101118	JP20100520118T	20080728
JP2010535233 T2	20101118	JP20100520122T	20080728
JP2011518786 T2	20110630	JP20110505138T	20090414
JP2015078199 A2	20150423	JP20140231450	20141114
JP5479337 B2	20140423	JP20100520122T	20080728
JP5491199 B2	20140514	JP20090546558T	20080118
KR101377688 B1	20140325	KR20087004227	20060721
KR20080068637 A	20080723	KR20087004227	20080221
KR20090111847 A	20091027	KR20097017247	20080118
KR20100092424 A	20100820	KR20107004742	20100302
KR20110014149 A	20110210	KR20107025394	20090414
KR20140098185 A	20140807	KR20147017261	20080728
MA31183 B1	20100201	MA20090032166	20090812
MA31881 B1	20101201	MA20100032636	20100219
MA32226 B1	20110401	MA20100033245	20101014
MX2008002114 A1	20080417	MX20080002114	20080213
MX2009007661 A1	20091214	MX20090007661	20090717
MX2010001244 A1	20100831	MX20100001244	20100129
MX2010011314 A1	20101112	MX20100011314	20101014
NZ582929 A	20120330	NZ20080582929	20080728
PT1912636 T	20140724	PT20060788078T	20060721
SG189784 A1	20130531	SG20130002837	20090414
SI1912636 T1	20140829	SI20060031805T	20060721
SV2010003469 A	20100430	SV20100003469	20100129
TW200951107 A	20091216	TW20090107166	20090305
TW1481590 B	20150421	TW20090107166	20090305
UA99731 C2	20120925	UA20100002026	20080728
US2008058340 AA	20080306	US20070830733	20070730
US2008255133 AA	20081016	US20080016897	20080118
US2009082457 AA	20090326	US20080323279	20081125
US2009227681 AA	20090910	US20090399848	20090306
US2010331334 AA	20101230	US20100879314	20100910
US2011033539 AA	20110210	US20090937630	20090414
US2011060049 AA	20110310	US20080671287	20080728
US2012016034 AA	20120119	US20110181864	20110713
US2012022076 AA	20120126	US20110243368	20110923
US2012302518 AA	20121129	US20120556605	20120724
US2013261339 AA	20131003	US20130905674	20130530
US2014303253 AA	20141009	US20140311720	20140623
US2014378466 AA	20141225	US20140478467	20140905
US7759518 BB	20100720	US20080323279	20081125
US7820664 BB	20101026	US20080016897	20080118
US8044240 BB	20111025	US20090399848	20090306
US8063049 BB	20111122	US20100879314	20100910
US8101799 BB	20120124	US20070830733	20070730
US8252842 BB	20120828	US20110181864	20110713
US8466316 BB	20130618	US20120556605	20120724
US8648116 BB	20140211	US20080671287	20080728
US8759577 BB	20140624	US20130905674	20130530
US8808742 BB	20140819	US20090937630	20090414
US8829052 BB	20140909	US20110243368	20110923
WO07014011 A2	20070201	WO2006US28326	20060721
WO07014011 A3	20090423	WO2006US28326	20060721
WO08089459 A1	20080724	WO2008US51518	20080118
WO09018233 A1	20090205	WO2008US71392	20080728
WO09018238 A1	20090205	WO2008US71397	20080728
WO09129246 A2	20091022	WO2009US40538	20090414
WO09129246 A3	20110331	WO2009US40538	20090414
ZA200801443 A	20090826	ZA20080001443	20080212


Priority:

US20050701814	20050721	US20050701814P	20050721	US20050731633P	20051028
US20050706719P	20050808	WO2006US28326	20060721	US20060833886P	20060707
US20060833886P	20060728	US20070830733	20070730	US20070885849P	20070119
US20080034466P	20080306	US20080034464P	20080306	US20080016897	20080118


WO2008US51518	20080118	EP20060788078	20060721	US20080044886P	20080414
US20080323279	20081125	US20090399848	20090306	WO2008US71392	20080728
US20090159778P	20090312	WO2008US71397	20080728	US20080034466	20080306
US20080034464	20080306	US20080044886	20080414	WO2009US40538	20090414
US20090159778	20090312	US20080671287	20080728	AU20080282338	20080728
US20080071392	20080728	US20080159778P	20080312	JP20100520118	20080728
US20100879314	20100910	US20090937630	20090414	US20110181864	20110713
US20110243368	20110923	US20120556605	20120724	US20130905674	20130530
US20140311720	20140623	US20140478467	20140905		
Probable Assignee: ARDEA BIOSCIENCES INC					
Assignee(s): (std): ABDELLAOUI HASSAN EL ; ADJEI ALEX ; ANDREA BIOSCIENCES INC ; ARDEA BIOSCIENCE INC ; ARDEA BIOSCIENCES ; BARAWKAR DINESH ; CHAMAKURA VARAPRASAD ; ARDEA BIOSCIENCES INC ; CHAPMAN MARK S ; HONG ZHI ; MADERNA ANDREAS ; KOH YUNG HY0 ; ROWLINGS COLIN EDWARD ; QUART BARRY ; GIRARDET JEAN LUC ; DIMOCK STUART ; MINER JEFFREY N ; QUART BARRY D ; EL ABDELLAOUL HASSAN ; EL ABDELLAOUI HASSAN ; ARDEA BIOSCINENCES INC ; PHILIP MORRIS PRODUCTS SA ; VALEANT RES AND DEV ; VERNIER JEAN MICHEL ; YU CHUNRONG					
Assignee(s): VALEANT RESEARCH AND DEVELOPMENT ; BARCLAYS BANK PLC SUCCESSOR AGENT AS ; INTRABIOTICS PHARMACEUTICALS INC ; GOLDMAN SACHS LENDING PARTNERS LLC COLLATERAL AGENT AS ; GOLDMAN SACHS LENDING PARTNERS LLC COLLATERAL AGEN ; DOW PHARMACEUTICAL SCIENCES ; PRESTWICK PHARMACEUTICALS INC ; VALEANT BIOMEDICALS INC ; VALEANT PHARMACEUTICALS INT ; VALEANT PHARMACEUTICALS NORTH AMERICA LLC ; BAYER SCHERING PHARMA AG ; ATON PHARMA INC ; CORIA LABORATORIES LTD					
Inventor(s): (std): ABDELLAOUI HASSAN EL ; ADJEI ALEX ; ANDREAS MADERNA ; BARAWKAR DINESH ; BARAWKAR DINESH A ; BARRY D QUART ; BARRY QUART ; CHAMAKURA VARAPRASAD ; CHAPMAN MARK S ; COLIN EDWARD ROWLING ; COLIN EDWARD ROWLINGS ; DIMOCK STUART ; DINESH BARAWKAR ; EDWARD ROWLINGS COLIN ; EL ABDELLAOUI HASSAN ; EL ABDELLAOUL HASSAN ; GI RARDET JEAN LUC ; GIRARDET JEAN LUC ; HASSAN EL ABDELLAOUI ; HONG ZHI ; JEAN LUC GIRARDET ; JEAN LUC GIRARDET J ; JEAN MICHAEL VERNIER ; JEAN MICHEL VERNIER ; JEAN MICHEL VERNIER J ; JEFFREY MINER ; KOH Y UNG HY0 ; KOH YUNG HY0 ; MADERNA ANDREAS ; MINER JEFF ; MINER JEFFREY ; MINER JEFFREY N ; RARDET JEAN LUC ; ROWLINGS COLIN EDWARD ; ROWLINGS COLLIN EDWARD ; STUART DIMOCK ; VARAPRASAD CHAMAKURA ; VERNIER JEAN MICAH EL ; VERNIER JEAN MICHEL ; YU CHUNRONG ; YUNG HY0 KOH ; ZHI HONG ; QUART BARRY ; QUART BARRY D					
Inventor(s): ABDELLAOUI HASSAN ; VERNIER JEAN MICHAEL ; JEFFREY N MINER ; DINESH A BARAWKAR					
Agent(s): VIERING JENTSCHURA AND PARTNER; WILLIAMS PAUL HOWARD; WILSON SONSINI GOODRICH AND ROSATI; MILLEN WHITE ZELANO AND BRANIGAN PC; MILLEN WHITE ZELANO AND BRANIGAN P C; MILLEN WHITE ZELANO BRANIGAN PC; REESE HEIDI; WITT ERIC ET AL; HADDACH AUBREY A ET AL					
Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW					

Title: PYRAZOLE DERIVATIVES HAVING TYROSINE KINASE ACTIVITY

Abstract: Source: US2008207647A Compounds of the formula (I), in which R, X, R¹, R², R³ and R⁴ have the meanings indicated in Claim (1), are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.



Classifications:
International (IPC 8-9): A61K31/41 A61K31/415 A61K31/4178 A61K31/4188 A61K31/4375 A61K31/50 A61K31/505 A61K31/519 A61K31/52 A61K45/00 A61P13/08 A61P15/00 A61P17/00 A61P17/02 A61P17/06 A61P19/00 A61P19/02 A61P27/00 A61P27/02 A61P29/00 A61P35/00 A61P35/02 A61P37/00 A61P37/02 A61P43/00 C07D231/38 C07D231/40 C07D403/12 C07D471/04 C07D471/06 C07D473/00 C07D473/30 C07D473/34 C07D487/04 C07D491/14 (Advanced/Invention); A61K31/41 A61K31/415 A61K31/4164 A61K31/50 A61K31/505 A61K31/519 A61K45/00 A61P13/00 A61P15/00 A61P17/00 A61P19/00 A61P27/00 A61P29/00 A61P35/00 A61P37/00 A61P43/00 C07D403/00 C07D471/00 C07D473/00 C07D487/00 C07D491/00 (Core/Invention)
International (IPC 1-7): A61K31/4188 A61P35/00 C07D231/56
CPC: C07D403/12 C07D471/04 C07D473/00 C07D487/04 C07D491/14
European: C07D403/12 C07D471/04 C07D473/00 C07D487/04 C07D491/14
US: 514/263.2 514/263.200P 514/264.1 514/264.11 514/264.110S 514/265.1 514/265.100S 514/386 514/407 514/407S 544/236 544/236S 544/265 544/277 544/280 548/312.4 548/312.400S



Family:

Publication number	Publication date	Application number	Application date
AR056024 AA	20070912	AR2006P103477	20060809
AU2006278862 AA	20070215	AU20060278862	20060724
AU2006278862 BB	20111117	AU20060278862	20060724
CA2618524 AA	20080207	CA20062618524	20060724
CA2618524 C	20140513	CA20062618524	20060724
DE102005037499 A1	20070215	DE200510037499	20050809
EP1912998 A1	20080423	EP20060776357	20060724
EP1912998 B1	20130306	EP20060776357	20060724
ES2406737 T3	20130607	ES20060776357T	20060724
JP2009504582 T2	20090205	JP20080525422T	20060724
US2008207647 AA	20080828	US20060063020	20060724
US7662827 BB	20100216	US20060063020	20060724
WO07017083 A1	20070215	WO2006EP07245	20060724

Priority:
DE200510037499 20050809 WO2006EP07245 20060724

Probable Assignee: MERCK PATENT GMBH

Assignee(s): (std): CRASSIER HELENE ; HOELZEMANN GUENTER ; RAUTENBERG WILFRIED ; MERCK PATENT GMBH

Assignee(s): MERCK KGAA ; MERCK PATENT GES MIT BESCHRAENKTER HAFTUNG ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUN ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG

Inventor(s): (std): GUNTER HOELZEMANN ; HELENE CRASSIER ; HOELZEMANN GUNTER ; WILFRIED RAUTENBERG ; RAUTENBERG WILFRIED ; HOELZEMANN GUENTER ; CRASSIER HELENE

Agent(s): BAKER AND DANIELS LLP; ARENT FOX LLP

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

Abstract: Source: US2008300246A The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, BMX, BTK, CHK2, b-RAF, c-RAF, CSK, c-SRC, Fes, FGFR3, Flt3, IKKα, IKKβ, JNK2α, 2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, **PDGFR**β, PKA, PKBα, PKD2, Rsk1, SAPK2α, SAPK2β, SAPK3, SGK, Tie2 and TrkB kinases.

Classifications:

International (IPC 8-9): A61K31/4375 A61K31/495 A61K31/519 A61K31/53 A61K31/5377 A61P1/04 A61P1/16 A61P11/06 A61P17/06 A61P17/12 A61P19/02 A61P19/10 A61P21/04 A61P25/00 A61P29/00 A61P3/10 A61P35/00 A61P35/02 A61P37/00 A61P37/02 A61P37/08 A61P43/00 A61P5/14 A61P7/02 A61P9/04 A61P9/10 C07D413/14 C07D471/02 C07D471/04 C07D471/12 C07D491/147 (Advanced/Invention); A61K31/4355 A61K31/495 A61K31/519 A61K31/53 A61K31/5355 A61P35/00 C07D413/12 C07D471/04 C07D491/147 (Advanced/Non-invention); A61K31/495 A61K31/53 A61P35/00 C07D471/00 (Core/Invention)

International (IPC 1-7): C07D471/04

CPC: C07D471/04 C07D471/14 C07D491/14

European: C07D471/04 C07D471/14 C07D491/14

US: 514/234.2 514/234.200P 514/264.1 514/264.11 514/264.110S 514/287 514/287S 514/293 514/300 514/300S 544/117 544/117S 544/279 544/279S 546/122 546/122S 546/64 546/64S 546/83

Family:

Publication number	Publication date	Application number	Application date
AT482958 E	20101015	AT20060801089T	20060809
AU2006279992 AA	20070222	AU20060279992	20060809
BRPI0614804 A2	20110412	BR2006P114804	20060809
CA2617359 AA	20080130	CA20062617359	20060809
CN101282975 A	20081008	CN200680037407	20060809
DE602006017281 D1	20101111	DE200660017281T	20060809
EP2099797 A2	20090916	EP20060801089	20060809
EP2099797 B1	20100929	EP20060801089	20060809
ES2351939 T3	20110214	ES20060801089T	20060809
IN00981DN2008 A	20080314	IN2008DN00981	20080205
JP2009504665 T2	20090205	JP20080526176T	20060809
KR20080033526 A	20080416	KR20087005630	20080307
MX2008001969 A1	20080411	MX20080001969	20080208
PT2099797 T	20110104	PT20060801089T	20060809
RU2008108898 A	20090920	RU20080108898	20060809
US2008300246 AA	20081204	US20060997113	20060809
US7868018 BB	20110111	US20060997113	20060809
WO07021795 A2	20070222	WO2006US31134	20060809
WO07021795 A3	20070531	WO2006US31134	20060809

Priority:

US20050708227P 20050809	US20050708227 20050809	WO2006US31134 20060809
WO2005US31134 20050809	US20060997113 20060809	WO2006US31134 20050809

Probable Assignee: KRKA

Assignee(s): (std): GRAY NATHANAEL S ; IRM LLC ; IRM LLC A DELAWARE LTD LIABILI ; XIE YONGPING ; WANG XING ; LIU YI ; ZHANG GUOBAO

Assignee(s): KRKA ; IRM LLC A DELAWARE LIABILITY CO LTD ; IRM LLC A DELAWARE LIMITED LIABILITY COMPANY

Inventor(s): (std): GRAY NATHANAEL S ; GUOBAO ZHANG ; LIU YI ; WANG XING ; XIE YONGPING ; XING WANG ; YI LIU ; YONGPING XIE ; ZHANG GUOBAO

Inventor(s): NATHANAEL S GRAY

Agent(s): KIDDLE SIMON JOHN; GENOMICS INSTITUTE OF THE, NOVARTIS RESEARCH FOUNDATION; GENOMICS INST OF NOVARTIS RESEARCH FOUNDATION; SCOTT W

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW



Title: INHIBITORS OF AKT ACTIVITY

Abstract: Source: US2008076763A Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

Classifications:


International (IPC 8-9): A61K31/4188 A61P35/00 A61K31/282 A61K31/337 A61K31/4245 A61K31/437 A61K31/4545 A61K31/475 A61K31/5355 A61K31/5377 A61K31/541 A61K31/542 A61K31/5517 A61K45/00 A61P19/02 A61P35/04 A61P43/00 C07D211/06 C07D295/00 C07D411/12 C07D413/02 C07D413/12 C07D471/02 C07D471/04 C07D487/04 (Advanced/Invention); A61K31/4245 A61K31/541 A61K31/5517 A61P19/02 A61P35/00 A61P35/04 C12N9/99 (Advanced/Non-invention); A61K31/28 A61K31/337 A61K31/4245 A61K31/4353 A61K31/4523 A61K31/475 A61K31/5375 A61K31/541 A61K31/542 A61K31/551 A61K45/00 A61P19/00 A61P35/00 A61P43/00 C07D211/00 C07D295/00 C07D471/00 (Core/Invention); A61P19/00 A61P35/00 C12N9/99 (Core/Non-invention); A61K C07D (Subclass/Invention)

International (IPC 1-7): A61K31/437 A61K31/541 A61P35/00 C07D471/04

CPC: C07D471/04

European: C07D471/04

US: 514/228.5 514/228.500 514/234.2 514/234.200 514/234.5 514/235.8 514/303 514/318 544/118 544/127 544/139 544/61 546/118 546/193



Family:

Publication number	Publication date	Application number	Application date
AP200804442 A0	20080430	AP20080004442	20061109
AR056786 AA	20071024	AR2006P104898	20061108
AU2006315805 AA	20070524	AU20060315805	20061109
BRPI0618309 A2	20110823	BR2006PI18309	20061109
CA2629429 AA	20080509	CA20062629429	20061109
CN101506206 A	20090812	CN200680050861	20061109
EA200801301 A1	20090227	EA20080001301	20061109
ECSPO88425 A	20080630	EC2008SP08425	20080505
EP1948188 A2	20080730	EP20060837170	20061109
EP1948188 A4	20110216	EP20060837170	20061109
IL190968 A0	20090211	IL20080190968	20080417
IN03428DN2008 A	20080725	IN2008DN03428	20080425
JP2009516653 T2	20090423	JP20080540168T	20061109
KR20080067646 A	20080721	KR200807011158	20080509
MA29935 B1	20081103	MA20080030904	20080505
NO20082414 A	20080805	NO20080002414	20080528
PE07722007 A1	20070802	PE20060001389	20061108
TW200736260 A	20071001	TW20060141228	20061108
US2008076763 AA	20080327	US20070823415	20070627
US2010056523 AA	20100304	US20060093032	20061109
US7625890 BB	20091201	US20070823415	20070627
UY29906 A1	20070531	UY20060029906	20061108
WO07058850 A2	20070524	WO2006US43513	20061109
WO07058850 A3	20090430	WO2006US43513	20061109
ZA200803485 A	20090325	ZA20080003485	20080421

Priority:

US20050735955	20051110	US20050735955P	20051110	US20060826928P	20060926
US20060772289P	20060210	US20060735955P	20060210	US20060826928	20060926
US20070823415	20070627	WO2006US43513	20061109	US20060093032	20061109

Probable Assignee: GLAXOSMITHKLINE LLC

Assignee(s): (std): CLARK TAMMY J ; GLAXOSMITHKLINE LLC ; HEERDING DIRK A ; ITHKLINE BEECHAM CORP ; LEBER JACK D ; SMITHKLINE BEECHAM CORP ; LEBER JACK DALE ; SAFONOV IGOR ; SMITHKLINE BECKMAN CORP

Assignee(s): SMITHKLINE BECHMAN CORP

Inventor(s): (std): HEERDING DIRK ; HEERDING DIRK A ; HEERING DIRK A ; JACK DALE LEBER ; LEBER JACK D ; LEBER JACK DALE ; SAFONOV IGOR ; CLARK TAMMY J ; CLARK TAMMY J ET AL ; IGOR SAFONOV ; DALE LEBER JACK

Inventor(s): DIRK A HEERDING ; CLARK TAMMY ; TAMMY J CLARK ; LEBER JACK

Agent(s): SEWELL RICHARD CHARLES; GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY - UW2220; GLAXOSMITHKLINE CORPORATE INTELLECTUAL PROPERTY UW2220; SMITHKLINE BEECHAM CORPORATE INTELLECTUAL PROPERTY US UW2220 CORP; WAYNE J; EDWARD R; CHARLES M

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: INHIBITORS OF AKT ACTIVITY

Abstract: Source: US2009227616A Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.


Classifications:

International (IPC 8-9): A61K31/282 A61K31/337 A61K31/437 A61K31/4545 A61K31/475 A61K31/54 A61K31/541 A61K38/55 A61K45/00 A61P1/04 A61P1/16 A61P1/18 A61P11/00 A61P13/08 A61P13/12 A61P15/00 A61P17/00 A61P19/02 A61P25/00 A61P35/00 A61P43/00 A61P5/14 C07D409/14 C07D413/14 C07D471/04 (Advanced/Invention); C12N15/09 C12N9/99 (Advanced/Non-invention); A61K31/28 A61K31/337 A61K31/4353 A61K31/4523 A61K31/475 A61K31/54 A61K31/541 A61K38/55 A61K45/00 A61P1/00 A61P11/00 A61P13/00 A61P15/00 A61P17/00 A61P19/00 A61P25/00 A61P35/00 A61P43/00 A61P5/00 C07D409/00 C07D413/00 C07D471/00 (Core/Invention); C12N15/09 C12N9/99 (Core/Non-invention)

CPC: C07D471/04

European: C07D471/04

US: 514/283 514/303 514/449 514/492 546/118



Family:

Publication number	Publication date	Application number	Application date
EP1948185 A2	20080730	EP20060837174	20061109
EP1948185 A4	20100421	EP20060837174	20061109
JP2009517342 T2	20090430	JP20080540170T	20061109
US2009227616 AA	20090910	US20060093172	20061109
WO07058852 A2	20070524	WO2006US43518	20061109
WO07058852 A3	20071227	WO2006US43518	20061109

Priority:
US20050735536P 20051110 WO2006US43518 20061109 US20060093172 20061109

Probable Assignee: SMITHKLINE BEECHAM CORP

Assignee(s): (std): CLARK TAMMY J ; GLAXOSMITHKLINE LLC ; HEERDING DIRK A ; LEBER JACK DALE ; LI MEI ; SAFONOV IGOR ; SMITHKLINE BEECHAM CORP ; SMITHKLINE BEECHAM CORP A CORP

Assignee(s): SMITHKLINE BEECHAM A CORP

Inventor(s): (std): CLARK TAMMY J ; HEERDING DIRK A ; LEBER JACK DALE ; LI MEI ; LI MIE ; SAFONOV IGOR

Agent(s): SEWELL RICHARD CHARLES; SMITHKLINE BEECHAM CORPORATE INTELLECTUAL PROPERTY US UW2220 CORP

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: INHIBITORS OF AKT ACTIVITY

Abstract: Source: US2008269131A Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

Classifications:

International (IPC 8-9): A61K31/282 A61K31/337 A61K31/437 A61K31/4545 A61K31/475 A61K31/535 A61K31/541 A61K38/00 A61K38/21 A61K45/00 A61P19/02 A61P35/00 C07D471/04 C12N9/12 (Advanced/Invention); A61P43/00 (Advanced/Non-invention); A61K31/28 A61K31/337 A61K31/4353 A61K31/4523 A61K31/475 A61K31/535 A61K31/541 A61K38/21 A61K45/00 A61P19/00 A61P35/00 C07D471/00 C12N9/12 (Core/Invention); A61P43/00 (Core/Non-invention)

CPC: C07D471/04

European: C07D471/04

US: 514/1.1 514/1.2 514/1.200P 514/12 514/228.5 514/228.500S 514/303 514/303S 544/61 544/61S 546/118 546/118S

Family:

Publication number	Publication date	Application number	Application date
EP1954286 A2	20080813	EP20060837230	20061109
JP2009515884 T2	20090416	JP20080540186T	20061109
US2008269131 AA	20081030	US20060093175	20061109
WO07058879 A2	20070524	WO2006US43617	20061109
WO07058879 A3	20080103	WO2006US43617	20061109

Priority:

US20050735938P 20051110 US20050735938P 20051110 WO2006US43617 20061109

US20060093175 20061109

Probable Assignee: SMITHKLINE BEECHAM CORP

Assignee(s): (std): HEERDING DIRK A ; LEBER JACK DALE ; SAFONOV IGOR ; SMITHKLINE BEECHAM CORP ; CLARK TAMMY J

Assignee(s): GLAXOSMITHKLINE LLC

Inventor(s): (std): CLARK TAMMY J ; HEERDING DIRK A ; LEBER JACK DALE ; SAFONOV IGOR

Agent(s): SEWELL RICHARD CHARLES; SMITHKLINE BEECHAM CORPORATE INTELLECTUAL PROPERTY US UW2220 CORP

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: BICYCLIC HETEROARYL COMPOUNDS

Abstract: Source: US2007191376A This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

FDA Data:

Application numberActive ingredientProprietary nameApplicantDate of approval203469 PONATINIB HYDROCHLORIDE ICLUSIG
ARIAD Apr 23, 2015203469 PONATINIB HYDROCHLORIDE ICLUSIG ARIAD Dec 14, 2012

Classifications:

International (IPC 8-9): A01N43/54 A61K31/395 A61K31/4164 A61K31/4178 A61K31/427 A61K31/435 A61K31/437 A61K31/4375 A61K31/44 A61K31/4439 A61K31/444 A61K31/4545 A61K31/4725 A61K31/4745 A61K31/495 A61K31/496 A61K31/497 A61K31/498 A61K31/4985 A61K31/501 A61K31/502 A61K31/5025 A61K31/503 A61K31/505 A61K31/506 A61K31/519 A61K31/52 A61K31/53 A61K31/535 A61K31/5365 A61K31/5377 A61K31/5383 A61K31/551 A61K31/675 A61K31/695 A61P17/00 A61P19/00 A61P19/02 A61P19/10 A61P29/00 A61P3/00 A61P35/00 A61P35/02 A61P35/04 A61P43/00 C07D C07D213/22 C07D213/56 C07D213/60 C07D213/73 C07D213/75 C07D213/78 C07D217/18 C07D231/12 C07D231/14 C07D233/61 C07D233/64 C07D233/88 C07D233/90 C07D237/26 C07D237/28 C07D239/02 C07D239/26 C07D239/42 C07D241/12 C07D241/20 C07D277/40 C07D401/04 C07D401/12 C07D401/14 C07D403/12 C07D403/14 C07D405/06 C07D413/12 C07D417/12 C07D417/14 C07D471/02 C07D471/04 C07D473/34 C07D487/00 C07D487/02 C07D487/04 C07D498/04 C07F7/10 C07F9/6561 E06B3/12 E06C7/16 (Advanced/Invention); A61K31/4178 A61K31/427 A61K31/437 A61K31/4375 A61K31/4439 A61K31/4725 A61K31/4745 A61K31/496 A61K31/497 A61K31/4985 A61K31/502 A61K31/5025 A61K31/506 A61K31/519 A61K31/53 A61K31/5365 A61P35/00 A61P43/00 C07D487/00 C07D487/02 C07D487/04 (Advanced/Non-invention); A61K31/00 A61K31/4164 A61K31/427 A61K31/4353 A61K31/4427 A61K31/4738 A61K31/496 A61K31/4965 A61K31/498 A61K31/4985 A61K31/501 A61K31/502 A61K31/5025 A61K31/503 A61K31/506 A61K31/519 A61K31/53 A61K31/5365 A61K31/5375 A61P17/00 A61P19/00 A61P29/00 A61P3/00 A61P35/00 A61P43/00 C07D213/00 C07D217/00 C07D231/00 C07D233/00 C07D237/00 C07D239/00 C07D241/00 C07D401/00 C07D403/00 C07D413/00 C07D417/00 C07D471/00 C07D487/00 C07D498/00 E06B3/04 E06C7/00 (Core/Invention); C07D (Subclass/Invention)

International (IPC 1-7): A61K31/53 B06C7/16 E06B3/12


CPC: C07D231/12 C07D233/64 C07D233/90 C07D277/40 C07D403/14 C07D417/14 C07D487/04 C07D473/34 C07D213/56 C07D213/73 C07D213/75 C07D213/78 C07D217/14 C07D217/22 C07D237/20 C07D237/28 C07D239/26 C07D241/12 C07D241/20 C07D401/12 C07D401/14 C07D403/12 C07D405/06 C07D413/12 C07D417/12 C07D471/04 C07D471/04

European: C07D213/56 C07D213/73 C07D213/75 C07D213/78 C07D217/14 C07D217/22 C07D231/12 C07D233/64 C07D233/90 C07D237/20 C07D237/28 C07D239/26 C07D241/12 C07D241/20 C07D277/40 C07D401/12 C07D401/14 C07D403/12 C07D403/14 C07D405/06 C07D413/12 C07D417/12 C07D417/14 C07D471/04 C07D487/04

US: 514/218 514/230.5 514/233.2 514/233.200P 514/235.5 514/235.500P 514/235.8 514/242 514/245 514/245S 514/246 514/248 514/248S 514/249 514/249S 514/252.05 514/252.11 514/252.14 514/252.140S 514/252.16 514/252.160S 514/253.01 514/253.04 514/253.040S 514/253.05 514/254.02 514/254.020P 514/254.05 514/254.050S 514/255.05 514/256 514/256S 514/259.1 514/259.3 514/259.300S 514/263.2 514/263.200S 514/269 514/300 514/300S 514/303 514/303S 514/307 514/341 514/341S 514/342 514/342S 514/370 514/371 514/371S 514/397 514/397S 540/575 544/105 544/117 544/117S 544/120 544/127 544/127S 544/131 544/131S 544/182 544/182S 544/212 544/212S 544/236 544/236S 544/237 544/238 544/277 544/277S 544/281 544/281S 544/295 544/295S 544/314 544/333 544/335 544/350 544/350S 544/357 544/359 544/360 544/362 544/362S 544/363 544/364 544/369 544/370 544/370S 544/371 544/371S 544/402 544/405 546/119 546/119S 546/121 546/121S 546/122 546/148 546/268.1 546/272.7 546/272.700S 548/194 548/194S 548/312.4 548/312.400S 548/312.7 548/312.700S 548/314.7 548/314.700S 548/335.1 548/518

Family:

Publication number	Publication date	Application number	Application date
AU2006331673 AA	20070705	AU20060331673	20061222
AU2006331673 BB	20130228	AU20060331673	20061222
AU2007249924 AA	20071122	AU20070249924	20070508
AU2007249924 BB	20130704	AU20070249924	20070508
AU2007249926 AA	20071122	AU20070249926	20070508
AU2007249926 AH	20131107	AU20070249926	20070508
AU2007249926 BB	20130704	AU20070249926	20070508
AU2007249926 BH	20131107	AU20070249926	20070508
AU2013201242 AA	20130328	AU20130201242	20130304
AU2013201242 BB	20150507	AU20130201242	20130304
AU2013201243 AA	20130328	AU20130201243	20130304
AU2013203914 AA	20130509	AU20130203914	20130411
AU2013203928 AA	20130613	AU20130203928	20130411
BRPI0621098 A2	20130402	BR2006PI21098	20061222
BRPI0710328 A2	20110809	BR2007PI10328	20070508
BRPI0710331 A2	20120320	BR2007PI10331	20070508
CA2634923 AA	20080623	CA20062634923	20061222
CA2634923 C	20150505	CA20062634923	20061222
CA2650273 AA	20081023	CA20072650273	20070508
CA2651822 AA	20081110	CA20072651822	20070508
CN101389338 A	20090318	CN200680053388	20061222
CN101389338 B	20130626	CN200680053388	20061222
CN101489558 A	20090722	CN200780025922	20070508
CN101490053 A	20090722	CN200780025995	20070508
CN101490053 B	20130911	CN200780025995	20070508
CN103044432 A	20130417	CN201210427822	20061222
CN103435595 A	20131211	CN20131036955	20070508
CN103467385 A	20131225	CN201310352392	20070508
DK1973545 T3	20130225	DK20060845939T	20061222
EA200870116 A1	20091030	EA20080070116	20061222
EA200870514 A1	20090428	EA20080070514	20070508
EA200870515 A1	20090630	EA20080070515	20070508
EP1973545 A2	20081001	EP20060845939	20061222
EP1973545 A4	20100310	EP20060845939	20061222
EP1973545 B1	20130130	EP20060845939	20061222
EP2023933 A2	20090218	EP20070756231	20070508
EP2023933 A4	20110223	EP20070756231	20070508
EP2024366 A2	20090218	EP20070756233	20070508
EP2024366 A4	20110629	EP20070756233	20070508
EP2495016 A1	20120905	EP20120169710	20061222
ES2403206 T3	20130516	ES20060845939T	20061222
IL191938 A0	20090803	IL20080191938	20080604
IL194677 A1	20140331	IL20080194677	20081012



IL194678 A0	20090615	IL20080194678	20081012
IL229350 A0	20131231	IL20130229350	20131110
IL229351 A0	20131231	IL20130229351	20131110
IN02328KN2008 A	20090116	IN2008KN02328	20080611
IN04427KN2008 A	20090313	IN2008KN04427	20081103
IN04428KN2008 A	20090313	IN2008KN04428	20081103
JP2009521462 T2	20090604	JP20080547538T	20061222
JP2009536650 T2	20091015	JP20090509819T	20070508
JP2009536652 T2	20091015	JP20090509821T	20070508
JP2013064004 A2	20130411	JP20120266072	20121205
JP5200939 B2	20130605	JP20080547538T	20061222
JP5273037 B2	20130828	JP20090509819T	20070508
JP5273038 B2	20130828	JP20090509821T	20070508
KR101436303 B1	20140902	KR20087018122	20061222
KR101441365 B1	20140918	KR20087029946	20070508
KR20080081191 A	20080908	KR20087018122	20061222
KR20090018104 A	20090219	KR20087029942	20081208
KR20090018942 A	20090224	KR20087029946	20070508
LU92327 I2	20140205	LU20130092327	20131205
MX2008008152 A1	20080912	MX20080008152	20080620
MX2008014289 A1	20081126	MX20080014289	20081107
MX2008014290 A1	20081126	MX20080014290	20081107
PT1973545 T	20130211	PT20060845939T	20061222
SI1973545 T1	20130430	SI20060031513T	20061222
US2007191376 AA	20070816	US20060644849	20061222
US2009149471 AA	20090611	US20070227130	20070508
US2009176781 AA	20090709	US20070227002	20070508
US2012135986 AA	20120531	US20120357745	20120125
US2013005738 AA	20130103	US20120612067	20120912
US2013018046 AA	20130117	US20120614838	20120913
US2013196979 AA	20130801	US20130801619	20130313
US2013231337 AA	20130905	US20130801116	20130313
US2014288082 AA	20140925	US20140296016	20140604
US8114874 BB	20120214	US20060644849	20061222
US8278307 BB	20121002	US20070227130	20070508
US8461167 BB	20130611	US20070227002	20070508
US8470851 BB	20130625	US20120357745	20120125
US8778942 BB	20140715	US20130801619	20130313
US9029533 BB	20150512	US20130801116	20130313
WO07075869 A2	20070705	WO2006US48758	20061222
WO07075869 A3	20071129	WO2006US48758	20061222
WO07133560 A2	20071122	WO2007US11134	20070508
WO07133560 A3	20081231	WO2007US11134	20070508
WO07133560 C2	20081113	WO2007US11134	20070508
WO07133562 A2	20071122	WO2007US11136	20070508
WO07133562 A3	20081002	WO2007US11136	20070508

Priority:

US20050754000P	20051223	US20050753962P	20051223	US20060756089P	20060103
US20060644849	20061222	US20060798472P	20060508	US20060833191P	20060725
WO2006US48758	20061222	WO2007US11134	20070508	WO2007US11136	20070508
EP20060845939	20061222	AU20060331673	20061222	JP20080547538	20061222
US20070920687P	20070329	US20070920688P	20070329	US20070227130	20070508
US20070227002	20070508	US20120357745	20120125	AU20130201242	20130304
AU20130201243	20130304	AU20070249924	20070508	AU20130203914	20070508
AU20070249926	20070508	AU20130203928	20130411	US20130801619	20130313
US20130801116	20130313	US20120612067	20120912	US20090227130	20090122
US20120614838	20120913	US20090227002	20090122	US20140296016	20140604

Probable Assignee: ARIAD PHARMACEUTICALS INC

Assignee(s): (std): DALGARNO DAVID C ; HUANG WEI SHENG ; METCALF CHESTER A ; METCALF CHESTER A III ; SHAKESPEARE WILLIAM C ; SAWYER TOMI K ; ROMERO JAN ANTIONETTE C ; QI JIWEI ; ROMERO JAN A C ; QL JIWEI ; ROMERO JAN ANTOINETTE C ; METCALF III CHESTER A ; SUNDARAMOORTHY RAJESWARI ; WANG YIHAN ; THOMAS R MATHEW ; ZHU XIAOTIAN ; ZOU DONG ; THOMAS R M ; THOMAS R MATTHEW ; ZHU DONG ; ARIAD PHARMA INC

Assignee(s): ARIAD PHARMACEUTICALS INC ; THOMAS R

Inventor(s): (std): DONG ZOU ; HUANG WEI SHENG ; JIWEI QI ; DALGARNO DAVID C ; METCALF CHESTER A ; METCALF CHESTER A III ; METCALF III CHESTER A ; QI JIWEI ; QL JIWEI ; RAJESWARI SUNDARAMOORTHY ; ROMERO JAN A C ; ROMERO JAN ANTIONETTE C ; ROMERO JAN ANTOINETTE C ; SHAKESPEARE WILLIAM C ; SHENG HUANG WEI ; SUNDARAMOORTHY RAJESWARI ; THOMAS MATHEW ; THOMAS MATHEW R ; THOMAS R M ; THOMAS R MATHEW ; THOMAS R MATTHEW ; SAWYER TOMI K ; WANG YIHAN ; XIAOTIAN ZHU ; YIHAN WANG ; ZHU DONG ; ZHU XIAOTIAN ; ZOU DONG

Inventor(s): WEI SHENG HUANG ; WILLIAM C SHAKESPEARE ; SHAKESPEARE WILLIAM ; TOMI K SAWYER ; THOMAS R ; SAWYER TOMI ; ROMERO JAN ANTOINETTE ; ROMERO JAN AC ; ROMERO JAN ; R MATHEW THOMAS ; METCALF CHESTER AIII ; DAVID C DALGARNO ; JIWEI QL ; MATHEW R THOMAS ; MATHEW THOMAS ; METCALF ; METCALF CHESTER ; JAN ANTIONETTE C ROMERO ; JAN ANTOINETTE C ROMERO ; CHESTER A ; CHESTER A METCALF ; CHESTER A METCALF III ; DALGARNO DAVID

Agent(s): VOSSIUS AND PARTNER; Duncan Garreth Andrew; DUNCAN GARRETH ANDREW; ARIAD PHARMACEUTICALS INC ARIAD GENE THERAPEUTICS INC; DAVID L; CHRISTOPHER J; GRETCHEN S

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: INHIBITORS OF Akt ACTIVITY

Abstract: Invented are novel thiophene compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

Classifications:

International (IPC 8-9): A61K31/282 A61K31/33 A61K31/337 A61K31/437 A61K31/444 A61K31/4545 A61K31/51 A61K31/519 A61K31/53 A61K31/5377 A61K45/00 A61P19/02 A61P35/00 A61P43/00 C07D471/04 C07D487/04 (Advanced/Invention); A61K31/28 A61K31/337 A61K31/4353 A61K31/4427 A61K31/4523 A61K31/51 A61K31/519 A61K31/5375 A61K45/00 A61P19/00 A61P35/00 A61P43/00 C07D471/00 C07D487/00 (Core/Invention)

CPC: C07D471/04 C07D487/04

European: C07D471/04 C07D487/04

Family:

Publication number	Publication date	Application number	Application date
EP1968568 A2	20080917	EP20060846739	20061221
EP1968568 A4	20110413	EP20060846739	20061221
JP2009521504 T2	20090604	JP20080547763T	20061221
WO07076423 A2	20070705	WO2006US62453	20061221
WO07076423 A3	20071129	WO2006US62453	20061221

Priority:
US20050753033P 20051222 US20060793198P 20060419 WO2006US62453 20061221

Probable Assignee: SMITHKLINE BEECHAM CORP

Assignee(s): (std): GLAXOSMITHKLINE LLC ; HAMAJIMA TOSHIHIRO ; HEERDING DIRK A ; JUNG DAVID KENDALL ; NAKAMURA HIROKO ; RENO MICHAEL JOHN ; ROUSE MEAGAN B ; SMITHKLINE BEECHAM CORP ; WANG JIZHOU ; REID PAUL R ; TANG JUN ; SEEFELD MARK ANDREW

Inventor(s): (std): HAMAJIMA TOSHIHIRO ; HEERDING DIRK A ; JUNG DAVID KENDALL ; NAKAMURA HIROKO ; REID PAUL R ; RENO MICHAEL JOHN ; ROUSE MEAGAN B ; SEEFELD MARK ANDREW ; TANG JUN ; WANG JIZHOU

Agent(s): SEWELL RICHARD CHARLES ET AL


Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS

Abstract: Source: US2010004239A The present invention relates to pyrrolo[3,2-c]pyridine-4-one 2-indolinone compounds of Formula (I) and

their pharmaceutically acceptable salts thereof, wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈X, Y and have the meaning cited in the specification. Also disclosed are the pharmaceutical compositions containing the foregoing compounds, methods for the preparation and pharmaceutical use thereof, particularly as protein kinase inhibitors. Formula (I).

(I)



Classifications:

International (IPC 8-9): A01N43/42 A01N43/90 A61K31/437 A61K31/44 A61K31/519 A61K31/535 A61K31/5377 A61K38/43 A61K39/395 A61P1/00 A61P1/16 A61P11/06 A61P13/08 A61P13/12 A61P17/00 A61P17/02 A61P17/06 A61P19/02 A61P25/00 A61P27/02 A61P27/06 A61P29/00 A61P33/00 A61P35/00 A61P35/02 A61P37/06 A61P43/00 A61P7/00 A61P7/02 A61P9/10 C07D413/14 C07D471/04 C07D487/04 C07D519/00 (Advanced/Invention); A61K31/4353 A61K31/519 A61K31/5375 A61P19/00 A61P27/00 A61P29/00 A61P33/00 A61P35/00 A61P43/00 C07D413/00 C07D471/00 C07D487/00 C07D519/00 (Core/Invention); A61K A61P C07D (Subclass/Invention)

International (IPC 1-7): C07D47/04

CPC: C07D471/04

European: C07D471/04

US: 424/130.1 424/130.100P 424/94.1 424/94.100S 514/234.2 514/234.200S 514/234.5

514/234.500P 514/234.500S 514/265.1 514/265.100S 514/300 514/300S 544/127 544/127S 544/280 544/280S 546/113 546/113P 546/113S

Family:

Publication number	Publication date	Application number	Application date
AU2007209689 AA	20070802	AU20070209689	20070124
AU2007209689 BB	20120315	AU20070209689	20070124
BRPI0707312 A2	20110503	BR2007PI07312	20070124
CA2636701 AA	20080709	CA20072636701	20070124
CA2636701 C	20140805	CA20072636701	20070124
CN101007814 A	20070801	CN200610065001	20060315
CN101007815 A	20070801	CN200610122000	20060830
CN101007815 B	20100623	CN200610122000	20060830
DK1973910 T3	20130812	DK20070702185T	20070124
EP1973910 A1	20081001	EP20070702185	20070124
EP1973910 A4	20100825	EP20070702185	20070124
EP1973910 B1	20130626	EP20070702185	20070124
ES2426448 T3	20131023	ES20070702185T	20070124
HK1115879 A1	20140307	HK20080111654	20081023
HK1115879 A3	20081212	HK20080111654	20081023
IN06792DN2008 A	20081024	IN2008DN06792	20080807
JP2009524604 T2	20090702	JP20080551631T	20070124
JP5256047 B2	20130807	JP20080551631T	20070124
KR101452520 B1	20141021	KR20087020816	20070124
KR20080091258 A	20081009	KR20087020816	20070124
MX2008009557 A1	20090107	MX2008009557	20080725
PT1973910 T	20130906	PT20070702185T	20070124
RU2008130458 A	20100310	RU20080130458	20070124
RU2410387 C2	20110127	RU20080130458	20070124
UA92776 C2	20101210	UA20080009752	20070124
US2010004239 AA	20100107	US20070223180	20070124
US2011301353 AA	20111208	US20110196386	20110802
US2012058107 AA	20120308	US20110196391	20110802
US8012966 BB	20110906	US20070223180	20070124
US8362251 BB	20130129	US20110196386	20110802
US8697692 BB	20140415	US20110196391	20110802
WO07085188 A1	20070802	WO2007CN00256	20070124
ZA200806313 A	20100127	ZA20080006313	20070124

Priority:

CN200610003229	20060127	CN200610065001	20060315	CN200610122000	20060830
WO2007CN00256	20070124	US20070223180	20070124	EP20070702185	20070124
US20080223180	20080724	US20110196386	20110802	US20110196391	20110802

Probable Assignee: SHANGHAI HENGRUI PHARM CO LTD

Assignee(s): (std): DENG BINGCHU ; JIANGSU HENGRUI MEDICINE CO ; JIANGSU HENGRUI MEDICINE CO LTD ; SHANGHAI HENGRUI PHARMACEUTICAL CO LTD ; SHANGHAI HENGRUI PHARM CO LTD ; SHANGHAI HENGRUI MEDICINE CO LTD ; ZHANG LEI ; XIAO LU ; SU YIDONG ; TANG PENG CHO ; SHANKHAJ KHEHNZHUJ FARMAS JUTIKAL SO LTD ; SHANGHAI HENGRUI

PHARMACEUTICAL

Assignee(s): SHANGHAI HENGRUI PHARMACETICAL CO ; SHANGHAI HENGRUI PHARMACEUTICAL COLTD ; SHANGHAI HENGRUI PHARMACEUTICAL CO LTDNO. 279, WENJING ROADMINXING DISTRICT, P.R.200245SHANGHAICN ; SHANGHAI HENGRUI MEDICINE CO ; SHANGHAI HENGRUI PHARMACEUTICAL CO LTD ; SHANGHAI HENGRUI PHARMACEUTICAL CO

Inventor(s): (std): SJAO LU ; SU IDUN ; SU YIDONG ; CHZHAN LEHJ ; DENG BINGCHU ; TAN PEHN CHO ; TANG PENG CHO ; XIAO LU ; ZHANG LEI ; ZHANG LAI ; YIDONG SU ; LU XIAO ; LEI ZHANG ; DENG BINGCHU SU ; BINGCHU DENG

Inventor(s): BINGCHU SU DENG ; LAI ZHANG ; ZHANG LEICN ; XIAO LUCN ; TANG PENG CHOCN ; PENG CHO TANG ; SU YIDONGCN

Agent(s): CROWHURST CHARLOTTE WAVENEY; BINGHAM MCCUTCHEN LLP; ROTHWELL FIGG ERNST AND MANBECK PC


Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES

Abstract: Source: US2009124633A The present invention relates to heterocyclic substituted N-Oxides of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Classifications:

International (IPC 8-9): A61K31/435 A61K31/4439 A61K31/495 A61K31/496 A61K45/00 A61P1/04 A61P11/06 A61P13/08 A61P13/12 A61P15/00 A61P17/02 A61P17/04 A61P19/02 A61P25/28 A61P29/00 A61P3/10 A61P31/04 A61P31/16 A61P35/00 A61P35/02 A61P37/00 A61P37/06 A61P43/00 A61P9/00 A61P9/10 C07D401/12 C07D471/04 (Advanced/Invention); A61K31/435 A61K31/4427 A61K31/495 A61K45/00 A61P1/00 A61P11/00 A61P13/00 A61P15/00 A61P17/00 A61P19/00 A61P25/00 A61P29/00 A61P3/00 A61P31/00 A61P35/00 A61P37/00 A61P43/00 A61P9/00 C07D401/00 (Core/Invention); C07D (Subclass/Invention) **CPC:** C07D401/12 C07D471/04 **European:** C07D401/12 C07D471/04 **US:** 514/253.12 514/253.120P 514/340 514/340S 544/365 544/365S 546/272.4 546/272.400S



Family:

Publication number	Publication date	Application number	Application date
AU2007236321 AA	20071018	AU20070236321	20070326
CA2649000 AA	20081010	CA20072649000	20070326
EP2004631 A1	20081224	EP20070723593	20070326
IL194425 A0	20090803	IL20080194425	20080928
JP2009533362 T2	20090917	JP20090504594T	20070326
US2009124633 AA	20090514	US20070296573	20070326
WO07115670 A1	20071018	WO2007EP02647	20070326

Priority:
EP20060007695 20060412 WO2007EP02647 20070326 EP20070723593 20070326

Probable Assignee: MERCK PATENT GES

Assignee(s): (std): JONCZYK ALFRED ; RAUTENBERG WILFRIED ; MERCK PATENT GMBH

Assignee(s): MERCK PATENT GES ; MERCK PATENT GES MIT BESCHRAENKTER HAFTUNG ; MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG

Inventor(s): (std): JONCZYK ALFRED ; RAUTENBERG WILFRIED

Inventor(s): WILFRIED RAUTENBERG ; ALFRED JONCZYK

Agent(s): MILLEN WHITE ZELANO AND BRANIGAN PC

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS

Abstract: Source: US2009312321A Described are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent disease or disordered associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activity of kinases such as Abl, ALK, AMPK, Aurora, Axl, Bcr-Abl, BIK, Bmx, BRK, BTK, c-Kit, CSK, cSrc, CDK1, CHK2, CK1, CK2, CaMKII, CaMKIV, DYRK2, EGFR, EphB1, FES, FGFR1, FGFR2, FGFR3, Flt1, Flt3, FMS, Fyn, GSK3 beta, IGF-1R, IKKa, IKK beta, IR, IRAK4, ITK, JAK2, JAK3, JNK1a1, JNK2a, KDR, Lck, LYN, MAPK1, MAPKAP-K2, MEK1, MET, MKK4, MKK6, MST2, NEK2, NLK, p70S6K, PAK2, **PDGFR**, PDGFRa, PDK1, Pim-2, Plk3, PKA, PKBa, PKCa, PKCtheta, PKD2, c-Raf, RET, ROCK-I, ROCK-II, Ron, Ros, Rsk1, SAPK2a, SAPK2b, SAPK3, SAPK4, SGK, SIK, Syk, Tie2, TrkB, WNK3, and ZAP-70.

Classifications:


International (IPC 8-9): A61K31/4375 A61K31/497 A61K31/513 A61K31/519 A61K31/53 A61K31/5355 A61K31/5377 A61P1/16 A61P11/00 A61P17/00 A61P17/06 A61P19/00 A61P19/02 A61P25/28 A61P27/02 A61P35/00 A61P35/02 A61P37/00 A61P37/06 A61P43/00 A61P7/02 A61P9/00 A61P9/12 C07D253/065 C07D413/12 C07D413/14 C07D471/04 C07D487/04 (Advanced/Invention); A61K31/519 A61P35/00 (Advanced/Non-invention); A61K31/4353 A61K31/4965 A61K31/513 A61K31/519 A61K31/53 A61K31/5355 A61K31/5375 A61P1/00 A61P11/00 A61P17/00 A61P19/00 A61P25/00 A61P27/00 A61P35/00 A61P37/00 A61P43/00 A61P7/00 A61P9/00 C07D253/00 C07D413/00 C07D471/00 C07D487/00 (Core/Invention); A61P35/00 (Core/Non-invention)

International (IPC 1-7): A61K31/519

CPC: C07D471/04 C07D487/04

European: C07D471/04 C07D487/04

US: 514/234.5 514/234.500P 514/252.16 514/252.160S 514/262.1 514/262.100S 514/300 514/300S 544/127 544/127S 544/256 544/256S 546/122 546/122S



Family:

Publication number	Publication date	Application number	Application date
AU2007254491 AA	20071129	AU20070254491	20070406
BRPI0711628 A2	20111206	BR2007PI11628	20070406
CA2650611 AA	20081028	CA20072650611	20070406
CN101460175 A	20090617	CN200780016465	20070406
EP2018167 A2	20090128	EP20070755084	20070406
EP2018167 A4	20100714	EP20070755084	20070406
IN09189DN2008 A	20090327	IN2008DN09189	20081103
JP2009537520 T2	20091029	JP20090510944T	20070406
KR20080109095 A	20081216	KR200807027934	20081114
MX2008014618 A1	20081128	MX20080014618	20081114
RU2008149245 A	20100620	RU20080149245	20070406
US2009312321 AA	20091217	US20070300088	20070406
WO07136465 A2	20071129	WO2007US08699	20070406
WO07136465 A3	20090122	WO2007US08699	20070406

Priority:

US20060747258P 20060515 WO2007US08699 20070406 US20070300088 20070406

Probable Assignee: IRM LLC

Assignee(s): (std): GRAY NATHANAEL ; HE YUN ; IRM LLC ; ZHANG GUOBAO ; REN PINGDA ; SIM TAEBO ; WANG XING ; XIE YONGPING ; YOU SHULI ; IRM LLC A DELAWARE LTD LIABILITY

Assignee(s): IRM LLC A DELAWARE LIMITED LIABILITY COMPANY ; IRM LLC A DELAWARE LIABILITY CO LTD

Inventor(s): (std): REN PINGDA ; SIM TAE BO ; SIM TAEBO ; WANG XING ; XIE YONGPING ; XING WANG ; YONGPING XIE ; YOU SHULI ; ZHANG GUOBAO ; YUN HE ; TAEBO SIM ; SHULI YOU ; PINGDA REN ; GUOBAO ZHANG ; GRAY NATHANAEL ; GRAY NATHANAEL S ; GRAY NATHANAEL SCHIANDER ; HE YUN ; NATHANAEL GRAY

Inventor(s): NATHANAEL SCHIANDER GRAY


Agent(s): KIDDLE SIMON JOHN ET AL; GENOMICS INSTITUTE OF THE,NOVARTIS RESEARCH FOUNDATION; GENOMICS INST OF NOVARTIS RESEARCH FOUNDATION

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS

Abstract: Source: US2008171769A Provided are compounds of the formula (I):


Formula (1)



thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.

Classifications:

International (IPC 8-9): A61K31/4188 A61K31/44 A61K31/4439 A61K31/444 A61K31/4545 A61K31/496 A61K31/5377 A61K31/541 A61K45/06 A61P17/06 A61P3/10 A61P35/00 A61P37/00 A61P9/10 C07D401/00 C07D401/14 C07D453/02 C07D455/04 C07D471/04 C07D471/22 C07D487/04 C12N9/99 (Advanced/Invention); A61K31/4164 A61P35/00 C07D487/00 (Core/Invention)
CPC: C07D487/04 A61K45/06 A61K31/4545 C07D471/04 A61K31/5377 C07D471/22 C07D455/04 A61K31/496 C07D453/02 A61K31/444 A61K31/541 A61K31/4439
European: C07D487/04
US: 435/184 435/184S 514/210.21 514/228.5 514/232.8 514/232.800P 514/253.09 514/279 514/292 514/294 514/305 514/318 514/318S 514/333 514/338 514/338S 544/131 544/131S 546/193 546/193S 546/194 546/194S 546/256 546/256S 546/273.1 546/273.100S



Family:

Publication number	Publication date	Application number	Application date
AU2007284542 AA	20080221	AU20070284542	20070813
AU2007284542 BB	20130131	AU20070284542	20070813
CA2660899 AA	20090213	CA20072660899	20070813
EP2066673 A2	20090610	EP20070836819	20070813
US2008171769 AA	20080717	US20070891604	20070810
US2012071473 AA	20120322	US20110242272	20110923
US2014228350 AA	20140814	US20140156314	20140115
US8063225 BB	20111122	US20070891604	20070810
US8686005 BB	20140401	US20110242272	20110923
WO08021369 A2	20080221	WO2007US18002	20070813
WO08021369 A3	20080529	WO2007US18002	20070813

Priority:

US20060837652P 20060814 US20070891604 20070810 WO2007US18002 20070813
 US20110242272 20110923 US20140156314 20140115

Probable Assignee: CHEMBRIDGE CORP

Assignee(s): (std): JIANG LUYONG ; GANTLA VIDYASAGAR REDDY ; MCGEE DANNY PETER CLAUDE ; CHUCHOWSKI ALEXANDER ; KADUSHKIN ALEXANDER ; LIU YAHUA ; GREGOR VLAD EDWARD ; MCGRATH DOUGLAS ERIC ; GREGOR VLAD E ; LEVY NELSON ; WEBB THOMAS R ; THIRUVAZHI MOHAN SANTHANAM ; ZHU TONG ; ZOZULYA SERGEY ; PICKENS JASON C ; YAN ZHENG ; VAIRAGOUNDAR RAJENDRAN ; MIKEL CHARLES ; VAVILALA GOVERDHAN REDDY ; WEBB THOMAS ; ANIKIN ALEXEY ; CHEMBRIDGE CORP ; CHEMBRIDGE RES LAB INC

Assignee(s): CHEMBRIDGE RESEARCH LABORATORIES INC

Inventor(s): (std): ANIKIN ALEXEY ; CHUCHOWSKI ALEXANDER ; GANTLA VIDYASAGAR REDDY ; JIANG LUYONG ; KADUSHKIN ALEXANDER ; LIU YAHUA ; MCGEE DANNY PETER CLAUDE ; MCGRATH DOUGLAS ERIC ; MIKEL CHARLES ; GREGOR VLAD E ; GREGOR VLAD EDWARD ; PICKENS JASON C ; VAIRAGOUNDAR RAJENDRAN ; VAVILALA GOVERDHAN REDDY ; THIRUVAZHI MOHAN SANTHANAM ; WEBB THOMAS ; WEBB THOMAS R ; YAN ZHENG ; ZHU TONG ; ZOZULYA SERGEY ; LEVY NELSON

Inventor(s): ZHENG YAN ; YAHUA LIU ; THOMAS R WEBB ; TONG ZHU ; VIDYASAGAR REDDY GANTLA ; VLAD EDWARD GREGOR ; RAJENDRAN VAIRAGOUNDAR ; SERGEY ZOZULYA ; JASON C PICKENS ; MOHAN SANTHANAM THIRUVAZHI ; LUYONG JIANG ; GOVERDHAN REDDY VAVILALA ; DANNY PETER CLAUDE MCGEE ; DOUGLAS ERIC MCGRATH ; CHARLES MIKEL ; ALEXANDER CHUCHOWSKI ; ALEXANDER KADUSHKIN ; ALEXEY ANIKIN

Agent(s): JONES DAY ; PEARL COHEN ZEDEK LATZER LLP ; MARK S ; LATZER BARATZ LLP ; PEARL COHEN ; RIEGER DALE L ET AL


Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES

Abstract: Source: US2008090856A The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules set forth in formulae Ia-Iww.

Classifications:

International (IPC 8-9): A01N43/54 A61K31/4155 A61K31/437 A61K31/44 A61K31/4412 A61K31/4427 A61K31/4439 A61K31/444 A61K31/454 A61K31/47 A61K31/4709 A61K31/4725 A61K31/498 A61K31/50 A61K31/5025 A61K31/505 A61K31/506 A61K31/54 A61K31/695 A61K38/16 A61K39/395 A61P1/00 A61P1/04 A61P11/00 A61P11/06 A61P11/16 A61P17/06 A61P19/02 A61P19/04 A61P19/06 A61P19/08 A61P25/00 A61P27/02 A61P29/00 A61P3/10 A61P31/00 A61P31/04 A61P35/00 A61P35/02 A61P35/04 A61P37/00 A61P37/02 A61P37/06 A61P39/02 A61P43/00 A61P7/00 A61P9/00 A61P9/10 C07D C07D213/00 C07D215/00 C07D239/02 C07D401/12 C07D401/14 C07D405/12 C07D409/12 C07D413/12 C07D413/14 C07D417/12 C07D417/14 C07D471/04 C12N9/99 (Advanced/Invention); C12N9/99 C12Q1/48 (Advanced/Non-invention); A61K31/44 A61K31/47 A61K31/505 A61K31/54 A61K39/395 A61P35/00 C07D213/00 C07D215/00 C07D239/00 C07D401/00 C07D413/00 C07D417/00 C07D471/00 (Core/Invention); A61K (Subclass/Invention) **CPC:** C07D401/14 C07D401/12 C07D413/14 C07D417/14 C07D471/04 **European:** C07D401/12 C07D401/14 C07D413/14 C07D417/14 C07D471/04 **US:** 424/133.1 424/142.1 435/184 435/184S 514/12.2 514/248 514/249 514/249S 514/252.18 514/252.19 514/253.06 514/256 514/256S 514/272 514/275 514/300 514/307 514/307S 514/310 514/314 514/314S 514/326 514/341 514/341S 514/345 514/345S 514/354 514/354S 514/406 514/406S 514/63 514/63P 544/297 544/297S 546/143 546/152 546/152S 546/162 546/268.1 546/300 546/300S 548/375.1



Family:

Publication number	Publication date	Application number	Application date
AU2007307679 AA	20080417	AU20070307679	20071011
AU2007307679 BB	20131031	AU20070307679	20071011
AU2007307679 BI	20131121	AU20070307679	20071011
BRPI0719195 A2	20150526	BR2007PI19195	20071011
CA2666563 AA	20090409	CA20072666563	20071011
CN101553233 A	20091007	CN200780045591	20071011
CN101553233 B	20130529	CN200780045591	20071011
EP2073811 A2	20090701	EP20070844173	20071011
EP2073811 A4	20091111	EP20070844173	20071011
EP2073811 B1	20150311	EP20070844173	20071011
ES2538215 T3	20150618	ES20070844173T	20071011
HK1139036 A1	20140307	HK20100103426	20100407
IL197933 A0	20091224	IL20090197933	20090405
IL197933 A1	20150226	IL20090197933	20090405
JP2010506850 T2	20100304	JP20090532577T	20071011
JP2012158606 A2	20120823	JP20120109422	20120511
JP5042314 B2	20121003	JP20090532577	20071011
JP5557872 B2	20140723	JP20120109422	20120511
KR101439823 B1	20140915	KR20097009667	20071011
KR20090080517 A	20090724	KR20097009667	20071011
MX2009003704 A1	20090812	MX20090003704	20090406
RU2009117615 A	20101120	RU20090117615	20071011
RU2482112 C2	20130520	RU20090117615	20071011
SG175640 A1	20111128	SG20110007558	20071011
US2008090856 AA	20080417	US20070870388	20071010
US2011136760 AA	20110609	US20100829561	20100702
US2012225057 AA	20120906	US20110228288	20110908
US7790756 BB	20100907	US20070870388	20071010
US8586565 BB	20131119	US20100829561	20100702
WO08046003 A2	20080417	WO2007US81098	20071011
WO08046003 A3	20080821	WO2007US81098	20071011

Priority:

US20060850834P 20061011	US20070870388 20071010	WO2007US81098 20071011
US20100829561 20100702	JP20090532577 20071011	EP20070844173 20071011
US20110228288 20110908		

Probable Assignee: DECIPHERA PHARMACEUTICALS LLC

Assignee(s): (std): DECIPHERA PHARMACEUTICALS LLC ; DESIFERA FARMAS JUTIKALZ EHLEHLSI ; FLYNN DANIEL L ; KAUFMAN MICHAEL D ; PETILLO PETER A

Assignee(s): BRIGHTSTAR ASSOCIATES LLC

Inventor(s): (std): FLYNN DANIEL L ; KAUFMAN MICHAEL D ; PETILLO PETER A ; PETILLO PITER A ; KAUFMAN MAJKL D ; FLINN DEHNIEL L

Inventor(s): MICHAEL D KAUFMAN ; PETER A PETILLO ; PETILLO PETER ; KAUFMAN MICHAEL ; DANIEL L FLYNN ; FLYNN DANIEL


Agent(s): BRAMLEY SARAH JANE; GRUND MARTIN; HOVEY WILLIAMS LLP; WILMER CUTLER PICKERING HALE AND DORR LLP; SKOCH GREGORY J

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LR LK LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ T2 TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND **PDGFR** RECEPTORS

Abstract: Source: US2008176846A The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRA, **PDGFR** beta, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF beta, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2 beta, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.

Classifications:
International (IPC 8-9): A61K31/435 A61K31/4375 A61K31/444 A61K31/4545 A61K31/4709 A61K31/496 A61K31/497 A61K31/501 A61K31/506 A61K31/5355 A61K31/5377 A61K45/00 A61P1/04 A61P1/16 A61P13/10 A61P13/12 A61P17/00 A61P17/06 A61P17/10 A61P19/02 A61P19/08 A61P21/02 A61P25/00 A61P25/04 A61P25/14 A61P25/16 A61P25/18 A61P25/22 A61P25/28 A61P25/36 A61P27/02 A61P29/00 A61P3/00 A61P3/04 A61P3/10 A61P31/04 A61P31/14 A61P31/18 A61P35/00 A61P35/02 A61P37/00 A61P37/02 A61P37/06 A61P37/08 A61P43/00 A61P9/00 A61P9/10 A61P9/12 C07D401/14 C07D413/14 C07D471/00 C07D471/02 C07D471/04 (Advanced/Invention); A61P17/10 A61P25/04 A61P25/28 A61P27/14 A61P29/00 A61P3/10 A61P31/00 A61P35/00 A61P9/00 A61P9/12 C07C205/06 C07C255/07 C07C301/00 C07C69/73 C07D213/61 C07D213/69 C07D213/74 C07D213/80 C07D471/04 (Advanced/Non-invention); A61K38/16 C07D217/04 C07D471/00 (Core/Invention); C07D (Subclass/Invention)
International (IPC 1-7): A61K31/4375 A61K38/16 A61P35/00 C07D217/04 C07D471/04
CPC: C07D471/04
European: C07D471/04
US: 514/232.5 514/234.5 514/234.500P 514/252.04 514/253.04 514/253.040S 514/275 514/275S 514/300 514/300S 544/119 544/127 544/127S 544/238 544/331 544/331S 544/362 544/362S 544/80 546/122 546/122S 546/123 546/296 546/297 546/310 546/318 558/410 558/44 560/60 568/705



Family:

Publication number	Publication date	Application number	Application date
AR063343 AA	20090121	AR2007P104639	20071019
AU2007309279 AA	20080502	AU20070309279	20071016
AU2007309279 BB	20110324	AU20070309279	20071016
BRPI0718162 A2	20131126	BR2007PI18162	20071016
CA2667010 AA	20090420	CA20072667010	20071016
CL2007003005 A1	20080523	CL20070003005	20071019
CL30052007 A1	20080523	CL20070003005	20071019
CN101528744 A	20090909	CN200780039037	20071016
CO6170361 A2	20100618	CO20090039151	20090417
CR10717 A	20090702	CR20090010717	20090416
EA200900573 A1	20091030	EA20090000573	20071016
ECSP099353 A	20090630	EC2009SP09353	20090520
EP2076513 A1	20090708	EP20070844322	20071016
IL197875 A0	20091224	IL20090197875	20090326
IN02178DN2009 A	20100702	IN2009DN02178	20090401
JP2010506948 T2	20100304	JP20090533484T	20071016
KR101079520 B1	20111103	KR20097008062	20090420
KR20090054477 A	20090529	KR20097008062	20090420
MA30888 B1	20091102	MA20090031869	20090513
MX2009004141 A1	20090501	MX20090004141	20090417
NO20091949 A	20090519	NO20090001949	20090519
PE12622008 A1	20081029	PE20070001422	20071019
SM200900027 A	20090714	SM20090000027	20090420
SMAP200900027 A	20090714	SM20090000027T	20090420
SMP200900027 B	20100119	SM20090000027T	20090420
TH98294 A	20090917	TH20071005283	20071019
TW200825081 A	20080616	TW20070139384	20071019
US2008176846 AA	20080724	US20070873196	20071016
US2010081656 AA	20100401	US20090629665	20091202
US7678792 BB	20100316	US20070873196	20071016
US8106068 BB	20120131	US20090629665	20091202
WO08051757 A1	20080502	WO2007US81538	20071016
ZA200902711 A	20100526	ZA20090002711	20090420

Priority:
US20060862430P 20061020 US20070873196 20071016 WO2007US81538 20071016
US20090629665 20091202

Probable Assignee: IRM LLC

Assignee(s): (std): CHIANELLI DONATELLA ; COW CHRISTOPHER ; HE YUN ; IRM LLC ; JIANG SONGCHUN ; LIU ZUOSHENG ; LIU XIAODONG ; YOU SHULI ; NABAKKA JULIET ; LOREN JON ; LI XIAOLIN ; MOLteni VALENTINA ; WANG XIAODONG ; SIM TAEBO ; REN PINGDA

Inventor(s): (std): CHRISTOPHER COW ; COLLINS JON LOREN ; COW CHRISTOPHER ; DONATELLA CHIANELLI ; HE YUN ; JIANG SONG CHUN ; JIANG SONGCHUN ; JON LOREN ; CHIANELLI DONATELLA ; CHIANELLI DONATELLA HE YUN LOR ; JULIET NABAKKA ; LI XIAO LIN ; LI XIAOLIN ; LIU XIADONG ; LIU XIAODONG ; LIU ZUOSHENG ; LOREN JON ; MOLteni VALENTINA ; NABAKKA JULIET ; PINGDA REN ; REN PINGDA ; REN PINGDA WANG XIAODONG ; SHULI YOU ; SIM TAE BO ; SIM TAEBO ; SONGCHUN JIANG ; TAEBO SIM ; VALENTINA MOLteni ; WANG XIAODONG ; WANG XIAOJING ; XIAODONG LIU ; XIAODONG WANG ; XIAOLIN LI ; YOU SHULI ; YUN HE ; ZUOSHENG LIU

Inventor(s): XIAOJING WANG ; LI, Xiaolin ; LI XIAO LIN AND ; CHIANELLI DONATELLA HE YUN LOREN JON NABAKKA JULIET COW CHRISTOPHER JIANG SONGCHUN LI XIAOLIN LIU XIADONG ; CHIANELLI DONATELLA HE YUN LOREN JON NABAKKA... ; CHIANNELLI DONATELLA ; JON LOREN COLLINS


Agent(s): KIDDLE SIMON JOHN; GENOMICS INSTITUTE OF THE, NOVARTIS RESEARCH FOUNDATION; GENOMICS INST OF NOVARTIS RESEARCH FOUNDATION; GENOMICS INSTITUTE OF THE,NOVARTIS RESEARCH FOUNDATION; EMILY TONGCO; GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION; TONGCO WU EMILY ET AL

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: COMPOUNDS

Abstract: Source: US2010093718A The invention relates to new bicyclic heterocyclic derivative compounds of Formula (I), to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer The compounds of Formula (I) are inhibitors of FGFR, VEGFR or **PDGFR**.

Classifications:
International (IPC 8-9): A61K31/433 A61K31/437 A61K31/4375 A61K31/444 A61K31/496 A61K31/497 A61K31/519 A61K31/5377 A61P35/00 A61P43/00 C07D401/14 C07D413/14 C07D417/14 C07D471/02 C07D471/04 C07D487/02 C07D487/04 (Advanced/Invention); A61K31/519 A61P35/00 C07D487/04 (Advanced/Non-invention); A61K31/433 A61K31/4353 A61K31/4427 A61K31/496 A61K31/4965 A61K31/519 A61K31/5375 A61P35/00 A61P43/00 C07D417/00 C07D471/00 C07D487/00 (Core/Invention)
International (IPC 1-7): A61K31/437 A61P35/00 C07D471/04
CPC: C07D471/04 C07D487/04
European: C07D471/04 C07D487/04
US: 514/233.2 514/233.200P 514/253.04 514/253.040S 514/259.3 514/259.300S 514/300 514/300S 544/127 544/127S 544/281 544/281S 544/362 544/362S 546/121 546/121S



Family:

Publication number	Publication date	Application number	Application date
AU2007337895 AA	20080703	AU20070337895	20071221
AU2007337895 BB	20140130	AU20070337895	20071221
AU2007337895 CA	20140731	AU20070337895	20071221
BRPI0721151 A2	20140401	BR2007PI21151	20071221
CA2672213 AA	20090610	CA20072672213	20071221
CN101679409 A	20100324	CN200780047742	20071221
CN101679409 B	20141126	CN200780047742	20071221
EP2121687 A2	20091125	EP20070848681	20071221
GB200625827 A0	20070207	GB20060025827	20061222
GB200719998 A0	20071121	GB20070019998	20071012
IN01339MN2009 A	20110506	IN2009MN01339	20090716
JP2010513448 T2	20100430	JP20090542227T	20071221
JP5442449 B2	20140312	JP20090542227T	20071221
MX2009006704 A1	20090630	MX20090006704	20090619
NO20092658 A	20090917	NO20090002658	20090713
RU2009128186 A	20110127	RU20090128186	20071221
RU2465275 C2	20121027	RU20090128186	20071221
US2010093718 AA	20100415	US20070520333	20071221
US8513276 BB	20130820	US20070520333	20071221
WO08078100 A2	20080703	WO2007GB04960	20071221
WO08078100 A3	20081113	WO2007GB04960	20071221

Priority:
GB20060025827 20061222 US20060871538P 20061222 GB20070019998 20071012
US20070979582P 20071012 WO2007GB04960 20071221 US20070520333 20071221

Probable Assignee: ASTEX THERAPEUTICS LTD

Assignee(s): (std): ASTEX THERAPEUTICS LTD ; BERDINI VALERIO ; BESONG GILBERT EBAI ; TAYLOR RICHARD DAVID ; CALLAGHAN OWEN ; CONGREVE MILES STUART ; GILL ADRIAN LIAM ; O BRIEN MICHAEL ALISTAIR ; GRIFFITHS JONES CHARLOTTE MARY ; NIJJAR RAJDEEP KAUR ; PIKE ANDREW ; MADIN ANDREW ; MURRAY CHRISTOPHER WILLIAM ; CARR MARIA GRAZIA ; SAXTY GORDON ; VICKERSTAFFE EMMA ; ASTEKS TERAP JUTIKS LTD

Assignee(s): ASTEX THERAPEUTICS LIMITED ; ASTEKS TERAP JUTIKS LIMITED

Inventor(s): (std): BESONG GILBERT EBAI ; BERDINI VALERIO ; BESONG GILBERT EBAI ; BEZONG GILBERT EHBAJ ; CALLAGHAN OWEN ; CARR MARIA GRAZIA ; CONGREVE MILES STUART ; DZHILL EHDRIAN LIEHM ; EBAI BESONG GILBERT ; ALISTAIR O BRIEN MICHAEL ; ANDREW MADIN ; GILL ADRIAN LIAM ; GRAZIA CARR MARIA ; GRIFFITHS JONES CHARLOTE MARY ; GRIFFITHS JONES CHARLOTTE MARY ; GRIFFITS DZHOUNZ SHARLOTT MEHRI ; KALLAGAN OUEHN ; KARR MARIJA GRATSIIA ; KAUR NIJJAR RAJDEEP ; KONGRIV MAJLZ STJUART ; LIAM GILL ADRIAN ; MADIN ANDREW ; MARY GRIFFITHS JONES CHARLOTTE ; MEHDIN EHND RJU ; MURRAY CHRISTOPHER WILLIAM ; NIDZHAR RADZHDIP KAUR ; NIJJAR RAJDEEP KAUR ; O BRAJEN MAJKL ALISTEHR ; O BRIEN MICHAEL ALISTAIR ; SAKSTI GORDON ; SAXTY GORDON ; STUART CONGREVE MILES ; TAYLOR RICHARD DAVID ; TEHJLOR RICHARD DEHVID ; VALERIO BERDINI ; VICKERSTAFFE EMMA ; VIKERSTAFF EHMMA ; WILLIAM MURRAY CHRISTOPHER ; OWEN CALLAGHAN ; PAJK EHND RJU ; PIKE ANDREW ; MJURREJ KRISTOFER UILL JAM

Inventor(s): MJURREJ KRISTOFER UILL JAM ; ADRIAN LIAM GILL ; RAJDEEP KAUR NIJJAR ; RICHARD DAVID TAYLOR ; O'BRAJEN MAJKL ALISTEHR ; O'BRIEN MICHAEL ALISTAIR ; MICHAEL ALISTAIR O BRIEN ; MILES STUART CONGREVE ; MARIA GRAZIA CARR ; GRIFFITS-DZHOUNZ SHARLOTT MEHRI ; GORDON SAXTY ; ANDREW PIKE ; EMMA VICKERSTAFFE ; GILBERT EBAI BESONG ; GILBERT EBAI BESONG ; CHARLOTE MARY GRIFFITHS JONES ; CHARLOTTE MARY GRIFFITHS JONES ; CHRISTOPHER WILLIAM MURRAY

Agent(s): TRUEMAN LUCY PETRA; HESLIN ROTHENBERG FARLEY AND MESITI PC; GIBSON MARK

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LR LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INAPPROPRIATE IKK1 ACTIVITY

Abstract: The present invention relates to pyrrolo-pyridine derivatives of formula (I) combinations, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, combinations, compositions and medicaments in the treatment of disorders associated with inappropriate kinase activity, in particular disorders associated with inappropriate IKK1 activity.

Classifications:


International (IPC 8-9): A61P25/00 A61P31/18 A61P9/00

C07D471/04 (Advanced/Invention);

A61P25/00 A61P31/00 A61P9/00 C07D471/00 (Core/Invention)

CPC: C07D471/04

European: C07D471/04



Family:

Publication number	Publication date	Application number	Application date
WO08110508 A1	20080918	WO2008EP52752	20080307

Priority:

US20070893896P 20070309

Probable Assignee: GLAXO GROUP LTD

Assignee(s): (std): BALDWIN IAN ROBERT ; BAMBOROUGH PAUL ; CHRISTOPHER JOHN ANDREW ; GLAXO GROUP LTD ; HAMADI AHMED MOKTAR ; LACKEY KAREN ELIZABETH ; SMITHKLINE BEECHAM CORP

Inventor(s): (std): BALDWIN IAN ROBERT ; BAMBOROUGH PAUL ; CHRISTOPHER JOHN ANDREW ; HAMADI AHMED MOKTAR ; LACKEY KAREN ELIZABETH


Agent(s): LEAROYD STEPHANIE ANNE ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: FUSED AMINO PYRIDINE AS HSP90 INHIBITORS

Abstract: Source: US2008234314A The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.

Classifications:
International (IPC 8-9): A61K31/4188 A61K31/437 A61K31/44 A61K31/4545 A61K31/4745 A61K31/506 A61K31/517 A61K31/52 A61K31/53 A61K31/5377 A61K31/675 A61K31/704 A61K31/7088 A61K39/395 A61P21/00 A61P25/00 A61P25/14 A61P25/16 A61P25/28 A61P27/02 A61P31/04 A61P35/00 A61P35/02 A61P35/04 A61P37/02 A61P37/06 A61P43/00 A61P9/00 C07D C07D401/00 C07D401/12 C07D471/02 C07D471/04 C07D487/04 (Advanced/Invention); A61P35/00 (Advanced/Non-invention); A61K31/4353 A61K31/44 A61K31/4523 A61P21/00 A61P25/00 A61P27/00 A61P35/00 A61P37/00 A61P43/00 A61P9/00 C07D401/00 C07D471/00 C07D487/00 (Core/Invention); A61K31/4188 A61P35/00 C07D471/02 (Core/Non-invention); C07D (Subclass/Invention)
International (IPC 1-7): C07D401/00
CPC: C07D471/04
European: C07D471/04
US: 424/133.1 424/141.1 514/110 514/210.21 514/234.5 514/241 514/252.18 514/263.22 514/266.24 514/266.4 514/283 514/303 514/33 514/34 514/44A 546/118 546/118S



Family:

Publication number	Publication date	Application number	Application date
AU2008229216 AA	20080925	AU20080229216	20080310
AU2008229216 BB	20130321	AU20080229216	20080310
BRPI0808301 A2	20130806	BR2008PI08301	20080310
CA2680778 AA	20080925	CA20082680778	20080310
CN101679347 A	20100324	CN200880016525	20080310
CN101679347 B	20141022	CN200880016525	20080310
DK2069324 T3	20130902	DK20080743755T	20080310
EA019103 B1	20140130	EA20090001263	20080310
EA200901263 A1	20100226	EA20090001263	20080310
EP2069324 A1	20090617	EP20080743755	20080310
EP2069324 A4	20110907	EP20080743755	20080310
EP2069324 B1	20130731	EP20080743755	20080310
ES2430217 T3	20131119	ES20080743755T	20080310
HK1131986 A1	20140321	HK20090111481	20091208
HR20130910 T1	20131025	HR20130000910	20130925
IL200924 A0	20100517	IL20090200924	20090914
IL200924 A1	20150226	IL20090200924	20090914
IN06360DN2009 A	20100611	IN2009DN06360	20091006
JP2010522184 T2	20100701	JP20090554633T	20080310
JP5401329 B2	20140129	JP20090554633T	20080310
KR101313804 B1	20131001	KR20097021910	20080310
KR20100015739 A	20100212	KR20097021910	20080310
MX2009009936 A1	20100211	MX20090009936	20090917
MY148860 A	20130614	MY20090003837	20080310
NZ579635 A	20110729	NZ20080579635	20080310
PT2069324 T	20131010	PT20080743755T	20080310
RS52978 B	20140228	RS20130000434	20080310
SI2069324 T1	20131030	SI20080031049T	20080310
TW200845967 A	20081201	TW20080108801	20080313
TWI471131 B	20150201	TW20080108801	20080313
UA104275 C2	20140127	UA20090100580	20080310
US2008234314 AA	20080925	US20080045509	20080310
US2012237508 AA	20120920	US20120424780	20120320
US2014221343 AA	20140807	US20130054273	20131015
US8324240 BB	20121204	US20080045509	20080310
US8586605 BB	20131119	US20120424780	20120320
US9040556 BB	20150526	US20130054273	20131015
WO08115719 A1	20080925	WO2008US56396	20080310
WO08115719 A9	20090226	WO2008US56396	20080310
ZA200906371 A	20100526	ZA20090006371	20090914

Priority:
US20070895921P 20070320 US20070015288P 20071220 US20070015288 20071220
US20080045509 20080310 WO2008US56396 20080310 US20120424780 20120320
EP20080743755 20080310 US20130054273 20131015

Probable Assignee: CURIS INC
Assignee(s): (std): CAI XIONG ; CURIS INC ; QIAN CHANGGENG ; ZHAI HAIXIAO
Assignee(s): CURIS INC US
Inventor(s): (std): CAI XIONG ; CHANGGENG QIAN ; HAIXIAO ZHAI ; QIAN CHANGGENG ; XIONG CAI ; ZHAI HAIXIAO
Agent(s): STEVENS IAN EDWARD; ELMORE PATENT LAW GROUP PC; ROY P; CAROLYN S; ELMORE PATENTS LAW GROUP PC; NAKAJIMA SUANNE K ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO

DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA
LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO
RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: LH-INDAZOLE-3-AMINE COMPOUNDS AS IKK1 INHIBITORS

Abstract: The present invention relates to pyrrolo-pyridine derivatives of Formula (I) combinations, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, combinations, compositions and medicaments in the treatment of disorders associated with inappropriate kinase activity, in particular disorders associated with inappropriate IKK1 activity.


Classifications:

International (IPC 8-9): A61K31/437 A61P35/00 C07D471/04 (Advanced/Invention); A61K31/4353 A61P35/00 C07D471/00 (Core/Invention)

CPC: C07D471/04

European: C07D471/04

PatBase - WO08132121_A1



Family:

Publication number	Publication date	Application number	Application date
WO08132121 A1	20081106	WO2008EP54970	20080424

Priority:

US20070914055P 20070426

Probable Assignee: SMITHKLINE BEECHAM CORP

Assignee(s): (std): CHRISTOPHER JOHN ANDREW ; GLAXO GROUP LTD ; JUNG DAVID KENDALL ; LACKEY KAREN ELIZABETH ; SMITHKLINE BEECHAM CORP


Inventor(s): (std): CHRISTOPHER JOHN ANDREW ; JUNG DAVID KENDALL ; LACKEY KAREN ELIZABETH

Agent(s): LEAROYD STEPHANIE ANNE ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIVES, THE PREPARATION AND THE PHARMACETICAL USE THEREOF

Abstract: Source: US2010075952A The invention provides new pyrrolo-nitrogenous heterocyclic derivatives represented by formula (I) or their salts, the preparation thereof, pharmaceutical compositions containing such derivatives and the use of such derivatives as therapeutic agents, especially as protein kinase inhibitors, wherein each substituent in formula (I) is same as defined in the description.



Classifications:

International (IPC 8-9): A61K31/404 A61K31/407 A61K31/41 A61K31/437 A61K31/55

A61P17/06 A61P19/02 A61P29/00 A61P3/10 A61P35/00 A61P35/02 A61P35/04 A61P37/02 A61P37/06 A61P41/00 A61P43/00 A61P9/00 C07D209/34 C07D471/04 C07D487/04 C07D519/00 C07D519/04 C12N9/10 C12N9/99 (Advanced/Invention); A61K31/41 A61K31/4353 A61K31/55 A61P17/00 A61P19/00 A61P29/00 A61P3/00 A61P35/00 A61P37/00 A61P41/00 A61P43/00 A61P9/00 C07D471/00 C07D487/00 C07D519/00 C12N9/10 (Core/Invention);

A61K31/55 A61P35/00 C07D487/04 (Core/Non-invention);


A61K A61P C07D (Subclass/Invention)

CPC: C07D471/04 C07D519/00 C07D487/04

European: C07D471/04 C07D487/04 C07D519/00

US: 435/184 435/193 435/193S 514/183 514/212.06 514/212.060P 514/412 514/414 540/461 540/521 540/521S 540/523

PatBase - W008138232_A1



Family:

Publication number	Publication date	Application number	Application date
AU2008250895 AA	20081120	AU20080250895	20080514
AU2008250895 BB	20120802	AU20080250895	20080514
BRPI0811865 A2	20141118	BR2008PI11865	20080514
CA2685757 AA	20081120	CA20082685757	20080514
CN101307052 A	20081119	CN200810087564	20080411
CN101307052 B	20110817	CN200810087564	20080411
CN101675061 A	20100317	CN200880015008	20080514
CN101675061 B	20120704	CN200880015008	20080514
EP2157093 A1	20100224	EP20080783545	20080514
EP2157093 A4	20120307	EP20080783545	20080514
HK1121757 A1	20120504	HK20090101628	20090220
HK1121757 A3	20090430	HK20090101628	20090220
HK1137027 A1	20130301	HK20100104918	20100519
IN07356DN2009 A	20131220	IN2009DN07356	20091112
JP2010526838 T2	20100805	JP20100507781T	20080514
JP5342547 B2	20131113	JP20100507781T	20080514
KR20100022003 A	20100226	KR20097023405	20080514
MX2009011964 A1	20091201	MX20090011964	20091105
RU2009141799 A	20110620	RU20090141799	20080514
RU2473543 C2	20130127	RU20090141799	20080514
TW200946530 A	20091116	TW20080117789	20080515
TWI409263 B	20130921	TW20080117789	20080515
UA99617 C2	20120910	UA20090101632	20080514
US2010075952 AA	20100325	US20080451466	20080514
US2013303518 AA	20131114	US20120628446	20120927
US8329682 BB	20121211	US20080451466	20080514
WO08138184 A1	20081120	WO2007CN03080	20071030
WO08138232 A1	20081120	WO2008CN01352	20080514

Priority:

CN200710107463 20070514 CN200810087564 20080411 WO2008CN01352 20080514
US20090451466 20091203 US20120628446 20120927 CN200880015008 20080514

Probable Assignee: SHANGHAI HENGRUI PHARMACEUTICAL CO LTD

Assignee(s): (std): BIE PINGYAN ; CHOTANG PENG CHO ; JIANGSU HANSOH PHARMACEUTICAL ; JIANGSU HANSOH PHARMACEUTICAL CO LTD ; LI YALI ; ZHOU YING ; ZHANG LEI ; ZHAO FUQIANG ; SU YIDONG ; TANG PENGCHO ; YANG JIALIANG ; TANG PENG CHO ; QIAN GUANGTAO ; JU MINGGANG ; SHANGHAI HENGRUI PHARM CO LTD ; JIANGSU HANSOH PHARMACEUTICAL LTD ; SHANGHAI INST OF PHARMACEUTICAL IND ; SHANGHAI INST PHARM IND ; SHANGHAI INST PHARM INDUSTRY

Assignee(s): SHANGHAI HENGRUI PHARMACEUTICAL COLTD ; SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY ; SHANGHAI HENGRUI PHARMACEUTICAL CO ; SHANGHAI HENGRUI PHARMACEUTICAL CO LTD ; JIANGSU HANSOH PHARMACEUTICAL CO

Inventor(s): (std): BIE PING YAN ; BIE PINGYAN ; BINGCHU DENG ; CHOTANG PENG CHO ; JIALIANG YANG ; JU MING GANG ; JU MINGGANG ; FUQIANG ZHAO ; GUANGTAO QIAN ; LEI ZHANG ; LI YA LI ; LI YALI ; MINGGANG JU ; PINGYAN BIE ; QIAN

Inventor(s): GUANG TAO ; QIAN GUANGTAO ; SU YI DONG ; SU YIDONG ; TANG PENG CHO ; TANG PENGCHO ; YALI LI ; YANG JIA LIANG ; YANG JIALIANG ; YIDONG SU ; YING ZHOU ; ZHANG LEI ; ZHAO FU QIANG ; ZHAO FUQIANG ; ZHOU YING

Agent(s): ZHOUYING ; TSJAN' GUAN'TAO ; TSZJUJ MINGAN ; TAN PEHN CHZHO ; SU IDUN ; PENG CHO TANG ; LI JALI ; JAN TSZJALJAN ; CHZHAN LEHJ ; CHZHAO FUTSJAN ; CHZHOU IN ; DENG BINGCHU ; BIEH PINJAN


Designated states: CROWHURST CHARLOTTE WAVENEY; PATENT GROUP MACDONALD ILLIG JONES AND BRITTON LLP; MACDONALD ILLIG JONES AND BRITTON LLP; JON L; JEEKAI AND PARTNERS

AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF


Abstract: Source: US2009163488A A compound represented by the formula (I):

(I)



wherein Z_1 , Z_2 , Z_3 and Z_4 are the following

combination, $(Z_1, Z_2, Z_3, Z_4) = (CR^4, N, CR^5, C)$, (N, N, CR^5, C) , (N, C, CR^5, N) , (S, C, CR^5, C) or (S, C, N, C) ; R^1 and R^2 are the same or different and each is (1) a hydrogen atom, (2) a halogen atom, (3) a group bonded via a carbon atom, (4) a group bonded via a nitrogen atom, (5) a group bonded via an oxygen atom or (6) a group bonded via a sulfur atom; R^3 is an amino optionally having substituent(s); R^4 and R^5 are the same or different and each is (1) a hydrogen atom, (2) a halogen atom, (3) a group bonded via a carbon atom, (4) a group bonded via a nitrogen atom, (5) a group bonded via an oxygen atom or (6) a group bonded via a sulfur atom; R^3 and R^4 optionally form a ring optionally having substituent



(s); and a group represented by the formula
a salt thereof.

Classifications:


International (IPC 8-9): A61K31/428 A61K31/429 A61K31/4353 A61K31/437 A61K31/438 A61K31/4545 A61K31/496 A61K31/517 A61K31/519 A61K31/5377 A61K31/541 A61P11/06 A61P13/12 A61P15/00 A61P17/06 A61P19/00 A61P19/02 A61P27/02 A61P29/00 A61P35/00 A61P35/04 A61P43/00 A61P9/10 A61P9/12 C07D277/62 C07D277/82 C07D345/00 C07D417/12 C07D471/00 C07D471/04 C07D471/14 C07D495/04 C07D513/04 (Advanced/Invention); A61K31/429 A61K31/437 A61P35/00 C07D277/82 C07D471/04 C07D513/04 (Advanced/Non-invention); A61K31/428 A61K31/429 A61K31/4353 A61K31/438 A61K31/4523 A61K31/496 A61K31/519 A61K31/5375 A61K31/541 A61P35/00 A61P43/00 C07D277/00 C07D417/00 C07D471/00 C07D513/00 (Core/Invention); A61K31/4353 (Core/Non-invention)

International (IPC 1-7): A61K31/4365 A61K31/437 A61P35/00 A61P9/10 C07D221/00 C07D249/00 C07D471/04 C07D513/04
CPC: C07D471/04 C07D417/12 C07D471/14 C07D513/04
European: C07D417/12 C07D471/04 C07D471/14 C07D513/04

US: 514/228.5 514/228.500P 514/233.2 514/233.200P 514/234.2 514/234.200S 514/252.16 514/252.160S 514/253.04 514/253.040S 514/260.1 514/260.100S 514/278 514/278S 514/300 514/300S 514/301 514/301S 514/303 514/303S 514/367 540/1 544/118 544/118S 544/127 544/127S 544/255 544/255S 544/362 544/362S 544/58.2 544/58.200S 544/58.6 544/58.600S 546/114 546/114S 546/119 546/119S 546/121 546/121S 546/15 546/15S 548/178

is a cyclic group optionally having substituent(s), or

PatBase - W009028629_A1



Family:

Publication number	Publication date	Application number	Application date
AR066845 AA	20090916	AR2008P102359	20080604
AR069567 AA	20100203	AR2008P105279	20081204
CA2689514 AA	20081211	CA20082689514	20080604
EP2162445 A1	20100317	EP20080765409	20080604
EP2162445 B1	20131127	EP20080765409	20080604
EP2184285 A1	20100512	EP20080828528	20080828
EP2184285 A4	20110720	EP20080828528	20080828
JP5350247 B1	20131127	JP20090530185T	20080828
JP5350247 B2	20131127	JP20090530185T	20080828
JP5352476 B2	20131127	JP20090549311T	20080604
PE03702009 A1	20090430	PE20080000947	20080604
PE12592009 A1	20090914	PE20080002012	20081203
TW200904816 A	20090201	TW20080120686	20080604
TW201004620 A	20100201	TW20080145882	20081127
US2009163488 AA	20090625	US20080133063	20080604
US2010249119 AA	20100930	US20080675663	20080828
US8304557 BB	20121106	US20080133063	20080604
US8344135 BB	20130101	US20080675663	20080828
WO08150015 A1	20081211	WO2008JP60629	20080604
WO09028629 A1	20090305	WO2008JP65454	20080828

Priority:

JP20070149781 20070605	JP20070223284 20070829	WO2008JP60629 20080604
JP20080187953 20080718	WO2008JP65454 20080828	JP20090549311 20080604
JP20090530185 20080828		

Probable Assignee: TAKEDA PHARMACEUTICAL CO LTD

Assignee(s): (std): CARY DOUGLAS R ; HAYASHI YOKO ; HIROSE MASAOKI ; IMAMURA SHINICHI ; OGURO YUYA ; OKANIWA MASANORI ; TAKEDA PHARMACEUTICAL ; TAKAGI TERUFUMI ; TAKEDA PHARMACEUTICALS COMPANY ; TAKEDA PHARMACEUTICALS CO

Assignee(s): TAKEDA PHARMACEUTICALS COMPANY LIMITED ; TAKEDA PHARMACEUTICAL CO LTD ; TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor(s): (std): CARY DOUGLAS R ; HAYASHI YOKO ; HIROSE MASAOKI ; HIROSI MASAOKI ; IMAMURA SHINICHI ; IMAMURA SHINISHI ; OGURO YUYA ; OKANIWA MASANORI ; TAKAGI TERUFUMI

Agent(s): JONES NICHOLAS ANDREW ; HAMRE SCHUMANN MUELLER AND LARSON PC ; TAKASHIMA HAJIME

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO


DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA
LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO
RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: 2-(2-OXOINDOLINE-3-YLIDENE)METHYL-5-(2-HYDROXY-3-MORPHOLIN-4-YL-PROPYL)-6,7-DIHYDRO-1H-PYRROL[3,2-C]PYRIDINE-4(5H)-ONE COMPOUNDS AND USE AS PROTEIN KINASE INHIBITORS

Abstract: Source: US2010160317A Pyrrolo[3,2-c]pyridine-4-one-2-indolinone compounds, especially 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl-propyl)-6,7-dihydro-1H-pyrrol[3,2-c]pyridine-4(5H)-one compounds. Their preparation and pharmaceutical composition, and pharmaceutical use as protein kinase inhibitors.

Classifications:
International (IPC 8-9): A61K A61K31/407 A61K31/437 A61K31/5375 A61K31/5377 A61P33/00 A61P35/00 A61P35/04 A61P43/00 C07D209/04 C07D209/30 C07D413/14 C07D417/04 C07D471/02 C07D471/04 C12N9/99 (Advanced/Invention); A61K31/437 C07D209/30 C07D413/14 C07D417/04 (Advanced/Non-invention); A61K31/4353 A61P33/00 C07D209/00 C07D417/00 (Core/Invention); A61K31/437 (Core/Non-invention)
International (IPC 1-7): A61K31/437 A61P33/00 C07D209/04 C07D209/30 C07D417/04
CPC: C07D471/04
European: C07D471/04
US: 435/184 435/184S 514/234.5 514/234.500P 544/127 544/127S

PatBase - TM201000100_A



Family:

Publication number	Publication date	Application number	Application date
AU2008288615 AA	20090226	AU20080288615	20080729
AU2008288615 BB	20130110	AU20080288615	20080729
BRPI0815358 A2	20150210	BR2008PI15358	20080729
CA2694380 AA	20100125	CA20082694380	20080729
CN101367801 A	20090218	CN200710141874	20070815
CN101367801 B	20110112	CN200710141874	20070815
EP2179998 A1	20100428	EP20080783579	20080729
EP2179998 A4	20100728	EP20080783579	20080729
EP2179998 B1	20120829	EP20080783579	20080729
IN00960DN2010 A	20130830	IN2010DN00960	20100211
JP2010535819 T2	20101125	JP20100520400T	20080729
KR20100059869 A	20100604	KR20107005749	20080729
MX2010001602 A1	20100315	MX20100001602	20100210
RU2010104752 A	20110920	RU20100104752	20080729
RU2472792 C2	20130120	RU20100104752	20080729
TW201000100 A	20100101	TW20080123295	20080623
UA98797 C2	20120625	UA20100001489	20080729
US2010160317 AA	20100624	US20080733193	20080729
US8299069 BB	20121030	US20080733193	20080729
VN11266 A1	20130527	VN20100000617	20080729
WO09024016 A1	20090226	WO2008CN01388	20080729

Priority:
CN200710141874 20070815 WO2008CN01388 20080729

Probable Assignee: JIANGSU HENGRUI MEDICINE CO LTD

Assignee(s): (std): TANG PENG CHO ; SU YIDONG ; SHANGHAI HENGRUI PHARM CO LTD ; SHANKHAJ KHEHNZHUJ FARMAS JUTIKAL KO LTD ; JIANGSU HENGRUI MEDICINE CO ; JIANGSU HENGRUI MEDICINE CO LT ; JIANGSU HENGRUI MEDICINE CO LTD ; YANG JIALIANG ; ZHAO FUQIANG ; TSZJANSU KHEHNZHUJ MEDSIN KO LTD

Assignee(s): TSZJANSU KHEHNZHUJ MEDSIN KO ; SHANGHAI HENGRUI PHARMACEUTICAL CO LTD ; SHANGHAI HENGRUI PHARMACEUTICAL CO ; SHANKHAJ KHEHNZHUJ FARMAS JUTIKAL KO ; SHANGHAI HENGRUI PHARMACEUTICAL COLTD ; JIANGSU HENGRUI MEDICINE CO LTDNO. 145 EAST RENMIN ROADXINPU DISTRICTLIANYUGANG222002JIANGSUCN ; SHANGHAI HENGRUI PHARMACEUTICAL CO LTD279 WENJING ROADMINHANG DRISTRIC200245SHANGHAICN ; HENGRUI PHARMACEUTICAL CO LTD

Inventor(s): (std): SU IDUN ; SU YI DONG ; SU YIDONG ; CHZHAO FUTSJAN ; JAN TSZJALJAN ; TAN PEHN CHZHO ; TANG PENG CHO ; YANG JIA LIANG ; YANG JIALIANG ; ZHAO FU QIANG ; ZHAO FUQIANG ; YIDONG SU ; JIALIANG YANG ; FUQIANG ZHAO ; BINGCHU DENG

Inventor(s): DENG BINGCHU ; ZHAO FUQIANGCN ; YANG JIALIANGCN ; TANG PENG CHO CN ; PENG CHO TANG ; SU YIDONGCN

Agent(s): COLLIN JEROME ; HEDMAN AND COSTIGAN PC ; JAMES V ; GE CHENG AND CO LTD

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: INHIBITORS OF AKT ACTIVITY

Abstract: Invented are novel substituted pyridine compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

Classifications:

International (IPC 8-9): A01N43/56 A61K31/415 A61K31/519 (Advanced/Invention); A01N43/48 A61K31/415 A61K31/519 (Core/Invention)

CPC: C07D471/04

European: C07D471/04

Family:

Publication number	Publication date	Application number	Application date
WO09032651 A1	20090312	WO2008US74370	20080827

Priority:

US20070969220P 20070831

Probable Assignee: SMITHKLINE BEECHAM CORP

Assignee(s): (std): HEERDING DIRK A ; LIN HONG ; SMITHKLINE BEECHAM CORP ; YAMASHITA DENNIS S

Inventor(s): (std): HEERDING DIRK A ; LIN HONG ; YAMASHITA DENNIS S

Agent(s): DUSTMAN WAYNE J ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: INHIBITORS OF AKT ACTIVITY

Abstract: Invented are novel substituted pyridine compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

Classifications:

International (IPC 8-9): A01N43/90 A61K31/415 A61K31/519 (Advanced/Invention);
A01N43/90 A61K31/415 A61K31/519 (Core/Invention)

CPC: C07D471/04

European: C07D471/04

Family:

Publication number	Publication date	Application number	Application date
WO09032652 A1	20090312	WO2008US74371	20080827

Priority:

US20070969224P 20070831

Probable Assignee: SMITHKLINE BEECHAM CORP

Assignee(s): (std): HEERDING DIRK A ; LIN HONG ; SMITHKLINE BEECHAM CORP ; YAMASHITA DENNIS A


Inventor(s): (std): HEERDING DIRK A ; LIN HONG ; YAMASHITA DENNIS A

Agent(s): DUSTMAN WAYNE J ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND **PDGFR** KINASE INHIBITORS

Abstract: Source: US2011183997A The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRa and **PDGFR** beta kinases.



Classifications:

International (IPC 8-9): A61K31/4353 A61K31/4375 A61K31/444 A61K31/497 A61K45/00 A61P1/00 A61P1/04 A61P1/16 A61P11/02 A61P11/06 A61P11/08 A61P13/12 A61P17/00 A61P17/04 A61P17/06 A61P19/02 A61P19/06 A61P21/02 A61P25/00 A61P25/04 A61P25/14 A61P25/16 A61P25/18 A61P25/22 A61P25/24 A61P25/28 A61P25/30 A61P25/36 A61P27/02 A61P29/00 A61P3/00 A61P3/04 A61P3/10 A61P31/14 A61P33/02 A61P33/06 A61P33/12 A61P35/00 A61P35/02 A61P37/00 A61P37/02 A61P37/06 A61P37/08 A61P43/00 A61P7/10 A61P9/00 A61P9/12 C07D471/02 C07D471/04 C12N9/99 (Advanced/Invention); A61K31/4375 A61P11/06 A61P17/00 A61P25/00 A61P29/00 A61P35/00 A61P37/00 A61P37/08 C07D471/04 (Advanced/Non-invention); A61K31/4353 A61P25/00 A61P29/00 A61P35/00 A61P37/00 A61P9/00 C07D471/00 (Core/Invention); A61K31/4375 A61P11/06 A61P17/00 A61P25/00 A61P35/00 A61P37/08 C07D471/04 (Core/Non-invention)

International (IPC 1-7): A61K31/4375 A61P25/00 A61P35/00 C07D471/04

CPC: C07D471/04

European: C07D471/04

US: 435/184 435/184S 514/255.05 514/255.050P 514/300 514/300S 544/405 544/405S 546/122 546/122S

Family:

Publication number	Publication date	Application number	Application date
AR070469 AA	20100407	AR2009P100626	20090224
AT551342 E	20120415	AT20090711557T	20090220
AU2009217356 AA	20090827	AU20090217356	20090220
AU2009217356 BB	20120503	AU20090217356	20090220
CA2714700 AA	20100820	CA20092714700	20090220
CA2714700 C	20130730	CA20092714700	20090220
CN102083828 A	20110601	CN200980113958	20090220
CN102083828 B	20131113	CN200980113958	20090220
EA018551 B1	20130830	EA20100001331	20090220
EA201001331 A1	20110429	EA20100001331	20090220
EP2252612 A1	20101124	EP20090711557	20090220
EP2252612 B1	20120328	EP20090711557	20090220
ES2383331 T3	20120620	ES20090711557T	20090220
IN05986DN2010 A	20110325	IN2010DN05986	20100823
JP2011513231 T2	20110428	JP20100547818T	20090220
JP5230755 B2	20130710	JP20100547818T	20090220
KR101216323 B1	20121227	KR20107021103	20090220
KR20100115379 A	20101027	KR20107021103	20100920
PE14922009 A1	20091022	PE20090000257	20090220
TW200940538 A	20091001	TW20090105719	20090223
US2011183997 AA	20110728	US20090918801	20090220
US8278452 BB	20121002	US20090918801	20090220
WO09105712 A1	20090827	WO2009US34778	20090220

Priority:

US20080030912P 20080222 US20080030912 20080222 WO2009US34778 20090220
US20090918801 20090220

Probable Assignee: IRM LLC A DELAWARE LIABILITY CORP LTD

Assignee(s): (std): CHIANELLI DONATELLA ; IRM LLC ; LI XIAOLIN ; NABAKKA JULIET ; LIU XIAODONG ; MOLTENI VALENTINA ; YEH VINCE ; LOREN JON

Assignee(s): IRM LLC A DELAWARE LIABILITY CORP LTD

Inventor(s): (std): XIAOLIN LI ; XIAODONG LIU ; VINCE YEH ; VALENTINA MOLTENI ; LAUREN JON C ; LI XIAO LIN ; LIU XIAO DONG ; LOREN JON C ; JULIET NABAKKA ; JON LOREN ; DONATELLA CHIANELLI ; YEH VINCE ; NABAKKA JULIET ; MOLTENI VALENTINA ; LOREN JON ; LIU XIAODONG ; LI XIAOLIN ; CHIANELLI DONATELLA

Inventor(s): CHIANELLI, Donatella ; YEH, Vince ; NABAKKA, Juliet ; MOLTENI, Valentina ; LIU, Xiaodong ; LI, Xiaolin

Agent(s): KIDDLE SIMON JOHN; DANIEL E; GENOMICS INST OF NOVARTIS RESEARCH FOUNDATION; REID SCOTT ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS

Abstract: Source: US2011166133A The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Ros, KDR, FMS, C-FMS, FLT3, c-Kit, JAK2, JAK3, Aurora, **PDGFR**, Lck, TrkA, TrkB, TrkC, IGF-IR, ALK4, ALK5 and ALK or combinations thereof.

Classifications:

International (IPC 8-9): A01N43/58 A61K31/4353 A61K31/495 A61K31/4985 A61K31/5025 A61K31/506 A61K31/5353 A61K31/5377 A61K35/00 A61K9/02 A61K9/08 A61K9/107 A61K9/12 A61K9/20 A61K9/48 A61K9/72 A61P1/04 A61P1/16 A61P11/00 A61P11/02 A61P11/06 A61P13/12 A61P17/00 A61P17/02 A61P17/06 A61P19/00 A61P19/02 A61P25/00 A61P25/04 A61P25/28 A61P27/02 A61P29/00 A61P3/00 A61P31/04 A61P31/12 A61P31/18 A61P35/00 A61P37/00 A61P37/04 A61P37/06 A61P43/00 A61P5/00 A61P9/00 C07D C07D295/02 C07D471/00 C07D471/04 C07D487/00 C07D487/04 C07D519/00 (Advanced/Invention); A61K31/5025 A61K31/5377 A61K9/02 A61K9/08 A61K9/107 A61K9/12 A61K9/20 A61K9/48 A61K9/72 A61P1/04 A61P1/16 A61P11/00 A61P11/02 A61P11/06 A61P13/12 A61P17/00 A61P17/02 A61P17/06 A61P19/00 A61P19/02 A61P25/00 A61P25/04 A61P25/28 A61P27/02 A61P29/00 A61P3/00 A61P31/04 A61P31/12 A61P31/18 A61P35/00 A61P37/00 A61P37/04 A61P37/06 A61P43/00 A61P9/00 (Advanced/Non-invention); A61K31/4353 A61K31/4985 A61K31/506 A61K35/00 A61P37/00 C07D471/00 C07D487/00 (Core/Invention); C07D487/04 (Core/Non-invention); C07D (Subclass/Invention)


International (IPC 1-7): A61K31/4162 A61K31/4353 A61K31/4985 A61K31/5025 A61P11/06 A61P31/18 A61P35/00 A61P35/04 A61P37/00 A61P37/08 C07D231/00 C07D237/00 C07D471/04 C07D487/04

CPC: C07D471/04 C07D487/04

European: C07D471/04 C07D487/04

US: 514/233.2 514/233.200P 514/248 514/248S 514/250 544/109 544/109S 544/236 544/236S

PatBase - TM201012820_R



Family:

Publication number	Publication date	Application number	Application date
AR071778 AA	20100714	AR2009P101724	20090513
AU2009246687 AA	20091119	AU20090246687	20090507
AU2009246687 BB	20120809	AU20090246687	20090507
CA2722418 AA	20101022	CA20092722418	20090507
CA2722418 C	20130917	CA20092722418	20090507
CN102056927 A	20110511	CN200980121828	20090507
CN102056927 B	20140625	CN200980121828	20090507
CO6321286 A2	20110920	CO20100153711	20101206
CR11797 A	20110216	CR20100011797	20101118
DOP20100349 A	20101130	DO20100000349	20101112
EA019507 B1	20140430	EA20100001774	20090507
EA201001774 A1	20110630	EA20100001774	20090507
ECSP10010676 A	20110131	EC2010SP10676	20101213
EP2300469 A2	20110330	EP20090747213	20090507
EP2300469 B1	20150624	EP20090747213	20090507
IL208993 A0	20110131	IL20100208993	20101028
JP2011520887 T2	20110721	JP20110509564T	20090507
JP2014098010 A2	20140529	JP20140014101	20140129
JP5492194 B2	20140514	JP20110509564T	20090507
KR101324804 B1	20131101	KR20107027784	20090507
KR20110016931 A	20110218	KR20107027784	20090507
MA32393 B1	20110601	MA20100033422	20101210
MX2010012457 A1	20101207	MX20100012457	20101112
PA8826501 A1	20100421	PA20090088265	20090513
PE18492009 A1	20091221	PE20090000671	20090513
SV2010003733 A	20110705	SV20100003733	20101112
TW201012820 A	20100401	TW20090115907	20090513
US2011166133 AA	20110707	US20090992027	20090507
US8507488 BB	20130813	US20090992027	20090507
UY31821 A1	20100105	UY20090031821	20090512
WO09140128 A2	20091119	WO2009US43073	20090507
WO09140128 A3	20100107	WO2009US43073	20090507

Priority:

US20080052879P 20080513 US20090152872P 20090216 WO2009US43073 20090507
US20090992027 20090507 JP20110509564 20090507

Probable Assignee: NOVARTIS AG

Assignee(s): (std): ALBAUGH PAMELA A ; CHOI HA SOON ; CHOIPIUK GREGORY ; FAN YI ; IRM LLC ; RUCKER PAUL VINCENT ; WANG ZHICHENG ; NOVARTIS AG

Assignee(s): NOVARTIS INT PHARMACEUTICAL LTD ; IRM LLCUS

Inventor(s): (std): CHOIPIUK GREGORY S ; GREGORY CHOIPIUK ; HA SOON CHOI ; PAMELA A ALBAUGH ; PAUL VICENT RUCKER ; PAUL VINCENT RUCKER ; RUCKER PAUL V ; WANG ZHI CHENG ; YI FAN ; ZHICHENG WANG ; WANG ZHICHENG ; WANG ZHICGENG ; VINCENT RUCKER PAUL ; RUCKER PAUL VINCENT ; RUCKER PAUL VICENT ; FAN YIN ; FAN YI ; CHOIPIUK GREGORY ; CHOL HA SOON ; CHOI HA SOON ; ALBAUGH PAMELA A


Inventor(s): YIN FAN ; ZHICGENG WANG ; PAUL V RUCKER ; CHOI, HA-SOON

Agent(s): BAILEY SAM ROGERSON; DANIEL E; GENOMICS INST OF NOVARTIS RESEARCH FOUNDATION; RAYMOND DANIEL E ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KS LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS

Abstract: Source: US2011212053A Provided are compounds according to Formula (I):



pharmaceutically acceptable salt forms thereof, wherein X, Y, R¹, R⁶, R⁷, and R⁸ are as defined, and which compounds are effective inhibitors of PI3-kinase and/or other medically and clinically relevant kinases. Also provided are pharmaceutical compositions and methods of using the compounds and compositions as PI3-kinase and kinase inhibitors. More particularly, the compounds of the invention provide treatments and therapeutics for human diseases regulated by, or associated with, the activity of, PI3-kinases and/or protein kinases, or mutant or variant forms thereof.

Classifications:

International (IPC 8-9): A61K31/437 A61K31/496 A61K31/501 A61K31/506 A61K31/5377 A61K31/573 A61K31/675 A61K33/24 A61K38/19 A61K38/20 A61K38/43 A61K38/50 A61P11/00 A61P11/06 A61P17/06 A61P19/02 A61P25/00 A61P29/00 A61P3/00 A61P3/04 A61P3/10 A61P35/00 A61P35/02 A61P37/02 A61P37/06 A61P37/08 A61P7/00 A61P9/00 A61P9/04 A61P9/10 C07D403/02 C07D471/04 C07D487/02 C07D487/04 C07D498/04 C07D513/04 C12N5/09 (Advanced/Invention)
CPC: A61K31/437 C07D471/04 C07D498/04 C07D513/04
European: A61K31/437 C07D471/04 C07D498/04 C07D513/04
US: 424/649 424/649S 424/85.1 424/85.100S 424/85.2 424/85.200P 424/94.1 424/94.100S 424/94.6 424/94.600S 435/375 435/375S 514/110 514/110S 514/180 514/180S 514/232.5 514/232.500S 514/232.8 514/232.800S 514/252.04 514/252.040S 514/253.03 514/253.030S 514/256 514/256S 514/293 514/293S 544/126 544/126S 544/238 544/238S 544/333 544/333S 544/361 544/361S 544/80 544/80S 546/82 546/82S 546/83 546/83S

Family:

Publication number	Publication date	Application number	Application date
EP2303890 A2	20110406	EP20090767836	20090619
EP2303890 A4	20120411	EP20090767836	20090619
US2011212053 AA	20110901	US20090737215	20090619
WO09155527 A2	20091223	WO2009US47970	20090619
WO09155527 A3	20100624	WO2009US47970	20090619
WO09155527 A9	20100506	WO2009US47970	20090619

Priority:

US20080073915P 20080619 WO2009US47970 20090619 US20090737215 20090619

Probable Assignee: PROGENICS PHARMACEUTICALS INC


Assignee(s): (std): HAMILTON MARK ; HAN AMY QI ; PROGENICS PHARM INC ; QI HAN AMY ; QIAN DAPENG ; WANG ERIC

Assignee(s): PROGENICS PHARMACEUTICALS INC

Inventor(s): (std): HAMILTON MARK ; HAN AMY QI ; QI HAN AMY ; QIAN DAPENG ; WANG ERIC

Agent(s): LUCAS BRIAN RONALD; HOFFMANN HANS PETER G


Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW



Title: PYRIDINOPYRIDINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

Abstract: Source: US2011124643A The present invention relates to pyridopyridone derivatives of formula (I):

(I)



in which the variables are as defined herein, to their preparation and to their therapeutic use as inhibitors of the kinase activity of PDGF (platelet-derived growth factor) ligand receptors and possibly of FLT3 (fms-like tyrosine kinase receptor) ligand receptors.

Classifications:

International (IPC 8-9): A61K31/4375 A61K31/444 A61K31/497 A61K31/506 A61K31/5355 A61K31/5377 A61P13/00 A61P13/12 A61P17/00 A61P17/06 A61P3/10 A61P35/00 A61P35/02 A61P37/00 A61P37/02 A61P37/06 A61P43/00 A61P7/02 A61P9/00 A61P9/04 A61P9/10 A61P9/12 C07D213/74 C07D213/82 C07D401/00 C07D403/10 C07D403/14 C07D413/14 C07D419/00 C07D471/00 C07D471/04 C07D471/06 (Advanced/Invention); A61K31/4375 A61P35/00 A61P37/00 C07B61/00 C07D403/10 C07D471/04 (Advanced/Non-invention); A61K31/4353 A61K31/4375 A61P13/00 A61P35/00 A61P37/00 A61P7/00 A61P9/00 C07D213/00 C07D471/00 C07D471/04 (Core/Invention); C07D471/04 (Core/Non-invention); A61K A61P C07D (Subclass/Invention)

International (IPC 1-7): A61K31/4375 A61P35/00 C07D471/04

CPC: C07D471/04

European: C07D471/04

US: 514/234.5 514/234.500P 514/255.05 514/255.050S 514/256 514/256S 514/300 514/300S 544/127 544/127S 544/333 544/333S 544/405 544/405S 546/122 546/123 546/123S

Family:

Publication number	Publication date	Application number	Application date
AR072798 AA	20100922	AR2009P102532	20090707
AU2009267827 AA	20100114	AU20090267827	20090706
AU2009267827 BB	20140109	AU20090267827	20090706
CA2729833 AA	20100114	CA20092729833	20090706
CN102149713 A	20110810	CN200980134845	20090706
CN102149713 B	20131211	CN200980134845	20090706
CO6341476 A2	20111121	CO20110001537	20110107
CR11866 A	20110314	CR20100011866	20101222
DOP20110008 A	20110215	DO20110000008	20110107
EA019362 B1	20140331	EA20110070154	20090706
EA201170154 A1	20110830	EA20110070154	20090706
ECSPI1010742 A	20110228	EC2011SP10742	20110105
EP2315767 A2	20110504	EP20090784467	20090706
EP2315767 B1	20130904	EP20090784467	20090706
ES2438540 T3	20140117	ES20090784467T	20090706
FR2933700 A1	20100115	FR20080003862	20080708
FR2933700 B1	20100730	FR20080003862	20080708
HK1159108 A1	20140808	HK20110113761	20111221
HK1159108 A3	20120727	HK20110113761	20111221
HN2011000076 A	20130722	HN20110000076	20110107
IL210514 A0	20110331	IL20110210514	20110106
IL210514 A1	20131128	IL20110210514	20110106
IN00089KN2011 A	20111125	IN2011KN00089	20110107
JP2011527320 T2	20111027	JP20110517200T	20090706
JP5606434 B2	20141015	JP20110517200T	20090706
KR20110031372 A	20110325	KR20117002883	20110207
MA32544 B1	20110801	MA20110033590	20110208
MX2011000330 A1	20110405	MX20110000330	20110107
MY149705 A	20130930	MY20110000087	20090706
NZ590862 A	20120629	NZ20090590862	20090706
PE04052011 A1	20110704	PE20110000014	20090706
SV2011003800 A	20110429	SV20110003800	20110107
TH123103 A	20130430	TH20091003025	20090703
TW201004955 A	20100201	TW20090122666	20090703
UA102858 C2	20130827	UA20110001399	20090706
US2011124643 AA	20110526	US20110985749	20110106
US8436011 BB	20130507	US20110985749	20110106
UY31971 A1	20100226	UY20090031971	20090708
WO10004197 A2	20100114	WO2009FR51321	20090706
WO10004197 A3	20100311	WO2009FR51321	20090706

Priority:


FR20080003862 20080708 WO2009FR51321 20090706 EP20090784467 20090706

Probable Assignee: SANOFI

Assignee(s): (std): BELLEVERGUE PATRICE ; LASSALLE GILBERT ; MARTIN VALERIE ; MCCORT GARY ; VOLLE CHALLIER CECILE ; SANOFI AVENTIS ; SAVI PIERRE ; SANOFI SA

Assignee(s): SANOFI

Inventor(s): (std): BELLEVERGUE PATRICE ; CECILE VOLLE CHALLIER ; LASALLE GILBERT ; LASSALLE GILBERT ; MARTIN VALERIE ; MARTIN VALRIE ; MARTIN VALURIE ; MCCORT GARY ; SAVI PIERRE ; VALERIE MARTIN ; VOLLE CHALLIER CCILE ; VOLLE



CHALLIER CECILE ; VOLLE CHALLIER CUCILE ; VOLLE CHALLIER CECILLE ; SAVI CECILE VOLLE CHALIER ; PIERRE SAVI ;
PATRICE BELLEVERGUE ; GILBERT LASSALLE ; GILBERT LASSALE ; GARY MCCORT

Inventor(s):

VOLLE CHALLIER CA CILE ; MARTIN VALA RIE ; GILBERT LASALLE

Agent(s):

BOURON ESTELLE; JANANN Y; MERLIER JOSIANE

Designated states:

AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM
DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ
LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL
PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS

Abstract: Described herein are compounds that are inhibitors of one or more protein kinases. Also described are pharmaceutical compositions and medicaments that include the compounds described herein. Also described herein are methods of using such protein kinase inhibitors, alone and in combination with other compounds, for conditions or diseases mediated or dependent upon protein kinases.

Classifications:

International (IPC 8-9): A61K31/437 A61K31/506 A61K31/5377 A61P35/00 A61P43/00 C07D403/04 C07D471/04 (Advanced/Invention)

CPC: C07D403/04 C07D471/04

European: C07D403/04 C07D471/04

Family:

Publication number	Publication date	Application number	Application date
CN101723936 A	20100609	CN200810201791	20081027
CN101723936 B	20140115	CN200810201791	20081027
WO10051781 A1	20100514	WO2009CN75214	20091130

Priority:

CN200810201791 20081027

Probable Assignee: SHANGHAI GENOMICS INC

Assignee(s): (std): LUO YING ; SHANGHAI GENOMICS INC ; SHU FANG

Inventor(s): (std): CUIPING GU ; FANG SHU ; GU CUIPING ; LUO YING ; SHU FANG ; SHUDONG WANG ; WANG SHUDONG ; WU JUN ; YING LUO

Agent(s): SHANGHAI PATENT AND TRADEMARK LAW OFFICE LLC


Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS

Abstract: Source: US2011263541A Described herein are compounds that are inhibitors of one or more protein kinases. Also described are pharmaceutical compositions and medicaments that include the compounds described herein. Also described herein are methods of using such protein kinase inhibitors, alone and in combination with other compounds, for conditions or diseases mediated or dependent upon protein kinases.

Classifications:

International (IPC 8-9): A61K31/437 A61K31/506 A61K31/5377 A61K31/635 A61P11/00 A61P11/06 A61P19/08 A61P25/28 A61P29/00 A61P3/00 A61P35/00 A61P37/06 A61P37/08 A61P7/00 C07D403/04 C07D471/04 F01D25/12 F15B21/04 (Advanced/Invention)
CPC: C07D403/04 C07D471/04 F02C7/14
European: C07D403/04 C07D471/04
US: 514/157 514/234.5 514/234.500S 514/235.8 514/252.14 514/252.18 514/252.180S 514/275 514/275S 544/122 544/122S 544/295 544/331 544/331S



Family:

Publication number	Publication date	Application number	Application date
CN101725377 A	20100609	CN200810201797	20081027
CN101725377 B	20110907	CN200810201797	20081027
US2011263541 AA	20111027	US20110095526	20110427
US8309550 BB	20121113	US20110095526	20110427

Priority:

CN200810201791 20081027 CN200810201797 20081027 WO2009CN75214 20091130
US20110095526 20110427

Probable Assignee: SHANGHAI GENOMICS INC

Assignee(s): (std): LUO YING ; SHANGHAI ELECTRIC POWER EQUIPM ; SHANGHAI ELECTRIC POWER EQUIPMENTS CO LTD ; SHANGHAI GENOMICS INC ; WANG SHUDONG ; SHU FANG

Assignee(s): SHANGHAI ELECTRIC POWER EQUIPMENTS CO

Inventor(s): (std): JINHUA BAO ; LUO YING ; MINGGANG CHEN ; SHU FANG ; WANG SHUDONG

Inventor(s): BAO JINHUA ; CHEN MINGGANG


Agent(s): MCDERMOTT WILL AND EMERY LLP

Title: 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS

Abstract: Source: US2012122895A The present invention provides 5,6-bicyclic heteroaryl-containing urea compounds of Formula I or II and use of the same for treating conditions mediated by protein kinase such as VEGFR2, c-Met, **PDGFR** and beta c-Kit, CSF1R, or EphA2.

Classifications:

International (IPC 8-9): A61K31/407 A61K31/416 A61K31/4162 A61K31/4184 A61K31/4188 A61K31/4192 A61K31/4196 A61K31/423 A61K31/437 A61K31/4738 A61K31/5025 A61K31/517 A61K31/519 A61K31/52 A61K31/5377 A61P13/12 A61P17/00 A61P17/06 A61P19/02 A61P27/02 A61P29/00 A61P3/10 A61P35/00 A61P37/00 A61P37/06 A61P43/00 A61P9/10 C07D C07D401/06 C07D401/10 C07D401/14 C07D403/02 C07D403/06 C07D403/14 C07D471/04 C07D473/00 C07D487/04 C07D513/02 (Advanced/Invention); C07D (Subclass/Invention) **CPC:** C07D471/04 **European:** C07D471/04 **US:** 514/263.1 514/263.100P 514/265.1 514/265.100S 514/300 514/300S 544/277 544/277S 544/280 544/280S 546/113 546/113S



Family:

Publication number	Publication date	Application number	Application date
AU2010289143 AA	20110303	AU20100289143	20100820
CA2769151 AA	20110303	CA20102769151	20100820
CN102066372 A	20110518	CN201080001560	20100820
CN102066372 B	20140917	CN201080001560	20100820
CO6491087 A2	20120731	CO20120012075	20120126
EA201290073 A1	20130130	EA20120090073	20100820
ECSP12011691 A	20120430	EC2012SP11691	20120223
EP2470533 A1	20120704	EP20100811241	20100820
EP2470533 A4	20130123	EP20100811241	20100820
HK1157779 A3	20120706	HK20110112347	20111115
IL218114 A0	20120430	IL20120218114	20120214
JP2013502444 T2	20130124	JP20120525875T	20100820
KR20120089459 A	20120810	KR20127006772	20100820
MA33559 B1	20120901	MA20120034647	20120222
MX2012002317 A1	20120625	MX20120002317	20120223
SG178092 A1	20120329	SG20120000491	20100820
US2012122895 AA	20120517	US20100922527	20100820
US8648086 BB	20140211	US20100922527	20100820
WO11023081 A1	20110303	WO2010CN76199	20100820

Priority:
US20090236274P 20090824 WO2010CN76199 20100820 US20100922527 20100820

Probable Assignee: ASCEPION PHARMACEUTICALS INC

Assignee(s): (std): ASCEPION PHARMACEUTICALS INC ; JIANG SHAN ; KONG REN ; XING XINGLONG ; WANG QISHAN ; PHARMACEUTICALS INC

Assignee(s): ASCEPION PHARMACEUTICALS

Inventor(s): (std): JIANG SHAN ; KONG REN ; QISHAN WANG ; REN KONG ; SHAN JIANG ; WANG QISHAN ; XING XINGLONG ; XINGLONG XING

Agent(s): FELDMANN UTE; GREENBERG TRAUIG LLP; WEISUN; SUNRAY INTELLECTUAL PROPERTY ATTORNEYS

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: PROTEIN KINASE CONJUGATES AND INHIBITORS

Abstract: Source: US2011117073A The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.

Classifications:

International (IPC 8-9): A61K31/381 A61K31/395 A61K31/4155 A61K31/416 A61K31/4245 A61K31/4365 A61K31/437 A61K31/44 A61K31/444 A61K31/4545 A61K31/496 A61K31/497 A61K31/502 A61K31/5025 A61K31/505 A61K31/506 A61K31/519 A61K31/53 A61K31/5365 A61K31/5377 A61K31/5383 A61K38/00 A61K38/45 A61K45/00 A61K47/48 A61P11/06 A61P19/00 A61P25/28 A61P27/02 A61P35/00 A61P37/02 A61P43/00 A61P9/00 C07D213/66 C07D213/81 C07D231/56 C07D239/42 C07D239/48 C07D333/68 C07D401/04 C07D401/12 C07D401/14 C07D403/04 C07D403/06 C07D403/12 C07D403/14 C07D405/14 C07D409/04 C07D409/14 C07D413/12 C07D417/12 C07D417/14 C07D471/04 C07D471/10 C07D487/04 C07D495/04 C07D498/04 C12N9/12 G01N G01N33/53 (Advanced/Invention); G01N (Subclass/Invention)

CPC: C12N9/96 A61K47/48061 A61K47/48238 C07D213/74 C07D213/81 C07D213/82 C07D215/22 C07D231/12 C07D239/42 C07D239/48 C07D333/68 C07D401/12 C07D401/14 C07D403/04 C07D403/06 C07D403/12 C07D403/14 C07D409/04 C07D409/12 C07D409/14 C07D413/12 C07D413/14 C07D417/12 C07D417/14 C07D471/04 C07D471/10 C07D487/04 C07D495/04 C07D498/04 C12N9/1205

European: A61K47/48H4H A61K47/48R C07D213/74 C07D213/81 C07D213/82 C07D215/22 C07D231/12 C07D239/42 C07D239/48 C07D333/68 C07D401/12 C07D401/14 C07D403/04 C07D403/06 C07D403/12 C07D403/14 C07D409/04 C07D409/12 C07D409/14 C07D413/12 C07D413/14 C07D417/12 C07D417/14 C07D471/04 C07D471/10 C07D487/04 C07D495/04 C07D498/04 C12N9/12C C12N9/96

US: 424/94.5 424/94.500P 435/194 435/194S 514/248 514/248S 514/255.05 514/255.050S 514/275 514/275S 514/350 514/350S 544/236 544/236S 544/295 544/295S 544/323 544/323S 546/298 546/298S

PatBase - US2011117073_A61

Irreversible Inhibitors Demonstrate Prolonged PD Relative to Sorafenib in EOL-1 cells with FIL1P1-PDGFR alpha fusion protein

Hours post washout	Sorafenib (% PDGFR pTyr)	Irreversible (% PDGFR pTyr)
0	20	20
1	25	20
2	28	55
4	20	55

Family:

Publication number	Publication date	Application number	Application date
AU2010295690 AA	20110324	AU20100295690	20100915
AU2010295690 AB	20120412	AU20100295690	20100915
CA2773985 AA	20120312	CA20102773985	20100915
CN102713618 A	20121003	CN201080050753	20100915
EP2478361 A2	20120725	EP20100817748	20100915
EP2478361 A4	20140521	EP20100817748	20100915
IL218678 A0	20120531	IL20120218678	20120315
JP2013505245 T2	20130214	JP20120529871T	20100915
KR20120093220 A	20120822	KR20127009760	20120416
MX2012003332 A1	20120803	MX20120003332	20120316
NZ598705 A	20140627	NZ20100598705	20100915
RU2012114902 A	20131027	RU20120114902	20100915
SG179172 A1	20120427	SG20120001854	20100915
US2011117073 AA	20110519	US20100882484	20100915
WO11034907 A2	20110324	WO2010US48916	20100915
WO11034907 A3	20110512	WO2010US48916	20100915

Priority:
US20090242988P 20090916 US20100882484 20100915 WO2010US48916 20100915

Probable Assignee: CELGENE AVILOMICS RESEARCH INC

Assignee(s): (std): GHOSH SHOMIR ; KLUGE ARTHUR ; SINGH JUSWINDER ; QIAO LIXIN ; NIU DEQIANG ; PETTER RUSSELL COLYN ; ZHU ZHENDONG ; LOBB ROY ; AVILA THERAPEUTICS INC ; CELGENE AVILOMICS RES INC

Assignee(s): CELGENE AVILOMICS RESEARCH INC

Inventor(s): (std): ARTHUR KLUGE ; COLYN PETTER RUSSELL ; DEQIANG NIU ; GHOSH SHOMIR ; JUSWINDER SINGH ; KLUGE ARTHUR ; LIXIN QIAO ; LOBB ROY ; NIU DEQIANG ; PETTER RUSSELL COLYN ; QIAO LIXIN ; ROY LOBB ; SHOMIR GHOSH ; SINGH JUSWINDER ; ZHENDONG ZHU ; ZHU ZHENDONG

Inventor(s): RUSSELL COLYN PETTER

Agent(s): MUELLER BORE AND PARTNER PATENTANWAELTE; UNDERWOOD ROBERT H

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Flt3, **PDGFR**, **PDGFR**, c-KIT, VEGFR1, VEGFR2, VEGFR3, c- RAF, AbI, Bcr-Abl, Aurora- A, AxI, BMX, CHK2, CSR0, Fes, FGFRi, FGFR3, IKKa, IR, JNK2a2, Lck, Met, MKK6, MST2, p70S6K, PKA, PKD2, ROCK-II, Ros, RskI, SAPK2a, SAPK2ss, SAPK3 SAPK4, Syk, Tie2, TrkA and/or TrkB Kinases.

Classifications:

International (IPC 8-9): A61K31/416 A61K31/5025 A61P11/00 A61P19/00 C07C273/18 C07D231/56 C07D471/04 (Advanced/Invention); C07C273/18 (Advanced/Non-invention)

CPC: A61K31/416 A61K31/5025 C07D231/56 C07D471/04

European: A61K31/416 A61K31/5025 C07D231/56 C07D471/04

Family:

Publication number	Publication date	Application number	Application date
CN102216300 A	20111012	CN201080003084	20100930
CN102216300 B	20141022	CN201080003084	20100930
WO11038579 A1	20110407	WO2010CN01541	20100930

Priority:

CN200910177355 20090930 WO2010CN01541 20100930 CN201080003084 20100930

Probable Assignee: ZHEJIANG BETA PHARMA INC


Assignee(s): (std): FINE RICHARD M ; HU YUNYAN ; KANG XINSHAN ; KLEBANSKY BORRIS ; LI HAIJUN ; LONG WEI ; MA CUNBO ; ZHEJIANG BETA PHARMA INC ; WANG YANPING ; WANG YINXIANG

Inventor(s): (std): FINE RICHARD M ; HU YUNYAN ; KANG XINSHAN ; KLEBANSKY BORRIS ; LI HAIJUN ; LONG WEI ; MA CUNBO ; WANG YANPING ; WANG YINXIANG ; YUNYAN HU ; YINXIANG WANG ; YANPING WANG ; XINSHAN KANG ; WEI LONG ; HAIJUN LI ; CUNBO MA ; BORRIS KLEBANSKY

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF

Abstract: Source: US2013005724A The present invention relates to derivatives of pyridino-pyridinones, and to their preparation and use thereof, having activity as inhibitors of kinase activity of receptors for PDGF (platelet derived growth factors) ligands and optionally of receptors for the FLT3 (fms-like tyrosine kinase receptor) ligand receptors, said derivatives comprising compounds of formula (I):



specifically defined herein. The compounds are suitable as therapeutics for the treatment of various proliferative diseases.

Classifications:

International (IPC 8-9): A61K31/04 A61K31/4375 A61K31/444 A61K31/497 A61K31/5377 A61P13/12 A61P17/00 A61P17/06 A61P19/04 A61P27/02 A61P3/10 A61P35/00 A61P35/02 A61P35/04 A61P37/00 A61P37/06 A61P43/00 A61P7/02 A61P9/00 A61P9/04 A61P9/08 A61P9/10 A61P9/12 C07D C07D211/88 C07D213/24 C07D213/72 C07D215/38 C07D233/54 C07D471/04 (Advanced/Invention); A61P35/00 A61P37/00 A61P9/00 C07B61/00 (Advanced/Non-invention); A61K31/4375 C07D471/04 (Core/Invention); A61K31/4375 A61P35/00 A61P37/00 A61P9/00 C07D471/04 (Core/Non-invention); C07D (Subclass/Invention)

International (IPC 1-7): A61K31/4375 A61P35/00 A61P35/02 A61P9/10 C07D471/04

CPC: C07D471/04

European: C07D471/04

US: 514/234.5 514/255.05 514/300 514/312 544/127 544/405 546/122 546/159

Family:

Publication number	Publication date	Application number	Application date
AR079077 AA	20111221	AR2010P104280	20101119
AU2010320692 AA	20110526	AU20100320692	20101122
CA2781935 AA	20110526	CA20102781935	20101122
CN102762558 A	20121031	CN201080062131	20101122
CO6481011 A2	20120716	CO20120084563	20120523
CR20120261 A	20120704	CR20120000261	20120521
EA201290383 A1	20130130	EA20120090383	20101122
ECSF12011916 A	20120731	EC2012SP11916	20120521
EP2504338 A1	20121003	EP20100799090	20101122
EP2504338 B1	20150318	EP20100799090	20101122
FR2952934 A1	20110527	FR20090005602	20091123
FR2952934 B1	20120622	FR20090005602	20091123
GT201200154 A	20131107	GT20120000154	20120518
IL219888 A0	20120731	IL20120219888	20120520
IN01231KN2012 A	20130125	IN2012KN01231	20120522
JP2013511501 T2	20130404	JP20120539393T	20101122
KR20120099732 A	20120911	KR20127016232	20101122
MA33819 B1	20121203	MA20120034962	20120614
MX2012005988 A1	20120907	MX20120005988	20120523
NZ600108 A	20130628	NZ20100600108	20101122
PE13382012 A1	20121015	PE20120000710	20101122
TH128153 A	20131015	TH20121002357	20101122
TW201121971 A	20110701	TW20100140242	20101122
TWI476197 B	20150311	TW20100140242	20101122
US2013005724 AA	20130103	US20120477778	20120522
US8623893 BB	20140107	US20120477778	20120522
UY33049 A1	20110630	UY20100033049	20101123
WO11061458 A1	20110526	WO2010FR52480	20101122

Priority:

FR20090005602 20091123 WO2010FR52480 20101122

Probable Assignee: SANOFI

Assignee(s): (std): LASSALLE GILBERT ; MARTIN VALERIE ; MCCORT GARY ; SANOFI AVENTIS ; VOLLE CHALLIER CECILE ; SANOFI SA


Assignee(s): SANOFI

Inventor(s): (std): CECILE VOLLE CHALLIER ; GILBERT LASSALLE ; LASALLE GILBERT ; LASSALLE GILBERT ; GARY MCCORT ; MARTIN VALERIE ; MCCORT GARY ; VALERIE MARTIN ; VOLLE CHALLIER CECILE ; VOLLE CHALLIER CECILE

Inventor(s): GILBERT LASALLE ; CECILE VOLLE CHALLIER ; 2MARTIN VALERIE ; 4VOLLE CHALLIER CECILE

Agent(s): CATILLON MARIE

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW



Title: HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION

Abstract: Source: US2013123284A Provided herein are compounds useful for kinase inhibition.

Classifications:

International (IPC 8-9): A61K31/4196 A61K31/437 A61K31/4375 A61K31/4439 A61K31/4709 A61K31/506 A61K31/517 A61K31/519 A61N5/10 A61P1/16 A61P11/00 A61P27/02 A61P35/00 A61P35/02 A61P43/00 A61P9/00 A61P9/10 C07D C07D249/14 C07D401/10 C07D401/12 C07D401/14 C07D403/10 C07D403/12 C07D403/14 C07D409/14 C07D413/12 C07D413/14 C07D417/12 C07D471/04 C07D487/04 C07D487/22 C12N5/09 (Advanced/Invention)

CPC: C07D401/12 C07D401/14 C07D403/14 C07D413/12 C07D413/14 C07D417/12 C07D471/04 C07D487/04 C07D409/14 C07D487/22 C12N5/0693 A61N5/10 C12N2501/48 C07D249/14 C07D403/12

European: C07D401/12 C07D401/14 C07D403/12 C07D403/14 C07D409/14 C07D413/12 C07D487/04

US: 514/265.1 514/266.23 514/269 514/272 514/273 514/274 514/300 514/309 514/312 514/340 514/383 544/280 544/284 544/298 544/310 544/316 544/319 544/321 546/113 546/141 546/153 546/157 546/269.1 546/272.4 548/264.8

Family:

Publication number	Publication date	Application number	Application date
AU2011232372 AA	20110929	AU20110232372	20110324
CA2794086 AA	20110929	CA20112794086	20110324
CN102884060 A	20130116	CN201180023503	20110324
EP2550266 A2	20130130	EP20110760266	20110324
EP2550266 A4	20131127	EP20110760266	20110324
IL222068 A0	20121129	IL20120222068	20120923
JP2013523652 T2	20130617	JP20130501501T	20110324
KR20130006485 A	20130116	KR20127027421	20110324
MX2012010980 A1	20130227	MX20120010980	20120924
RU2012144751 A	20140427	RU20120144751	20110324
US2013123284 AA	20130516	US20110636298	20110324
US2015158828 AA	20150611	US20150620527	20150212
US8957216 BB	20150217	US20110636298	20110324
WO11119894 A2	20110929	WO2011US29879	20110324
WO11119894 A3	20120223	WO2011US29879	20110324

Priority:

US20100317223P 20100324 WO2011US29879 20110324 US20110636298 20110324

US20150620527 20150212 US20120636298 20121203

Probable Assignee: AMITECH THERAPEUTIC SOLUTIONS INC

Assignee(s): (std): AMITECH THERAPEUTIC SOLUTIONS INC ; AMITECH THERAPEUTICS SOLUTIONS INC ; ARNOLD LEE DANIEL ; KINAGEN INC ; MURPHY ERIC A

Assignee(s): BERTAGNOLLI MARK A ; AYERS ROCK CAPITAL LLC

Inventor(s): (std): ARNOLD LEE DANIEL ; MURPHY ERIC A

Inventor(s): LEE DANIEL ARNOLD ; ERIC A MURPHY

Agent(s): Blance Stephen John; WILSON SONSINI GOODRICH AND ROSATI; HOSTETLER MICHAEL J ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS

Abstract: Source: US2013165475A The present invention provides deuterium-enriched heteroaryl-containing urea compounds (I) and use of the same for treating conditions mediated by protein kinase such as


Classifications:

International (IPC 8-9): A61K31/407 A61K31/416 A61K31/4162 A61K31/4184 A61K31/4188 A61K31/4192 A61K31/437 A61K31/4439 A61K9/06 A61K9/08 A61K9/12 A61K9/20 A61K9/48 A61P13/12 A61P17/06 A61P19/02 A61P27/02 A61P29/00 A61P3/10 A61P31/00 A61P35/00 A61P37/00 A61P37/06 A61P43/00 C07D401/06 C07D401/14 C07D403/06 C07D403/14 C07D471/04 (Advanced/Invention)

CPC: C07D401/06 C07D403/06 C07D471/04

European: C07D401/06 C07D403/06 C07D471/04

US: 514/300 514/339 546/113 546/277.4



Family:

Publication number	Publication date	Application number	Application date
CN103080109 A	20130501	CN201180041832	20110901
EP2611806 A1	20130710	EP20110821132	20110901
EP2611806 A4	20140507	EP20110821132	20110901
JP2013536806 T2	20130926	JP20130526309T	20110901
US2013165475 AA	20130627	US20110817505	20110901
WO12028106 A1	20120308	WO2011CN79231	20110901

Priority:

US20100379109P 20100901 WO2011CN79231 20110901 US20110817505 20110901

Probable Assignee: ASCEPION PHARMACEUTICALS INC

Assignee(s): (std): ASCEPION PHARMACEUTICALS INC ; GAO XIAOYONG ; JIANG SHAN ; WANG QISHAN

Inventor(s): (std): GAO XIAOYONG ; JIANG SHAN ; WANG QISHAN

Agent(s): PRINZ AND PARTNER; BEIJING ZBSD PATENT AND TRADEMARK AGENT LTD

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: CHEMICAL COMPOUNDS

Abstract: Source: US2013225524A The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R¹, R², R³, R⁴, and R⁵ are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.


Classifications:

International (IPC 8-9): A61K31/47 A61K31/4706 A61K31/4709 A61K31/496 A61K31/501 A61K31/506 A61K31/513 A61K31/517 A61K31/5377 A61K31/69 A61K45/00 A61K45/06 A61P35/00 A61P35/02 A61P43/00 C07D215/54 C07D401/00 C07D401/04 C07D401/10 C07D401/14 C07D405/14 C07D413/04 C07D413/08 C07D413/10 C07D413/14 C07D471/04 C07F5/02 (Advanced/Invention)

CPC: A61K31/506 A61K45/06 A61K31/4709 A61K31/4706 A61K31/496 A61K31/513 A61K31/69 A61K31/517 C07D401/10 C07D413/10 C07D215/54 C07D401/14 C07D405/14 C07D471/04 C07D413/14 C07D215/44 C07D401/04 C07D403/04 C07D403/14 C07D407/14 C07F5/025

European: C07D215/44 C07D401/04 C07D403/04 C07D403/14 C07D407/14 C07D413/04

US: 514/253.06 514/256 514/266.21 514/274 514/300 514/313 514/64 544/123 544/284 544/310 544/333 544/363 546/113 546/13 546/161



Family:

Publication number	Publication date	Application number	Application date
EP2635279 A2	20130911	EP20110838787	20111103
EP2635279 A4	20141029	EP20110838787	20111103
JP2014504269 T2	20140220	JP20130537810T	20111103
US2013225524 AA	20130829	US20110883023	20111103
WO12061557 A2	20120510	WO2011US59067	20111103
WO12061557 A3	20131114	WO2011US59067	20111103

Priority:

US20100410434P 20101105 WO2011US59067 20111103 US20110883023 20111103

Probable Assignee: GLAXOSMITHKLINE LLC

Assignee(s): (std): CHAI DEPING ; COLON MARIELA ; DODSON CHRISTOPHER ; DUFFY KEVIN J ; SHAW ANTONY NICHOLAS ; GLAXOSMITHKLINE LLC ; GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ; GLAXOSMITHKLINE IP NO 2 LTD

Assignee(s): GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO2 LTD ; GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LIMITED

Inventor(s): (std): CHAI DEPING ; COLON MARIELA ; DODSON CHRISTOPHER ; DUFFY KEVIN J ; SHAW ANTONY NICHOLAS

Agent(s): REED MICHAEL ANTONY; DINNER DARA L ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Abstract: Source: US2013102586A Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds.


Classifications:

International (IPC 8-9): A01N43/00 A61K31/497 A61K31/535 C07D401/04

C07D471/04 (Advanced/Invention)

CPC: C07D471/04

US: 514/210.21 514/234.2 514/252.11 514/253.04 514/255.05 514/256 514/303 544/120 544/328 544/357 544/362 544/405 546/119



Family:

Publication number	Publication date	Application number	Application date
US2013102586 AA	20130425	US20120435327	20120330
US2014309211 AA	20141016	US20140290125	20140529
US8791112 BB	20140729	US20120435327	20120330
WO12135631 A1	20121004	WO2012US31471	20120330
WO12135631 A8	20121206	WO2012US31471	20120330

Priority:

US20110469274P 20110330 US20120435327 20120330 US20140290125 20140529

Probable Assignee: ARRIEN PHARMACEUTICALS LLC

Assignee(s): (std): APPALANENI RAJENDRA P ; ARRIEN PHARMACEUTICALS LLC ; ARRIEN PHARMAEUTICALS LLC ; KRISHNA REDDY Y VEKATA ; KRISHNA REDDY Y VENKATA ; REDDY Y VENKATA KRISHNA ; VANKAYALAPATI HARIPRASAD

Assignee(s): REDDY Y

Inventor(s): (std): KRISHNA REDDY Y VEKATA ; KRISHNA REDDY Y VENKATA ; VANKAYALAPATI HARIPRASAD ; REDDY Y VENKATA KRISHNA ; APPALANENI RAJENDRA P

Inventor(s): REDDY Y

Agent(s): TIMOTHY X; GIBSON AND DERNIER LLP; GIBSON TIMOTHY X


Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Abstract: Source: US2014163026A Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.

Classifications:

International (IPC 8-9): A61K31/44 A61K31/517 A61K31/519 A61K31/5377 A61K31/541 A61K45/00 A61P25/00 A61P25/18 A61P25/24 A61P25/28 A61P35/00 A61P35/02 A61P43/00 C07D C07D413/14 C07D471/04 C07D487/04 (Advanced/Invention); A61P25/18 A61P25/28 A61P35/00 (Advanced/Non-invention); C07D (Subclass/Invention)
CPC: C07D519/00 A61K9/0014 A61K9/0019 A61K9/0031 A61K9/0043 A61K9/0048 A61K9/0056 A61K9/0078 A61K9/06 A61K9/2054 A61K9/4866 C07D471/04 A61K45/06
US: 514/234.2 514/252.16 514/255.05 514/264.11 544/117 544/279



Family:

Publication number	Publication date	Application number	Application date
AR085958 AA	20131106	AR2012P101217	20120409
AU2012313399 AA	20130328	AU20120313399	20120409
AU2012313399 AH	20130801	AU20120313399	20120409
CA2832309 AA	20131003	CA20122832309	20120409
CN103596951 A	20140219	CN201280027839	20120409
EP2694504 A2	20140212	EP20120834216	20120409
EP2694504 A4	20140827	EP20120834216	20120409
IL228681 A0	20131231	IL20130228681	20131002
JP2014513079 T2	20140529	JP20140504076T	20120409
KR20140040715 A	20140403	KR20137029538	20120409
MX2013011518 A1	20140604	MX20130011518	20131003
RU2013149800 A	20150520	RU20130149800	20120409
TW201300385 A	20130101	TW20120112563	20120409
US2014163026 AA	20140612	US20120110670	20120409
WO13043232 A2	20130328	WO2012US32803	20120409
WO13043232 A3	20130613	WO2012US32803	20120409
WO13043232 A8	20130912	WO2012US32803	20120409

Priority:

US20110473683P 20110408 WO2012US32803 20120409 US20120110670 20120409

Probable Assignee: AFRAXIS HOLDINGS INC

Assignee(s): (std): AFRAXIS HOLDINGS INC ; AFRAXIS INC ; CAMPBELL DAVID ; DURON SERGIO G

Inventor(s): (std): CAMPBELL DAVID ; DURON SERGIO G

Agent(s): WYTENBURG WILHELMUS JOHANNES; HOSTETLER MICHAEL J; REANEY SHANNON

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: COMPOUNDS AND COMPOSITIONS AS **PDGFR** KINASE INHIBITORS

Abstract: Source: US2014206682A The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of **PDGFR** (PDGFRa, **PDGFR** beta) kinases or c-kit and **PDGFR** (PDGFRa, **PDGFR** beta) kinases.

Classifications:

International (IPC 8-9): A61K31/437 A61K31/444 A61K31/4545 A61K31/5377 A61P1/00 A61P1/04 A61P1/16 A61P11/00 A61P11/06 A61P13/10 A61P15/00 A61P17/00 A61P17/04 A61P19/02 A61P25/00 A61P27/02 A61P29/00 A61P3/00 A61P3/10 A61P35/00 A61P35/02 A61P37/00 A61P37/06 A61P37/08 A61P43/00 A61P9/00 A61P9/12 C07D471/04 C07D487/04 (Advanced/Invention)

CPC: C07D471/04

US: 514/233.2 514/300 544/127 546/121

Family:

Publication number	Publication date	Application number	Application date
AU2012301675 AA	20130307	AU20120301675	20120831
CA2845798 AA	20140218	CA20122845798	20120831
CN104039783 A	20140910	CN201280053750	20120831
EA201490542 A1	20140829	EA20140090542	20120831
EP2751107 A1	20140709	EP20120766749	20120831
JP2014525462 T2	20140929	JP20140528666T	20120831
KR20140105433 A	20140901	KR20147008109	20120831
MX2014002486 A1	20141208	MX20140002486	20140228
US2014206682 AA	20140724	US20120241886	20120831
WO13033620 A1	20130307	WO2012US53498	20120831

Priority:

US20110530056P 20110901 US20120674999P 20120724 WO2012US53498 20120831
US20120241886 20120831

Probable Assignee: IRM LLC

Assignee(s): (std): BERMAN ASHLEY MITCHELL ; FURMINGER VIKKI ; GIBNEY MICHAEL ; IRM LLC ; LI XIAOLIN ; LEWIS SARAH ; MOLTENI VALENTINA ; LIANG FANG ; LOREN JON ; NOVARTIS AG ; YEY VINCE ; SHAW DUNCAN ; NOVARTIS PHARMACEUTICALS UK LTD ; NOVARTIS INT AG

Assignee(s): NOVARTIS PHARMACEUTICALS UK LIMITED ; NOVARTIS PHARMACEUTICALS UK LTDFRIMLEY BUSINESS PARKFRIMLEYSURREY GU16 7SRCAMBERLEYGB ; IRM LLC131 FRONT STREETP.O. BOX HM 2899HM LXHAMILTONBM ; NOVARTIS AGLICHTSTRASSE 35CH-4056BASELCH

Inventor(s): (std): BERMAN ASHLEY MITCHELL ; FURMINGER VIKKI ; GIBNEY MICHAEL ; LEWIS SARAH ; LI XIAOLIN ; LIANG FANG ; LOREN JON ; SHAW DUNCAN ; MOLTENI VALENTINA ; YEY VINCE

Inventor(s): YEY VINCEUS ; MOLTENI VALENTINAUS ; SARAH LEWIS ; SHAW DUNCANGB ; VALENTINA MOLTENI ; VIKKI FURMINGER ; VINCE YEY ; XIAOLIN LI ; ASHLEY MITCHELL BERMAN ; LOREN JONUS ; MICHAEL GIBNEY ; LIANG FANGUS ; LI XIAOLINUS ; LEWIS SARAHGB ; GIBNEY MICHAELUS ; JON LOREN ; FURMINGER VIKKIGB ; BERMAN ASHLEY MITCHELLUS ; DUNCAN SHAW ; FANG LIANG

Agent(s): MARTI CHRISTIANE; RAYMOND DANIEL E ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS


Abstract: Source: US2013059832A The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and **PDGFR** (PDGFRa, **PDGFR** beta) kinases.

Classifications:

International (IPC 8-9): A61K31/351 A61K31/397 A61K31/4184 A61K31/4245 A61K31/437 A61K31/439 A61K31/444 A61K31/4545 A61K31/496 A61K31/5377 A61K31/5386 A61P1/00 A61P1/04 A61P1/16 A61P11/00 A61P11/02 A61P11/06 A61P17/00 A61P17/04 A61P29/00 A61P3/00 A61P3/04 A61P3/10 A61P37/00 A61P37/08 A61P43/00 A61P7/00 A61P9/12 C07D C07D403/14 C07D407/14 C07D413/04 C07D413/14 C07D471/04 C07D491/044 C07D491/048 C07D491/107 C07D498/04 C07D498/08 C07D519/00 (Advanced/Invention); A61P1/00 A61P11/00 A61P17/00 A61P3/10 A61P9/12 (Advanced/Non-invention); A61P11/00 A61P17/00 A61P29/00 A61P3/00 (Core/Invention); C07D (Subclass/Invention)

CPC: C07D491/048 C07D491/044 C07D471/04 C07D491/107 C07D498/04

US: 514/210.18 514/210.21 514/233.2 514/249 514/253.04 514/300 514/302 514/49 544/127 544/362 546/115 546/121 546/15



Family:

Publication number	Publication date	Application number	Application date
AP201407493 A0	20140331	AP20140007493	20120829
AR087753 AA	20140416	AR2012P103223	20120831
AU2012302042 AA	20130307	AU20120302042	20120829
CA2845169 AA	20140212	CA20122845169	20120829
CL2014000492 A1	20141003	CL20140000492	20140227
CN103797011 A	20140514	CN201280042743	20120829
CO6900141 A2	20140320	CO20140043417	20140228
CR20140107 A	20140502	CR20140000107	20140228
CU20140024 A7	20140424	CU20140000024	20140227
EA201490545 A1	20140730	EA20140090545	20120829
EP2751104 A1	20140709	EP20120756885	20120829
IL231227 A0	20140430	IL20140231227	20140227
JP2014525448 T2	20140929	JP20140528537T	20120829
KR20140075692 A	20140619	KR20147008107	20120829
MA35460 B1	20140901	MA20140036864	20140328
MX2014002484 A1	20141125	MX20140002484	20140228
PE09092014 A1	20140720	PE20140000295	20120829
TW201313717 A	20130401	TW20120131942	20120831
US2013059832 AA	20130307	US20120598213	20120829
US2014031333 AA	20140130	US20130031792	20130919
US2014228347 AA	20140814	US20140258963	20140422
US8569283 BB	20131029	US20120598213	20120829
US8754071 BB	20140617	US20130031792	20130919
US9023839 BB	20150505	US20140258963	20140422
UY34301 A1	20130405	UY20120034301	20120829
WO13033167 A1	20130307	WO2012US52802	20120829

Priority:
US20110530038P 20110901 US20120598213 20120829 US20130031792 20130919
WO2012US52802 20120829 US20140258963 20140422

Probable Assignee: IRM LLC

Assignee(s): (std): JANSSEN PHARMACEUTICA NV ; NABAKKA JULIET ; LI XIAOLIN ; MOLTENI VALENTINA ; LIU XIAODONG ; NGUYEN BAO ; LOREN JON ; MOLENTI VALENTINA ; PETRASSI HANK MICHAEL JAMES ; YEH VINCE ; IRM ; IRM LLC

Assignee(s): IRM LLC A DELAWARE LIABILITY CO LTD ; NOVARTIS INST FOR FUNCTIONAL GENOMICS INC DBA GENOMICS INST OF NOVARTIS RESEARCH FOUNDATION ; NOVARTIS INST FOR FUNCTIONAL GENOMICS ; NOVARTIS INT PHARMACEUTICAL LTD ; NOVARTIS AG

Inventor(s): (std): BAO NGUYEN ; HANK MICHAEL JAMES PETRASSI ; JON LOREN ; JULIET NABAKKA ; LI XIAO LIN ; LI XIAOLIN ; LIU XIADONG ; LIU XIAO DONG ; LIU XIAODONG ; LOREN JON ; MOLENTI VALENTINA ; MOLTENI VALENTINA ; NABAKKA JULIET ; NGUYE BAO ; NGUYEN BAO ; PETRASSI HANK MICHAEL JAMES ; VALENTINA MOLTENI ; VINCE YEH ; XIADONG LIU ; XIAOLIN LI ; YEH VINCE

Agent(s): KIDDLE SIMON JOHN; DANIEL E; GENOMICS INST OF NOVARTIS RESEARCH FOUNDATION; RAYMOND DANIEL E ET AL


Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

Abstract: Source: US2013059846A The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and **PDGFR** (PDGFRa, **PDGFR** beta) kinases.

Classifications:

International (IPC 8-9): A61K31/4155 A61K31/4184 A61K31/4192 A61K31/4245 A61K31/437 A61K31/4545 A61K31/496 A61K31/5377 A61P1/00 A61P11/00 A61P11/02 A61P11/04 A61P11/06 A61P17/00 A61P19/04 A61P21/00 A61P29/00 A61P3/00 A61P3/04 A61P3/10 A61P37/02 A61P37/06 A61P37/08 A61P43/00 A61P9/00 A61P9/12 C07D C07D403/14 C07D413/10 C07D413/14 C07D471/04 (Advanced/Invention); A61P1/00 A61P11/00 A61P17/00 A61P3/10 A61P9/12 (Advanced/Non-invention); A61P11/00 A61P17/00 A61P29/00 A61P3/00 (Core/Invention); C07D (Subclass/Invention)
CPC: C07D471/04
US: 514/233.2 514/253.04 514/300 544/127 544/362 546/121 546/15



Family:

Publication number	Publication date	Application number	Application date
AP201407494 A0	20140331	AP20140007494	20120828
AR087752 AA	20140416	AR2012P103222	20120831
AU2012300248 AA	20130307	AU20120300248	20120828
CA2845159 AA	20140212	CA20122845159	20120828
CL2014000494 A1	20140905	CL20140000494	20140227
CN103764653 A	20140430	CN201280042763	20120828
CO6900140 A2	20140320	CO20140043411	20140228
CR20140106 A	20140502	CR20140000106	20140228
CU20140023 A7	20140424	CU20140000023	20140227
EA201490540 A1	20140630	EA20140090540	20120828
EP2751102 A1	20140709	EP20120756879	20120828
IL231226 A0	20140430	IL20140231226	20140227
JP2014525444 T2	20140929	JP20140528513T	20120828
KR20140071382 A	20140611	KR20147008106	20120828
MA35459 B1	20140901	MA20140036863	20140328
MX2014002482 A1	20141125	MX20140002482	20140228
PE10332014 A1	20140830	PE20140000294	20120828
TW201313716 A	20130401	TW20120131940	20120831
US2013059846 AA	20130307	US20120595575	20120827
UY34300 A1	20130405	UY20120034300	20120829
WO13033070 A1	20130307	WO2012US52621	20120828

Priority:
US20110530028P 20110901 US20120595575 20120827 WO2012US52621 20120828

Probable Assignee: NOVARTIS AG

Assignee(s): (std): IRM ; IRM LLC ; LI XIAOLIN ; LIU XIAODONG ; NABAKKA JULIET ; YEH VINCE ; MOLTENI VALENTINA ; PETRASSI HANK MICHAEL JAMES ; NGUYEN BAO ; LOREN JON

Assignee(s): NOVARTIS INT PHARMACEUTICAL LTD ; NOVARTIS AG

Inventor(s): (std): JULIET NABAKKA ; LI XIAO LIN ; LI XIAOLIN ; LIU XIAO DONG ; LIU XIAODONG ; LOREN JON ; LOREN JON CHRISTOPHER ; MOLTENI VALENTINA ; NABAKKA JULIET ; NGUYEN BAO ; PETRASSI HANK MICHAEL JAMES ; VALENTINA MOLTENI ; VINCE YEH ; XIAODONG LIU ; XIAOLIN LI ; YEH VINCE ; BAO NGUYEN ; HANK MICHAEL JAMES PETRASSI ; JON CHRISTOPHER LOREN

Inventor(s): JON LOREN

Agent(s): KIDDLE SIMON JOHN; RAYMOND DANIEL E ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

Abstract: Source: US2015011508A The invention provides compounds of formulae (I) and (II) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and **PDGFR** (PDGFR α , **PDGFR** β) kinases.


Classifications:

International (IPC 8-9): A61K31/437 A61K31/444 A61K31/496 A61K31/497 A61K31/506 A61K31/5377 A61K31/675 A61P1/00 A61P1/16 A61P11/00 A61P11/02 A61P11/06 A61P17/00 A61P17/04 A61P29/00 A61P3/00 A61P3/10 A61P37/06 A61P37/08 A61P43/00 A61P9/00 A61P9/12 C07D413/10 C07D471/04 C07F9/6561 (Advanced/Invention)

CPC: C07F9/6561 C07D471/04 A61K31/4245

US: 514/233.2 514/253.04 514/300 514/80 544/127 544/362 546/121 546/23

PatBase - WO13033116_A1



Family:

Publication number	Publication date	Application number	Application date
AU2012302176 AA	20130307	AU20120302176	20120828
CA2845785 AA	20140218	CA20122845785	20120828
CN104024254 A	20140903	CN201280053311	20120828
EA201490537 A1	20140730	EA20140090537	20120828
EP2751103 A1	20140709	EP20120756884	20120828
JP2014525447 T2	20140929	JP20140528527T	20120828
KR20140071383 A	20140611	KR20147008112	20120828
US2015011508 AA	20150108	US20120241883	20120828
WO13033116 A1	20130307	WO2012US52704	20120828

Priority:

US20110530020P 20110901 US20120675119P 20120724 WO2012US52704 20120828
US20120241883 20120828

Probable Assignee: IRM LLC

Assignee(s): (std): IRM LLC ; LI XIAOLIN ; LIU XIAODONG ; LOREN JON ; NABAKKA JULIET ; YEH VINCE ; MOLTENI VALENTINA ; PETRASSI HANK MICHAEL JAMES ; NGUYEN BAO

Inventor(s): (std): LI XIAOLIN ; LIU XIAODONG ; LOREN JON ; MOLTENI VALENTINA ; NABAKKA JULIET ; NGUYEN BAO ; PETRASSI HANK MICHAEL JAMES ; YEH VINCE

Agent(s): MARTI CHRISTIANE; RAYMOND DANIEL E ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

Abstract: Source: US2015051206A The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and **PDGFR** (PDGFRa, **PDGFR** beta) kinases.

Classifications:

International (IPC 8-9): A61K31/4245 A61K31/437 A61K31/4439 A61K31/496 A61K31/497 A61K31/506 A61K31/5377 A61P1/00 A61P11/00 A61P11/02 A61P11/06 A61P17/00 A61P17/04 A61P29/00 A61P3/00 A61P3/10 A61P37/06 A61P37/08 A61P43/00 A61P9/12 C07D413/10 C07D471/04 (Advanced/Invention)

CPC: C07D471/04

US: 514/233.2 514/252.04 514/253.04 514/255.05 514/256 514/300 544/127 544/238 544/333 544/362 544/405 546/121

PatBase - CN103930424_R

权利要求书6页 说明书90页

Family:

Publication number	Publication date	Application number	Application date
AU2012302080 AA	20130307	AU20120302080	20120829
CA2845791 AA	20140218	CA20122845791	20120829
CN103930424 A	20140716	CN201280053232	20120829
EA201490539 A1	20140630	EA20140090539	20120829
EP2751105 A1	20140709	EP20120762445	20120829
JP2014525450 T2	20140929	JP20140528547T	20120829
KR20140071384 A	20140611	KR20147008113	20120829
US2015051206 AA	20150219	US20120241884	20120829
WO13033203 A1	20130307	WO2012US52850	20120829

Priority:

US20110530046P 20110901 WO2012US52850 20120829 US20120241884 20120829

Probable Assignee: IRM LLC

Assignee(s): (std): IRM LLC ; LI XIAOLIN ; LIU XIAODONG ; LOREN JON ; NABAKKA JULIET ; PETRASSI HANK MICHAEL JAMES ; MOLTENI VALENTINA ; RUCKER PAUL VINCENT ; NGUYEN BAO ; YEH VINCE

Inventor(s): (std): LI XIAOLIN ; LIU XIAODONG ; LOREN JON ; MOLTENI VALENTINA ; NABAKKA JULIET ; NGUYEN BAO ; PETRASSI HANK MICHAEL JAMES ; RUCKER PAUL VINCENT ; V YE ; YEH VINCE

Agent(s): MARTI CHRISTIANE; RAYMOND DANIEL E ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF

Abstract: Source: US2013096113A Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFRbeta kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

Classifications:

International (IPC 8-9): A61K31/423 A61K31/428 A61K31/429 A61K31/437 A61K31/4439 A61K31/454 A61K31/4545 A61K31/496 A61K31/497 A61K31/4985 A61K31/5025 A61K31/52 A61K31/535 A61K31/5377 A61P1/00 A61P1/04 A61P11/00 A61P11/02 A61P11/06 A61P11/08 A61P13/12 A61P15/00 A61P15/08 A61P17/00 A61P17/02 A61P17/06 A61P19/02 A61P19/04 A61P19/08 A61P19/10 A61P25/00 A61P25/28 A61P29/00 A61P3/00 A61P3/04 A61P3/10 A61P3/14 A61P35/00 A61P35/02 A61P37/00 A61P37/02 A61P37/04 A61P37/06 A61P37/08 A61P43/00 A61P5/14 A61P5/50 A61P7/00 A61P9/08 A61P9/10 C07D C07D413/06 C07D413/10 C07D413/14 C07D417/06 C07D417/10 C07D417/14 C07D471/04 C07D473/00 C07D473/40 C07D487/04 C07D513/04 C07D519/00 (Advanced/Invention); A61P35/00 (Advanced/Non-invention); C07D (Subclass/Invention)


CPC: C07D417/06 C07D413/06 C07D413/14 C07D417/14 C07D471/04 C07D487/04

US: 514/233.2 514/234.2 514/234.5 514/248 514/263.2 514/303 514/367 514/375 514/535 544/117 544/127 544/135 544/236 544/264 546/118 548/159 548/222

PatBase - US2013096113_AA

Patent Application Publication Apr. 18, 2013 Sheet 1 of 6 US 2013/096113 A1

FIG. 1



Family:

Publication number	Publication date	Application number	Application date
AR089568 AA	20140903	AR2012P103819	20121012
AU2012322095 AA	20130418	AU20120322095	20121012
CA2851155 AA	20140403	CA20122851155	20121012
CN104066730 A	20140924	CN201280062194	20121012
EP2766359 A2	20140820	EP20120780613	20121012
IL231927 A0	20140528	IL20140231927	20140403
JP2014528482 T2	20141027	JP20140535928T	20121012
KR20140075010 A	20140618	KR20147012791	20121012
MX2014004252 A1	20140611	MX20140004252	20140408
TW201321376 A	20130601	TW20120137842	20121012
US2013096113 AA	20130418	US20120651312	20121012
US8952058 BB	20150210	US20120651312	20121012
WO13056070 A2	20130418	WO2012US59983	20121012
WO13056070 A3	20130801	WO2012US59983	20121012

Priority:

US20110547637P 20111014 US20120638990P 20120426 US20120651312 20121012
WO2012US59983 20121012

Probable Assignee: AMBIT BIOSCIENCES CORP

Assignee(s): (std): AMBIT BIOSCIENCES CORP

Assignee(s): HADD MICHAEL J ; HOCKER MICHAEL D ; HOLLADAY MARK W ; ROWBOTTOM MARTIN W ; XU SHIMIN ; LIU GANG

Inventor(s): (std): HADD MICHAEL J ; HOCKER MICHAEL D ; HOLLADAY MARK W ; LIU GANG ; ROWBOTTOM MARTIN W ; XU SHI MIN ; XU SHIMIN

Inventor(s): SHIMIN XU ; GANG LIU ; MARK W HOLLADAY ; MARTIN W ROWBOTTOM ; MICHAEL D HOCKER ; MICHAEL J HADD

Agent(s): JONES DAY ; INSOGNA ANTHONY M ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK)

Abstract: Source: US2014309249A The present invention provides novel compounds according to Formula (I): where Ring A, Ring B, X, L1, L2, RA, RC, RD, RE, m, n, and p are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of human diseases associated with kinase activity, for example, proliferative diseases, neurodegenerative diseases, metabolic disorders, inflammatory diseases, and cardiovascular diseases.


Classifications:

International (IPC 8-9): A61K31/437 A61K31/444 A61K31/506 A61P25/00 A61P25/16 A61P25/18 A61P25/28 A61P29/00 A61P3/00 A61P3/10 A61P35/00 A61P43/00 A61P9/10 C07D401/04 C07D417/04 C07D471/04 (Advanced/Invention)

CPC: A61K31/444 C07D403/04 C07D403/06 C07D417/06 A61K31/437 C07D401/04 C07D417/04 C07D471/04

US: 514/275 544/331

PatBase - US2014309249_AA



Family:

Publication number	Publication date	Application number	Application date
AU2012340200 AA	20130523	AU20120340200	20121116
CA2856291 AA	20140516	CA20122856291	20121116
EP2822935 A1	20150114	EP20120849203	20121116
JP2014533695 T2	20141215	JP20140542506T	20121116
US2014309249 AA	20141016	US20120358606	20121116
WO13074986 A1	20130523	WO2012US65618	20121116

Priority:

US20110561078P 20111117 WO2012US65618 20121116 US20120358606 20121116

Probable Assignee: DANA FARBER CANCER INST INC

Assignee(s): (std): DANA FARBER CANCER INST INC ; DANA FARBER CANCER INTITUTE INC

Assignee(s): GRAY NATHANAEL ; ZHANG TINGHU ; DANA FARBER CANCER INST INC450 BROOKLINE AVENUEBOSTONMA02215-5450US ; DANA FARBER CANCER INSTITUTE INC

Inventor(s): (std): GRAY NATHANAEL ; ZHANG TINGHU

Inventor(s): ZHANG TINGHUUS ; GRAY NATHANAELUS

Agent(s): CROOKS ELIZABETH CAROLINE; BAKER C HUNTER

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS

Abstract: Source: US2013237537A The present invention relates to a method of treating ophthalmic diseases and conditions, e.g. diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, etc., in a subject comprising administering to said subject a therapeutically effective amount of at least one compound of formula I or a prodrug, pharmaceutically acceptable salt, racemic mixtures or enantiomers of said compound. The compounds of formula I are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.


Classifications:

International (IPC 8-9): A61K31/437 A61K31/4375 A61K31/519 A61P27/02 C07D471/04 C07D487/04 (Advanced/Invention)

CPC: C07D471/04 C07D487/04 A61K31/437 A61K31/4375 A61K31/519

US: 514/234.5 514/264.1 514/264.11 514/265.1 514/300

Figure 1: Hypothetical Orientation of Example 1 in ATP site of VEGFR2 receptor. R¹ and R² substituents are oriented towards solvent exposed protein surface.



Family:

Publication number	Publication date	Application number	Application date
EP2825166 A1	20150121	EP20130712064	20130312
US2013237537 AA	20130912	US20130796928	20130312
WO13138393 A1	20130919	WO2013US30625	20130312

Priority:

US20120609742P 20120312 US20130796928 20130312 WO2013US30625 20130312

Probable Assignee: ALLERGAN INC

Assignee(s): (std): ALLERGAN INC

Inventor(s): (std): HULL III CLARENCE E ; MALONE THOMAS C

Agent(s): HOFFMANN EITLE; BANERJEE KRISHNA ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: NOVEL A-NAPHTHYLUREA DERIVATIVE AND MEDICAL APPLICATION OF SAME

Abstract: The present invention relates to a novel a-Naphthylurea derivative. This substance can remarkably depress phosphorylation of VEGFR2 and **PDGFR-** beta receptor protein tyrosine kinases at the level of nanomolar concentration, and is a novel protein tyrosine kinase depressor, which can be used to cure a disease or symptom induced by the protein tyrosine kinase, such as a malignant tumor or an eye disease accompanied by pathological new vessels.

Classifications:

International (IPC 8-9): A61K31/416 A61K31/437 A61P27/02 A61P27/06 A61P35/00 A61P35/02 A61P35/04 C07D231/56 C07D471/04 (Advanced/Invention)

CPC: C07D231/56 C07D471/04 A61K31/416 A61K31/437

Family:

Publication number	Publication date	Application number	Application date
CN103524421 A	20140122	CN201310455924	20130929
CN103524421 B	20150401	CN201310455924	20130929
WO15043342 A1	20150402	WO2014CN84816	20140820

Priority:

CN201310455924 20130929

Probable Assignee: ZHENJIANG RADIANT PHARMACRUTICAL TECHNOLOGY CO LTD

Assignee(s): (std): RADIANT PHARMA AND TECH CO LTD ; ZHENJIANG RADIANT PHARMACRUTICAL TECHNOLOGY CO LTD

Assignee(s): RADIANT PHARMA AND TECH CO ; ZHENJIANG RADIANT PHARMACRUTICAL TECHNOLOGY CO

Inventor(s): (std): FENG ZHONGYING ; HAN LI ; HU YINGJIAN ; LU HONGFEI ; LUO ZHIBIN ; WANG YUN ; XIE PING ; ZHANG YANHONG

Agent(s): SUZHOU CREATOR PATENT AND TRADEMARK AGENCY LTD

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: HETEROCYCLIC BENZAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AS WELL AS APPLICATION THEREOF

Abstract: Source: CN103539784A The invention discloses heterocyclic benzamide compounds with structural characteristics of formula (1) or pharmaceutically acceptable salts or steric isomers or prodrug molecules thereof. The heterocyclic benzamide compounds as well as pharmaceutically acceptable salts thereof can effectively restrain growth of a plurality of tumor cells, can generate inhibiting effect to proteases such as BCR-ABL, c-Kit and **PDGFR**, can be used for preparing anti-tumor drugs and can be used for overcoming existing drug (Gleevec)-induced drug resistance.

Classifications:

International (IPC 8-9): A61K31/437 A61K31/4545 A61K31/496 A61K31/5025 A61K31/506 A61K31/517 A61K31/519 A61K31/5377 A61K31/551 A61P35/00 A61P35/02 C07D249/06 C07D403/04 C07D471/04 C07D487/04 C07D519/00 (Advanced/Invention)

CPC: C07D403/04 C07D249/06 C07D471/04 C07D487/04 C07D519/00

Family:

Publication number	Publication date	Application number	Application date
CN103539784 A	20140129	CN201210236713	20120709

Priority:

CN201210236713 20120709

Probable Assignee: GUANGZHOU INST BIOMED AND HEALTH

Assignee(s): (std): GUANGZHOU INST BIOMED AND HEALTH

Assignee(s): GUANGZHOU INST OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCES

Inventor(s): (std): DING KE ; LENG FANG ; LI YUPENG ; LONG HUOYOU ; LU XIAOYUN ; SHEN MENGJIE ; ZHANG ZHANG

Title: 3,4-DISUBSTITUTED(1H-PYRAZOLE[3,4-B]PYRIDINE) COMPOUND AND USE THEREOF

Abstract: Source: CN103923078A The invention mainly relates to a 3,4-disubstituted(1H-pyrazole[3,4-b]pyridine) compound and a use thereof. The 3,4-disubstituted(1H-pyrazole[3,4-b]pyridine) compound is a compound represented by the formula I or a pharmaceutically acceptable salt thereof (referring to the description or claims for details). The compound provided by the invention shows a stronger inhibitory activity on tyrosine kinase (including c-Kit, **PDGFR**[alpha], VEGFR2 and FGFR1) related to occurrence and development of four tumors. The compound is indicated to be used as a multi-target kinase inhibitor, and is developed into a targeted anti-tumor drug in allusion to acute granulocytic leukemia and solid tumors.

Classifications:
International (IPC 8-9): A61P35/00 A61P35/02 C07D471/04 (Advanced/Invention)
CPC: C07D471/04

Family:

Publication number	Publication date	Application number	Application date
CN103923078 A	20140716	CN201310013356	20130115

Priority:
CN201310013356 20130115

Probable Assignee: SHANGHAI HUFA CHEMICAL IND CO LTD
Assignee(s): (std): EAST CHINA UNIV OF SCIENCE AND TECHNOLOGY ; SHANGHAI HUFA CHEMICAL IND CO LTD ; UNIV EAST CHINA SCIENCE AND TECH
Assignee(s): SHANGHAI CHEMICAL TECHNOLOGY CO HAIR LAKE ; SHANGHAI HUFA CHEMICAL IND CO
Inventor(s): (std): CHE PENG ; CHEN YULONG ; LI JIAN ; LOU JIANGPING ; NI SHUAISHUAI


Title: ANTI-ANGIOGENIC COMPOUND

Abstract: Provided in the present invention are a new anti-angiogenic compound and a preparation method and use thereof. The compound of the present invention has a good anti-angiogenic effect, and this compound is initially considered to act by inhibiting VEGFR2 (i.e. KDR), thereby generating activity. Such compounds can be used for the treatment of diseases caused by abnormal protein kinase such as neovascularization, VEGFR2, **PDGFR**- beta, and KIT, for example, wet macular degeneration, malignant tumours etc.

Classifications:

International (IPC 8-9): A61K31/506 A61K31/519 A61P27/02 A61P27/06 A61P3/10 A61P9/10 C07D401/12 C07D401/14 C07D403/12 C07D417/12 C07D417/14 C07D471/04 C07D487/04 (Advanced/Invention)

CPC: A61K31/506 A61K31/519 C07D401/12 C07D401/14 C07D403/12 C07D417/12 C07D417/14 C07D471/04 C07D487/04



Family:

Publication number	Publication date	Application number	Application date
CN104072481 A	20141001	CN201410125752	20140328
WO14154173 A1	20141002	WO2014CN74306	20140328

Priority:

CN201310106154 20130328 CN201410125752 20140328

Probable Assignee: GUANGZHOU KANGRUI BIOMEDICAL TECHNOLOGY CO LTD

Assignee(s): (std): GUANGZHOU KANG RUI BIOLOG PHARMACEUTICAL TECHNOLOGY CO LTD ; GUANGZHOU KANGRUI BIOMEDICAL TECHNOLOGY CO LTD

Assignee(s): GUANGZHOU KANG RUI BIOLOGICAL PHARMACEUTICAL TECHNOLOGY CO LTD ; GUANGZHOU KANGRUI BIOMEDICAL TECHNOLOGY CO ; GUANGZHOU RUI KANG BIOMEDICAL TECHNOLOGY CO LTD

Inventor(s): (std): LUO HONGRONG ; HOU RUI

Agent(s): GAOYUNG INTELLECTUAL PROPERTY AGENCY

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF

Abstract: Source: US2015065468A Biaryl acetamide compounds and compositions and their methods of use are provided for modulating the activity of class III receptor tyrosine kinases and for the treatment, prevention or amelioration of one or more symptoms of disease of disorder mediated by class III receptor tyrosine kinases.

Classifications:
International (IPC 8-9): A61K31/421 A61K31/4353 A61K31/4365 A61K31/437 A61K31/4375 A61K31/4545 A61K31/47 A61K31/4709 A61K31/495 A61K31/498 A61K31/4985 A61K31/5377 A61K31/5386 A61K31/541 A61K31/553 A61K31/655 A61K45/06 A61P35/00 A61P35/02 C07D403/12 C07D413/12 C07D413/14 C07D471/04 C07D487/04 C07D487/08 C07D491/056 C07D495/04 C07D498/08 C07D498/14 (Advanced/Invention)
CPC: C07D498/08 A61K31/498 A61K45/06 A61K31/47 A61K31/4985 A61K31/4365 C07D471/04 A61K31/4375 A61K31/437 A61K31/5377 A61K31/655 A61K31/5386 C07D403/12 C07D413/14 C07D498/14 C07D413/12 C07D487/04 C07D495/04
US: 514/150 514/210.18 514/210.21 514/230.5 514/234.8 514/249 514/293 514/300 514/301 514/303 514/314 544/105 544/119 544/345 544/350 544/353 546/113 546/114 546/119 546/122 546/173

Family:

Publication number	Publication date	Application number	Application date
TW201520207 A	20150601	TW20140130045	20140829
US2015065468 AA	20150305	US20140473597	20140829
WO15031613 A1	20150305	WO2014US53156	20140828

Priority:

US20130872400P 20130830 US20140473597 20140829

Probable Assignee: AMBIT BIOSCIENCES CORP

Assignee(s): (std): AMBIT BIOSCIENCES CORP

Inventor(s): (std): HOLLADAY MARK W ; LIU GANG ; ROWBOTTOM MARTIN W ; ROWBOTTON MARTIN W

Agent(s): RIEGER DALE L ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT


Abstract: Source: US2015111857A Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.

Classifications:

International (IPC 8-9): A61K31/53 A61K31/535 A61K31/5377 A61K31/5415 A61K31/55 A61K31/553 A61K31/635 A61K31/675 A61K45/06 A61P35/00 C07D401/14 C07D403/12 C07D403/14 C07D405/14 C07D413/14 C07D417/14 C07D471/04 C07F9/6521 (Advanced/Invention)

CPC: C07D413/14 A61K45/06 C07D403/12 A61K31/53 A61K31/5377 C07D401/14 C07D403/14 C07D405/14 A61K31/55 A61K31/553 C07D471/04 C07F9/65217 A61K31/675 A61K31/635 C07D417/14 A61K31/5415

US: 514/157 514/210.2 514/211.09 514/213.01 514/226.5 514/236.2 514/242 514/245 514/84 540/552 540/593 544/113 544/182 544/195 544/209 544/49



Family:

Publication number	Publication date	Application number	Application date
US2015111857 AA	20150423	US20140517480	20141017
WO15058129 A1	20150423	WO2014US61211	20141017

Priority:
US20130892077P 20131017 US20140517480 20141017

Probable Assignee: BLUEPRINT MEDICINES CORP

Assignee(s): (std): BLUEPRINT MEDICINES CORP ; HODOUS BRIAN L ; ZHANG YULIAN ; WILSON DOUGLAS ; KIM JOSEPH L ; MIDUTURU CHANDRASEKHAR V

Inventor(s): (std): HODOUS BRIAN L ; KIM JOSEPH L ; MIDUTURU CHANDRASEKHAR V ; WILSON DOUGLAS ; ZHANG YULIAN

Agent(s): GEORGES EVANGELINOS ASIMINA T

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW